Fusion protein
Abstract
The invention relates to a fusion protein, composed of mutants or variants of human interleukin-3 (hIL-3) fused to a second colony stimulating factor (CFS) including cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant with or without a linker, which is administrated as a pharmaceutical composition for increasing the hematopoietic cells production in a mammal.

Term
Term ended
Expired 2 February 2015, 11.6 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
18 claims: 1 independent, 17 dependent
- 1Proteină de fuziune, având structura corespunzătoare formulei (I):X-(L) f Y (I) caracterizată prin aceea că X este R! sau R z și Y este R, sau R 2 , L este un linker capabil să se lege la radicalii X și Y, J este 0 sau 1, iar R, este o polipeptidă mutantă de interleukină3 umană, având un profil de activitate îmbunătățită, cu formula Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 45 1015 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 2530 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 5560 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 7075 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 8590 RO 118016 Β1 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100105 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115120 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115120 Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala lle Phe 125130 (Secvența nr.: 1) în care Xaa la poziția 17 este Ser, Lys, Gly, Asp, Met, Gin sau Arg;Xaa la poziția 18 este Asn, His, Leu, lle, Phe, Arg sau Gin;Xaa la poziția 19 este Met, Phe, lle, Arg, Gly, Ala sau Cys;Xaa la poziția 20 este lle, Cys, Gin, Glu, Arg, Pro sau Ala;Xaa la poziția 21 este Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser sau Val;Xaa la poziția 22 este Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val sau Gly;Xaa la poziția 23 este lle, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser sau Arg;Xaa la poziția 24 este lle, Gly, Val, Arg, Ser, Phe sau Leu;Xaa la poziția 25 este Thr, His, Gly, Gin, Arg, Pro sau Ala;Xaa la poziția 26 este His, Thr, Phe, Gly, Arg, Ala sau Trp;Xaa la poziția 27 este Leu, Gly, Arg, Thr, Ser sau Ala;Xaa la poziția 28 este Lys, Arg, Leu, Gin, Gly, Pro, Val sau Trp;Xaa la poziția 29 este Gin, Asn, Leu, Pro, Arg sau Val;Xaa la poziția 30 este Pro, His, Thr, Gly, Asp, Gin, Ser, Leu sau Lys;Xaa la poziția 31 este Pro, Asp, Gly, Ala, Arg, Leu sau Gin;Xaa la poziția 32 este Val, Arg, Gin, Asn, Gly, Ala sau Glu;Xaa la poziția 33 este Pro, Leu, Gin, Ala, Thr sau Glu;Xaa la poziția 34 este Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, lle sau Met;Xaa la poziția 35 este Leu, Ala, Gly, Asn, Pro, Gin sau Val;Xaa la poziția 36 este Asp, Leu sau Val;Xaa la poziția 37 este Phe, Ser, Pro, Trp sau lle;Xaa la poziția 38 este Asn sau Ala;Xaa la poziția 40 este Leu, Trp sau Arg;Xaa la poziția 41 este Asn, Cys, Arg, Leu, His, Met sau Pro;Xaa la poziția 42 este Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, lle, Met sau Ala;Xaa la poziția 43 este Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly sau Ser;Xaa la poziția 44 este Asp, Ser, Leu, arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala sau Pro;Xaa la poziția 45 este Gin, Pro, Phe, Val, Met, Leu, Thr, Lys,Trp, Asp, Asn, Arg, Ser, Ala, lle, Glu sau His Xaa la poziția 46 este Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val sau Gly;Xaa la poziția 47 este lle, Gly, Val, Ser, Arg, Pro sau His;Xaa la poziția 48 este Leu, Ser, Cys, Arg, lle, His, Phe, Glu, Lys, Thr, Ala, Met, Val sau Asn;Xaa la poziția 49 este Met, Arg, Ala, Gly, Pro, Asn, His sau Asp;Xaa la poziția 50 este Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, lle, Val, His, Phe, Met sau Gin;Xaa la poziția 51 este Asn, Arg, Met, Pro, Ser, Thr sau His;Xaa la poziția 52 este Asn, His, Arg, Leu, Gly, Ser sau Thr;14370 14375 14380 14385 14390 14395 14400 14405 14410 14415 RO1180Î6B1 Xaa la poziția 53 este Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, sau Met;Xaa la poziția 54 este Arg, Asp, lle, Ser, Val, Thr, Gin, Asn, Lys, His, Ala sau Leu;14420 Xaa la poziția 55 este Arg, Thr, Val, Ser, Leu sau Gly;Xaa la poziția 56 este Pro, Gly, Cys, Ser, Gin, Glu, Arg, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val sau Lys;Xaa la poziția 57 este Asn sau Gly;Xaa la poziția 58 este Leu, Ser, Asp, Arg, Gin, Val sau Cys;14425 Xaa la poziția 59 este Glu, Tyr, His, Leu, Pro sau Arg;Xaa la poziția 60 este Ala, Ser, Pro, Tyr, Asn sau Thr;Xaa la poziția 61 este Phe, Asn, Glu, Pro, Lys, Arg su Ser;Xaa la poziția 62 este Asn, His, Val, Arg, Pro, Thr, Asp sau lle;Xaa la poziția 63 este Arg, Tyr, Trp, Lys, Ser, His, Pro sau Val;14430 Xaa la poziția 64 este Ala, Asn, Pro, Ser sau Lys;Xaa la poziția 65 este Val, Thr, Pro, His, Leu, Phe sau Ser;Xaa la poziția 66 este Lys, lle, Arg, Val, Asn, Glu sau Ser;Xaa la poziția 67 este Ser, Ala, Phe, Val, Gly, Asn, lle, Pro sau His Xaa la poziția 68 este Leu, Val, Trp, Ser, lle, Phe, Thr sau His;14435 Xaa la poziția 69 este Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, sau Leu;Xaa la poziția 70 este Asn, Leu, Val, Trp, Pro sau Ala;Xaa la poziția 71 este Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin,Trp sau Asn;Xaa la poziția 72 este Ser, Glu, Met, Ala, His, Asn, Arg sau Asp;Xaa la poziția 73 este Ala, Glu, Asp, Leu, Ser, Gly, Thr sau Arg;14440 Xaa la poziția 74 este lle, Met, Thr, Pro, Arg, Gly sau Ala;Xaa la poziția 75 este Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin sau Leu;Xaa la poziția 76 este Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, sau Asp;Xaa la poziția 77 este lle, Ser, Arg, Thr sau Leu;Xaa la poziția 78 este Leu, Ala, Ser, Glu, Phe, Gly sau Arg;14445 Xaa la poziția 79 este Lys, Thr, Asn, Met, Arg, lle, Gly sau Asp;Xaa la poziția 80 este Asn, Trp, Val, Gly, Thr, Leu, Glu sau Arg;Xaa la poziția 81 este Leu, Gin, Gly, Ala, Trp, Arg, Val sau Lys;Xaa la poziția 82 este Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, lle, Met sau Val;14450 Xaa la poziția 83 este Pro, Ala, Thr, Trp, Arg sau Met;Xaa la poziția 84 este Cys, Glu, Gly, Arg, Met sau Val;Xaa la poziția 85 este Leu, Asn, Val sau Gin;Xaa la poziția 86 este Pro, Cys, Arg, Ala sau Lys;Xaa la poziția 87 este Leu, Ser, Trp sau Gly;14455 Xaa la poziția 88 este Ala, Lys, Arg, Val sau Trp;Xaa la poziția 89 este Thr, Asp, Cys, Leu, Val, Glu, His, Asn, sau Ser;Xaa la poziția 90 este Ala, Pro, Ser, Thr, Gly, Asp, lle sau Met;Xaa la poziția 91 este Ala, Pro, Ser, Thr, Phe, Leu, Asp sau His;Xaa la poziția 92 este Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, lle sau Leu;14460 Xaa la poziția 93 este Thr, Asp, Ser, Asn, Pro, Ala, Leu sau Arg;Xaa la poziția 94 este Arg, lle, Ser, Glu, Leu, Val, Gin, Lys, His, Ala sau Pro;Xaa la poziția 95 este His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, lle sau Tyr;Xaa la poziția 96 este Pro, Lys, Tyr, Gly, lle sau Thr;14465 Xaa la poziția 97 este lle, Val, Lys, Ala sau Asn;RO 118016 Β1 Xaa la poziția 98 este His, lle, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr sau Pro;Xaa la poziția 99 este lle, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe sau His;Xaa la poziția 100 este Lys, Tyr, Leu, His, Arg, lle, Ser, Gin, sau Pro;Xaa la poziția 101 este Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, lle, Leu sau Gin;Xaa la poziția 102 este Gly, Leu, Glu, Lys, Ser, Tyr sau Pro;Xaa la poziția 103 este Asp sau Ser;Xaa la poziția 104 este Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Phe sau Gly;Xaa la poziția 105 este Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, lle, Asp sau His;Xaa la poziția 106 este Glu, Ser, Ala, Lys, Thr, lle, Gly sau Pro;Xaa la poziția 108 este Arg, Lys, Asp, Leu, Thr, lle, Gin, His, Ser, Ala sau Pro;Xaa la poziția 109 este Arg, Thr, Pro, Glu, Tyr, Leu, Ser sau Gly;Xaa la poziția 110 este Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, Ala sau Trp;Xaa la poziția 111 este Leu, lle, Arg, Asp sau Met;Xaa la poziția 112 este Thr, Val, Gin, Tyr, Glu, His, Ser sau Phe;Xaa la poziția 113 este Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, lle, Val sau Asn;Xaa la poziția 114 este Tyr, Cys, Gis, Ser, Trp, Arg sau Leu;Xaa la poziția 115 este Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp sau Met;Xaa la poziția 116 este Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, sau lle;Xaa la poziția 117 este Thr, Ser, Asn, lle, Trp, Lys sau Pro;Xaa la poziția 118 este Leu, Ser, Pro, Ala, Glu, Cys, Asp sau Tyr;Xaa la poziția 119 este Glu, Ser, Lys, Pro, Leu, Thr, Tyr sau Arg;Xaa la poziția 120 este Asn, Ala, Pro, Leu, His, Val sau Gin;Xaa la poziția 121 este Ala, Ser, lle, Asn, Pro, Lys, Asp sau Gly;Xaa la poziția 122 este Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr sau Cys;Xaa la poziția 123 este Ala, Met, Glu, His, Ser, Pro, Tyr sau Leu;și care, suplimentar, au Met-, care precede aminoacidul din poziția 1;în care aminoacizii de la pozițiile 1 la 14 de la capătul N-terminal pot fi îndepărtați și/sau aminoacizii de la pozițiile 1 la 15 de la capătul C-terminal, pot fi îndepărtați și aminoacizii de la pozițiile 4 la 44 desemnați prin Xaa sunt diferiți de aminoacizii corespunzători interleukinei3 umane native (1-133), R 2 este un factor stimulator de colonie, ales dintre GM-CSF, CSF-1, CSF-G(CSFgranulocitar), C-mpI ligand, M-CSF, eritropoietină (EPO), IL-1, IL-4, IL-2JL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3/flk2, hormonul creșterii umane, factorul de creștere al celulei B, factorul diferențierii celulei B, factorul diferențierii eozinofilului și factorul celulei stem(SCF) în care radicalii X și Y sunt uniți direct sau printr-un linker (L), cu condiția că, dacă X este R 2 , Y nu poate fi R 2 .
- 2Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că R 1 este Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 5 1015 Cys Xaa Xaa Xaa lle Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa 20 2530 Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa 35 4045 Xaa lle Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa 50 5560 14470 14475 14480 14485 14490 14495 14500 14505 14510 RO 118016 Β1 Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu 65 7075 Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala 80 8590 Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa 95 100105 Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa 110 115120 Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala Ile Phe 125130 (Secvența nr.:2) în care Xaa la poziția 17 este Ser, Gly, Asp, Met sau Gin;Xaa la poziția 18 este Asn, His sau Ile;Xaa la poziția 19 este Met sau Ile;Xaa la poziția 21 este Asp sau Glu;Xaa la poziția 23 este Ile, Ala, Leu sau Gly;Xaa la poziția 24 este Ile, Val sau Leu;Xaa la poziția 25 este Thr, His, Gin sau Ala;Xaa la poziția 26 este His sau Ala;Xaa la poziția 29 este Gin, Asn sau Val;Xaa la poziția 30 este Pro, Gly sau Gin;Xaa la poziția 31 este Pro, Asp, Gly sau Gin;Xaa la poziția 32 este Leu, Arg, Gin, Asn, Gly, Ala sau Glu;Xaa la poziția 33 este Pro sau Glu;Xaa la poziția 34 este Leu, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, Ile, Phe, Thr sau Met;Xaa la poziția 35 este Leu, Ala, Asn, Pro, Gin sau Val;Xaa la poziția 37 este Phe, Ser, Pro sau Trp;Xaa la poziția 38 este Asn sau Ala;Xaa la poziția 42 este Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr sau Arg;Xaa la poziția 44 este Asp sau Glu;Xaa la poziția 45 este Gin, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser sau Lys;Xaa la poziția 46 este Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu, His, Ile, Lys, Tyr, Val sau Cys;Xaa la poziția 50 este Glu, Ala, Asn, Ser sau Asp;Xaa la poziția 51 este Asn, Arg, Met, Pro, Ser, Thr sau His;Xaa la poziția 54 este Arg sau Ala;Xaa la poziția 55 este Arg, Thr, Val, Leu sau Gly;Xaa la poziția 56 este Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leu, Thr, Val sau Lys;Xaa la poziția 60 este Ala sau Ser;Xaa la poziția 62 este Asn, Pro, Thr sau Ile;Xaa la poziția 63 este Arg sau Lys;Xaa la poziția 64 este Ala sau Asn;Xaa la poziția 65 este Val sau Thr;Xaa la poziția 66 este Lys sau Arg;Xaa la poziția 67 este Ser, Phe sau His;Xaa la poziția 68 este Leu, Ile, Phe sau His;Xaa la poziția 69 este Gin, Ala, Pro, Thr, Glu, Arg sau Gly;Xaa la poziția 71 este Ala, Pro sau Arg;Xaa la poziția 72 este Ser, Glu, Arg sau Asp;RO 118016 Β1 Xaa la poziția 73 este Ala sau Leu;Xaa la poziția 76 este Ser, Val, Ala, Asn, Trp, Glu, Pro sau Gly;Xaa la poziția 77 este Ile sau Leu;Xaa la poziția 79 este Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, sau Asp;Xaa la poziția 80 este Asn, Gly, Glu sau Arg;Xaa la poziția 82 este Leu, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr sau Val;Xaa la poziția 83 este Pro sau Thr;Xaa la poziția 85 este Leu sau Val;Xaa la poziția 87 este Leu sau Ser;Xaa la poziția 88 este Ala sau Trp;Xaa la poziția 91 este Ala sau Pro;Xaa la poziția 93 este Thr, Asp, Ser, Pro, Ala, Leu sau Arg;Xaa la poziția 95 este His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser sau Tyr;Xaa la poziția 96 este Pro sau Tyr;Xaa la poziția 97 este Ile sau Val;Xaa la poziția 98 este His, Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gin, Leu, Lys, Met, Ser, Tyr, Val sau Pro;Xaa la poziția 99 este Ile, Leu sau Val;Xaa la poziția 100 este Lys, Arg, Ile, Gin, Pro sau Ser;Xaa la poziția 101 este Asp, Pro, Met, Lys, His, Thr, Pro, Asn,Ile, Leu sau Tyr;Xaa la poziția 104 este Trp sau Leu;Xaa la poziția 105 este Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp sau His;Xaa la poziția 106 este Glu sau Gly;Xaa la poziția 108 este Arg, Ala sau Ser;Xaa la poziția 109 este Arg, Thr, Glu, Leu sau Ser;Xaa la poziția 112 este Thr, Val sau Gin;Xaa la poziția 114 este Tyr sau Trp;Xaa la poziția 115 este Leu sau Ala;Xaa la poziția 116 este Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr sau Ile;Xaa la poziția 117 este Thr sau Ser;Xaa la poziția 120 este Asn, Pro, Leu, His, Val sau Gin;Xaa la poziția 121 este Ala, Ser, Ile, Asn, Pro, Asp sau Gly;Xaa la poziția 122 este Gin, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr sau Cys;Xaa la poziția 123 este Ala, Met, Glu, His, Ser, Pro, Tyr sau Leu;și care, suplimentar, au Met-, care precede aminoacidul din poziția 1;în care aminoacizii de la pozițiile 1 la 14 de la capătul N-terminal pot fi îndepărtați și/sau aminoacizii de la pozițiile 1 la 15, de la capătul C-terminal, pot fi îndepărtați și aminoacizii de la pozițiile 4 la 35, desemnați prin Xaa, sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (1-133).
- 3Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că, R 2 este Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 5 1015 Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa 20 2530 Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa 35 4045 Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala 50 5560 14565 14570 14575 14580 14585 14590 14595 14600 14605 14610 RO 118016 Β1 Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu 65 7075 Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala 80 8590 Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa 95 100105 Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa 110 115120 Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala Ile Phe 125130 (Secvența nr.:3) în care Xaa la poziția 17 este Ser, Gly, Asp, Met sau Gin;Xaa la poziția 18 este Asn, His sau Ile;Xaa la poziția 23 este Ile, Ala, Leu sau Gly;Xaa la poziția 25 este Thr, His sau Gin;Xaa la poziția 26 este His sau Ala;Xaa la poziția 29 este Gin sau Val;Xaa la poziția 30 este Pro sau Gly;Xaa la poziția 32 este Leu, Arg, Asn sau Ala;Xaa la poziția 34 este Leu, Val, Ser, Ala, Arg, Gin, Glu, Ile, Phe, Thr sau Met;Xaa la poziția 35 este Leu, Ala, Asn sau Pro;Xaa la poziția 38 este Asn sau Ala;Xaa la poziția 42 este Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr sau Arg;Xaa la poziția 45 este Gin, Val, Met, Leu, Thr, Ala, Asn, Glu, sau Lys;Xaa la poziția 46 este Asp, Phe, Ser, Gin, Glu, His, Val sau Thr;Xaa la poziția 50 este Glu, Asn, Ser sau Asp;Xaa la poziția 51 este Asn, Arg, Pro, Thr sau His;Xaa la poziția 55 este Arg, Leu sau Gly;Xaa la poziția 56 este Pro, Gly, Ser, Ala, Asn, Val, Leu sau Gin;Xaa la poziția 62 este Asn, Pro sau Thr;Xaa la poziția 64 este Ala sau Asn;Xaa la poziția 65 este Val sau Thr;Xaa la poziția 67 este Ser sau Phe;Xaa la poziția 68 este Leu sau Phe;Xaa la poziția 69 este Gin, Ala, Glu sau Arg;Xaa la poziția 76 este Ser, Val, Asn, Pro sau Gly;Xaa la poziția 77 este Ile sau Leu;Xaa la poziția 79 este Lys, Asn, Met, Arg, Ile sau Gly;Xaa la poziția 80 este Asn, Gly, Glu, sau Arg;Xaa la poziția 82 este Leu, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr sau Val;Xaa la poziția 87 este Leu sau Ser;Xaa la poziția 88 este Ala sau Trp;Xaa la poziția 91 este Ala sau Pro;Xaa la poziția 93 este Thr, Asp sau Ala;Xaa la poziția 95 este His, Pro, Arg, Val, Gly, Asn, Ser sau Tyr;Xaa la poziția 98 este His, Ile, Asn, Ala, Thr, Leu, Gin, Glu, Lys, Met, Ser, Tyr, Val sau Pro;Xaa la poziția 99 este Ile sau Leu;RO 118016 Β1 Xaa la poziția 100 este Lys sau Arg;Xaa la poziția 101 este Asp, Pro, Met, Lys, Thr, His, Pro, Asn, lle, Leu sau Tyr;Xaa la poziția 105 este Asn, Pro, Ser, lle sau Asp;Xaa la poziția 108 este Arg, Ala sau Ser;Xaa la poziția 109 este Arg, Thr, Glu, Leu sau Ser;Xaa la poziția 112 este Thr sau Gin;Xaa la poziția 116 este Lys, Val, Trp, Ala, His, Phe, Tyr sau lle;Xaa la poziția 117 este Thr sau Ser;Xaa la poziția 120 este Asn, Pro, Leu, His, Val sau Gin;Xaa la poziția 121 este Ala, Ser, lle, Pro sau Asp;Xaa la poziția 122 este Gin, Met, Trp, Phe, Pro, His, lle sau Tyr;Xaa la poziția 123 este Ala, Met, Glu, Ser sau Leu;
- 4Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că, în R, aminoacizii care diferă de reziduul corespunzător al IL-3 umane native sunt selectați din grupul constând din:Xaa la poziția 42 este Gly, Asp, Ser, lle, Leu, Met, Tyr sau Arg;Xaa la poziția 45 este Gin, Val, Met sau Asn;Xaa la poziția 46 este Asp, Ser, Gin, His sau Val;Xaa la poziția 50 este Glu sau Asp;Xaa la poziția 51 este Asn, Pro sau Thr;Xaa la poziția 62 este Asn sau Pro;Xaa la poziția 76 este Ser sau Pro;Xaa la poziția 82 este Leu, Trp, Asp, Asn, Glu, His, Phe, Ser, Tyr sau Val;Xaa la poziția 95 este His, Arg, Thr, Asn sau Ser;Xaa la poziția 98 este His, lle, Leu, Ala, Gin, Lys, Met, Ser,Tyr sau Val;Xaa la poziția 100 este Lys sau Arg;Xaa la poziția 101 este Asp, Pro, His, Asn, lle sau Leu;Xaa la poziția 105 este Asn sau Pro;Xaa la poziția 108 este Arg, Ala sau Ser;Xaa la poziția 116 este Lys, Val, Trp, Ala, His, Phe sau Tyr;Xaa la poziția 121 este Ala sau lle;Xaa la poziția 122 este Gin, lle și Xaa la poziția 123 este Ala, Met sau Glu;
- 5Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că, R, este Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 5 1015 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa 20 2530 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 4045 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 5560 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 7075 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 8590 Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100105 Xaa Xaa Xaa Xaa Gin Gin 110 14665 14670 14675 14680 14685 14690 14695 14700 14705 14710 RO 118016 Β1 (Secvența nr.:4) în care Xaa la poziția 3 este Ser, Lys, Gly, Asp, Met, Gin sau Arg;Xaa la poziția 4 este Asn, His, Leu, lle, Phe, Arg sau Gin;14715 Xaa la poziția 5 este Met, Phe, lle, Arg, Gly, Ala sau Cys;Xaa la poziția 6 este lle, Cys, Gin, Glu, Arg, Pro sau Ala;Xaa la poziția 7 este Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser sau Val;Xaa la poziția 8 este Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, 14720 Gin, Leu, Val sau Gly;Xaa la poziția 9 este lle, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser sau Arg;Xaa la poziția 10 este lle, Gly, Val, Arg, Ser, Phe sau Leu;Xaa la poziția 11 este Thr, His, Gly, Gin, Arg, Pro sau Ala;14725 Xaa la poziția 12 este Thr, Phe, Gly, Arg, Ala sau Trp;Xaa la poziția 13 este Leu, Gly, Arg, Thr, Ser sau Ala;Xaa la poziția 14 este Lys, Arg, Leu, Gin, Gly, Pro, Val sau Trp;Xaa la poziția 15 este Gin, Asn, Leu, Pro, Arg sau Val;Xaa la poziția 16 este Pro, His, Thr, Gly, Asp, Gin, Ser, Leu sau Lys;14730 Xaa la poziția 17 este Pro, Asp, Gly, Ala, Arg, Leu sau Gin;Xaa la poziția 18 este Leu, Val, Arg, Gin, Asn, Gly, Ala sau Glu;Xaa la poziția 19 este Pro, Leu, Gin, Ala, Thr sau Glu;Xaa la poziția 20 este Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, lle sau Met;14735 Xaa la poziția 21 este Leu, Ala, Gly, Asn, Pro, Gin sau Val;Xaa la poziția 22 este Asp, Leu sau Val;Xaa la poziția 23 este Phe, Ser, Pro, Trp sau lle;Xaa la poziția 24 este Asn sau Ala;Xaa la poziția 26 este Leu, Trp sau Arg;14740 Xaa la poziția 27 este Asn, Cys, Arg, Leu, His, Met sau Pro;Xaa la poziția 28 este Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu Val, Glu, Phe, Tyr, lle sau Met;Xaa la poziția 29 este Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Gly sau Ser;Xaa la poziția 30 este Asp, Ser, Leu, arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala sau Pro;14745 Xaa la poziția 31 este Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, Ser, Ala, lle, Glu, His sau Trp. Xaa la poziția 32 este Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val sau Gly;Xaa la poziția 33 este lle, Gly, Val, Ser, Arg, Pro sau His;14750 Xaa la poziția 34 este Leu, Ser, Cys, Arg, lle, His, Phe, Glu, Lys, Thr, Ala, Met, Val sau Asn;Xaa la poziția 35 este Met, Arg, Ala, Gly, Pro, Asn, His sau Asp;Xaa la poziția 36 este Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, lle, Val, His, Phe, Met sau Gin;Xaa la poziția 37 este Asn, Arg, Met, Pro, Ser, Thr sau His;14755 Xaa la poziția 38 este Asn, His, Arg, Leu, Gly, Ser sau Thr;Xaa la poziția 39 este Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, sau Met;Xaa la poziția 40 este Arg, Asp, lle, Ser, Val, Thr, Gin, Asn, Lys, His, Ala sau Leu;Xaa la poziția 41 este Arg, Thr, Val, Ser, Leu sau Gly;Xaa la poziția 42 este Pro, Gly, Cys, Ser, Gin, Glu, Arg, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val 14760 sau Lys;RO 118016 Β1 Xaa la poziția 43 este Asn sau Gly;Xaa la poziția 44 este Leu, Ser, Asp, Arg, Gin, Val sau Cys;Xaa la poziția 45 este Glu, Tyr, His, Leu, Pro sau Arg;Xaa la poziția 46 este Ala, Ser, Pro, Tyr, Asn sau Thr;Xaa la poziția 47 este Phe, Asn, Glu, Pro, Lys, Arg sau Ser;Xaa la poziția 48 este Asn, His, Val, Arg, Pro, Thr, Asp sau lle;Xaa la poziția 49 este Arg, Tyr, Trp, Lys, Ser, His, Pro sau Val;Xaa la poziția 50 este Ala, Asn, Pro, Ser sau Lys;Xaa la poziția 51 este Val, Thr, Pro, His, Leu, Phe sau Ser;Xaa la poziția 52 este Lys, lle, Arg, Val, Asn, Glu sau Ser;Xaa la poziția 53 este Ser, Ala, Phe, Val, Gly, Asn, lle, Pro, sau His;Xaa la poziția 54 este Leu, Val, Trp, Ser, lle, Phe, Thr sau His;Xaa la poziția 55 este Gin, Ala, Pro, Thr, Glu, Arg, Trpn Gly, sau Leu;Xaa la poziția 56 este Asn, Leu, Val, Trp, Pro sau Ala;Xaa la poziția 57 este Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp sau Asn;Xaa la poziția 58 este Ser, Glu, Met, Ala, His, Asn, Arg sau Asp;Xaa la poziția 59 este Ala, Glu, Asp, Leu, Ser, Gly, Thr sau Arg;Xaa la poziția 60 este lle, Met, Thr, Pro, Arg, Gly sau Ala;Xaa la poziția 61 este Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin sau Leu;Xaa la poziția 62 este Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, sau Asp;Xaa la poziția 63 este lle, Ser, Arg, Thr sau Leu;Xaa la poziția 64 este Leu, Ala, Ser, Glu, Phe, Gly sau Arg;Xaa la poziția 65 este Lys, Thr, Asn, Met, Arg, lle, Gly sau Asp;Xaa la poziția 66 este Asn, Trp, Val, Gly, Thr, Leu, Glu sau Arg;Xaa la poziția 67 este Leu, Gin, Gly, Ala, Trp, Arg, Val sau Lys;Xaa la poziția 68 este Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, lle, Met sau Val;Xaa la poziția 69 este Pro, Ala, Thr, Trp, Arg sau Met;Xaa la poziția 70 este Cys, Glu, Gly, Arg, Met sau Val;Xaa la poziția 71 este Leu, Asn, Val sau Gin;Xaa la poziția 72 este pro, Cys, Arg, Ala sau Lys;Xaa la poziția 73 este Leu, Ser, Trp sau Gly;Xaa la poziția 74 este Ala, Lys, Arg, Val sau Trp;Xaa la poziția 75 este Thr, Asp, Cys, Leu, Val, Glu, His, Asn sau Ser;Xaa la poziția 76 este Ala, Pro, Ser, Thr, Gly, Asp, lle sau Met;Xaa la poziția 77 este Ala, Pro, Ser, Thr, Phe, Leu, Asp sau His;Xaa la poziția 78 este Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, lle sau Leu;Xaa la poziția 79 este Thr, Asp, Ser, Asn, Pro, Ala, Leu sau Arg;Xaa la poziția 80 este Arg, lle, Ser, Glu, Leu, Val, Gin, Lys, His, Ala sau Pro;Xaa la poziția 81 este His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, lle sau Tyr;Xaa la poziția 82 este Pro, Lys, Tyr, Gly, lle sau Thr;Xaa la poziția 83 este lle, Val, Lys, Ala sau Asn;Xaa la poziția 84 este His, lle, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr sau Pro;Xaa la poziția 85 este lle, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe sau His;Xaa la poziția 86 este Lys, Tyr, Leu, His, Arg, lle, Ser, Gin, sau Pro;Xaa la poziția 87 este Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, lle, Leu sau Gin;14765 14770 14775 14780 14785 14790 14795 14800 14805 RO 118016 Β1 Xaa la poziția 88 este Gly, Leu, Glu, Lys, Ser, Tyr sau Pro;Xaa la poziția 89 este Asp sau Ser;Xaa la poziția 90 este Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu Gin, Lys, Ala, Phe sau Gly;Xaa la poziția 91 este Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, lle, Asp sau His;Xaa la poziția 92 este Glu, Ser, Ala, Lys, Thr, lle, Gly sau Pro;Xaa la poziția 94 este Arg, Lys, Asp, Leu, Thr, lle, Gin, His, Ser, Ala sau Pro;Xaa la poziția 95 este Arg, Thr, Pro, Glu, Tyr, Leu, Ser sau Gly;Xaa la poziția 96 este Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, Ala sau Trp;Xaa la poziția 97 este Leu, lle, Arg, Asp sau Met;Xaa la poziția 98 este Thr, Val, Gin, Tyr, Glu, His, Ser sau Phe;Xaa la poziția 99 este Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, lle, Val sau Asn;Xaa la poziția 100 este Tyr, Cys, His, Ser, Trp, Arg sau Leu;Xaa la poziția 101 este Leu, Asn, Val, Pro, Arg, Ala, His, Thr,Trp sau Met;Xaa la poziția 102 este Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin sau lle;Xaa la poziția 103 este Thr, Ser, Asn, lle, Trp, Lys sau Pro;Xaa la poziția 104 este Leu, Ser, Pro, Ala, Glu, Cys, Asp sau Tyr;Xaa la poziția 105 este Glu, Ser, Lys, Pro, Leu, Thr, Tyr sau Arg;Xaa la poziția 106 este Asn, Ala, Pro, Leu, His, Val sau Gin;Xaa la poziția 107 este Ala, Ser, lle, Asn, Pro, Lys, Asp sau Gly;Xaa la poziția 108 este Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr sau Cys;Xaa la poziția 109 este Ala, Met, Glu, His, Ser, Pro, Tyr sau Leu;și care, suplimentar, au Met- sau Met-Ala- care precede aminoacidul din poziția 1;în care aminoacizii de la pozițiile 1 la 14 de la capătul N-terminal și/sau aminoacizii de la pozițiile 1 la 15 de la capătul C-terminal pot fi îndepărtați și aminoacizii de la pozițiile 4 la 44 desemnați prin Xaa sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (1-133), R 2 este II-3, o variantă II-3 sau un factor stimulator de colonie ales dintre GM-CSF, CSF-1, CSF-G(CSF-granulocitar), C-mpl ligand, M-CSF, eritropoeietină (EPO), IL-1, IL-4, IL-2.IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3/flk2, hormonul de creștere umană, factorul creșterii celulei B, factorul diferențierii celulei B, factorul diferențierii eozinofilului și factorul celulei stem(SCF);și L este un linker capabil de legare a radicalului X la Y.
- 6Proteină de fuziune, conform revendicării 5, caracterizată prin aceea că, R, este Asn Cys Xaa Xaa Xaa lle Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa 5 1015 Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa 20 2530 Xaa Xaa lle Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu 35 4045 Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa lle 50 5560 Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr 65 7075 Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa 80 8590 Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu 95 100105 Xaa Xaa Xaa Xaa Gin Gin 110 RO 118016 Β1 Secvența nr.:5 în care Xaa la poziția 3 este Ser, Lys, Gly, Asp, Met sau Gin;Xaa la poziția 4 este Asn, His sau Ile;Xaa la poziția 5 este Met sau Ile;Xaa la poziția 7 este Asp sau Glu;Xaa la poziția 9 este Ile, Ala, Leu sau Gly;Xaa la poziția 10 este Ile, Val sau Leu;Xaa la poziția 11 este Thr, His, Gin sau Ala;Xaa la poziția 12 este His sau Ala;Xaa la poziția 15 este Gin, Asn sau Val;Xaa la poziția 16 este Pro, Gly sau Gin;Xaa la poziția 17 este Pro, Asp, Gly sau Gin;Xaa la poziția 18 este Leu, Arg, Gin, Asn, Gly, Ala sau Glu;Xaa la poziția 19 este Pro sau Glu;Xaa la poziția 20 este Leu, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, Ile, Phe, Thr sau Met;Xaa la poziția 21 este Leu, Ala, Asn, Pro, Gin sau Val;Xaa la poziția 23 este Phe, Ser, Pro sau Trp;Xaa la poziția 24 este Asn sau Ala;Xaa la poziția 28 este Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Ile sau Met;Xaa la poziția 30 este Asp sau Glu;Xaa la poziția 31 este Gin, Val, Met, Leu, Thr, Ala, Asp, Glu, Ser sau Lys;Xaa la poziția 32 este Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu,His, Ile, Lys, Tyr, Val sau Cys;Xaa la poziția 36 este Glu, Ala, Asn, Ser sau Asp;Xaa la poziția 40 este Arg sau Ala;Xaa la poziția 41 este Arg, Thr, Val, Leu sau Gly;Xaa la poziția 42 este Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leu, Thr, Val sau Lys;Xaa la poziția 46 este Ala sau Ser;Xaa la poziția 48 este Asn, Pro, Thr sau Ile;Xaa la poziția 49 este Arg sau Lys;Xaa la poziția 50 este Ala sau Asn;Xaa la poziția 51 este Val sau Thr;Xaa la poziția 52 este Lys sau Arg;Xaa la poziția 53 este Ser, Phe sau His;Xaa la poziția 54 este Leu, Ile, Phe sau His;Xaa la poziția 55 este Gin, Ala, Pro, Thr, Glu, Arg sau Gly;Xaa la poziția 57 este Ala, Pro sau Arg;Xaa la poziția 58 este Ser, Glu, Arg sau Asp;Xaa la poziția 59 este Ala sau Leu;Xaa la poziția 62 este Ser, Val, Ala, Asn, Glu, Pro sau Gly;Xaa la poziția 63 este Ile sau Leu;Xaa la poziția 65 este Lys, Thr, Gly, Asn, Met, Arg, Ile, sau Asp;Xaa la poziția 66 este Asn, Gly, Glu sau Arg;Xaa la poziția 68 este Leu, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr sau Val;Xaa la poziția 69 este Pro sau Thr;Xaa la poziția 71 este Leu sau Val;Xaa la poziția 73 este Leu sau Ser;Xaa la poziția 74 este Ala sau Trp;14860 14865 14870 14875 14880 14885 14890 14895 14900 14905 RO 118016 Β1 Xaa la poziția 77 este Ala sau Pro;Xaa la poziția 79 este Thr, Asp, Ser, Pro, Ala, Leu sau Arg;Xaa la poziția 81 este His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser sau Thr;Xaa la poziția 82 este Pro sau Tyr;Xaa la poziția 83 este Ile sau Val;Xaa la poziția 84 este His, Ile, Asn, Leu, Ala, Thr, Arg, Gin, Lys, Met, Ser, Tyr, Val sau Pro;Xaa la poziția 85 este Ile, Leu sau Val;Xaa la poziția 86 este Lys, Arg, Ile, Gin, Pro sau Ser;Xaa la poziția 87 este Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu sau Tyr;Xaa la poziția 90 este Trp sau Leu;Xaa la poziția 91 este Asn, Pro, Ala, Ser, Trp, Gin, Tyr, Leu, Lys, Ile, Asp sau His;Xaa la poziția 92 este Glu sau Gly;Xaa la poziția 94 este Arg, Ala sau Ser;Xaa la poziția 96 este Arg, Thr, Glu, Leu sau Ser;Xaa la poziția 98 este Thr, Val sau Gin;Xaa la poziția 100 este Tyr sau Trp;Xaa la poziția 101 este Leu sau Ala;Xaa la poziția 102 este Lys, Thr, Val, trp, Ser, Ala, His, Met, Phe, Tyr sau Ile;Xaa la poziția 103 este Thr sau Ser;Xaa la poziția 106 este Asn, Pro, Leu, His, Val sau Gin;Xaa la poziția 107 este Ala, Ser, Ile, Asn, Pro, Asp sau Gly;Xaa la poziția 108 este Gin, Ser, Met, Trp, Arg, Phe, Pro sau His, Ile, Tyr, Cys;Xaa la poziția 109 este Ala, Met, Glu, His, Ser, Pro, Tyr sau Leu;și care, suplimentar, au Met- sau Met-Ala-, care precede aminoacidul din poziția 1;în care aminoacizii de la pozițiile 1 la 14, de la capătul N-terminal pot fi îndepărtați și/sau aminoacizii din pozițiile 1 la 15, de la capătul C-terminal, pot fi îndepărtați și aminoacizii de la pozițiile 4 la 35, desemnați prin Xaa, sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (1-133).
- 7Proteină de fuziune, conform revendicării 5, caracterizată prin aceea că R, este Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa 5 1015 Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp 20 2530 Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu 35 4045 Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile 50 5560 Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr 65 7075 Ala Xaa Pro Xaa Arg Xaa Pro Ile Phe Xaa Xaa Xaa Gly Asp Trp 80 8590 Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu 95 100105 Xaa Xaa Xaa Xaa Gin Gin 110 Secvența nr.;6 în care Xaa la poziția 3 este Ser, Gly, Asn sau Gin;Xaa la poziția 4 este Asn, His sau Ile;Xaa la poziția 9 este Ile, Ala, Leu sau Gly;RO 118016 Β1 Xaa la poziția 11 este Thr, His sau Gin;Xaa la poziția 12 este His sau Ala;Xaa la poziția 15 este Gin sau Asn;Xaa la poziția 16 este Pro sau Gly;Xaa la poziția 18 este Leu, Arg, Asn sau Ala;Xaa la poziția 20 este Leu, Val, Ser, Ala, Arg, Gin, Glu, lle, Phe, Thr sau Met;Xaa la poziția 21 este Leu, Ala, Asn sau Pro;Xaa la poziția 24 este Asn sau Ala;Xaa la poziția 28 este Gly, Asp, Ser, Ala, Asn, lle, Leu, Met, Tyr sau Arg;Xaa la poziția 31 este Gin, Val, Met, Leu, Ala, Asn, Glu sau Lys;Xaa la poziția 32 este Asp, Phe, Ser, Ala, Gin, Glu, His, Val, sau Thr;Xaa la poziția 36 este Glu, Asn, Ser sau Asp;Xaa la poziția 37 este Asn, Arg, Pro, Thr sau His;Xaa la poziția 41 este Arg, Leu sau Gly;Xaa la poziția 42 este Pro, Gly, Ser, Ala, Asn, Val, Leu sau Gin;Xaa la poziția 48 este Asn, Pro sau Thr;Xaa la poziția 50 este Ala sau Asn;Xaa la poziția 51 este Val sau Thr;Xaa la poziția 53 este Ser sau Phe;Xaa la poziția 54 este Leu sau Phe;Xaa la poziția 55 este Gin, Ala, Glu sau Arg;Xaa la poziția 62 este Ser, Val, Asn, Pro sau Gly;Xaa la poziția 63 este lle sau Leu;Xaa la poziția 65 este Lys, Asn, Met, Arg, lle sau Gly;Xaa la poziția 66 este Asn, Gly, Glu sau Arg;Xaa la poziția 68 este Leu, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr sau Val;Xaa la poziția 73 este Leu sau Ser;Xaa la poziția 74 este Ala sau Trp;Xaa la poziția 77 este Ala sau Pro;Xaa la poziția 79 este Thr, Asp sau Ala;Xaa la poziția 81 este His, Pro, Arg, Val, Gly, Asn, Ser sau Thr;Xaa la poziția 84 este His, lle, Asn, Ala, Thr, Arg, Gin, Glu, Lys, Met, Ser, Tyr, Val sau Leu;Xaa la poziția 85 este lle sau Leu;Xaa la poziția 86 este Lys sau Arg;Xaa la poziția 87 este Asp, Pro, Met, Lys, His, Asn, lle, Leu, sau Tyr;Xaa la poziția 91 este Asn, Pro, Ser, lle sau Asp;Xaa la poziția 94 este Arg, Ala sau Ser;Xaa la poziția 95 este Arg, Thr, Glu, Leu sau Ser;Xaa la poziția 98 este Thr sau Gin;Xaa la poziția 102 este Lys, Val, Trp sau lle;Xaa la poziția 103 este Thr, Ala, His, Phe sau Ser;Xaa la poziția 106 este Asn, Pro, Leu, His, Val sau Gin;Xaa la poziția 107 este Ala, Ser, lle, Pro sau Asp;Xaa la poziția 108 este Gin, Met, Trp, Phe, Pro, His, lle sau Tyr;Xaa la poziția 109 este Ala, Met, Glu, Ser sau Leu;care, suplimentar, au Met- sau Met-Ala- care precede aminoacidul din poziția 1;în care aminoacizii de la pozițiile 1 la 14 de la capătul N-terminal pot fi îndepărtați și/sau aminoacizii de la pozițiile 1 la 15 de la capătul C-terminal pot fi îndepărtați și aminoacizii de la pozițiile 4 la 26 desemnați prin Xaa sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (1-133) 14960 14965 14970 14975 14980 14985 14990 14995 15000 15005 RO 118016 Β1
- 8Proteină de fuziune, conform revendicării 8, caracterizată prin aceea că R, este (Met) m -Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr 1 510 Ser Trp Val Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa lle 1520 Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa 25 3035 Xaa Asn Leu Asn Xaa Glu Asp Xaa Asp lle Leu Xaa Glu 40 4550 Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa 5560 Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa lle Glu Xaa 65 7075 lle Leu Xaa Asn Leu Xaa Pro Cys Xaa Pro Xaa Xaa Thr 8085 Ala Xaa Pro Xaa Arg Xaa Pro lle Xaa lle Xaa Xaa Gly 90 95100 Asp Thr Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu 105 40115 Xaa Xaa Leu Glu Xaa Ala Gin Xaa Gin Gin Thr Thr Leu 120125 Ser Leu Ala lle Phe 130 (Secvența nr. 7) în care m este 0 sau 1 Xaa la poziția 18 este Asn, lle;Xaa la poziția 19 este Met, Ala sau lle;Xaa la poziția 20 este lle, Pro sau Ser;Xaa la poziția 23 este lle, Ala sau Leu;Xaa la poziția 25 este Thr sau His;Xaa la poziția 29 este Gin, Arg, Val sau lle;Xaa la poziția 32 este Leu, Ala, Asn sau Arg;Xaa la poziția 34 este Leu sau Ser;Xaa la poziția 37 este Phe, Pro sau Ser;Xaa la poziția 38 este Asn sau Ala;Xaa la poziția 42 este Gly, Ala, Ser, Asp sau Asn;Xaa la poziția 45 este Gin, Val sau Met;Xaa la poziția 46 este Asp sau Ser;Xaa la poziția 49 este Met, lle, Leu sau Asp;Xaa la poziția 50 este Glu sau Asp;Xaa la poziția 51 este Asn, Arg sau Ser;Xaa la poziția 55 este Arg, Leu sau Thr;Xaa la poziția 56 este Pro sau Ser;Xaa la poziția 59 este Glu sau Leu;Xaa la poziția 60 este Ala sau Ser;Xaa la poziția 62 este Asn, Val sau Pro;Xaa la poziția 63 este Arg sau His;Xaa la poziția 65 este Val sau Ser;RO 118016 Β1 Xaa la poziția 67 este Ser, Asn, His sau Gin;Xaa la poziția 69 este Gin sau Glu;Xaa la poziția 73 este Ala sau Gly;Xaa la poziția 76 este Ser, Ala sau Pro;Xaa la poziția 79 este Lys, Arg sau Ser;Xaa la poziția 82 este Leu, Glu, Val sau Trp;Xaa la poziția 85 este Leu sau Val;Xaa la poziția 87 este Leu, Ser sau Tyr;Xaa la poziția 88 este Ala sau Trp;Xaa la poziția 91 este Ala sau Pro;Xaa la poziția 93 este Pro sau Ser;Xaa la poziția 95 este His sau Thr;Xaa la poziția 98 este His, Ile sau Thr;Xaa la poziția 100 este Lys sau Arg;Xaa la poziția 101 este Asp, Ala sau Met;Xaa la poziția 105 este Asn sau Glu;Xaa la poziția 109 este Arg, Glu sau Leu;Xaa la poziția 112 este Thr sau Gin;Xaa la poziția 116 este Lys, Val, Trp sau Ser;Xaa la poziția 117 este Thr sau Ser;Xaa la poziția 120 este Asn, Gin sau His;Xaa la poziția 123 este Ala sau Glu;cu condiția ca aminoacizii de la pozițiile 4 la 44 desemnați prin Xaa sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (1-133).
- 9Proteină de fuziune, conform revendicării 5, caracterizată prin aceea că R, este (Met m -Ala n ) p -Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa Ile 1 510 Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa 1520 Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu Xaa Glu 25 3035 Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa 40 4550 Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa 5560 Ile Leu Xaa Asn Xaa Xaa Pro Cys Xaa Pro Xaa Xaa Thr 65 7075 Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Ile Xaa Xaa Gly 8085 Asp Thr Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu 90 95100 Xaa Xaa Leu Glu Xaa Ala Gin Xaa Gin Gin 105 110 (Secvența Nr.:8) în care m este 0 sau 1;n este 0 sau 1;Peste 0 sau 1;Xaa la poziția 4 este Asn sau Ile;Xaa la poziția 5 este Met, Ala sau Ile;Xaa la poziția 6 este Ile, Pro sau Leu;15060 15065 15070 15075 15080 15085 15090 15095 15100 RO 118016 Β1 Xaa la poziția 9 este lle, Ala sau Leu;Xaa la poziția 11 este Thr sau His;Xaa la poziția 15 este Gin, Arg, Val sau lle;Xaa la poziția 18 este Leu, Ala, Asn sau Arg;Xaa la poziția 20 este Leu sau Ser;Xaa la poziția 23 este Phe, Pro sau Ser;Xaa la poziția 24 este Asn sau Ala;Xaa la poziția 28 este Gly, Ala, Ser, Asp sau Asn;Xaa la poziția 31 este Gin, Val sau Met;Xaa la poziția 32 este Asp sau Ser;Xaa la poziția 35 este Met, lle, Leu sau Asp;Xaa la poziția 36 este Glu sau Asp;Xaa la poziția 37 este Asn, Arg sau Ser;Xaa la poziția 41 este Arg, Leu sau Thr;Xaa la poziția 42 este Pro sau Ser;Xaa la poziția 45 este Glu sau Leu;Xaa la poziția 46 este Ala sau Ser;Xaa la poziția 48 este Asn, Val sau Pro;Xaa la poziția 49 este Arg sau His, Xaa la poziția 51 este Val sau Ser;Xaa la poziția 53 este Ser, Asn, His sau Gin;Xaa la poziția 55 este Gin sau Glu;Xaa la poziția 59 este Ala sau Gly Xaa la poziția 62 este Ser, Ala sau Pro;Xaa la poziția 65 este Lys, Arg sau Ser;Xaa la poziția 67 este Leu, Gin sau Val;Xaa la poziția 68 este Leu, Glu, Val sau Trp;Xaa la poziția 71 este Leu sau Val;Xaa la poziția 73 este Leu, Ser sau Tyr;Xaa la poziția 74 este Ala sau Trp;Xaa la poziția 77 este Ala sau Pro;Xaa la poziția 79 este Pro sau Ser;Xaa la poziția 81 este His sau Thr;Xaa la poziția 84 este His, lle sau Thr;Xaa la poziția 86 este Lys sau Arg;Xaa la poziția 87 este Asp, Ala sau Met;Xaa la poziția 91 este Asn sau Glu;Xaa la poziția 95 este Arg, Glu sau Leu;Xaa la poziția 98 este Thr sau Gin;Xaa la poziția 102 este Lys, Val, Trp sau Ser;Xaa la poziția 103 este Thr sau Ser;Xaa la poziția 106 este Asn, Gin sau His;Xaa la poziția 109 este Ala sau Glu;cu condiția ca aminoacizii de la pozițiile 4 la 44 desemnați prin Xaa sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (15-125). RO 118016 Β1
- 10Proteină de fuziune, conform revendicării 5, caracterizată prin aceea că R 1 este Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu 15150 RO 118016 Β1 Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Asn Cys Ser Asn Met ile Asp Glu Ile Ile Thr His Leu Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu RO 118016 Β1 Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin Gin [Secv. nr.:14] 15220 Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu [Secv. nr.:15] 15245 Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu 15260 RO 118016 Β1 Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu [Secv. nr.: 19] Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu [Secv. nr.: 20] Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu [Secv. nr.: 21] Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu RO 118016 Β1 [Secv. nr.: 22] 15320 Asn Cys Ser lle Met Xle Asp Glu lle lle His His Leu [Secv. nr.: 23] 15325 15330 Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu [Secv. nr.: 24] 15345 15350 RO 118016 Β1 Gin [Secv. nr.: 25] RO 118016 Β1 15430 15435 15440 RO 118016 Β1 Asn Ser Glu Asp Met Asp lle Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Val RO 118016 Β1 Gin [Secv. nr.: 39] 15525 Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp lle Leu Met Asp Arg Asn Leu Arg Leu Ser Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu 15530 Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro RO 118016 Β1 Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. nr.: 42] Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val Asp Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. nr.: 43] Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu RO 118016 Β1 Asn Asp Glu Asp Met Ser Ile Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe val Arg Ala val Lys Asn Leu 15595 Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. nr.: 45] Met Ala Tyr Pro Glu Thr Asp Tyr Lys Asp Asp Asp AspLys Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His LeuLys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala15605 Glu Asp Val Asp Ile Leu Met Glu Arg Asn Leu Arg LeuPro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu GluAsn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin ProCys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile15610 Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. nr.: 46] 15615 15620 RO 118016 Β1
- 11Proteină de fuziune, conform revendicării 10, caracterizată prin aceea că R 1 are formula:Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp lle Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro lle lle lle Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin (SECV. ID NR.: 30)
- 12Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că R 2 este G-CSF sau GM-CSF.
- 13Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că este selectată dintre:SECV. ID NR. 121;SECV. ID NR. 122;SECV. ID NR. 123;SECV. ID NR. 124;SECV. ID NR. 125;SECV. ID NR. 126;SECV. ID NR. 127;SECV. ID NR. 128;SECV. ID NR. 129;SECV. ID NR. 130;SECV. ID NR. 131;SECV. ID NR. 132;SECV. ID NR. 133;SECV. ID NR. 134;SECV. ID NR. 135;SECV. ID NR. 136;SECV. ID NR. 137;SECV. ID NR. 138;SECV. ID NR. 139;SECV. ID NR. 140;SECV. ID NR. 141;SECV. ID NR. 142;SECV. ID NR. 143;SECV. ID NR. 144;SECV. ID NR. 145;SECV. ID NR. 146;SECV. ID NR. 147;SECV. ID NR. 148;SECV. ID NR. 149;SECV. ID NR. 150;SECV. ID NR. 151;SECV. ID NR. 152;SECV. ID NR. 153;SECV. ID NR. 154;SECV. ID NR. 155;SECV. ID NR. 156;SECV. ID NR. 157;SECV. ID NR. 158;SECV. ID NR. 159;SECV. ID NR. 165;SECV. ID NR. 166;SECV. ID NR. 167;SECV. ID NR. 168;
- 14Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că este selectată dintre:SECV. ID NR. 124;SECV. ID NR. 133;SECV. ID NR. 154;SECV. ID NR. 155;
- 15Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că se administrează sub forma unei compoziții farmaceutice, care conține proteina de fuziune, definită în revendicările 1...14, pentru creșterea producerii celulei hematopoietice, la un mamifer. RO 118016 Β1
- 16Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că proteina de fuziune, definită în revendicările 1...14, se administrează ca metodă de creștere a producerii de celule hematopoietice, la un mamifer.
- 17Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că proteina de fuziune, definită în revendicările 1...14, este exprimată recombinant, dintr-un vector care cuprinde o secvență DNA, selectată din grupul constând din:SECV. ID NR. 53;SECV. ID NR. 54;SECV. ID NR. 55;SECV. ID NR. 56;SECV. ID NR. 57;SECV. ID NR. 58;SECV. ID NR. 59;SECV. ID NR. 60;SECV. ID NR. 61;SECV. ID NR. 62;SECV. ID NR. 63;SECV. ID NR. 64;SECV. ID NR. 65, SECV. ID NR. 66;SECV. ID NR. 67;SECV. ID NR. 68;SECV. ID NR. 69;SECV. ID NR. 70;SECV. ID NR. 71;SECV. ID NR. 72;SECV. ID NR. 73;SECV. ID NR. 74;SECV. ID NR. 75;SECV. ID NR. 76;SECV. ID NR. 77;SECV. ID NR. 78;SECV. ID NR. 79;SECV. ID NR. 80;SECV. ID NR. 81;SECV. ID NR. 82;SECV. ID NR. 83;SECV. ID NR. 84;SECV. ID NR. 85;SECV. ID NR. 86;SECV. ID NR. 87, SECV. ID NR. 88;SECV. ID NR. 89;SECV. ID NR. 90;SECV. ID NR. 183;SECV. ID NR. 184;SECV. ID NR. 185 și SECV. ID NR. 186;
- 18Proteină de fuziune, conform revendicării 1, caracterizată prin aceea că proteina de fuziune, definită în revendicările 1...14, este exprimată recombinant dintr-un vector care cuprinde o secvență DNA, selectată din grupul constând din:SECV. ID NR. 60;SECV. ID NR. 64;SECV. ID NR. 89 și SECV. ID NR. 98;
Independent claims18
7,615 paragraphs in 1,193 sections, as filed
The invention relates to a fusion protein, composed of mutants or variants of human interleukin-3 (hlL-3), fused to a second colony-stimulating factor (CSF), including cytokine, lymphoxine, interleukin, hematopoietic growth factor, or IL-3 variant with or without a linker, used to obtain a pharmaceutical composition, which is administered to increase the production of hematopoietic cell, in a mammal.
They are known from WO 91/02754 and WO 92/04455 fusion proteins, but do not exhibit any specific mutation. WO 91/02754 describes a fusion protein, composed of GM-CSF and IL-3, which has biological activity, increased compared to GM-CSF or to IL-3 alone. Also, non-glycosylated IL-3 and GMCSF protein analogues are described as components of the fusion. In WO 92/04455, fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G-CSF are described. .
It is also known that colony-stimulating factors (CSFs), which stimulate bone marrow cell differentiation and / or proliferation, generate great interest, due to their therapeutic potential for restoring low levels of hematopoietic cells derived from the cell. breastbone. CSFs were identified in both human and murine systems and separated according to their activities. For example, CSF-granulocyte (G-CSF) and CSF-macrophage (M-CSF) stimulate the in vitro formation of neutrophil granulocyte and macrophage colonies, respectively, while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both neutrophilic granulocyte macrophage colonies and eosinophilic granulocytes. IL-3 also stimulates the formation of mast cells, megakaryocytes and pure or mixed erythroid colonies.
Due to its ability to stimulate the proliferation of many different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells, to normal amounts, in those situations where cell numbers have decreased, due to diseases or therapeutic treatments, such as irradiation and / or chemotherapy.
Interleukin-3 (IL-3) is a hematopoietic growth factor, which has the property of being able to initiate survival, growth and differentiation of hematopoietic cells. Among the biological properties of IL-3 are (a) the ability to support growth and differentiation of progenitor cells, from which all or indeed all blood cell lines are formed, (b) to interact with multipotential early stem cells; (c) to support the growth of pluripotent precursor cells, (d) to stimulate the proliferation of myelogenous, chronic (CML) leukemia cells, (e) to stimulate the proliferation of mast cells, eosinophils and basophils, (f) to stimulate DNA synthesis. of acute myelogenous leukemia (AML) cells, (g) to initiate cells to produce leukotriene and histamine, (h) to induce leukocyte chemotaxis, and (i) inducing the molecules on the surface of the cell required for attachment of the leukocyte.
Mature human interleukin-3 (hlL) -3) consists of 133 amino acids. It has a disulfide bridge and 2 potential glycosylation sites (Yang. Et al., Cell 47: 3 (1986)).
Murine IL-3 (mlL-3) was initially identified by Ihle et al., J.Immunol 126: 2184 (1981), as a factor inducing the expression of a 20-hydroxysteroid dehydrogenase enzyme associated with T cell. purified to homogeneity and has been shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells.
In 1984, cDNA clones encoding murine IL-3 were isolated (Fung et al., Nature, 307: 233 (1984) and Yokota, et al., Proc. Natl. Acad. Sci. USA 81: 1070 ( 1984) The murine DNA sequence encoded a 166 amino acid polypeptide, including an initiating signal peptide.
RO 118016 Β1
The gibbon IL-3 sequence was obtained, using a gibbon cDNA expression bank, 50 sequences which were subsequently used as a probe against a human genomic bank to obtain the human IL-3 sequence.
Homologues of gibbon and human genomic DNA of murine IL-3 sequence have been described by Yang et al., In Cell 47: 3 (1986). The human sequence reported by Yang et al., Included a serine residue, at position 8 of the mature protein sequence. After this discovery, others reported the isolation of Pro cDNAs<sup>8</sup> hlL-3, which have proline at position 8 of the protein sequence. Thus, it appears that there may be 2 allelic forms of hlL-3.
Dorssers et al., In Gene 55: 115 (1987), found a clone from a human cDNA bank, which hybridized with mlL-3. This hybridization was the result of the high degree of homology between the non-coding regions 3 'of mlL-3 and hlL-3. This cDNA encoded for 60 hlL-3 sequences (Pro<sup>8</sup>).
US Patent Nos. 4877729 and US 4959454 describe human IL-3 and gibbon IL-3 cDNAs and the protein sequences they encode. The described hlL-3 has, rather, serine than proline at position 8 in the protein sequence.
Clark-Lewis, et al., Science 231: 134 (1986) performed a functional analysis of murine IL-3 analogues synthesized with an automatic peptide synthesizer. The authors concluded that, for a total activity, the stable tertiary structure of the complete molecule was required. A study of the role of disulfide bridges showed that the replacement of all 4 Cys with Ala gives a molecule with 1/500 of the activity of the native molecule. replacement of two of the Cys residues by Ala (Cys<sup>79</sup>, Cys<sup>140</sup> - Alas<sup>79</sup>, Allah<sup>140</sup>) led to increased activity. The authors concluded that a single disulfide bridge between cysteines 17 and 80 is required in murine IL-3 to give biological activity, which approximates the physiological levels and that this structure probably stabilizes the tertiary structure of the protein to give a conformation. which is optimal for the function (Clark-Lewis, et al., in Proc. Atlantic Academy USA 85: 7897 (1988). 75
International publication WO 88/00598 describes IL-3, similar to gibbon and human-like. hlL-3 contains a replacement, namely, Ser<sup>8</sup> - Pro<sup>8</sup>. Suggestions have been made for the replacement of Cys by Ser, thereby breaking the disulfide bridge and for replacing one or more amino acids at the glycosylation sites.
EP-A-0275598 (WO 88/04691) illustrates that Ala<sup>1</sup> it can be deleted, while maintaining the biological activity in 80. Several hlL-3 mutant sequences are given, for example, two double mutants, Ala<sup>1</sup> - Asp<sup>1</sup>, Trp<sup>13</sup> - Arg<sup>13</sup> (pGB / IL-302) and Ala<sup>1</sup> - Asp<sup>1</sup>, Met<sup>3</sup> - Thr<sup>3 </sup>(pGB / IL-304) and a triple Ala mutant<sup>1</sup> - Asp<sup>1</sup>, Leo<sup>9</sup> - Pro<sup>9</sup>, Trp<sup>13</sup> - Arg<sup>13</sup> (PGB / IL-303).
WO 88/05469 describes how deglycosylation mutants can be obtained and suggests Arg mutants<sup>54</sup>Arg<sup>55</sup> and Arg<sup>108</sup>Arg<sup>109</sup>Lys<sup>110</sup> to avoid proteolysis to expression in 85 Saccharomyces cerevisiae by KEX2 protease. No mutant protein is described, in this context, glycosylation and KEX2 protease activity are important only in yeast expression.
WO 88/06161 mentions various mutants that, theoretically, may be conformationally and antigenically neutral. The mutations obtained at present are only Met<sup>2</sup> - him<sup>2</sup> and lle<sup>131</sup> - Leo<sup>131</sup>. No 90 is described if, for these two mutations, the envisaged neutralities were obtained.
WO 91/00350 describes non-glycosylated hlL-3 analog proteins, for example, hlL3 (Pro<sup>8</sup>Asp<sup>15</sup>Asp<sup>70</sup>), MefrhulL-3 (Pro<sup>8</sup>Asp<sup>15</sup>Asf7<sup>0</sup>) Thi<sup>4</sup> rhulL-3 (Prcf Asp<sup>15</sup>I | i<sup>0</sup>) and Thf rhuIL3 (Pro<sup>8</sup>Asp<sup>15</sup>Asp<sup>70</sup>). It is claimed that these protein compositions do not exhibit certain adverse side effects, associated with native hlL-3, such as urticaria resulting from the infiltration of 95 mast cells and lymphocytes into the dermis. The described hlL-3 protein analog may have the N-terminus at Met<sup>3</sup>, Thr<sup>4</sup>, or Thr<sup>6</sup>.
RO 118016 Β1
WO 90/12874 discloses variants of IL-3, which have added cysteine (CAVs), which have at least one Cys residue substituted for a naturally occurring amino acid residue.
U.S. Patent No. 48,10643 discloses the DNA sequence encoding human G-CSF.
J
The problem solved by the invention is a fusion protein, which contains a multisubstituted IL-3 variant, administered to a mammal, to increase the production of hematopoietic cell.
The fusion protein, according to the invention, has the structure corresponding to formula (I): X- (L)<sub>e</sub>-Y (I) wherein X is R<sub>1</sub> or R<sub>2</sub>, Y is or R<sub>2</sub>, L is a linker capable of binding to X and Y radicals, a is 0 or 1 and R is a human interleukin-3 mutant polypeptide having an improved activity profile of the formula
Ala Pro Met Thr Gin ThrThrSerLeu Lys Thr Ser Trp Val Asn
1015
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
2530
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
4045
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
5560
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
7080
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
9095
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100 105110
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
115 120125
Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala lle Phe
130135
Sequence no .: 1 in which:
Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin or Arg;
Xaa at position 18 is Asn, His, Leo, lle, Phe, Arg or Gin;
Xaa at position 19 is Met, Phe, lle, Arg, Gly, Ala or Cys;
Xaa at position 20 is lle, Cys, Gin, Glu, Arg, Pro or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin,
Asn, Thr, Ser or Val;
Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn,
Gin, Leo, Val or Gly;
Xaa at position 23 is lle, Val, Ala, Leo, Gly, Trp, Lys, Phe,
Leo, Serum or Arg;
Xaa at position 24 is lle, Gly, Val, Arg, Ser, Phe or Leo;
Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp;
Xaa at position 27 is Leo, Gly, Arg, Thr, Ser or Ala;
Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;
Xaa at position 29 is Gin, Asn, Leo, Pro, Arg or Val;
RO 118016 Β1
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leo or Lys;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leo or Gin;
Xaa at position 32 is Val, Arg, Gin, Asn, Gly, Ala or Glu;
Xaa at position 33 is Pro, Leo, Gin, Ala, Thr or Glu;
Xaa at position 34 is Leo, Val, Gly, Ser, Lys, Glu, Gin, Thr, 150
Arg, Ala, Phe, lle or Met;
Xaa at position 35 is Leo, Ala, Gly, Asn, Pro, Gin or Val;
Xaa at position 36 is Asp, Leo or Val;
Xaa at position 37 is Phe, Ser, Pro, Trp or lle;
Xaa at position 38 is Asn or Ala; 155
Xaa at position 40 is Leo, Trp or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leo, His, Met or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leo
Val, Glu, Phe, Tyr, Lle, Met or Ala;
Xaa at position 43 is Glu, Asn, Tyr, Leo, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly or Ser; 160
Xaa at position 44 is Asp, Serum, Leo, arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro;
Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leo, Thr, Lys,
Trp, Asp, Asn, Arg, Ser, Ala, lle, Glu or His
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val or
Gly; 165
Xaa at position 47 is lle, Gly, Val, Ser, Arg, Pro or His;
Xaa at position 48 is Leo, Ser, Cys, Arg, lle, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp;
Xaa at position 50 is Glu, Leo, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, lle, Val, His, Phe, Met or
Gin; 170
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His;
Xaa at position 52 is Asn, His, Arg, Leo, Gly, Ser or Thr;
Xaa at position 53 is Leo, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;
Xaa at position 54 is Arg, Asp, lle, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu;
Xaa at position 55 is Arg, Thr, Val, Ser, Leo or Gly; 175
Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, Arg, His, Thr, Ala, Tyr, Phe, Leo, Val or Lys;
Xaa at position 57 is Asn or Gly;
Xaa at position 58 is Leo, Serum, Asp, Arg, Gin, Val or Cys;
Xaa at position 59 is Glu, Tyr, His, Leo, Pro or Arg; 180
Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn or Thr;
Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg su Ser;
Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or lle;
Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val;
Xaa at position 64 is Ala, Asn, Pro, Ser or Lys; 185
Xaa at position 65 is Val, Thr, Pro, His, Leo, Phe or Ser;
Xaa at position 66 is Lys, lle, Arg, Val, Asn, Glu or Ser;
Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, lle, Pro, or His
Xaa at position 68 is Leo, Val, Trp, Ser, lle, Phe, Thr or His; 190
Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leo;
Xaa at position 70 is Asn, Leo, Val, Trp, Pro or Ala;
Xaa at position 71 is Ala, Met, Leo, Pro, Arg, Glu, Thr, Gin, Trp or Asn;
Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp;
RO 118016 Β1
Xaa at position 73 is Ala, Glu, Asp, Leo, Ser, Gly, Thr or Arg;
Xaa at position 74 is lle, Met, Thr, Pro, Arg, Gly or Ala;
Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin or Leo;
Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
Xaa at position 77 is lle, Ser, Arg, Thr or Leo;
Xaa at position 78 is Leo, Ala, Ser, Glu, Phe, Gly or Arg;
Xaa at position 79 is Lys, Thr, Asn, Met, Arg, lle, Gly or Asp;
Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leo, Glu or Arg;
Xaa at position 81 is Leo, Gin, Gly, Ala, Trp, Arg, Val or Lys;
Xaa at position 82 is Leo, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, lle, Met or Val;
Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met;
Xaa at position 84 is Cys, Glu, Gly, Arg, Met or Val;
Xaa at position 85 is Leo, Asn, Val or Gin;
Xaa at position 86 is Pro, Cys, Arg, Ala or Lys;
Xaa at position 87 is Leo, Ser, Trp or Gly;
Xaa at position 88 is Ala, Lys, Arg, Val or Trp;
Xaa at position 89 is Thr, Asp, Cys, Leo, Val, Glu, His, Asn, or Ser;
Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, lle or Met;
Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leo, Asp or His;
Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, lle or Leo;
Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leo or Arg;
Xaa at position 94 is Arg, lle, Ser, Glu, Leu, Val, Gin, Lys, His, Ala or Pro;
Xaa at position 95 is His, Gin, Pro, Arg, Val, Leo, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, lle or Tyr;
Xaa at position 96 is Pro, Lys, Tyr, Gly, lle or Thr;
Xaa at position 97 is lle, Val, Lys, Ala or Asn;
Xaa at position 98 is His, lle, Asn, Leo, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 99 is lle, Leo, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe or His;
Xaa at position 100 is Lys, Tyr, Leu, His, Arg, lle, Ser, Gin, or Pro;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, lle, Leo or Gin;
Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro;
Xaa at position 103 is Asp or Ser;
Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leo, Gin, Lys, Phe or Gly;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leo, Lys, lle, Asp or His;
Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, lle, Gly or Pro;
Xaa at position 108 is Arg, Lys, Asp, Leo, Thr, lle, Gin, His, Ser, Ala or Pro;
Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leo, Ser or Gly;
Xaa at position 110 is Lys, Ala, Asn, Thr, Leo, Arg, Gin, His, Glu, Ser, Ala or Trp;
Xaa at position 111 is Leo, lle, Arg, Asp or Met;
Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser or Phe;
Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, lle, Val or Asn;
Xaa at position 114 is Tyr, Cys, Gis, Ser, Trp, Arg or Leo;
Xaa at position 115 is Leo, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met;
Xaa at position 116 is Lys, Leo, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala,
Tyr, Phe, Gin, or lle;
Xaa at position 117 is Thr, Ser, Asn, lle, Trp, Lys or Pro;
RO 118016 Β1
Xaa at position 118 is Leo, Ser, Pro, Ala, Glu, Cys, Asp or Tyr;
Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg; 245
Xaa at position 120 is Asn, Ala, Pro, Leo, His, Val or Gin;
Xaa at position 121 is Ala, Ser, lle, Asn, Pro, Lys, Asp or Gly;
Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo;
and which, in addition, have Met- which precedes the amino acid at position 1; 250 wherein the amino acids at positions 1 to 14 at the N-terminus can be removed and / or the amino acids at positions 1 to 15 at the C-terminus can be removed and the amino acids at positions 4 through 44 designated by Xaa are different from amino acids corresponding to native human interleukin3 (1-133),
R<sub>2</sub> is a colony-stimulating factor selected from GM-CSF, CSF-1, CSF-G (CSF-255 granulocyte), C-mpI ligand, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL -2JL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3 / flk2, human growth hormone, growth factor of B cell, B cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF) in which the X and Y radicals are joined directly or via a linker (L), provided that
X is R<sub>2</sub>, Y cannot be R<sub>2</sub>. 260
By applying the invention, the following advantages are obtained:
- biological or physiological activity greater than a simple summed function of the presence of IL-3 or the second colony-stimulating factor alone;
- may provide an increased effect on activity or activity other than that expected by the presence of IL-3 or the second colony-stimulating factor or variant IL-3; 265
- an improved activity profile, which may include the reduction of unwanted biological activities associated with hlL-3.
The invention also includes mutants of hlL-3 in which deletions of 1 to 14 amino acids at the N-terminus and / or 1 to 15 amino acids have been deleted from the C-terminus, containing multiple amino acid substitutions, to which 270 a second colony-stimulating factor or IL-3 variant was fused. The fusion proteins, preferred in the present invention, are composed of hlL-3 variants, wherein amino acids 1-14 are deletioned from the N-terminus, amino acids 126 to 133 deletion from the C-terminus and contain from about 4 to about 26 amino acid substitutions, in the sequence of the polypeptide fused to the second colony-stimulating factor or IL-3 variant. 275
Also, the present invention provides fusion proteins, which may function as IL-3 antagonists or as antigenic, concrete fragments, for the production of antibodies useful in immunostaining and immunotherapy protocols.
HlL-3 antagonists would be particularly useful in blocking the growth of certain cancer cells, such as AML, CML, and certain types of lymphoid cancers B. Other conditions where 280 antagonists would be useful include those in which certain cells Blood vessels are produced in abnormally large numbers or activated by endogenous ligands. Antagonists could compete effectively for hematopoietic ligands, probably naturally occurring, including but not limited to, IL-3, GM-CSF, and IL-5, which can trigger or enhance the growth of cancer cells by virtue of their ability to it binds to the IL-3 receptor complex, in 285 at the same time diminishing the intrinsic activating properties of the ligand. Also, IL-3, GM-CSF and / or IL-S play a role in certain asthmatic responses. An IL-3 receptor antagonist may be useful in this disease by blocking the activation and recruitment of receptor-mediated inflammatory cells.
In addition to using the fusion proteins of the present invention in vivo, it is contemplated that in vitro uses would include the ability to stimulate bone marrow and to activate and grow blood cells and growth prior to infusion into the patient.
RO 118016 Β1
The invention also comprises recombinant variants of human interleukin-3- (hlL-3) or mutant proteins (muteins) fused to themselves, IL-3, or a second colony-stimulating factor (CSF), including, but not limited to, without being limited to, cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant with or without a linker. This invention comprises mixed-function colony-stimulating factors, formed of covalently linked polypeptides, each of which can act through a different and specific cellular receptor, to initiate complementary biological activities. Hematopoiesis requires a complete series of cellular events, in which stem cells continuously generate large populations of cells that mature in all major lines. There are currently at least 20 known regulators with proliferative hematopoietic activity. Most of these proliferative regulators can stimulate the formation of one or another type of colony in vitro, the precise image of colony formation stimulated by each regulator being clearly distinct. Neither regulator stimulates exactly the same sequence of colony formation, as assessed by the number of colonies or, more importantly, by the line and spectrum of maturation of the cells that make up the developing colonies. The proliferative responses can be easily analyzed in simplified in vitro culture systems. 3 different parameters can be clearly distinguished, namely, change of colony size, change of number of colonies and cell line. Two or more factors may act on the progenitor cell, inducing the formation of a greater number of offspring, thereby increasing the size of the colony. Two or more factors may allow a larger number of progenitor cells to proliferate, either because of distinct subsets of existing progenitor cells that respond exclusively to one factor, or because of progenitors requiring stimulation by two or more factors before be able to respond. Activation of additional receptors on a cell, by using two or more factors, is similar to the increase of mitotic signal, due to the coalescence of signal pathways, which initially differ in a common final path, reaching the nucleus (Metcalf, 1989). Other mechanisms might explain synergism. For example, if a signaling pathway is limited by a further activation of an additional signaling pathway, by a second factor, it may result in an over-response. In some cases, activation of one type of receptor may induce increased expression of other receptors (Metcalf, 1993). Two or more factors can lead to a different spectrum of cell lines, than from a single factor. The use of fusion molecules may have the potential clinical advantage, due to a proliferative response, which is not possible by a single factor.
Hematopoietic factors and other growth factors can be grouped into two distinct families of related receptors: (1) tyrosine kinase receptors, including those for epidermal growth factor, M-CSF (Sherr, 1990) and SCF (Yarden et al., 1987). ) and (2) hematopoietic receptors, which do not contain a tyrosine kinase domain, but which have obvious homology in their extracellular domain (Bazan, 1990). The latter group includes erythropoietin (EPO) (D'Adrea et al., 1989), GM-CSF (Gearing et al., 1989), IL-3 (Kitamura et al., 1991), G-CSF (Fukunaga et al., 1990), IL-4 (Harada et al., 199 =), IL-5 (Takaki et al.,
1990), IL-6 (Yamasaki et al., 1988), IL-7 (Goodwin et al., 1990), LIF (Gearing et al., 1991), and IL-2 (Cosman et al., 1987).
Most of the receptors of the latter group exist in the form of high affinity, as heterodimers. After ligand binding, α-specific chains become associated with at least one other receptor chain (β-chain, γ-chain). Many of these factors share a receptor subunit. The chains a, for GM-CSF IL-3, IL-5 share the same β chain (Kitamura et al.,
1991) Takaki et al., 1991) and receptor complexes for IL-6, LIF, and IL-11 share the common β chain (gp130) (Taga et al., 1989; Gearing et al., 1992). The IL-2, IL-4 and IL-7 receptor complexes share a common γ chain (Londo et al., 1993; Russell et al., 1993; Nogochi et al., 1993).
RO 118016 Β1
345
The use of multiple factors can also have the potential advantage by lowering the demands placed on cells that produce their factors and induction systems. If there is a limit on the ability of a cell to produce a factor, then by decreasing the concentrations required by each of the factors by using them in combination, the demands on the cells that produce the factor can be useful reduced. Using multiple factors can reduce the number of factors that will be needed, possibly reducing the likelihood of adverse responses.
Complementary activity is the activity that increases or changes the response for another cellular modeler. The R1 polypeptide is fused either directly or via a linker segment to the R2 polypeptide. The term "direct" defines fusions in which the polypeptides are bound without a linker peptide. Thus, L represents a chemical bond or polypeptide segment, in which both R1 and R2 are fused together, most often L is a linear peptide to which R1 and R2 are linked by amide bonds, which bind the C-terminal end of of R1 at the N-terminus of L and the C-terminus of L at the N-terminus of R2. By "merged within the framework", it is understood that there is no translation of termination or interruption between the reading frames of R1 and R2. A non-exclusive list of other growth factors, colony-stimulating factors (CSFs), cytokine, lymphokine, interleukin, hematopoietic growth factor within the definition of R2, which may be fused to a hlL-3 variant of the present invention, include GM-CSF, CSF-1, G-CSF, Meg-CSF (more recently known as c-mp1 ligand), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-5 , IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3 ligand, human growth hormone, B cell growth factor, B cell differentiation factor, eusenophil differentiation factor, stem cell factor (SCF) also known as steel factor or kit c ligand. Additionally, this invention comprises the use of modified or mutated R2 molecules or modified DNA sequences, which encodes these R2 molecules. Also disclosed herein is the fusion of molecules wherein R 2 is a hlL-3 variant which means an IL-3 in which an amino acid is substituted and which portions of the removed hlL-3 molecule can be removed as described in WO. 94/12638 and WO 94/12639 as well as other variants known in the art.
The binding group (L) is generally a polypeptide with a length between 1 and 500 amino acids. The linkers linking the two molecules are preferably designated for: (1) allow the two molecules to fold and act independently of each other, (2) they do not have a predilection for the development of an ordered secondary structure, which could interfere with the functional domains of the two proteins, (3) minimal hydrophobicity or loading characteristics, which could interact with the functional protein domains and (4) ensure the historical separation of R1 and R2, so that R1 and R2 could interact, simultaneously, with their corresponding receptors, on a single cell. Typically, the surface area of the amino acids in the flexible regions of the protein includes Gly, Asn, and Ser. Indeed, any permutation of the amino acid sequences containing Gly, Asn, and Ser would be expected to meet the above criteria for a linker sequence. Other neutral amino acids such as Thr, and Ala can also be used in the linker sequence. Additionally, additional amino acids may be included in the linkers, due to the addition of unique restriction sites in the linker sequence, to facilitate the construction of fusions.
Preferred linkers of the present invention include sequences selected from the formula group: (Gly3Ser)<sub>n</sub>, (Gly4Ser)<sub>n</sub>, (Gly5Ser)<sub>n</sub>, (Gly<sub>n</sub>Serum)<sub>n</sub> or (AlaGlySer)<sub>n</sub>.
An example of a high flexibility linker is the rich spacer region (GlySer), present in the pili protein of filamentous bacteriophages, for example, bacteriophages M13 or fd (Schaller et al., 1975). This region provides a long, flexible spacing region between the two domains of the pili protein surface.
The spacer region consists of the amino acid sequence:
350
355
360
365
370
375
380
385
RO 118016 Β1
GlyGlyGlySerGIyFlyGlySerGIyGlySergluGlyGlyGlySergluGlyGlyGlySer GluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ. No. 50).
The present invention also includes linkers in which an endopeptidase recognition sequence is included. Such a cleavage site may be useful for separating the individual components of the fusion, to determine whether they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kalikrein, urokinase, tissue plasminogen activator, clostripaine, chemosine, collagenase, Russell's venom protease, postproline cleavage enzyme, V8 protease, thrombin, and factor X8. .
Linker peptide segments from the base region of the heavy chain immunoglobulin IgG, IgA, IgM, IgD or IgE provide a rigid relationship between the attached polypeptides. Particularly useful are those core regions, where the cysteines are replaced by serines. Preferred linkers of the present invention include sequences derived from the murine IgG gamma 2b base region, in which the cysteines were changed to serines. These linkers may also include an endopeptidase cleavage site. Examples of such linkers include the following sequences chosen from the sequence group.
IleSerGIuProSerGIyProlleSerThrlIeAsnProSerProProSerLys GluSerHisLysSerPro (SEQ.51)
IleGluGlyArgIleSerGIuProSerGIyProlleSerThrIleAsnProSer ProProSerLysGluSerHisLysSerPro (SECV.Nr.52)
However, the present invention is not limited by the form, size or number of the linker sequences used, and there is only a requirement that the linker does not interfere, in a harmful manner, with the folding and function of the individual molecules of the fusion.
An alternative method for connecting two hematopoietic growth factors is through non-covalent interaction. Such complex proteins can be described by one of the formulas:
R1-C1 + R2-C2; or C1-R1 + C2-R2; C1-R1 + R2-C2; or C1-R1 + R2-C2, where R1 is a hlL-3 variant, which contains multiple amino acid substitutions and may have distant portions of the hlL-3 molecule, R2 is a colony-stimulating factor with different but complementary activity. A non-exclusive list of other growth hormones, colony-stimulating factors (CSFs), cytokine, lymphokine, interleukin, hematopoietic growth factor, within the definition of R2, which may be fused to an hlL-3 variant of the invention. front, include GM-CSF, CSF-1, G-CSF, Meg-CSF (more recently known as c-mpl ligand), M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3 ligand, human growth hormone, B cell growth factor, B cell differentiation factor, eusenophil differentiation factor and stem cell factor (SCF) also known as steel factor or kit-c ligand. Domains C1 and C2 are chemical structures, either identical or different, usually protein, which can form a specific non-covalent association. The complex between C1 and C2 results in a stoichiometric relationship between R1 and R2 for each complex. Examples of the domains that are associated are the "zipper leucine" domains of transcription factors, the dimerization domains of bacterial transcription repressors and the constant immunoglobulin domains. Covalent bonds link R1 and C1 and R2 to C2 respectively. As indicated in the formula, the C1 and C2 domains may be present at both the N-terminal and C-terminus of the corresponding hematopoietic growth factor (R). These domains of multimerization (C1 and C2) include those derived from the bZIP family of proteins (Abel et al., 1989; Landshulz et al., 1988; Pu et al., 1993; Kozarides et al., 1988) as well as multimerization domains of the helix-loop-helix family of proteins (Abel et al., 1989; Murre et al., 1989; Tapscott et al., 1988; Fischer et al., 1991). Preferred fusions of the present invention include dimerized colony-stimulating factors for
RO 118016 Β1
440 their incorporation as translational fusions to the leucine zipper dimerization domains of the bZIP Fos and Jun protein families. The leucine zipper domain of Jun is able to interact with identical domains. On the other hand, the Fos leucine zipper domain interacts with the Jun leucine zipper domain, but does not interact with other Fos leucine zipper domains. The mixtures of Fos and Jun result predominantly from the formation of Fos-Jun heterodimers. As a result, when fused to the colony-stimulating factor, the Jun domain can be used to direct the formation of either homo- or heterodimers. The preferential formation of heterodimers can be achieved if one of the colony-stimulating factor partners is processed to possess the Jun zipper leucine domain, while another is processed to possess the Fos zipper.
Peptides may also be added to facilitate the purification or identification of fusion proteins (eg, poly-His).
Also, a strongly antigenic peptide can be added, which will allow rapid analysis and easy purification of the fusion protein by a specific monoclonal antibody.
The present invention relates to novel fusion molecules, composed of novel variants of human interleukin-3 (hiL-3), in which amino acid substitutions have been made, at four or more positions in the amino acid sequence of the polypeptide fused to one. the second colony-stimulating factor or IL-3 variant. Preferred fusion molecules of the present invention are deletion mutants (15-125) hlL-3, which have deletions of 1 to 14 amino acids at the N-terminus and 126 to 133 at the C-terminus C and which also have , 4 or more amino acid substitutions, in the polypeptide fused to a second colony-stimulating factor or IL-3 variant. The present invention includes mutant polypeptides, comprising at least 15 to 118 amino acid residues of hlL-3 with or without additional amino acid extensions at the N-terminus and / or C-terminus, which additionally contain 4 or more amino acid substitutions in the amino acid sequence. of the polypeptide fused to another colony-stimulating factor or IL-3 variant.
As used herein, human interleukin-3 corresponds to the amino acid sequence (1-133), as illustrated in Figs. 1 and (15-125) hlL-3 and corresponds to the amino acid sequence 15 to 125 of the hlL- polypeptide. 3. Naturally encountered variants of the amino acids of the hlL-3 polypeptide are also included in the present invention (for example, the allele in which proline is rather than serine at position 8 in the sequence of the hlL-3 polypeptide) such as molecule variants. hlL-3, which are post-translationally modified (eg, glycosylation).
"Mutant amino acid sequence," mutant protein "or" mutant polypeptide "refers to a polypeptide having an amino acid sequence, which varies from the native sequence or is encoded by a nucleotide sequence, made, intentionally, variant from the native sequence. . "Mutant protein", "variant protein" or "mutein" means a protein that comprises a mutant amino acid sequence and includes polypeptides that differ from the native hlL-3 amino acid sequence due to amino acid deletions, substitutions or both. "Native sequence" refers to an amino acid or nucleic acid sequence, which is identical to a wild or native form of a gene or protein.
Human IL-3 can be characterized by its ability to stimulate colony formation by human hematopoietic progenitor cells. Formed colonies include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and combinations thereof. Human IL-3 has a capacity to restore bone marrow function and peripheral blood cell populations to therapeutically useful levels, in studies performed initially in primates and subsequently in humans (Gillio, PA et al., (1990); Ganser, A. et al., (1990); Falk S. et al. (1991). Additional activities of hlL-3 include the ability to stimulate leukocyte migration and chemotaxis; the ability to initiate human leukocytes to produce high levels of
445
450
455
460
465
470
475
480
485
RO 118016 Β1 inflammatory mediators, such as leukotrienes and histamine; the ability to induce expression on the cell surface of the molecules required for leukocyte adhesion; and the ability to trigger inflammatory dermal and fever responses. Many or all of these biological activities of hlL-3 involve signal transduction and high affinity for receptor binding. The fusion molecules of the present invention may have useful properties, having similar or greater biological activity, compared to native hlL-3 or having an enhanced half-life or side effects, adverse, low, or a combination of these properties. They can also be useful as antagonists. Fusion proteins that have little or no activity, compared to native hlL-3, may still be useful as antagonists, as antigens for producing antibodies used in immunology or immunotherapy, as genetic probes, or as intermediates used to build other hlL muteins. -3 useful.
The novel fusion proteins of the present invention will preferably have at least one biological property of human IL-3 and another colony-stimulating factor or other IL-3 variant, to which it is fused and may have more than a biological property, such as IL-3 or an improved property, or a reduction of an undesirable biological property, of human IL-3. Some mutant polypeptides of the present invention may also have an enhanced side effect profile. For example, they may exhibit a decrease in leucotrein release or histamine release compared with native hlL-3 or (15125) hlL-3. Such hlL-3 or similar hlL-3 biological properties may include one or more of the following biological characteristics and in vivo and in vitro activities.
Such a property is to support the growth and differentiation of the progenitor cells, passed to the erythroid, lymphoid and myeloid lines. For example, in a standard human bone marrow assay, a biological property such as IL-3 is the stimulation of granulocyte-like colonies, megakaryocytic-type colonies, monocyte / macrophage colonies, and erythroid occurrences. Other properties such as IL-3 are the interaction with early multipotent stem cells, support the growth of pluripotent precursor cells, the ability to stimulate chronic myelogenous leukemia (CML) cell proliferation, stimulate mast cell proliferation, the ability to support the growth of various cell lines. and the ability to trigger the immature, bone marrow progenitors. Other biological properties of IL-3 have been described in the literature. Human IL-3 also has some biological activities, which in some cases may be undesirable, for example, the ability to stimulate leukotriene release and the ability to stimulate increased histamine synthesis in spleen and bone marrow and bone marrow cultures. vivo.
The biological activity of hlL-3 and hlL-3 fusion proteins of the present invention is determined by DNA synthesis from human acute myelogenous leukemia (AML) cells. The factor-dependent AML 193 cell line was adapted for use in biological assay activity. The biological activity of hlL-3 and hlL-3 fusion proteins of the present invention is also determined by counting colony forming units in a bone marrow test.
Other in vitro cell-based assays may also be useful for determining the activity of fusion molecules, depending on the colony-stimulating factors that the fusion comprises.
It is an object of the present invention to provide the hlL-3 variant with four or more amino acids substituted in the sequence of the polypeptide fused to a second colony-stimulating factor with IL-3 variant, which has biological activity, similar or enhanced to native hlL-3. , or the second colony-stimulating factor or IL-3 variant.
The hlL-3 variant fusion proteins of the present invention may have hlL-3 activity or similar hlL-3 activity. For example, they may possess one or more of the biological activities of hlL-3 and may be useful in stimulating the production of hematopoietic cells,
RO 118016 Β1 by primate or human progenitor cells. The fusion molecules of the present invention and the pharmaceutical compositions containing them may be useful in the treatment of reducing or destroying hematopoietic cell populations due to disease or treatments, such as irradiation or chemotherapy. Pharmaceutical compositions containing the fusion molecules of the present invention may be administered parenterally, intravenously or subcutaneously.
The native HIL-3 possesses considerable inflammatory activity and has been shown to stimulate synthesis of the metabolites of arhidonic acid LTC4, LTD4 and LTE4, histamine synthesis and histamine release. Human clinical studies with native hlL-3 have substantiated inflammatory responses (Biesma et al., Blood, 80: 1141-1148 (1992) and Postmus et al., J.CIin.Oncol. 10: 11311140 (1992)). A recent study has shown that leukotrienes are involved in IL-3 actions in vivo, and can significantly contribute to the biological effects of IL-3 treatment (Denzlinger C. et al., Blood, 81: 2466-2470 (1993)).
Some of the fusion proteins of the present invention may have an improved therapeutic profile compared to native hlL-3. For example, some fusion molecules of the present invention may have similar or stronger growth factor activity relative to hlL-3, without having similar or appropriate growth in leukotriene or histamine stimulation. These fusion molecules will be expected to have a more favorable therapeutic profile, because the amount of the polypeptide that is required to be given the desired growth factor activity (eg, cell proliferation) will have a leukotriene or histamine stimulation effect. smaller. In studies with native hlL-3, stimulation of inflammatory factors was an undesirable side effect of treatment. Reducing or releasing the stimulation of inflammation mediators will provide an advantage over native hlL-3 use.
The novel fusion proteins of the present invention may also be useful as antagonists that block the hlL-3 receptor by specifically binding to it and preventing agonist binding.
A potential advantage of the new fusion products, of the present invention, in particular, those that retain similar or better acidity than native hlL-3, is that it may be possible to use a lower amount of biologically active mutein, for producing the desired therapeutic effect. The use of smaller quantities may also reduce the possibility of any potential antigenic effects or other possible undesirable side effects. For example, if a desired therapeutic effect can be achieved with a smaller amount of polypeptide, it may be possible to reduce or eliminate the side effects associated with the administration of native IL-3, such as leukotene stimulation and / or histamine release. The novel fusion molecules of the present invention may also be useful in activating stem or progenitor cells, which have low receptor numbers.
Also included in the present invention are DNA sequences, which encode fusion proteins, DNA sequences that are substantially similar, and perform substantially the same function and DNA sequences, which differ from the DNAs that encode fusion proteins. of the invention, only due to the degeneracy of the genetic code. Also included in the present invention are oligonucleotide intermediates used for the construction of mutant DNAs and polypeptides encoded by these oligonucleotides. These polypeptides may be useful as antagonists or with fragments for the production of antibodies useful in immunotherapy and immunotherapy protocols.
The compounds of this invention are preferably made by genetic engineering techniques, henceforth referred to in the art, US Pat. No. 4935233 and Sambrook et al., “Molecular Cloning. The Laboratory Manual, Cold Spring Harbor Laboratory (1989). One method of creating the preferred hlL-3 mutant genes (15-125) is the mutagenesis cassette (Wells et al., 1989) in which a portion of the hlL-3 coding sequence of a plasmid is replaced by oligonucleotides. synthetic, which encodes the desired amino acid substitutions in a portion of the gene
540
545
550
555
560
565
570
575
580
585
RO 118016 Β1 of 2 restriction sites. Similarly, amino acid substitutions can be made in the whole hlL-3 gene or genes encoding variants of hlL-3 in which from 1 to 14 amino acids have been removed from the N-terminus and / or from the 1-terminus. up to 15 amino acids were removed from the C-terminus. When properly assembled, these oligonucleotides will modify the hlL-3 variant with the desired amino acid substitutions and / or deletions at the N-terminal and / or C-terminal end. These and other mutations can be created by those skilled in the art by other methods of mutagenesis, including oligonucleotide, oriented mutagenesis / Zoller and Smith (1982, 1983, 1984), Smith (1985), Kunkel (1985), Taylor et al. , (1985), Geng and Nickoloff (1992)) or polypeptide chain reaction (PCR) techniques (Seiki, (1985)).
Synthetic, complementary oligonucleotide pairs encoding the desired gene can be obtained and normalized. The DNA sequence of the oligonucleotide will encode the sequence for the amino acids of the desired gene, except those substituted and / or removed from the sequence.
Plasmid DNA can be treated with restriction endonucleases, chosen, and then bind to normalized oligonucleotides. The ligated mixtures can be used to transform JM101 cells competent for resistance to a suitable antibiotic. Single colonies can also be collected and the plasmid DNA examined by restriction analysis and / or DNA sequencing to identify the plasmids with the desired genes.
By fusing the DNA sequences of the hlL3 variant with the DNA sequence of another factor that
J 1 stimulates colony or IL-3 variant, can be obtained by using intermediate vectors. Alternatively, a gene can be cloned directly into a vector containing another gene. For linking DNA sequences as well as replacing lost sequences, linkers or adapters may be used when a restriction site has been internal to the region of interest. Thus, genetic material (DNA) encoding a polypeptide, linker peptide and other polypeptide is introduced into an appropriate expression vector, which is used to transform bacteria, yeasts, insect cells or mammalian cells. The transformed organism grows and the protein is isolated by standard techniques. The resultant product is therefore a novel protein, which has a hlL-3 variant bound by a linker region to a second colony-stimulating factor or IL-3 variant.
Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these novel fusion molecules. These vectors contain novel DNA sequences, described above, which code for novel polypeptides of the invention. Suitable vectors, which can transform microorganisms capable of expressing fusion molecules, include expression vectors, comprising nucleotide sequences, which code for the fusion molecules linked to the transcriptional and translational regulatory sequence, which are chosen according to the host cells used.
Vectors incorporating modified sequences, as described above, are included in the present invention and are useful in the production of fusion polypeptides. The vector used in the method also contains regulatory sequences, selected in functional association with the coding DNA sequences, of the invention and capable of directing their replication and expression in the chosen host cells.
As another aspect of the present invention, there is provided a method for producing novel fusion molecules. The method of the present invention involves culturing a corresponding cell or cell line, which has been transformed with a vector containing a DNA sequence, which encodes the expression of a variant of the novel hlL-3 fusion molecule. Suitable cells or cell lines may be bacterial cells, for example, various strains of E.coli are well known as host cells in the field of biotechnology. Examples of such strains include E.coli strains GM101 (Yanish-Perron et al. (1985)) and MON105 (Obukowicz et al. (1992)). Also included in the present invention is the expression of the fusion protein, which uses an E.coli chromosomal expression vector, based on the bacteriophage Mu (Weinberg et al., (1993)). Also, in this method, various strains can be used
RO 118016 Β1 of B. subtilis. Numerous yeast cell strains, known to those skilled in the art 635, are also accessible as host cells, for expression of the polypeptides of the present invention. When expressed in the cytoplasm of the E.coli cell, the mutant variants of the hlL-3 fusion protein mentioned above can be constructed with Met-Ala- at the N-terminus, so that upon expression, Met cleaves leaving Ala at the N-terminal end. The fusion proteins of the present invention may include fusion polypeptides, having Met-, Ala- or Met-640 Al-attached at the N-terminus. When the fusion molecules are expressed in the cytoplasm of the E.coli cell, polypeptides are obtained with and without Met attached to the N-terminus. The N-terminal ends of the protein in the cytoplasm of the E.coli cell are affected by posttranslational methionine-amino-peptidase processing (Sen-Bassat et al., 1987) and possibly by other peptidases. These mutant fusion proteins may also be expressed in E.coli by 645 fusion of a signal peptide at the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. Secretion in E.coli can be used to obtain the correct amino acid at the N-terminus (eg, Asn<sup>15</sup> in polypeptide (15125) (hlL-3), due to the precise nature of the signal peptidase. This is distinct from the heterogeneity often observed, at the N-terminus, of proteins expressed in the 650c cytoplasm of the E.coli cell.
Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary (CHO) cells. General methods for the expression of foreign genes in mammalian cells are provided by Kaufman, RJ (1987) in High levelproduction ofproteins in mammalian cells, in Genetic engineering, Principles and 655 Methods, vol.9, JKSetlow, publisher, Plenum Press, New York. An expression vector is constructed, in which a strong promoter capable of functioning, in mammalian cells, directs the transcription of a coding region of the eukaryotic secretion signal peptide, which fused translationally to the coding region of the fusion molecule. For example, plasmids such as pcDNAI / Neo, pRc / RSV and pRc / aCMV (obtained from Invitrogen Corp., San 660 Diego, California) can be used. The coding region of the eukaryotic secretion signal peptide may be from the hlL-3 gene or may be from another mammalian secreted protein (Bayne, ML et al., (1987) Proc. Natl. Acad. Sci. USA, 84 2638-2542). After constructing the vector containing the hlL-3 variant gene, the DNA vector is transfected into mammalian cells. Such cells may be, for example, COS7, HeLa, BHK, CHO or mouse lines L. The cells may be cultured, for example, in DMEM (DRH Scientific) media. The hlL-3 variant secreted in media can be recovered by standard biochemistry, after transient expression, at 24-72 h, after transfection of cells or after establishing stable cell lines, following selection, for neomycin resistance. The selection of host cells, mammals, suitable and methods for transformation, culture, amplification, sorting and production of the product and purification are known in the art. See, for example, Gething and Sambrook Nature, 293: 620-625 (1981) or alternatively, Kaufman et al., Mol.Cell.Biol., 5 (7): 1750-1759 (1985) or Howley et al., US 4419446. Another suitable mammalian cell line is the COS-1 monkey cell line. A similarly useful mammalian cell line is the CV-1 cell line.
When desired in the method of the present invention, 675 insect cells can be used as host cells. See for example, Miller et al., Genetic engineering, 8: 277-298 (Plenum Press 1986) and references cited here. Additionally, general methods for the expression of foreign genes in the insect cell using Baculovirus vectors are described in Summers, MD and Smith G. E., (1987) A manual of methods for Baculivirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. A 680 expression vector, including a Baculovirus transfer vector, is constructed, in which a strong Baculovirus promoter (as the polyhedron promoter) drives the transcription of the coding region of the eukaryotic secretion peptide, which is translationally fused, to the region of
RO 118016 Β1 coding of the fusion polypeptide. For example, plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, California) can be used. After constructing the vector carrying the coding gene of the fusion polypeptide, 2 / zg of this DNA is counter-infected with 1 μg Baculovirus DNA (see Summers & Smith, 1989) in insect cells, strain SF9. Pure recombinant Baculovirus, which carries the fusion protein, is used to infect cultured cells, for example, in serum-free Excell 401 (JRN Biosciences, Lenexa Kansas). The fusion protein, secreted into the environment, can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells, which express the fusion protein, can initially be concentrated using any of the numerous commercial concentration units.
The fusion proteins of the present invention may be useful in the treatment of diseases characterized by a low level of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they can be used to activate myeloid and / or lymphoid mature cells. Among the conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in peripheral blood. Leukopenia can be induced by exposure to certain viruses or radiation. It is often a side effect of various forms of cancer therapy, such as exposure to chemotherapeutic drugs, radiation and infection or hemorrhage. The therapeutic treatment of leukopenia with these fusion molecules of the present invention may avoid the undesirable side effects produced by treatment with currently accessible drugs.
The fusion proteins of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of conditions such as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythromatosus (SLE), leukemia, myelodysplastic syndrome myelofibrosis.
The fusion protein of the present invention may be useful in the treatment or prevention of thrombocytopenia. Currently, thrombocytopenia therapy is only platelet transfusion, which is costly and has significant risks of infection (HIV, HBV) and immunization. The fusion protein can ease or lessen the need for platelet transfusions. Severe thrombocytopenia can result from genetic defects, such as Fanconi's anemia, Wiscott-AIdrich or May-Hegglin's syndromes. Acquired thrombocytopenia may result from auto- or allo-antibodies, such as in immune thrombocytopenic purpura, systemic lupus erythromatosis, hemolytic anemia or fetal, maternal incompatibilities. In addition, they may lead to splenomegaly thrombocytopenia, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, infection, or cardiac protection valves. Severe thrombocytopenia may also result from cancer chemotherapy and / or radiation therapy. Thrombocytopenia may also result from marrow invasion through carcinomas, lymphomas, leukemia or fibrosis.
The fusion proteins of the present invention may be useful in mobilizing hematopoietic and sternal progenitor cells, such as peripheral ones. The progenitors derived from peripheral blood have been shown to be effective in restoring patients, in stabilizing the autologous marrow transplant. Autologous growth factors including G-CSF and GM-CSF have been shown to increase the number of circulating systemic progenitor cells in peripheral blood. This simplified the procedure for collecting peripheral stem cells and dramatically lowered the cost of the procedure by decreasing the number of decks needed. The fusion protein may be useful in mobilizing stem cells and further enhancing the efficiency of peripheral stem cell transplantation.
Another clinically designed use of growth factors was in vitro activation of hematopoietic progenitors and stem cells for gene therapy. in order to have the gene of interest embedded in the genome of the hematopoietic progenitor or stem cell,
111 it is necessary to stimulate cell division and DNA replication. The cycle of hematopoietic stem cells is a very low frequency, which means that growth factors may be useful for initiating gene transduction and, thus, increasing clinical prospects, for gene therapy.
Many drugs can cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents, and antimetabolites used in chemotherapy, antibiotics, such as chloramphenicol, penicillin, ganciclovir, daunomycin, and sulfa, phenothiazone, tranquilizer such as meprobamate, analgesics like aminopyronev, carbinevazine or , antithyroid like propylouracil and metimazole and diuretics. The fusion molecules of the present invention may be useful in the prevention or treatment of bone marrow suppression or hematopoietic deficiencies, which are often encountered in patients treated with these drugs.
Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of the treatment of kidney disease or renal failure, for example, dialysis. The fusion molecules of the present invention may be useful in treating such hematopoietic deficiencies.
Treatment of hematopoietic deficiency may include administration of a pharmaceutical composition, which contains fusion molecules, to a patient. The fusion molecules of the present invention may also be useful for activating and amplifying hematopoietic cells, precursors by treating, in vitro, these cells with the fusion proteins of the present invention before injecting the cells into a patient.
Various immunodeficiencies, for example, in T and / or B lymphocytes or immune disorders, for example, rheumatoid arthritis, may also be beneficially influenced by treatment with the fusion molecules of the present invention. Immunodeficiencies may be the result of viral infections, for example, HTLVI, HTLVII, HTLVIII, severe radiation exposure, cancer therapy, or other medical treatment. The fusion proteins of the present invention may also be used alone or in combination with other hematopoietics, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency) or anemia. Other uses of these novel polypeptides are in the recovery of patients from in vivo and ex vivo bone marrow transplants, and in the development of monoclonal and polyclonal antibodies, generated by standard method, for diagnosis or therapeutic use.
Other aspects of the present invention are therapeutic methods and compositions for treating the conditions described above. Such compositions comprise a therapeutically effective amount of one or more of the fusion molecules of the present invention in admixture with a pharmaceutically acceptable carrier. This composition can be administered both parenterally, intravenously and subcutaneously.
When administered, the therapeutic composition for use in this invention is preferably in the form of an aqueous solution, parenterally acceptable and free of pyrogens. The preparation of such a parenterally acceptable protein solution, having the appropriate pH, isotony, stability and the like can be found in the prior art.
The dosage regimen, involved in a method for treating the conditions described above, will be established by the doctor, considering various factors that modify the action of the medicines, for example, the condition, body weight, sex and diet of the patient, the severity of any infection, the time of administration and other clinical factors. Generally, a daily regimen will be in the range of 0.2-150 / zg / kg of fusion protein per kg. This dosage regimen is for a standard level of biological activity, which recognizes that, in general, native IL-3 possesses an EC<sub>50</sub> at or about 10 µM to 100 µM in the AML proliferation assay described herein.
735
740
745
750
755
760
765
770
775
780
RO 118016 Β1
Therefore, the doses will be adjusted based on the activity of the fusion protein against the native IL-3 activity (reference) and it will not be incredible, to note that the dosing regimen may include low doses, up to 0 , 1 and as high as 1 mg / kg hours / day. In addition, there may be specific circumstances where the doses of the fusion molecule could be adjusted above or below the 10-200 / ^ g / kg range. These include administration with another colony-stimulating factor or IL-3 variant or growth factors, administration with chemotherapeutic drugs and / or irradiation, use of glycosylated fusion protein, and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include administration with other human factors. A non-exclusive list of other suitable hematopoietics, cytokine CSFs, lymphokines, hematopoietic growth factors and interleukins for simultaneous or alternate administration with the polypeptides of this invention, includes GM-CSF, CSF-1, G-CSF, Meg-CSF (known, more recently, as ligand c-mpl), MCSF, erythropoietin, (EPO), IL-1, IL-4, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9 , IL-10, IL-11, IL-12, IL13, LIF, fit 3 ligands, B cell growth factors, B cell differentiation factors, eusenophil differentiation factor, stem cell factor (SCF), also known as steel factor or kit-c ligand, or combinations thereof. The dosage listed above will be corrected, to compensate for such additional components in the therapeutic composition. The progress of the treated patient can be controlled by periodic analysis of the hematological profile, for example, the counting differentiate by cells and the like.
A preferred embodiment of the invention is a fusion protein of the structural formula defined in claim 1 wherein
Rf is Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1015
Cys Xaa Xaa Xaa li Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa 20 2530
Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa
4045
Xaa Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa
5560
Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa li Glu
7075
Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala
8590
Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa 95 100105
Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa
110 115120
Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala lle Phe
125130
Sequence no .: 2 in which:
Xaa at position 17 is Ser, Gly, Asp, Met or Gin;
Xaa at position 18 is Asn, His or lle;
Xaa at position 19 is Met or lle; Xaa at position 21 is Asp or Glu;
Xaa at position 23 is lle, Ala, Leo or Gly;
Xaa at position 24 is lle, Val or Leu;
RO 118016 Β1
Xaa at position 25 is Thr, His, Gin or Ala;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gin, Asn or Val;
Xaa at position 30 is Pro, Gly or Gin;
Xaa at position 31 is Pro, Asp, Gly or Gin;
Xaa at position 32 is Leo, Arg, Gin, Asn, Gly, Ala or Glu;
Xaa at position 33 is Pro or Glu;
Xaa at position 34 is Leo, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, lle, Phe, Thr or Met;
Xaa at position 35 is Leo, Ala, Asn, Pro, Gin or Val;
Xaa at position 37 is Phe, Ser, Pro or Trp;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, lle, Leo, Met, Tyr or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gin, Val, Met, Leo, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu, His, lle, Lys, Tyr, Val or Cys;
Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His;
Xaa at position 54 is Arg or Ala;
Xaa at position 55 is Arg, Thr, Val, Leo or Gly;
Xaa at position 56 is Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leo, Thr, Val or Lys;
Xaa at position 60 is Ala or Ser;
Xaa at position 62 is Asn, Pro, Thr or lle;
Xaa at position 63 is Arg or Lys;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 66 is Lys or Arg;
Xaa at position 67 is Ser, Phe or His;
Xaa at position 68 is Leo, lle, Phe or His;
Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg or Gly;
Xaa at position 71 is Ala, Pro or Arg;
Xaa at position 72 is Ser, Glu, Arg or Asp;
Xaa at position 73 is Ala or Leo;
Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro or Gly;
Xaa at position 77 is lle or Leo;
Xaa at position 79 is Lys, Thr, Gly, Asn, Met, Arg, lle, Gly, or Asp;
Xaa at position 80 is Asn, Gly, Glu or Arg;
Xaa at position 82 is Leo, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, lle, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 83 is Pro or Thr;
Xaa at position 85 is Leo or Val;
Xaa at position 87 is Leo or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leo or Arg;
Xaa at position 95 is His, Pro, Arg, Val, Leo, Gly, Asn, Phe, Ser or Tyr;
Xaa at position 96 is Pro or Tyr;
Xaa at position 97 is lle or Val;
Xaa at position 98 is His, lle, Asn, Leu, Ala, Thr, Leu, Arg, Gin, Leu, Lys, Met, Ser, Tyr, Val or Pro;
830
835
840
845
850
855
860
865
870
875
RO 118016 Β1
Xaa at position 99 is lle, Leo or Val;
Xaa at position 100 is Lys, Arg, lle, Gin, Pro or Ser;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn, lle, Leo or Tyr;
Xaa at position 104 is Trp or Leo;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leo, Lys, lle, Asp or His; Xaa at position 106 is Glu or Gly;
Xaa at position 108 is Arg, Ala or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leo or Ser;
Xaa at position 112 is Thr, Val or Gin;
Xaa at position 114 is Tyr or Trp;
Xaa at position 115 is Leo or Ala;
Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or lle;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leo, His, Val or Gin;
Xaa at position 121 is Ala, Ser, lle, Asn, Pro, Asp or Gly;
Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo;
and which, in addition, have Met- which precedes the amino acid at position 1;
wherein the amino acids at positions 1 to 14 from the N-terminus can be removed and / or the amino acids from positions 1 to 15 from the C-terminus can also be removed from the amino acids at positions 4 to 35, designated by Xaa, are different from the amino acids corresponding to native human interleukin-3 (1-133).
Another preferred aspect of the invention is a fusion protein, of structural formula, as defined in claim 1, wherein R<sub>2</sub> It is
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1015
Cys Xaa Xaa Met him Asp Glu Xaa lle Xaa Xaa Leu Lys Xaa Xaa
2530
Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa
4045
Xaa him Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala
5560
Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala lle Glu
7075
Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala
8590
Xaa Pro Xaa Arg Xaa Pro le Xaa Xaa Xaa Xaa Gly Asp Trp Xaa
100105
Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa
110 115120
Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala lle Phe
125130
Sequence no .; 3 in which:
Xaa at position 17 is Ser, Gly, Asp, Met or Gin;
Xaa at position 18 is Asn, His or lle;
Xaa at position 23 is lle, Ala, Leo or Gly;
Xaa at position 25 is Thr, His or Gin;
Xaa at position 26 is His or Ala;
RO 118016 Β1
Xaa at position 29 is Gin or Val;
Xaa at position 30 is Pro or Gly;
Xaa at position 32 is Leo, Arg, Asn or Ala; 930
Xaa at position 34 is Leo, Val, Ser, Ala, Arg, Gin, Glu, lle, Phe, Thr or Met;
Xaa at position 35 is Leo, Ala, Asn or Pro;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, lle, Leo, Met, Tyr or Arg;
Xaa at position 45 is Gin, Val, Met, Leo, Thr, Ala, Asn, Glu, or Lys; 935
Xaa at position 46 is Asp, Phe, Ser, Gin, Glu, His, Val or Thr;
Xaa at position 50 is Glu, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Pro, Thr or His;
Xaa at position 55 is Arg, Leo or Gly;
Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leo or Gin; 940
Xaa at position 62 is Asn, Pro or Thr;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 67 is Ser or Phe;
Xaa at position 68 is Leo or Phe; 945
Xaa at position 69 is Gin, Ala, Glu or Arg;
Xaa at position 76 is Ser, Val, Asn, Pro or Gly;
Xaa at position 77 is lle or Leo;
Xaa at position 79 is Lys, Asn, Met, Arg, lle or Gly;
Xaa at position 80 is Asn, Gly, Glu, or Arg; 950
Xaa at position 82 is Leo, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val; Xaa at position 87 is Leo or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp or Ala; 955
Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Tyr;
Xaa at position 98 is His, lle, Asn, Ala, Thr, Leo, Gin, Glu, Lys, Met, Ser, Tyr, Val or Pro; Xaa at position 99 is lle or Leo;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, lle, Leo or Tyr; 960
Xaa at position 105 is Asn, Pro, Ser, lle or Asp;
Xaa at position 108 is Arg, Ala or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leo or Ser;
Xaa at position 112 is Thr or Gin;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or lle; 965
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leo, His, Val or Gin;
Xaa at position 121 is Ala, Ser, lle, Pro or Asp;
Xaa at position 122 is Gin, Met, Trp, Phe, Pro, His, lle or Tyr;
Xaa at position 123 is Ala, Met, Glu, Ser or Leo; 970
Another preferred aspect is the fusion protein wherein R, are amino acids that differ from the corresponding residue of native human IL-3 are selected from the group consisting of: Xaa at position 42 is Gly, Asp, Ser, lle, Leu, Met, Tyr or Arg; Xaa at position 45 is Gin, Val, Met or Asn; Xaa at position 46 is Asp, Ser, Gin, His or Val;
Xaa at position 50 is Glu or Asp;
975
RO 118016 Β1
Xaa at position 51 is Asn, Pro or Thr;
Xaa at position 62 is Asn or Pro;
Xaa at position 76 is Ser or Pro;
Xaa at position 82 is Leo, Trp, Asp, Asn, Glu, His, Phe, Ser, Tyr or Val;
Xaa at position 95 is His, Arg, Thr, Asn or Ser;
Xaa at position 98 is His, lle, Leo, Ala, Gin, Lys, Met, Ser, Tyr or Val;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, His, Asn, lle or Leo;
Xaa at position 105 is Asn or Pro;
Xaa at position 108 is Arg, Ala or Ser;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe or Tyr;
Xaa at position 121 is Ala or lle;
Xaa at position 122 is Gin, lle and
Xaa at position 123 is Ala, Met or Glu;
Another preferred aspect is a fusion protein of the structural formula defined in claim wherein R, is
Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1015
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa
2530
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
4045
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
5560
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
7075
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
8590
Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100105
Xaa Xaa Xaa Xaa Gin Gin
110
Sequence no .: 4 in which:
Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gin or Arg;
Xaa at position 4 is Asn, His, Leo, lle, Phe, Arg or Gin;
Xaa at position 5 is Met, Phe, lle, Arg, Gly, Ala or Cys;
Xaa at position 6 is lle, Cys, Gin, Glu, Arg, Pro or Ala;
Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;
Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leo, Val or Gly;
Xaa at position 9 is lle, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser or Arg;
Xaa at position 10 is lle, Gly, Val, Arg, Ser, Phe or Leo;
Xaa at position 11 is Thr, His, Gly, Gin, Arg, Pro or Ala;
Xaa at position 12 is Thr, Phe, Gly, Arg, Ala or Trp;
Xaa at position 13 is Leo, Gly, Arg, Thr, Ser or Ala;
Xaa at position 14 is Lys, Arg, Leo, Gin, Gly, Pro, Val or Trp;
Xaa at position 15 is Gin, Asn, Leo, Pro, Arg or Val;
Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leo, or Lys;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leo or Gin;
RO 118016 Β1
Xaa at position 18 is Leo, Val, Arg, Gin, Asn, Gly, Ala or Glu;
Xaa at position 19 is Pro, Leo, Gin, Ala, Thr or Glu;
Xaa at position 20 is Leo, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, lle or Met;
Xaa at position 21 is Leo, Ala, Gly, Asn, Pro, Gin or Val;
Xaa at position 22 is Asp, Leo or Val;
Xaa at position 23 is Phe, Ser, Pro, Trp or lle;
Xaa at position 24 is Asn or Ala;
Xaa at position 26 is Leo, Trp or Arg;
Xaa at position 27 is Asn, Cys, Arg, Leo, His, Met or Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, lle or Met;
Xaa at position 29 is Glu, Asn, Tyr, Leo, Phe, Asp, Ala, Cys, Gin, Arg, Gly or Ser;
Xaa at position 30 is Asp, Serum, Leo, arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro;
Xaa at position 31 is Gin, Pro, Phe, Val, Met, Leo, Thr, Lys, Asp, Asn, Arg, Ser, Ala, lle, Glu, His or Trp.
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val or Gly;
Xaa at position 33 is lle, Gly, Val, Ser, Arg, Pro or His;
Xaa at position 34 is Leo, Ser, Cys, Arg, lle, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp;
Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, lle, Val, His, Phe, Met or Gin;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr or His;
Xaa at position 38 is Asn, His, Arg, Leo, Gly, Ser or Thr;
Xaa at position 39 is Leo, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met;
Xaa at position 40 is Arg, Asp, lle, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu;
Xaa at position 41 is Arg, Thr, Val, Ser, Leo or Gly;
Xaa at position 42 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, Arg, His, Thr, Ala, Tyr, Phe, Leo, Val or Lys;
Xaa at position 43 is Asn or Gly;
Xaa at position 44 is Leo, Serum, Asp, Arg, Gin, Val or Cys;
Xaa at position 45 is Glu, Tyr, His, Leo, Pro or Arg;
Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn or Thr;
Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg or Ser;
Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp or lle;
Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val;
Xaa at position 50 is Ala, Asn, Pro, Ser or Lys;
Xaa at position 51 is Val, Thr, Pro, His, Leo, Phe or Ser;
Xaa at position 52 is Lys, lle, Arg, Val, Asn, Glu or Ser;
Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, lle, Pro, or His;
Xaa at position 54 is Leo, Val, Trp, Ser, lle, Phe, Thr or His;
Xaa at position 55 is Gin, Ala, Pro, Thr, Glu, Arg, Trpn Gly or Leo;
Xaa at position 56 is Asn, Leo, Val, Trp, Pro or Ala;
Xaa at position 57 is Ala, Met, Leo, Pro, Arg, Glu, Thr, Gin, Trp or Asn;
Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp;
Xaa at position 59 is Ala, Glu, Asp, Leo, Ser, Gly, Thr or Arg;
Xaa at position 60 is lle, Met, Thr, Pro, Arg, Gly or Ala;
Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin or Leo;
Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
Xaa at position 63 is lle, Ser, Arg, Thr or Leo;
1030
1035
1040
1045
1050
1055
1060
1065
1070
RO 118016 Β1
Xaa at position 64 is Leo, Ala, Ser, Glu, Phe, Gly or Arg;
Xaa at position 65 is Lys, Thr, Asn, Met, Arg, lle, Gly or Asp;
Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leo, Glu or Arg;
Xaa at position 67 is Leo, Gin, Gly, Ala, Trp, Arg, Val or Lys;
Xaa at position 68 is Leo, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, lle, Met or Val;
Xaa at position 69 is Pro, Ala, Thr, Trp, Arg or Met;
Xaa at position 70 is Cys, Glu, Gly, Arg, Met or Val;
Xaa at position 71 is Leo, Asn, Val or Gin;
Xaa at position 72 is pro, Cys, Arg, Ala or Lys;
Xaa at position 73 is Leo, Ser, Trp or Gly;
Xaa at position 74 is Ala, Lys, Arg, Val or Trp;
Xaa at position 75 is Thr, Asp, Cys, Leo, Val, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, lle or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leo, Asp or His;
Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, lle or Leo;
Xaa at position 79 is Thr, Asp, Ser, Asn, Pro, Ala, Leo or Arg;
Xaa at position 80 is Arg, lle, Ser, Glu, Leu, Val, Gin, Lys, His, Ala or Pro;
Xaa at position 81 is His, Gin, Pro, Arg, Val, Leo, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, lle or Tyr;
Xaa at position 82 is Pro, Lys, Tyr, Gly, lle or Thr;
Xaa at position 83 is lle, Val, Lys, Ala or Asn;
Xaa at position 84 is His, lle, Asn, Leo, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 85 is lle, Leo, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe or His;
Xaa at position 86 is Lys, Tyr, Leo, His, Arg, lle, Ser, Gin, or Pro;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, lle, Leo or Gin;
Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro;
Xaa at position 89 is Asp or Ser;
Xaa at position 90 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leo, Gin, Lys, Ala, Phe or Gly;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leo, Lys, lle, Asp or His;
Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, lle, Gly or Pro;
Xaa at position 94 is Arg, Lys, Asp, Leo, Thr, lle, Gin, His, Ser, Ala or Pro;
Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leo, Ser or Gly;
Xaa at position 96 is Lys, Ala, Asn, Thr, Leo, Arg, Gin, His, Glu, Ser, Ala or Trp;
Xaa at position 97 is Leo, lle, Arg, Asp or Met;
Xaa at position 98 is Thr, Val, Gin, Tyr, Glu, His, Ser or Phe;
Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, lle, Val or Asn;
Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg or Leo;
Xaa at position 101 is Leo, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met;
Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lle;
Xaa at position 103 is Thr, Ser, Asn, lle, Trp, Lys or Pro;
Xaa at position 104 is Leo, Ser, Pro, Ala, Glu, Cys, Asp or Tyr;
Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr or Arg;
Xaa at position 106 is Asn, Ala, Pro, Leo, His, Val or Gin;
Xaa at position 107 is Ala, Ser, lle, Asn, Pro, Lys, Asp or Gly;
Xaa at position 108 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys;
RO 118016 Β1
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo;
and which additionally have Met- or Met-Ala- which precedes the amino acid at position 1;
wherein the amino acids at positions 1 to 14 from the N-terminal end and / or the amino acids from positions 1 to 15 from the C-terminal end can be removed and the amino acids from positions 4 to 44 designated by Xaa are different from the corresponding amino acids native human interleukin-3 (1-133),
R<sub>2</sub> is II-3, a variant II-3 or a colony-stimulating factor selected from GM-CSF, CSF-1, CSF-G (CSF-granulocyte), C-mpI ligand, M-CSF, erythropoietin (EPO), IL -1, IL-4, IL-2.IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, LIF, flt3 / flk2, human growth hormone, B cell growth factor, B cell differentiation factor, eosinophil differentiation factor, and stem cell factor (SCF);
and L is a linker capable of binding the radical X to Y.
Another preferred aspect of the invention is the fusion protein of the structural formula defined in claim 1 wherein R, is
Asn Cys Xaa Xaa Xaa le Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa
1015
Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa
2530
Xaa Xaa Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu
4045
Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa li
5560
Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr
7075
Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa
8590
Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu
100105
Xaa Xaa Xaa Xaa Gin Gin
110
Sequence no .: 5 in which:
Xaa at position 3 is Ser, Lys, Gly, Asp, Met or Gin;
Xaa at position 4 is Asn, His or lle;
Xaa at position 5 is Met or lle;
Xaa at position 7 is Asp or Glu;
Xaa at position 9 is lle, Ala, Leo or Gly;
Xaa at position 10 is lle, Val or Leu;
Xaa at position 11 is Thr, His, Gin or Ala;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gin, Asn or Val;
Xaa at position 16 is Pro, Gly or Gin;
Xaa at position 17 is Pro, Asp, Gly or Gin;
Xaa at position 18 is Leo, Arg, Gin, Asn, Gly, Ala or Glu;
Xaa at position 19 is Pro or Glu;
Xaa at position 20 is Leo, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, lle, Phe, Thr or Met;
Xaa at position 21 is Leo, Ala, Asn, Pro, Gin or Val;
Xaa at position 23 is Phe, Ser, Pro or Trp;
Xaa at position 24 is Asn or Ala;
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
RO 118016 Β1
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, lle, Leo, Met, Tyr, lle or Met;
Xaa at position 30 is Asp or Glu;
Xaa at position 31 is Gin, Val, Met, Leo, Thr, Ala, Asp, Glu, Ser or Lys;
Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu, His, lle, Lys, Tyr, Val or Cys;
Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 40 is Arg or Ala;
Xaa at position 41 is Arg, Thr, Val, Leo or Gly;
Xaa at position 42 is Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leo, Thr, Val or Lys;
Xaa at position 46 is Ala or Ser;
Xaa at position 48 is Asn, Pro, Thr or lle;
Xaa at position 49 is Arg or Lys;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 52 is Lys or Arg;
Xaa at position 53 is Ser, Phe or His;
Xaa at position 54 is Leo, lle, Phe or His;
Xaa at position 55 is Gin, Ala, Pro, Thr, Glu, Arg or Gly;
Xaa at position 57 is Ala, Pro or Arg;
Xaa at position 58 is Ser, Glu, Arg or Asp;
Xaa at position 59 is Ala or Leo;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro or Gly;
Xaa at position 63 is lle or Leo;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, lle, or Asp;
Xaa at position 66 is Asn, Gly, Glu or Arg;
Xaa at position 68 is Leo, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, lle, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro or Thr;
Xaa at position 71 is Leo or Val;
Xaa at position 73 is Leo or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leo or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leo, Gly, Asn, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is lle or Val;
Xaa at position 84 is His, lle, Asn, Leo, Ala, Thr, Arg, Gin, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is lle, Leo or Val;
Xaa at position 86 is Lys, Arg, lle, Gin, Pro or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, lle, Leo or Tyr;
Xaa at position 90 is Trp or Leo;
Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gin, Tyr, Leo, Lys, lle, Asp or His;
Xaa at position 92 is Glu or Gly;
Xaa at position 94 is Arg, Ala or Ser;
Xaa at position 96 is Arg, Thr, Glu, Leo or Ser;
Xaa at position 98 is Thr, Val or Gin;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leo or Ala;
Xaa at position 102 is Lys, Thr, Val, trp, Ser, Ala, His, Met, Phe, Tyr or lle;
Xaa at position 103 is Thr or Ser;
RO 118016 Β1
Xaa at position 106 is Asn, Pro, Leo, His, Val or Gin;
Xaa at position 107 is Ala, Ser, lle, Asn, Pro, Asp or Gly;
Xaa at position 108 is Gin, Ser, Met, Trp, Arg, Phe, Pro or His, lle, Tyr, Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo;
and which additionally have Met- or Met-Ala- which precedes the amino acid at position 1;
wherein the amino acids at positions 1 to 14 at the N-terminus can be removed and / or the amino acids at positions 1 to 15 at the C-terminus can be removed and the amino acids at positions 4 to 35 designated by Xaa are different from the amino acids corresponding to native human interleukin-3 (1-133).
Another preferred aspect of the invention is a fusion protein of the structural formula defined in claim 1 wherein R, is
Asn Cys Xaa Xaa Xaa le Asp Glu Xaa le Xaa Xaa Leu Lys Xaa
1015
Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp
2530
Xaa Xaa Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu
4045
Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala lle
5560
Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr
7075
Ala Xaa Pro Xaa Arg Xaa Pro le Phe Xaa Xaa Xaa Gly Asp Trp
8590
Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu
100105
Xaa Xaa Xaa Xaa Gin Gin
110
Sequence no .: 6 in which:
Xaa at position 3 is Ser, Gly, Asn or Gin;
Xaa at position 4 is Asn, His or lle;
Xaa at position 9 is lle, Ala, Leo or Gly;
Xaa at position 11 is Thr, His or Gin;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gin or Asn;
Xaa at position 16 is Pro or Gly;
Xaa at position 18 is Leo, Arg, Asn or Ala;
Xaa at position 20 is Leo, Val, Ser, Ala, Arg, Gin, Glu, lle, Phe, Thr or Met;
Xaa at position 21 is Leo, Ala, Asn or Pro;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, lle, Leo, Met, Tyr or Arg;
Xaa at position 31 is Gin, Val, Met, Leo, Ala, Asn, Glu or Lys;
Xaa at position 32 is Asp, Phe, Ser, Ala, Gin, Glu, His, Val, or Thr;
Xaa at position 36 is Glu, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Pro, Thr or His;
Xaa at position 41 is Arg, Leo or Gly;
Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leo or Gin;
Xaa at position 48 is Asn, Pro or Thr;
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
RO 118016 Β1
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 53 is Ser or Phe;
Xaa at position 54 is Leo or Phe;
Xaa at position 55 is Gin, Ala, Glu or Arg;
Xaa at position 62 is Ser, Val, Asn, Pro or Gly;
Xaa at position 63 is lle or Leo;
Xaa at position 65 is Lys, Asn, Met, Arg, lle or Gly;
Xaa at position 66 is Asn, Gly, Glu or Arg;
Xaa at position 68 is Leo, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val; Xaa at position 73 is Leo or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp or Ala;
Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 84 is His, lle, Asn, Ala, Thr, Arg, Gin, Glu, Lys, Met, Ser, Tyr, Val or Leo; Xaa at position 85 is lle or Leo;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Asn, lle, Leu, or Tyr;
Xaa at position 91 is Asn, Pro, Ser, lle or Asp;
Xaa at position 94 is Arg, Ala or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leo or Ser;
Xaa at position 98 is Thr or Gin;
Xaa at position 102 is Lys, Val, Trp or lle;
Xaa at position 103 is Thr, Ala, His, Phe or Ser;
Xaa at position 106 is Asn, Pro, Leo, His, Val or Gin;
Xaa at position 107 is Ala, Ser, lle, Pro or Asp;
Xaa at position 108 is Gin, Met, Trp, Phe, Pro, His, lle or Tyr;
Xaa at position 109 is Ala, Met, Glu, Ser or Leo;
which additionally have Met- or Met-Ala- which precedes the amino acid at position 1; wherein the amino acids from positions 1 to 14, from the N-terminal end, can be removed and / or the amino acids from positions 1 to 15, from the C-terminal end, the amino acids from positions 4 to 26 may also be removed, designated by Xaa, are different from amino acids corresponding to native human interleukin-3 (1-133)
Another preferred aspect of the invention is the fusion protein of the structural formula as defined in claim 1, wherein R is (Met)<sub>m</sub>-Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr
510
Ser Trp Val Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa him
1520
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa
3035
Xaa Asn Leu Asn Xaa Glu Asp Xaa Asp lle Leu Xaa Glu
4550
Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa
5560
Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa li Glu Xaa
7075
RO 118016 Β1 Leu Xaa Asn Leu Xaa Pro Cys Xaa Pro Xaa Xaa Thr 8085
Ala Xaa Pro Xaa Arg Xaa Pro le Xaa le Xaa Xaa Gly
95100
Asp Thr Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu
105 110115
Xaa Xaa Leu Glu Xaa Ala Gin Xaa Gin Gin Thr Thr Leu 120125
Be Leu Ala le Phe
130 wherein m is 0 or 1
Xaa at position 18 is Asn, lle;
Xaa at position 19 is Met, Ala or lle;
Xaa at position 20 is lle, Pro or Ser;
Xaa at position 23 is lle, Ala or Leo;
Xaa at position 25 is Thr or His;
Xaa at position 29 is Gin, Arg, Val or lle;
Xaa at position 32 is Leo, Ala, Asn or Arg;
Xaa at position 34 is Leo or Ser;
Xaa at position 37 is Phe, Pro or Ser;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Ala, Ser, Asp or Asn;
Xaa at position 45 is Gin, Val or Met;
Xaa at position 46 is Asp or Ser;
Xaa at position 49 is Met, lle, Leo or Asp;
Xaa at position 50 is Glu or Asp;
Xaa at position 51 is Asn, Arg or Ser;
Xaa at position 55 is Arg, Leo or Thr;
Xaa at position 56 is Pro or Ser;
Xaa at position 59 is Glu or Leo;
Xaa at position 60 is Ala or Ser;
Xaa at position 62 is Asn, Val or Pro;
Xaa at position 63 is Arg or His;
Xaa at position 65 is Wave or Ser;
Xaa at position 67 is Ser, Asn, His or Gin;
Xaa at position 69 is Gin or Glu;
Xaa at position 73 is Ala or Gly;
Xaa at position 76 is Ser, Ala or Pro;
Xaa at position 79 is Lys, Arg or Ser;
Xaa at position 82 is Leo, Glu, Val or Trp;
Xaa at position 85 is Leo or Val;
Xaa at position 87 is Leo, Ser or Tyr;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Pro or Ser;
Xaa at position 95 is His or Thr;
Xaa at position 98 is His, lle or Thr;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Ala or Met;
1320
1325 (Sequence no. 7)
1330
1335
1340
1345
1350
1355
1360
1365
RO 118016 Β1
Xaa at position 105 is Asn or Glu;
Xaa at position 109 is Arg, Glu or Leo;
Xaa at position 112 is Thr or Gin;
Xaa at position 116 is Lys, Val, Trp or Ser;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Gin or His;
Xaa at position 123 is Ala or Glu;
provided that the amino acids at positions 4 to 44, designated by Xaa, are different from the amino acids corresponding to native human interleukin-3 (1-133).
Another preferred aspect of the invention is a fusion protein of the structural formula as defined in claim 1, wherein it is (Met<sub>m</sub>-That<sub>n</sub>)<sub>p</sub>-Asn Cys Ser Xaa Xaa Xaa Asp Glu Xaa him
510
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Xaa Leu Asp Xaa
1520
Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa leu Xaa Glu
3035
Xaa Asn Leu Arg Xaa Xaa Asn Leu Xaa Xaa Phe Xaa Xaa
4550
Ala Xaa Lys Xaa Leu Xaa Asn Ala Ser Xaa li Glu Xaa
5560 you read Xaa Asn Xaa Xaa Pro Cys Xaa Pro Xaa Xaa Thr
7075
Ala Xaa Pro Xaa Arg Xaa Pro le Xaa le Xaa Xaa Gly
8085
Asp Thr Xaa Glu Phe Arg Xaa Lys Leu Xaa Phe Tyr Leu
95100
Xaa Xaa Leu Glu Xaa Ala Gin Xaa Gin Gin
105 110 (Sequence Nr .: 8) where m is 0 or 1; n is 0 or 1; P is 0 or 1;
Xaa at position 4 is Asn or lle;
Xaa at position 5 is Met, Ala or lle;
Xaa at position 6 is lle, Pro or Leo;
Xaa at position 9 is lle, Ala or Leo;
Xaa at position 11 is Thr or His;
Xaa at position 15 is Gin, Arg, Val or lle;
Xaa at position 18 is Leo, Ala, Asn or Arg;
Xaa at position 20 is Leo or Ser;
Xaa at position 23 is Phe, Pro or Ser;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Ala, Ser, Asp or Asn;
Xaa at position 31 is Gin, Val or Met;
Xaa at position 32 is Asp or Ser;
Xaa at position 35 is Met, lle, Leo or Asp;
Xaa at position 36 is Glu or Asp;
Xaa at position 37 is Asn, Arg or Ser;
Xaa at position 41 is Arg, Leo or Thr;
Xaa at position 42 is Pro or Ser;
Xaa at position 45 is Glu or Leo;
RO 118016 Β1
Xaa at position 46 is Ala or Ser;
Xaa at position 48 is Asn, Val or Pro;
Xaa at position 49 is Arg or His,
Xaa at position 51 is Wave or Ser;
Xaa at position 53 is Ser, Asn, His or Gin;
Xaa at position 55 is Gin or Glu;
Xaa at position 59 is Ala or Gly
Xaa at position 62 is Ser, Ala or Pro;
Xaa at position 65 is Lys, Arg or Ser;
Xaa at position 67 is Leo, Gin or Val;
Xaa at position 68 is Leo, Glu, Val or Trp;
Xaa at position 71 is Leo or Val;
Xaa at position 73 is Leo, Ser or Tyr;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Pro or Ser;
Xaa at position 81 is His or Thr;
Xaa at position 84 is His, lle or Thr;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Ala or Met;
Xaa at position 91 is Asn or Glu;
Xaa at position 95 is Arg, Glu or Leo;
Xaa at position 98 is Thr or Gin;
Xaa at position 102 is Lys, Val, Trp or Ser;
Xaa at position 103 is Thr or Ser;
Xaa at position 106 is Asn, Gin or His;
Xaa at position 109 is Ala or Glu;
cu condiția că aminoacizii de la pozițiile 4 la 44, desemnați prin Xaa, sunt diferiți de aminoacizii corespunzători interleukinei-3 umane native (15-125).
Un alt aspect preferat este proteina de fuziune, în care R, este
1420
1425
1430
1435
1440
1445
Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu
<td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td>
<td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
<td colspan="3">[Secv. nr.:9]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu
<td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td></td>
<td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td><td></td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td><td> 1460</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td><td></td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td></td>
<td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td><td></td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td><td></td>
<td colspan="3">[Secv. nr.:10]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 1465</td>
RO 118016 Β1
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
<td>Lys</td><td>Val</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
<td colspan="3">[Secv. nr.:11]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin.</td><td>Gin</td>
[Secv. nr.:12]
Asn Cys Ser Asn Met Ile Asp Glu ile ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
[Secv. nr.:13]
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td>
<td>pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
RO 118016 Β1
Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin Gin [Secv. nr.:14]
1515
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
<td colspan="3">[Secv. nr.:15]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
1520
1525
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>Thr</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
1530
1535 [secv. nr.:16]
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
1540
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
<td colspan="3">[Secv. nr.:17]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
1545
1550
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
1555
RO 118016 Β1
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td>
<td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
<td colspan="3">[Secv. nr.:18]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td>
<td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
[Secv. nr.: 19]
Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td>
<td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
[Secv. nr.: 20]
Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu
<td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Arg</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Gin</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>C-lu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td>
<td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
[Secv. nr.: 21]
Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu
RO 118016 Β1
1605
<td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td colspan="2">Lys Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
<td colspan="2">[Secv. nr.</td><td> : 22]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td colspan="13">Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Lei</td>
<td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
[Secv. nr.: 23]
1610
<img file="RO118016B1_D0001.tif" />
1620
1625
Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu
<td>Lys</td><td>Val</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td>
<td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td>
<td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>ser</td><td>Ala</td><td>Ile</td><td>Glu</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Pro</td>
<td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td>
<td>His</td><td>Ile</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td>Leu</td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td>
[Secv. nr.: 24]
1630
1635
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>Thr</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Arg</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td>
<td>Gin</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
1640
1645
RO 118016 Β1
Gin [Secv. nr.: 25]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Asn</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>Thr</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Arg</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td>
<td>Gin</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td colspan="3">Gin [Secv. nr.:</td><td> 26]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Asn</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>Thr</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Arg</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ala</td><td>Phe</td><td>Asn</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Ser</td><td>Leu</td>
<td>Gin</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
Gin [Secv. nr.: 27]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 28]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td>
RO 118016 Β1
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td> 1695</td>
<td>lle</td><td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td></td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td></td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 29]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 1700</td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td></td>
<td>Leu</td><td>Lys</td><td>Val</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td><td></td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td></td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td rowspan="2"> 1705</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Ala</td><td>lle</td><td>Glu</td><td>Ser</td><td>lle</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Leu</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Arg</td><td>His</td><td>Pro</td><td></td>
<td>lle</td><td>His</td><td>lle</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Arg</td><td>Lys</td><td></td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td rowspan="2">Lys</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td></td>
<td colspan="3">Gin [Secv. nr.:</td><td> 30]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 1710</td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 31]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
Gin [Secv. nr.: 32]
1715
1720
1725
1730
<td>Met</td><td>Ala</td><td>Asn Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Val Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td>
1735
RO 118016 Β1
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 33]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td colspan="2">Arg Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Thr</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 34]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Val</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Thr</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
Gin [Secv. nr.: 35]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Thr</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 36]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
RO 118016 Β1
1785
<td>Met</td><td>Ala</td><td>Asn</td><td>cys</td><td>Ser</td><td>lle :</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Val</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>ASP</td><td>Ser</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>G1U</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 37]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 38]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Zle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>. Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>. Glu</td><td>Gin</td>
Gin [Secv. nr.: 39]
1790
1795
1800
1805
1810
1815
1820
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser Tle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Ser</td><td>Asn</td><td>Leu</td><td>Glu Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
1825
RO 118016 Β1
<td colspan="6">Ile Ile Ile Lys Ala Gly</td><td colspan="8">Asp Trp Gin Glu Phe Arg Glu Lys</td>
<td colspan="4">Leu Thr Phe Tyr</td><td rowspan="2">Leu</td><td rowspan="2">Val</td><td rowspan="2">Thr</td><td colspan="3" rowspan="2">Leu Glu Gin</td><td rowspan="2">Ala</td><td rowspan="2">Gin</td><td colspan="2" rowspan="2">Glu Gin</td>
<td>Gin</td><td colspan="3">[Secv. nr.: 40]</td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ala</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Met</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 41]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Met</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="3">[Secv. nr.: 42]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
Gin [Secv. nr.: 43]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
RO 118016 Β1
1875
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="3">[Secv. nr.: 44]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
1880
1885
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>ASp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Met</td><td>Ser</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 45]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Tyr</td><td>Pro</td><td>Glu</td><td>Thr</td><td>Asp</td><td>Tyr</td><td>Lys</td><td>Asp</td><td>Asp</td><td>Asp</td><td>Asp</td><td>Lys</td>
<td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ala</td>
<td>Glu</td><td>Asp</td><td>Val</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td><td>Pro</td>
<td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Asn</td>
<td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td>
<td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td>
<td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td>
<td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
[Secv. nr.: 46]
1890
1895
1900
1905
1910
<td>Met</td><td>Ala</td><td>Tyr</td><td>Pro</td><td>Glu</td><td>Thr</td><td>ASp</td><td>Tyr</td><td>Lys</td><td>Asp</td><td>Asp</td><td>Asp</td><td>Asp</td><td>Lys</td>
<td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td>
<td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td>
<td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td>
<td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td>
1915
RO 118016 Β1
<td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td>
<td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td>
<td colspan="2">Phe Tyr [Secv, nr.:</td><td colspan="2">Leu Val 47] și</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>Leu</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>lle</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Leu</td><td>Asp</td><td>Ser</td><td>Ala</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 48].</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
în continuare sunt date exemple de proteine de fuziune în conformitate cu prezenta invenție
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>ile</td><td>Met</td><td>lle</td><td>ASp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Cys</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td>Gin</td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td>Thr</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td>
RO 118016 Β1
<td>Gin</td><td colspan="2">Gly Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td> 1965</td>
<td>Ala</td><td colspan="2">Gly Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td></td>
<td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td><td></td>
<td colspan="2">[Secv. nr.:</td><td> 121]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 1970</td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td></td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td></td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td></td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td> 1975</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td></td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td></td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td></td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td rowspan="2"> 1980</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td><td></td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td><td></td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td><td rowspan="2"> 1985</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td><td></td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td>Gin</td><td></td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td><td></td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td>Thr</td><td> 1990</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td><td></td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td><td></td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td></td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td> 1995</td>
<td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td><td></td>
<td colspan="2">[Secv. nr.</td><td> : 122]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
2000
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
2005
RO 118016 Β1
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Lys</td><td>lle</td><td>Ser</td><td>Pro</td><td colspan="3">Gly Gly Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td>Gin</td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td>Thr</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td>
<td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td>
<td colspan="2">[Secv. nr.</td><td> : 123]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Mec</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td>Gin</td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td>Thr</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td>
RO 118016 Β1
Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro [Secv. nr.: 124]
2055
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td>
<td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td>
<td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td>
<td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td>
<td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td>
<td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td>
<td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 125]</td><td></td><td></td><td></td><td></td><td></td>
2060
2065
2070
2075
2080
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro .-.sn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Mec Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu C-lv</td><td>Lys</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn l-lec</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td>
<td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td>
<td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td>
<td>Ala</td><td>val</td><td>Lys</td><td>His</td><td>Leu Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td>
<td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td>
2085
2090
2095
RO 118016 Β1
Pro Ser Arg His Pro lle lle lle Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. nr.: 126]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td>
<td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td>
<td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td>
<td>Ala</td><td>val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td>
<td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td>
<td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>val</td><td>Thr</td><td>Leu</td><td>Glu</td>
<td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.</td><td> : 127]</td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
<td>Gly</td><td>Pro</td><td>lle</td><td>Ser</td><td>Thr</td><td>lle</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td>
<td>Ser</td><td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Cys</td><td>Leu</td><td>Glu</td><td>Gin</td>
<td>Val</td><td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td>
RO 118016 Β1
<td>Leu</td><td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Șer</td><td> 2145</td>
<td>Ser</td><td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td colspan="2">Gly Cys</td><td>Leu</td><td>Ser</td><td></td>
<td>Gin</td><td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td></td>
<td>Ala</td><td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td></td>
<td>Thr</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td> 2150</td>
<td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td></td>
<td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td></td>
<td>Arg</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td></td>
<td>Leu</td><td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td><td> 2155</td>
[Secv. nr.: 128]
Met Ala Asn Cys
Ser lle Met lle Asp Glu lle lle His His
<td colspan="3" rowspan="2">Leu Lys Arg</td><td colspan="5" rowspan="2">Pro Pro Asn Pro Leu</td><td colspan="7">Leu Asp Pro Asn Asn Leu</td>
<td rowspan="2">Met</td><td rowspan="2">Glu</td><td rowspan="2">Arg</td><td colspan="3" rowspan="2">Asn Leu Arg</td><td rowspan="2"> 2160</td>
<td colspan="2">Asn Ser</td><td>Glu</td><td>Asp</td><td colspan="2">Met Asp</td><td colspan="2">lle Leu</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td></td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td></td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td></td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td> 2165</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Lys</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td><td></td>
<td>Gly</td><td>Pro</td><td>lle</td><td>Ser</td><td>Thr</td><td>lle</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td><td></td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td> 2170</td>
<td>Ser</td><td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Cys</td><td>Leu</td><td>Glu</td><td>Gin</td><td></td>
<td>Val</td><td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td></td>
<td>Leu</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td></td>
<td>Leu</td><td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td> 2175</td>
<td>Ser</td><td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td></td>
<td>Gin</td><td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td></td>
<td>Ala</td><td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td></td>
<td>Thr</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td> 2180</td>
<td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td></td>
<td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td></td>
<td>Arg</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td></td>
<td>Leu</td><td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>. Ala</td><td>. Gin</td><td>Pro</td><td></td>
[Secv. nr.: 129]
Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His
RO 118016 Β1
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
<td>Gly</td><td>Pro</td><td>Ile</td><td>Ser</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td>
<td>Ser</td><td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>cys</td><td>Leu</td><td>Glu</td><td>Gin</td>
<td>Val</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td>
<td>Leu</td><td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td>
<td>Ser</td><td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td>
<td>Gin</td><td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td>
<td>Ala</td><td>Leu</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td>
<td>Thr</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td>
<td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td>
<td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td>
<td>Arg</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td>
<td>Leu</td><td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td>
[Secv. nr.: 130]
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>Ile</td><td>Glu</td><td>Ala</td><td>Ile</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
<td>Gly</td><td>Pro</td><td>Ile</td><td>Ser</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>Ile</td><td>Met</td><td>Ile</td>
<td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td>
RO 118016 Β1
2235
<td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td>
<td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td>
<td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td>
<td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td>
<td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td>
2240
<td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 131]</td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Lys</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
<td>Gly</td><td>Pro</td><td>lle</td><td>Ser</td><td>Thr</td><td>lle</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td>
<td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td>
<td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td>
<td>Met</td><td>Glu</td><td>Arg.</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td>
<td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td>
<td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td>
<td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td>
<td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.</td><td> : 132]</td><td></td><td></td><td></td><td></td>
2245
2250
2255
2260
2265
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
2270
2275
RO 118016 Β1
<td>Gly</td><td>Pro</td><td>lle</td><td>Ser</td><td>Thr</td><td>lle</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td>
<td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td>
<td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>lle</td><td>Leu</td>
<td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td><td>Phe</td><td>Val</td>
<td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td>
<td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td>
<td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td>
<td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.</td><td colspan="2"> : 133]</td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle l</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>lle</td><td>Leu</td><td>Met</td><td>ASp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Cys</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td><td>Gin</td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>ASp</td><td>Thr</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td></td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>l Ser</td><td>Phe</td><td>Leu</td>
<td>Glu</td><td>. Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>; Arg</td><td>His</td><td colspan="5">Leu Ala Gin Pro</td>
[Secv. nr.: 134]
Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His
RO 118016 Β1
2325
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>lle</td><td>Leu</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td><td>Ser</td>
<td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Val</td>
<td>Arg</td><td>Lys</td><td>lle</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Leu</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td><td>Leu</td>
<td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>lle</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td><td>Ser</td>
<td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>ser</td><td>Gin</td>
<td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td><td>Ala</td>
<td>Leu</td><td>Glu</td><td>Gly</td><td>lle</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td><td>Thr</td>
<td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>lle</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Val</td><td>Leu</td><td>Val</td><td>Ala</td><td>Ser</td><td>His</td><td>Leu</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td>
<td>Glu</td><td>Val</td><td>Ser</td><td>Tyr</td><td>Arg</td><td>Val</td><td>Leu</td><td>Arg</td><td>His</td><td>Leu</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td>
[Secv. nr.: 135]
2330
2335
2340
2345
2350
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>lle</td><td>Leu</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu</td><td>Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Ser</td><td>Asn</td><td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td>
<td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val</td><td>Ser</td><td>lle</td><td>Leu</td><td>Met</td>
<td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Ser</td><td>Phe</td><td>G.1</td><td>Arg</td>
2355
2360
2365
RO 118016 Β1
<td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td><td>lle</td>
<td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td>
<td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td>Glu</td>
<td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 136]</td><td></td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
Asn Asp Glu Asp Val Ser lle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro lle lle lle Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val lle Glu Gly Arg lle Ser Pro Gly Glu Pro Ser Gly Pro lle Ser Thr lle Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val
<td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu Gin</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td>
<td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His Pro</td><td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td>
<td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu Lys</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td>
<td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu Gin</td><td>Gin</td><td colspan="2">[Secv. nr.:</td><td> 137]</td><td></td><td></td><td></td><td></td>
<td>Met</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser lle</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>lle</td><td>lle</td><td>His</td><td>His</td>
<td>Leu</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro Ala</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Val Ser</td><td>lle</td><td>Leu</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td>
<td>Leu</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Glu Ser</td><td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn</td><td>Leu</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly lle</td><td>Glu</td><td>Ala</td><td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Ser</td><td>Arg</td><td>His</td><td>Pro</td>
<td>lle</td><td>lle</td><td>lle</td><td>Lys</td><td>Ala Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu Val</td><td>Thr</td><td>Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Val</td><td>lle</td><td>Glu Gly</td><td>Arg</td><td>lle</td><td>Ser</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Ser</td>
<td>Gly</td><td>Pro</td><td>lle</td><td>Ser</td><td>Thr lle</td><td>Asn</td><td>Pro</td><td>Ser</td><td>Pro</td><td>Pro</td><td>Ser</td><td>Lys</td><td>Glu</td>
<td>Ser</td><td>His</td><td>Lys</td><td>Ser</td><td>Pro Asn</td><td>Met</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Ala</td>
RO 118016 Β1
2415
<td>Ser</td><td>Ser</td><td>Leu</td><td>Pro</td><td>Gin</td><td>Ser</td><td>Phe</td><td>Leu</td><td>Leu</td><td>Lys</td><td>Ser</td><td>Leu</td><td>Glu</td><td>Gin</td>
<td>Val</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Glu</td><td>Lys</td>
<td>Leu</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Leu</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Val</td>
<td>Leu</td><td>Leu</td><td>Gly</td><td>His</td><td>Ser</td><td>Leu</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Tip</td><td>Ala</td><td>Pro</td><td>Leu</td><td>Ser</td>
<td>Ser</td><td>Cys</td><td>Pro</td><td>Ser</td><td>Gin</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Leu</td><td>Ser</td>
<td>Gin</td><td>Leu</td><td>His</td><td>Ser</td><td>Gly</td><td>Leu</td><td>Phe</td><td>Leu</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Leu</td><td>Leu</td><td>Gin</td>
<td>Ala</td><td>Leu</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Ser</td><td>Pro</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Leu</td><td>Asp</td>
<td>Thr</td><td>Leu</td><td>Gin</td><td>Leu</td><td>Asp</td><td>Val</td><td>Ala</td><td>Asp</td><td>Phe</td><td>Ala</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td>
<td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Leu</td><td>Gly</td><td>Met</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Leu</td><td>Gin</td><td>Pro</td>
<td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>Met</td><td>Pro</td><td>Ala</td><td>Phe</td><td>Ala</td><td>Ser</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td>
<td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td><td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td>
<td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td><td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td>
<td colspan="2">[Secv. No..</td><td> : 138]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td>
2420
2425
2430
Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Aisp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu
2435
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td><td>with</td><td>To be</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Hours</td>
<td>Asn</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>To be</td><td>Gly</td><td>Asp</td>
<td>Faction</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td>
<td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>To be</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td>
<td>Angry</td><td>list</td><td>with</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>hour</td><td>Lion</td>
<td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td><td>Gly</td><td>with</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td>
<td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gin</td>
<td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td><td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td><td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td><td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td>
2440
2445
2450
2455
RO 118016 Β1
2460 Ala Gly Gly Val Leu Val
Glu Val Ser Tyr Arg Val [Secv. no .: 139]
Ala Ser His Leu Gin Ser Phe Leu
Leu Arg His Leu Ala Gin Pro
2465
2470
2475
2480
2485
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td><td>with</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Angry</td><td>To be</td><td>Pro</td><td>To be</td><td>Pro</td>
<td>To be</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td>Glu</td><td>His</td><td>Hours</td><td>Asn</td><td>Ala</td><td>with</td><td>Gin</td><td>Glu</td><td>Ala</td>
<td>Angry</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>To be</td><td>Angry</td><td>Asp</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Glu</td><td>With</td>
<td>Asn</td><td>Glu</td><td>Thr</td><td>Hours</td><td>Glu</td><td>Hours</td><td>with</td><td>To be</td><td>Glu</td><td>With</td><td>Faction</td><td>Asp</td><td>Lion</td><td>Gin</td>
<td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Angry</td><td>Lion</td><td>Glu</td><td>Lion</td><td>Tyr</td><td>list</td><td>Gin</td>
<td>Gly</td><td>Lion</td><td>Angry</td><td>Gly</td><td>To be</td><td>Lion</td><td>Thr</td><td>list</td><td>Lion</td><td>list</td><td>Gly</td><td>Pro</td><td>Lion</td><td>Thr</td>
<td>With</td><td>With</td><td>Ala</td><td>To be</td><td>His</td><td>Tyr</td><td>list</td><td>Gin</td><td>His</td><td>Cys</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td>
<td>Glu</td><td>Thr</td><td>To be</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Gin</td><td>with</td><td>with</td><td>Thr</td><td>Faction</td><td>Glu</td><td>To be</td><td>Faction</td>
<td>list</td><td>Glu</td><td>Asn</td><td>Lion</td><td>list</td><td>Asp</td><td>Faction</td><td>Lion</td><td>Lion</td><td>Hours</td><td>with</td><td>Pro</td><td>Faction</td><td>Asp</td>
2490
2495
<td>Cys</td><td>Trp</td><td>Glu</td><td>Pro</td><td>Hours</td><td>Gin</td><td>Glu</td><td colspan="2">[Secv. no .:</td><td> 141]</td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td><td>with</td><td>To be</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Hours</td>
<td>Asn</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>To be</td><td>Gly</td><td>Asp</td>
<td>Faction</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Angry</td><td>to be</td><td>Pro</td><td>To be</td><td>Pro</td>
2500
RO 118016 Β1
2505
<td>To be</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td>Glu</td><td>His</td><td>Hours</td><td>Asn</td><td>Ala</td><td>with</td><td>Gin</td><td>Glu</td><td>Ala</td>
<td>Angry</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>To be</td><td>Angry</td><td>Asp</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Glu</td><td>With</td>
<td>Asn</td><td>Glu</td><td>Thr</td><td>Hours</td><td>Glu</td><td>Hours</td><td>with</td><td>To be</td><td>Glu</td><td>With</td><td>Faction</td><td>Asp</td><td>Lion</td><td>Gin</td>
<td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Angry</td><td>Lion</td><td>Glu</td><td>Lion</td><td>Tyr</td><td>list</td><td>Gin</td>
<td>Gly</td><td>Lion</td><td>Angry</td><td>Gly</td><td>To be</td><td>Lion</td><td>Thr</td><td>list</td><td>Lion</td><td>list</td><td>Gly</td><td>Pro</td><td>Lion</td><td>Thr</td>
<td>With</td><td>With</td><td>Ala</td><td>To be</td><td>His</td><td>Tyr</td><td>list</td><td>Gin</td><td>His</td><td>cys</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td>
<td>Glu</td><td>Thr</td><td>To be</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Gin</td><td>with</td><td>with</td><td>Thr</td><td>Faction</td><td>Glu</td><td>To be</td><td>Faction</td>
<td>list</td><td>Glu</td><td>Asn</td><td>Lion</td><td>list</td><td>Asp</td><td>Faction</td><td>Lion</td><td>Lion</td><td>Hours</td><td>with</td><td>Pro</td><td>Faction</td><td>Asp</td>
<td>cys</td><td>Trp</td><td>Glu</td><td>Pro</td><td>Hours</td><td>Gin</td><td>Glu</td><td colspan="2">[Secv. no .:</td><td> : 142]</td><td></td><td></td><td></td><td></td>
2510
2515
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>G1U</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>Pro</td><td>Hours</td><td>Asn</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Gly</td><td colspan="2">Gly Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Gly</td><td>To be</td><td>Gly</td><td>Asn</td><td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td>
<td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td>
<td>Angry</td><td>list</td><td>with</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td>
<td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td><td>Gly</td><td>with</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td>
<td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gin</td>
<td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td><td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td>
2520
2525
2530
2535
<td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td><td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td>
<td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td><td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td><td>hour</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td>
<td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td><td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td>
[Secv. no .: 143]
2540
2545
Met Ala Asn Cys Ser With Met With Asp Glu With His His
RO 118016 Β1
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>for</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>hour</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>for</td><td>Glu</td><td>Gly</td><td>Angry</td><td>for</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td>
<td>Gly</td><td>Pro</td><td>for</td><td>To be</td><td>Thr</td><td>for</td><td>Asn</td><td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td>
<td>To be</td><td>His</td><td>list</td><td>To be</td><td>Pro</td><td>Asn</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Angry</td><td>To be</td><td>Pro</td><td>To be</td>
<td>Pro</td><td>To be</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td>Glu</td><td>His</td><td>Hours</td><td>Asn</td><td>Ala</td><td>for</td><td>Gin</td><td>Glu</td>
<td>Ala</td><td>Angry</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>To be</td><td>Angry</td><td>Asp</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Glu</td>
<td>With</td><td>Asn.</td><td>Glu</td><td>Thr</td><td>Hours</td><td>Glu</td><td>Hours</td><td>for</td><td>To be</td><td>Glu</td><td>With</td><td>Faction</td><td>Asp</td><td>Lion</td>
<td>Gin</td><td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Angry</td><td>Lion</td><td>Glu</td><td>Lion</td><td>Tyr</td><td>list</td>
<td>Gin</td><td>Gly</td><td>Lion</td><td>Angry</td><td>Gly</td><td>To be</td><td>Lion</td><td>Thr</td><td>list</td><td>Lion</td><td>list</td><td>Gly</td><td>Pro</td><td>Lion</td>
<td>Thr</td><td>With</td><td>With</td><td>Ala</td><td>To be</td><td>His</td><td>Tyr</td><td>list</td><td>Gin</td><td>His</td><td>Cys</td><td>Pro</td><td>Pro</td><td>Thr</td>
<td>Pro</td><td>Glu</td><td>Thr</td><td>To be</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Gin</td><td>for</td><td>for</td><td>Thr</td><td>Faction</td><td>Glu</td><td>To be</td>
<td>Faction</td><td>list</td><td>Glu</td><td>Asn</td><td>Lion</td><td>list</td><td>Asp</td><td>Faction</td><td>Lion</td><td>Lion</td><td>Hours</td><td>for</td><td>Pro</td><td>Faction</td>
<td>Asp</td><td>Cys</td><td>Trp</td><td>Glu</td><td>Pro</td><td>Hours</td><td>Gin</td><td>Glu</td><td colspan="2">[Secv. no .:</td><td> : 144]</td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>for</td><td>Lion</td><td>With</td><td>G1U</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>for</td><td>Glu</td><td>Gly</td><td>Angry</td><td>for</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Pro</td><td>Hours</td><td>Pro</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Asp</td>
<td>To be</td><td>list</td><td>Asp</td><td>Hours</td><td>Ala</td><td>Ala</td><td>Pro</td><td>His</td><td>Angry</td><td>Gin</td><td>Pro</td><td>Lion</td><td>Thr</td><td>To be</td>
<td>To be</td><td>Glu</td><td>Angry</td><td>for</td><td>Asp</td><td>list</td><td>Gin</td><td>for</td><td>Angry</td><td>Tyr</td><td>for</td><td>Lion</td><td>Asp</td><td>Gly</td>
<td>for</td><td>To be</td><td>Ala</td><td>Lion</td><td>Angry</td><td>list</td><td>Glu</td><td>Thr</td><td>Cys</td><td>Asn</td><td>list</td><td>To be</td><td>Asn</td><td>With</td>
<td>Cys</td><td>Glu</td><td>To be</td><td>To be</td><td>list</td><td>Glu</td><td>Ala</td><td>Lion</td><td>Ala</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td>
<td>Lion</td><td>Pro</td><td>list</td><td>With</td><td>Ala</td><td>Glu</td><td>list</td><td>Asp</td><td>Gly</td><td>Cys</td><td>Faction</td><td>Gin</td><td>To be</td><td>Gly</td>
<td>Faction</td><td>Asn</td><td>Glu</td><td>Glu</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Hours</td><td>list</td><td>for</td><td>for</td><td>Thr</td><td>Gly</td><td>Lion</td>
<td>Lion</td><td>Glu</td><td>Faction</td><td>Glu</td><td>Hours</td><td>Tyr</td><td>Lion</td><td>Glu</td><td>Tyr</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Angry</td><td>Faction</td>
RO 118016 Β1
<td>Glu</td><td>To be</td><td>To be</td><td>Glu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Angry</td><td>Ala</td><td>Hours</td><td>Gin</td><td>With</td><td>To be</td><td>Thr</td><td> 2595</td>
<td>Lys</td><td>Hours</td><td>Lion</td><td>for</td><td>Gin</td><td>Faction</td><td>Lion</td><td>Gin</td><td>list</td><td>list</td><td>Ala</td><td>list</td><td>Asn</td><td>Lion</td><td></td>
<td>Asp</td><td>Ala</td><td>for</td><td>Thr</td><td>Thr</td><td>Pro</td><td>Asp</td><td>Pro</td><td>Thr</td><td>Thr</td><td>Asn</td><td>Ala</td><td>To be</td><td>Lion</td><td></td>
<td>Lion</td><td>Thr</td><td>list</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Asn</td><td>Gin</td><td>Trp</td><td>Lion</td><td>Gin</td><td>Asp</td><td>With</td><td></td>
<td>Thr</td><td>Thr</td><td>His</td><td>Lion</td><td>for</td><td>Lion</td><td>Angry</td><td>To be</td><td>Faction</td><td>list</td><td>Glu</td><td>Faction</td><td>Lion</td><td>Gin</td><td> 2600</td>
<td>To be</td><td>To be</td><td>Lion</td><td>Angry</td><td>Ala</td><td>Lion</td><td>Angry</td><td>Gin</td><td>With</td><td colspan="2">[Secv. no .:</td><td> 145]</td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td><td></td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td><td> 2605</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td><td></td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td><td></td>
<td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td><td></td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td colspan="2">Gly Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td><td rowspan="2"> 2610</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td><td></td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td><td></td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td><td></td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td><td> 2615</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td><td></td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>for</td><td>Glu</td><td>Gly</td><td>Angry</td><td></td>
<td>for</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td></td>
<td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td> 2620</td>
Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
Glu Asp Met Asp lle Leu Met Glu Arg Asn Leu Arg Thr Pro
Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn
<td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td>
<td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td>
<td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td>
<td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td colspan="2">[Secv. No..</td><td> : 146]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Read Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys Lee</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Read Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Wing Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
RO 118016 Β1
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td colspan="2">Gly Gly</td><td>hour</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td>
<td>with</td><td>To be</td><td>Pro</td><td>Gly</td><td colspan="2">Gly Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td>
<td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td><td>Lion</td><td>list</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td>
<td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>with</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td>
<td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td>
<td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td>
<td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with</td><td>with</td>
<td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td>
<td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td colspan="2">[Secv. no .:</td><td> : 147]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>with</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>with</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td>
<td>Hours</td><td>Asn</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>To be</td><td>Gly</td>
<td>Asp</td><td>Faction</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td>
<td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td>
<td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>hour</td><td>To be</td><td>with</td><td>Lion</td>
RO 118016 Β1
2685
<td colspan="5" rowspan="3">Met Asp Arg Asn Leu Glu Asn Ala Ser Gly Pro Cys Leu Pro Ser Ile Ile Ile Lys Ala</td><td colspan="9">Arg Leu Val Arg Ala Val List Asn Leu</td>
<td colspan="2" rowspan="2">Ile Glu Ala Thr Gly Asp</td><td colspan="7">Ala Hair Leu Arg Asn Leu Gin</td>
<td colspan="2">Do not start Trp Gin</td><td colspan="5">Pro Ser Arg His Pro Glu Phe Arg Glu List</td>
<td rowspan="2">Lion Gin</td><td colspan="4">Thr Phe Tyr Leu</td><td rowspan="2">Hours</td><td rowspan="2">Thr</td><td rowspan="2">Lion</td><td rowspan="2">Glu</td><td rowspan="2">Gin</td><td rowspan="2">Ala</td><td rowspan="2">Gin</td><td colspan="2" rowspan="2">Glu Gin</td>
<td colspan="2">[Secv. no .:</td><td colspan="2"> 148]</td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>with</td><td>Gin</td><td>Gly</td>
<td colspan="2">Asp Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>with</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td colspan="2">Gly Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pto</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td>
<td>with</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td><td>Gly</td><td>Pro</td><td>with</td><td>To be</td><td>Thr</td><td>with</td><td>Asn</td>
2690
2695
2700
2705
Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser Ile Met Ile Asp Glu Ile Ile His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser Ile Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly Ile Glu Ala Ile Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro Ile Ile Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin [Secv. no .: 149]
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala
2710
2715
2720
2725
RO 118016 Β1
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td>
<td>with</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td><td>Gly</td><td>Pro</td><td>with</td><td>To be</td><td>Thr</td><td>with</td><td>Asn</td>
<td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td><td>To be</td><td>His</td><td>list</td><td>To be</td><td>Pro</td><td>Asn</td><td>With</td>
<td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td><td>Lion</td>
<td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td>
<td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Thr</td>
<td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td>
<td>Cys</td><td>Lion</td><td>Pro</td><td>to be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with</td>
<td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td>
<td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td>
<td colspan="2">[Secv. No..</td><td> : 150]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>with</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>with</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>with</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>with</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td>
<td>with</td><td>To be</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Hours</td><td>Asn</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td>
<td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td>
<td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td>
<td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>To be</td><td>Gly</td><td>Asp</td><td>Faction</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>With</td><td>Ala</td>
RO 118016 Β1
<td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td> 2775</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td></td>
<td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>for</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Thr</td><td>Pro</td><td></td>
<td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td></td>
<td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td> 2780</td>
<td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td><td></td>
<td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td></td>
<td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td>
[Secv. no .: 151]
2785
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>ASp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td>
<td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>To be</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td>
<td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td> 2800</td>
<td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td></td>
<td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td><td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td></td>
<td>Cys</td><td>Pro</td><td>To be</td><td>Gin.</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>to be</td><td>Gin</td><td></td>
<td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td><td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td> 2805</td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td></td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td><td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td><td>Gin</td><td></td>
<td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td></td>
<td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td><td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td rowspan="2"> 2810</td>
<td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td><td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td>
<td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td><td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td></td><td></td>
[Secv. no .: 152]
Met Ala Asn Cys Ser lle Met lle Asp Glu lle lle His His
Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu
2815
RO 118016 Β1
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td>
<td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td>
<td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td>
<td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td>
<td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td>
<td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td>
<td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv. No..</td><td colspan="2"> : 153]</td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Asn</td><td>cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>for</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td>
<td>Gly</td><td>Pro</td><td>for</td><td>To be</td><td>Thr</td><td>for</td><td>Asn</td><td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td>
<td>To be</td><td>His</td><td>list</td><td>To be</td><td>Pro</td><td>Asn</td><td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td>
<td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>To be</td><td>Lion</td><td>Glu</td><td>Gin</td>
<td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td>
<td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td><td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td>
<td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td>
<td>Gin</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td><td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td>
<td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td>
<td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td><td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td>
RO 118016 Β1
Gin
Thr
Angry
Lion
With
Lion
Asn
Lion
Glu
Pro lle
Lion
Gin
Gly
To be
<td colspan="3">Gin Met Glu</td><td colspan="10">Glu Leu Gly Met Ala Pro Ala Leu Gin Pro</td>
<td colspan="2" rowspan="2">Gin Gly Ala Gly</td><td rowspan="3">Ala Gly To be</td><td colspan="2">With Pro</td><td colspan="4">Ala Phe Ala Ser</td><td colspan="4" rowspan="2">Ala Phe Gin Arg Leu Gin Ser Phe</td>
<td rowspan="2">Hours Tyr</td><td rowspan="2">Lion Angry</td><td rowspan="2">hour Hours</td><td colspan="3">Ala Ser His</td>
<td>Glu in. No .:</td><td>Hours 154]</td><td>Lion</td><td colspan="2">Arg His</td><td colspan="2">Read Allah</td><td colspan="2">Gin Pro</td>
<td>Ala</td><td>Asn</td><td>cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td>
<td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td>
<td>Pro</td><td>for</td><td>To be</td><td>Thr</td><td>for</td><td>Asn</td><td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td>
<td>His</td><td>list</td><td>Set</td><td>Pro</td><td>Asn</td><td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td>
<td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td>
2865
2870
2875
2880
2885
Asp
<td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td>
<td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td>
<td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>c-ln</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td>
<td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td>
<td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td>
<td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>C-ln</td><td>Gin</td><td colspan="2">[Secv. no .:</td><td> 155]</td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gly</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
2890
2895
2900
2905
RO 118016 Β1
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td><td>Gly</td><td>Pro</td><td>for</td><td>To be</td><td>Thr</td><td>for</td><td>Asn</td>
<td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td><td>To be</td><td>His</td><td>list</td><td>To be</td><td>Pro</td><td>Asn</td><td>With</td>
<td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td>
<td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td>
<td>Asp</td><td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td>
<td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td>
<td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td>
<td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td>
<td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td>
<td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td colspan="2">Gin Glu</td><td>Gin</td><td>Gin</td>
[Secv. no .: 156]
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>To be</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gly</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td>Tyr</td><td>Angry</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>To be</td><td>Gly</td><td>Pro</td><td>for</td><td>To be</td><td>Thr</td><td>for</td><td>Asn</td>
<td>Pro</td><td>To be</td><td>Pro</td><td>Pro</td><td>To be</td><td>list</td><td>Glu</td><td>To be</td><td>His</td><td>list</td><td>To be</td><td>Pro</td><td>Asn</td><td>With</td>
<td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td>
Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lle Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle Glu Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro lle lle lle Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin
RO 118016 Β1 [Sec. no .: 157]
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly lle Pro Trp Wing Pro Leu Being Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gly Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lle Being Pro Glu Leu Gly pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lle Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr Val Glu Gly Gly Gly Gly Being Pro Gly Gly Gly Being Gly Gly Gly Being Asn Met Ala Asn Cys Being Met Met Asp Glu lle lle His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp As Glu Asp Val Ser le Leu Met Asp Arg Asn Leu Arg Leu Pro
2955
2960
2965
2970
2975
<td colspan="14">Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn</td>
<td colspan="5" rowspan="4">Ala Ser Gly lle Glu Leu Pro Ser Ala Thr lle Lys Ala Gly Asp Phe Tyr Leu Val Thr</td><td colspan="2">Come on</td><td colspan="7">Leu Arg Asn Leu Gin Pro Cys</td>
<td rowspan="4">Ala Trp Lion</td><td rowspan="4">Ala Gin Glu</td><td colspan="5">Pro Ser Arg His Pro</td><td colspan="2">lle lle</td>
<td colspan="2">Glu Phe</td><td rowspan="3">Angry Gin</td><td colspan="2">Glu Lys</td><td rowspan="3">Lion Gin</td><td rowspan="3">Thr</td>
<td rowspan="2">Gin</td><td rowspan="2">Ala</td><td rowspan="2">Glu</td><td rowspan="2">Gin</td>
<td colspan="2">[Secv. no .:</td><td colspan="3"> 158]</td>
<td>With</td><td>Ala</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Ala</td><td>To be</td><td>To be</td><td>Lion</td><td>Pro</td><td>Gin</td><td>To be</td>
<td>Faction</td><td>Lion</td><td>Lion</td><td>list</td><td>To be</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Hours</td><td>Angry</td><td>list</td><td>for</td><td>Gin</td><td>Gly</td>
<td>Asp</td><td>Gly</td><td>Ala</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Glu</td><td>list</td><td>Lion</td><td>Cys</td><td>Ala</td><td>Thr</td><td>Tyr</td><td>list</td>
<td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>To be</td><td>Lion</td>
<td>Gly</td><td>for</td><td>Pro</td><td>Trp</td><td>Ala</td><td>Pro</td><td>Lion</td><td>To be</td><td>To be</td><td>Cys</td><td>Pro</td><td>To be</td><td>Gin</td><td>Ala</td>
<td>Lion</td><td>Gin</td><td>Lion</td><td>Ala</td><td>Gly</td><td>Cys</td><td>Lion</td><td>To be</td><td>Gly</td><td>Lion</td><td>His</td><td>To be</td><td>Gly</td><td>Lion</td>
<td>Faction</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>Ala</td><td>Lion</td><td>Glu</td><td>Gly</td><td>for</td><td>To be</td>
<td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Hours</td>
<td>Ala</td><td>Asp</td><td>Faction</td><td>Ala</td><td>Thr</td><td>Thr</td><td>for</td><td>Trp</td><td>Gin</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>With</td><td>Ala</td><td>Pro</td><td>Ala</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>Ala</td><td>With</td><td>Pro</td>
<td>Ala</td><td>Faction</td><td>Ala</td><td>To be</td><td>Ala</td><td>Faction</td><td>Gin</td><td>Angry</td><td>Angry</td><td>Ala</td><td>Gly</td><td>Gly</td><td>Hours</td><td>Lion</td>
2980
2985
2990
2995
RO 118016 Β1
<td>Hours</td><td>Ala</td><td>To be</td><td>His</td><td>Lion</td><td>Gin</td><td>To be</td><td>Faction</td><td>Lion</td><td>Glu</td><td>Hours</td><td>To be</td><td colspan="2">Tyr Arg</td>
<td>Hours</td><td>Lion</td><td>Angry</td><td>His</td><td>Lion</td><td>Ala</td><td>Gin</td><td>Pro</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td colspan="2">Gly Gly</td>
<td>Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td>
<td>Asn</td><td>Cys</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td>
<td>Glu</td><td>Asp</td><td>Hours</td><td>To be</td><td>for</td><td>Lion</td><td>With</td><td>Asp</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td>
<td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td><td>Faction</td><td>hour</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td>
<td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td>
<td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td>
<td>for</td><td>list</td><td>Ala</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td>
<td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td colspan="2">[Secv. no .:</td><td> : 159]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>Asn i</td><td>Cys</td><td>To be</td><td>lle!</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td>
<td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>background</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td>
<td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>for</td><td>Glu</td><td>Gly</td><td>Angry</td><td>for</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>To be</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Cys</td>
<td>Asp</td><td>Lion</td><td>Angry</td><td>Hours</td><td>Lion</td><td>To be</td><td>list</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Asp</td><td>To be</td><td>His</td><td>Hours</td>
<td>Lion</td><td>His</td><td>To be</td><td>Angry</td><td>Lion</td><td>To be</td><td>Gin</td><td>Cys</td><td>Pro</td><td>Glu</td><td>Hours</td><td>His</td><td>Pro</td><td>Lion</td>
<td>Pro</td><td>Thr</td><td>Pro</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Ala</td><td>Hours</td><td>Asp</td><td>Faction</td><td>To be</td><td>Lion</td><td>Gly</td>
<td>Glu</td><td>Trp</td><td>list</td><td>Thr</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Thr</td><td>list</td><td>Ala</td><td>Gin</td><td>Asp</td><td>for</td>
<td>Lion</td><td>Gly</td><td>Ala</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Hours</td><td>With</td><td>Ala</td><td>Ala</td>
<td>Angry</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>To be</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td>
<td>Gin</td><td>Lion</td><td>To be</td><td>Gly</td><td>Gin</td><td>Hours</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Ala</td><td>Lion</td><td>Gin</td>
<td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Thr</td><td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Angry</td><td>Thr</td><td>Thr</td>
<td>Ala</td><td>His</td><td>list</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Ala</td><td>for</td><td>Faction</td><td>Lion</td><td>To be</td><td>Faction</td><td>Gin</td><td>His</td>
<td>Lion</td><td>Lion</td><td>Angry</td><td>Gly</td><td>list</td><td>hour</td><td>Angry</td><td>Faction</td><td>Lion</td><td>With</td><td>Lion</td><td>Hours</td><td>Gly</td><td>Gly</td>
<td>To be</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Hours</td><td>Angry</td><td colspan="2">[Secv. No..</td><td colspan="2"> 165]</td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>. Asn</td><td>l Cys</td><td>To be</td><td>• lle</td><td>i Met</td><td colspan="2">Asp</td><td colspan="4">to Glu place where His</td><td>; His</td>
<td colspan="2">Leu Lys</td><td>in Arg</td><td>C Pro</td><td>i Pro</td><td colspan="2">i Asn Prc</td><td>• Leo</td><td colspan="6">and Leu Asp Pro Asn Asn Leu</td>
RO 118016 Β1
<td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td> 3045</td>
<td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td></td>
<td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td></td>
<td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td></td>
<td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td> 3050</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td>Gin</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td colspan="2">Gly Gly</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td></td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>To be</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Cys</td><td></td>
<td>Asp</td><td>Lion</td><td>Angry</td><td>Hours</td><td>Lion</td><td>To be</td><td>list</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Asp</td><td>To be</td><td>His</td><td>Hours</td><td rowspan="2"> 3055</td>
<td>Lion</td><td>His</td><td>To be</td><td>Angry</td><td>Lion</td><td>To be</td><td>Gin</td><td>Cys</td><td>Pro</td><td>Glu</td><td>Hours</td><td>His</td><td>Pro</td><td>Lion</td>
<td>Pro</td><td>Thr</td><td>Pro</td><td>Hours</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Ala</td><td>Hours</td><td>Asp</td><td>Faction</td><td>To be</td><td>Lion</td><td>Gly</td><td></td>
<td>Glu</td><td>Trp</td><td>list</td><td>Thr</td><td>Gin</td><td>With</td><td>Glu</td><td>Glu</td><td>Thr</td><td>list</td><td>Ala</td><td>Gin</td><td>Asp</td><td>with</td><td></td>
<td>Lion</td><td>Gly</td><td>Ala</td><td>hour</td><td>Thr</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Hours</td><td>With</td><td>Ala</td><td>Ala</td><td rowspan="2"> 3060</td>
<td>Angry</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>To be</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td>
<td>Gin</td><td>Lion</td><td>To be</td><td>Gly</td><td>Gin</td><td>Hours</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Ala</td><td>Lion</td><td>Gin</td><td></td>
<td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Thr</td><td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Angry</td><td>Thr</td><td>Thr</td><td></td>
<td>Ala</td><td>His</td><td>list</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Ala</td><td>with</td><td>Faction</td><td>Lion</td><td>To be</td><td>Faction</td><td>Gin</td><td>His</td><td></td>
<td>Lion</td><td>Lion</td><td>Angry</td><td>Gly</td><td>list</td><td>Hours</td><td>Angry</td><td>Faction</td><td>Lion</td><td>With</td><td>Lion</td><td>Hours</td><td>Gly</td><td>Gly</td><td> 3065</td>
<td>To be</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Hours</td><td>Angry</td><td colspan="2">[Secv. No..</td><td colspan="2"> : 166]</td><td></td><td></td><td></td><td></td><td></td>
<td>With</td><td>Ala</td><td>To be</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Cys</td><td>Asp</td><td>Lion</td><td>Angry</td><td>Hours</td><td>Lion</td><td></td>
<td>To be</td><td>list</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Asp</td><td>To be</td><td>His</td><td>Hours</td><td>Lion</td><td>His</td><td>To be</td><td>Angry</td><td>Lion</td><td> 3070</td>
<td>To be</td><td>Gin</td><td>Cys</td><td>Pro</td><td>Glu</td><td>Hours</td><td>His</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Hours</td><td>Lion</td><td></td>
<td>Lion</td><td>Pro</td><td>Ala</td><td>Hours</td><td>Asp</td><td>Faction</td><td>To be</td><td>Lion</td><td>Gly</td><td>Glu</td><td>Trp</td><td>list</td><td>Thr</td><td>Gin</td><td></td>
<td>With</td><td>Glu</td><td>Glu</td><td>Thr</td><td>list</td><td>Ala</td><td>Gin</td><td>Asp</td><td>with</td><td>Lion</td><td>Gly</td><td>Ala</td><td>hour</td><td>Thr</td><td></td>
<td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Hours</td><td>With</td><td>Ala</td><td>Ala</td><td>Angry</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td rowspan="2"> 3075</td>
<td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>To be</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Gin</td><td>Lion</td><td>To be</td><td>Gly</td><td>Gin</td>
<td>Hours</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Ala</td><td>Lion</td><td>Gin</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Thr</td><td></td>
<td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Angry</td><td>Thr</td><td>Thr</td><td>Ala</td><td>His</td><td>list</td><td>Asp</td><td>Pro</td><td></td>
<td>Asn</td><td>Ala</td><td>with</td><td>Faction</td><td>Lion</td><td>To be</td><td>Faction</td><td>Gin</td><td>His</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Gly</td><td>list</td><td rowspan="2"> 3080</td>
<td>Hours</td><td>Angry</td><td>Faction</td><td>Lion</td><td>With</td><td>Lion</td><td>Hours</td><td>Gly</td><td>Gly</td><td>To be</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Hours</td>
<td>Angry</td><td>Tyr</td><td>Hours</td><td>with</td><td>Glu</td><td>Gly</td><td>Angry</td><td>with</td><td>To be</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td></td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td></td>
<td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td></td>
<td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td> 3085</td>
<td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td></td>
<td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td>with</td><td></td>
RO 118016 Β1
<td colspan="9">Leu Arg Asn Leu Gin Pro Cys Leu Pro</td><td rowspan="4">To be Ala Lion</td><td colspan="4" rowspan="2">Ala Thr Ala Ala Gly Asp Trp Gin</td>
<td colspan="3" rowspan="3">Pro Ser Arg Glu Phe Arg Gin Ala Gin</td><td colspan="5">His Pro loves you</td><td rowspan="3">list Tyr 167]</td>
<td colspan="2">Glu Lys</td><td colspan="3">Read Thr Phe</td><td rowspan="2">Hours</td><td colspan="3" rowspan="2">Thr Leu Glu</td>
<td>Glu</td><td>Gin</td><td>Gin</td><td colspan="2">[Secv, no .:</td>
<td>With</td><td>Ala</td><td>To be</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Cys</td><td>Asp</td><td>Lion</td><td>Angry</td><td>Hours</td><td>Lion</td>
<td>To be</td><td>list</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Asp</td><td>To be</td><td>His</td><td>Hours</td><td>Lion</td><td>His</td><td>To be</td><td>Angry</td><td>Lion</td>
<td>To be</td><td>Gin</td><td>Cys</td><td>Pro</td><td>Glu</td><td>Hours</td><td>His</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Hours</td><td>Lion</td>
<td>Lion</td><td>Pro</td><td>Ala</td><td>Hours</td><td>Asp</td><td>Faction</td><td>To be</td><td>Lion</td><td>Gly</td><td>Glu</td><td>Trp</td><td>list</td><td>Thr</td><td>Gin</td>
<td>With</td><td>Glu</td><td>Glu</td><td>Thr</td><td>list</td><td>Ala</td><td>Gin</td><td>Asp</td><td>for</td><td>Lion</td><td>Gly</td><td>Ala</td><td>Hours</td><td>Thr</td>
<td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Hours</td><td>With</td><td>Ala</td><td>Ala</td><td>Angry</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td>
<td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>To be</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Gin</td><td>Lion</td><td>To be</td><td>Gly</td><td>Gin</td>
<td>Hours</td><td>Angry</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Ala</td><td>Lion</td><td>Gin</td><td>To be</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Thr</td>
<td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Angry</td><td>Thr</td><td>Thr</td><td>Ala</td><td>His</td><td>list</td><td>Asp</td><td>Pro</td>
<td>Asn</td><td>Ala</td><td>for</td><td>Faction</td><td>Lion</td><td>To be</td><td>Faction</td><td>Gin</td><td>His</td><td>Lion</td><td>Lion</td><td>Angry</td><td>Gly</td><td>list</td>
<td>Hours</td><td>Angry</td><td>Faction</td><td>Lion</td><td>With</td><td>Lion</td><td>Hours</td><td>Gly</td><td>Gly</td><td>To be</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Hours</td>
<td>Angry</td><td>Glu</td><td>Faction</td><td>His</td><td>Ala</td><td>Tyr</td><td>Hours</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Pro</td>
<td colspan="2">Gly Gly</td><td>Gly</td><td>To be</td><td>Gly</td><td>Gly</td><td>Gly</td><td>To be</td><td>Asn</td><td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td>
<td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry</td><td>Pro</td><td>Pro</td>
<td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td>
<td>Asp</td><td>for</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Now</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td>
<td>Ala</td><td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td>
<td>for</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td>
<td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for</td><td>for</td><td>for</td><td>list</td><td>Ala</td>
<td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td>
<td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>. Gin</td><td>. Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td colspan="2">Gin</td><td></td><td></td><td></td>
[Secv. no .: 168]
Materials and methods for the expression of the fusion molecule in E. coli.
Except where noted, all chemical materials are obtained from Sigma Co., (St. Louis, Mo). Resting endonucleases, T4 polynucleotidinase, large fragment DNA polymerase I E. coli (Klenow) and T4 DNA ligase are obtained from New England Biolabs (Beverly, Massachusatts).
Escherichia coli strains
JM101 strain: delta (pro lac), supE, thi, F '(traD36, rpoAB, lacl-Q, LacZdeltaM15) (Messing, 1979). This strain can be obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, lockville, Maryland 20852, accession number 33876. MON105 (W3110 rpoH358) is a derivative of W3110 (Bachmann, 1972) and has been assigned the number access code ATCC 55204. GM48 strain: dam-3, dcn-6, gal, ara, lac, thr, leu, tonA, tsx (Marinus, 1973) is used to obtain plasmid DNA that is not methylated at the GATC sequence.
Gene and plasmids
The gene used to produce hlL-3 in E.coli is obtained from British Biotechnology Incorporated, Cambridge, England, catalog number BBG14. This gene is contained by a pUC-based plasmid designated pP0518. Many other human CSF genes can be obtained from R&D Systems, Inc. (Ninn, MN) including IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, G-CSF, GM-CSF and LIF.
RO 118016 Β1
3140
Plasmids used for the production of hlL-3 in E.coli contain genetic elements whose use has been described (Olins et al., 1988; Olins and Rangwala, 1990). The replicon used is that of pBR327 (Covarrubias et al., 1981), which is maintained in a number of copies of about 100 in the cell (Soberon et al., 1980). A plasmid gene encodes the deta-lactamase protein. This protein gives the cell ampicillin resistance. This resistance serves as a selectable phenotype for the presence of the plasmid in the cell.
For cytoplasmic expression of vectors, the transcription promoter is derived from the recA gene of E.coli (Sancar et al., 1980). This promoter, designated precA, includes the RNA polymerase binding site and the lexA repressor binding site (the operator). This DNA segment provides the high level of transcription that is bound even when the recA promoter is on a plasmid with the origin of pBR327 replication (Olins et al., 1988) incorporated herein by reference).
The binding site of the ribozone used is that of gene 10 of phage 17 (Olins et al., 1988). It is encoded in a fragment of 100 base pairs (bp), placed adjacent to precA. In the plasmids used herein, the recognition sequence for the Ncol enzyme (CCATGG) follows glo-L. It is at this Ncol site, to which the hlL-3 genes are linked to the plasmid. It is expected that the nucleotide sequence at this junction is recognized in the mRNA as a functional starting site for translation (Olins et al., 1988). The hlL-3 genes were processed to have a HindiII recognition site (AAGCTT), downstream of the gene coding sequence. At this Hindlll site, there is a Rsal fragment of 514 base pairs, which contains the origin of the single-stranded phage replication fl (Dente et al., 1983; Olins et al., 1990) both incorporated herein by reference. A plasmid containing these elements is pMON2341. Another plasmid containing these elements is pMON5847, which is stored at the ATCC, under accession number 68912.
In secretion expression plasmids, the transcriptional promoter is derived from the E. coli B, A and D genes (Greenfield et al., 1978). This promoter is designated pAraBAD and is contained on a restriction fragment Sacii, Bglll of 323 base pairs. The LamB secretion leader (Wong et al., 1988, Clement et al., 1981) is fused to the Nterminal end of the hlL-3 gene in the recognition sequence for the Ncol enzyme (5'CCATGG3 '). The hlL-3 genes used were processed to have a Hindlll recognition site (5'AAGCTT3 '), which follows the gene coding sequence.
Metode DNA recombinant.
Synthetic gene assembly
The hlL-3 variant genes and other CSF genes can be constructed by assembling synthetic oligonucleotides. Synthetic oligonucleotides are designated such that they will normalize into complementary pairs with single stranded ends, which exit out and, when the pairs are properly assembled, will result in a DNA sequence, which encodes a portion of the desired gene. Amino acid substitutions, in the hlL-3 gene, are made by designating oligonucleotides to encode desired substitutions. Complementary oligonucleotides are normalized to a concentration of 1 pmol / pl in ligation buffer plus 50 mM NaCl. The samples are heated in a 100 ml laboratory vessel with hot water and allowed to cool slowly, at room temperature. From each normalized oligonucleotide pair, 1 pmol is ligated with approximately 0.2 pmol of plasmid DNA, digested with the appropriate restriction enzymes in ligation buffer (25 mM Tris pH 8.0, 10 mM MgC12, 10 mM dithiothreitol, 1 mM ATP, 2 mM spermidine) with T4 DNA ligase obtained from New England Biolabs (Beverly, Massachusetts) in a total volume of 20 µl, at room temperature, overnight.
3145
3150
3155
3160
3165
3170
3175
3180
RO 118016 Β1
The polymerization chain reaction in the polymerase chain reaction techniques (hereinafter referred to as PCR) (Saiki, 1985) used the reagent kit and the thermal cycler from Perkin-Elmer Cetus (Norwalk, CT.). PCR is based on a thermostable DNA polymerase from Thermus Aquaticus. PCR technique is a method of DNA amplification, which mimics the process of natural DNA replication, in which the number of DNA molecules doubles after each cycle, in a similar way to in vivo replication. DNA polymerase, which mediates extension, is in a 5 'to 3' direction. The term "primer", as used herein, refers to an oligonucleotide sequence, which provides an end at which DNA polymerase can add the nucleotide which is complementary to a nucleotide sequence. The last nucleotide sequence is called a "matrix, where the polymers are normalized. The amplified PCR product is defined as the region between the 5 'ends of the extension primers. Because the primers have defined sequences, the product will have precise ends, which correspond to the primer sequences. The primer extension reaction is performed using 20 pmol of each oligonucleotide and 1 µg of template DNA plasmid for 35 cycles (1 cycle is defined as 94 ° C for 1 min, 50 ° C for 2 min and 72 ° C for 3 min. ). The reaction mixture is extracted with an equal volume of phenol / chloroform (50% phenol and 50% chloroform, volume by volume), for protein removal. The aqueous phase containing the amplified DNA and the solvent phase are separated by centrifugation, 5 min., In a microcentrifuge (Model 5414 Eppendorf Inc. Fremont CA.). To precipitate the amplified DNA, remove and transfer to a new tube with 1/10 volume of 3 M NaUAc (pH 5.2) and 2.5 volumes of ethanol (100%, stored at - 20 °). C). The solution is mixed and placed on dry ice, 20 min. Pellet the DNA by centrifugation, 10 minutes, in a microcentrifuge and remove the solution from the pellet. The DNA pellet was washed with 70% ethanol, the ethanol was removed and dried in a vacuum concentrator (Savant, Fermingdale, New York). The pellet was resuspended in 25 μΙ TE (20 mM Tris-HCl, pH 7.9, 1 mM EDTA). Alternatively, the DNA is precipitated by adding an equal volume of 4 M NH<sub>4</sub>OAc and 1 volume of isopropanol (Treco et al. (1988)). The solution was mixed, incubated at room temperature, 10 min., And centrifuged. These conditions precipitate selectively DNA fragments, that is, on those larger than about 20 bases and are used for the removal of the primary oligonucleotides. One quarter of the reaction is digested with restriction enzymes (Higuchi, (1989)) on a heating supplement, up to 70 ° C, for enzyme inactivation.
Recovery of recombinant plasmids from ligand mixtures
GM101 E.coli cells are competent for DNA uptake. Usually, 20 to 100 ml of cells are grown in LB medium to a density of about 150 Klett units and then collected by centrifugation. The cells are resuspended in a culture medium of 50 mM CaCl<sub>2</sub> and kept at 4 ° C for 1 h. DNA was added to a volume of 150 μΙ of these cells and the samples maintained at 4 ° C for 30 min. The samples are passed at 42 ° C, for 1 min, 1 ml of LB is added and the samples are stirred at 37 ° C, 1 h. The cells in these samples are disseminated on plates containing ampicillin for selecting the transformants. The plates are incubated overnight at 37 ° C. Single colonies are collected, grown in LB supplemented with ampicillin overnight at 37 ° C with agitation. From these cultures, DNA is isolated for restriction analysis.
Culture environment
For cell growth, in order to isolate DNA, LB medium is used (Maniatis et al., 1982). For cultures where the recombinant fusion molecule is produced, the minimal medium M9, supplemented with 1.0% casamino acid, hydrolyzed casein acid Difco (Detroit, Michigan) is used. The ingredients in the M9 environment are the following: 3 g / l KH<sub>2</sub>PO<sub>4</sub>, 6 g / l In<sub>2</sub>HPO<sub>4</sub>, 0.5 g / l NaCI, 1 g / l NH<sub>4</sub>CI, 1.2 mM MgSO<sub>4</sub>, 0.025 mM CaCI<sub>2</sub>, 0.2% glucose
RO 118016 Β1 (0.2% glycerol with AraBAD promoter), 1% casamino acids, 0.1 ml / l microelements (per liter 108 g FeCl<sub>3</sub>,6H<sub>2</sub>O, 4.0 g ZnSO<sub>4</sub>, 7H<sub>2</sub>O, 7.0 gCOCI<sub>2</sub>, 2H<sub>2</sub>O, 7.0 g Na<sub>2</sub>MoO<sub>4</sub>.2H<sub>2</sub>O, 8,0 g CuSO<sub>4</sub>,5H<sub>2</sub>O, 2,0 g H<sub>3</sub>BO<sub>3</sub>, 5.0 g MgSO ^ .I- ^ O, 100 ml concentrated HCl). For solid media, Bacto agar is used and ampicillin is added to both liquid and solid LB media at 200 / zg / ml.
Production of fusion molecules in E.coli, with vectors using the recA promoter
E.coli strains, where the plasmids of interest are stored, are raised to 37 ° C, in M9 medium, in which casein acids are added, with stirring in a Geyrotory water bath, Model G76 from New Brunswick Scientific (Edison , New Jersey). Growth is monitored with a Klett Summerson measurement (green filter 54). Klett Mfg.Co. (New York, New York). At a Klett value of about 150, a culture sample (usually 1 ml) is taken for protein analysis. To the remaining culture, nalidixic acid (10 mg / ml) in 0.1 N NaOH is added to a final concentration of 50 / zg / ml. The cultures are stirred 3 to 4 h after the addition of nalidixic acid. In order to reach the maximum production of the desired gene product, in the bacterial culture a high degree of aeration is maintained. The cells are examined under a light microscope for the presence of inclusion bodies. Take 1 ml of aliquots of the culture to analyze the protein content.
Fractionation of E.coli cells, which produce fusion proteins in the cytoplasm
The first step in purifying the fusion molecules is sonication of the culture Aliquots cells, which are resuspended from the cell pellets in sonication buffer: 10 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl and 0.1 mM PMSF. These resuspended cells undergo several repeated sonication cycles, using the micropipette from a Sonicator cell destroyer, Model W-375, obtained from Heat Systems-Ultrasonics Inc (Farmingdale, New York). The size of the sonication is pursued by examining the homogenates under a light microscope. When almost all the cells are broken, the homogenates are divided by centrifugation. Pellets that contain most inclusion bodies are strongly enriched in fusion proteins.
Methods: extraction, folding and purification of fusion molecules, expressed as inclusion bodies in E.coli
These fusion proteins can be purified by a variety of standard methods. Some of these methods are described in detail in "Methods in enzymology, vol.182 Guide to Protein Purification" edited by Murray Deutscher, Academic Press, San Diego, CA (1990).
The fusion proteins, which are produced in E.coli, in the form of insoluble inclusion bodies, can be solubilized in high concentrations of denaturant such as guanidine HCI or urea, including dithiothretol or beta mercaptoethanol, as reducing agent. The folding of the protein to an active conformation can be obtained by sequential dialysis, at lower concentrations of the denaturant, without reducing agent.
In some cases, folded proteins can be affinity purified, using affinity reagents such as mAbs or receptor subunits attached to a corresponding matrix. Alternatively, (or in addition) purification can be achieved using any of a variety of chromatographic methods, such as ion exchange, gel filtration, or hydrophobic chromatography or reverse phase HPLC.
ELISA sandwich hlL-3
The concentrations of the fusion protein can be determined using an ELISA sandwich method, based on a purified affinity antibody, correspondingly. Coat microtiter plates (Dynatech Immulon II) with 150 μl goat anti-rhlL-3 at a concentration of
3235
3240
3245
3250
3255
3260
3265
3270
3275
Approximately 1 / zg / ml in 100 mM NaHCO<sub>3</sub>pH 8.2. The plates are incubated overnight at room temperature in a room where 100% humidity is maintained. The wells are emptied and the reactive sites, which remain on the plate, are blocked with 200 µl of solution containing 10 mM PBS, 3% BSA and 0.05% Tween 20, pH = 7.4, for 1 h, at 37 ° C and 100% humidity. The wells are emptied and washed 4 times with 150 mM NaCl, which contains 0.05% Tween 20 (wash buffer). Each well is then given 150 µl dilution buffer (10 mM PBS, containing 0.1% BSA, 0.01% Tween 20, pH 7.4) containing standard rhlL-3, control, sample or only dilution buffer. A standard curve is prepared, with concentrations in the range from 0.125 ng / ml to 5 ng / ml, using a stock solution of rhlL-3 (concentration determined by analyzing the amino acid composition). Plates were incubated for 2.5 h at 37 ° C and 100% humidity. The wells are emptied and each plate is washed 4 times with washing pad. Each well was then given 150 µ of optimal dilution (determined in a checkerboard test), goat anti-rhlL-3 conjugated axis, conjugated to horseradish peroxidase. The plates are incubated 1.5 h, at 37 ° C and 100% humidity. The wells are emptied and each plate is washed 4 times with washing pad. The wells were then given 150 μl ABTS substrate solution (Kirkegaard and Perry). Plates were incubated at room temperature, until the color of standard wells, containing 5 ng / ml rhlL-3, was sufficient to give an absorbance between 0.5-1.0, when read at a test wavelength of 410 nm and a reference wavelength of 570 nm, on a Dynatech microtiter plate reader. Immunoreactive rhlL-3 concentration, in unknown samples, is calculated from the standard curve, using the software provided with the plate reader.
In the following, 70 embodiments are presented.
Example 1. Construction of the expression plasmid for fusion molecules
Construction of a plasmid encoding a fusion protein, composed of IL-3 variant protein, found in plasmid pMON13288 (WO 94/12638), followed by a proteolytic cleavage site factor Xa, followed by the murine IgG 2b major region, in which cysteines were replaced by serine, as a polypeptide linker sequence between the 2 fusion proteins and followed by GGSF. Plasmid pMON 13288 is digested with EcoRI (which is internal, in IL-3 variant gene) and Hind III (which is after stop codons for IL-3 variants) and the restriction fragment EcoRI, Hind III of 3990 bp is purified. Genetic elements derived from pMON13288 are the beta-lactamase (AMP) gene, the origin of PBR327 replication, the recA promoter, the g1pL ribosomal binding site, the bases encoding amino acids 15-105 of the variant gene (15-125) IL-3, and the origin of phage replication. fl. Complementary pairs of synthetic oligonucleotides are designated to replace the IL-3 variant gene portion, after the EcoRI site (bases encoding amino acids 106-125), the DNA sequence encoding the cleavage factor Xa site, the DNA sequence encoding the polypeptide linker, and the restriction site Afllll, to allow donation of the second gene from the fusion. When the oligonucleotides were properly assembled, a DNA sequence resulted, encoding, within the components mentioned above with EcoRI and HindIII restriction ends. In this DNA sequence, unique restriction sites have also been created to allow the subsequent replacement of specific regions with a sequence, which has a similar function (eg, alternative polypeptide linker region). A unique SnaBI restriction site is created, at the end of gene 13288, which allows the donation of other genes, at the position of the C-terminal end of the fusion. A unique Xmal site is created, between the sequence encoding the cleavage site factor Xa and the region encoding the linker polypeptide. A unique Afllll site is created, after the linker region, which allows for cloning of the protein at the N-terminus of the fusion. The 3900 bp fragment of pMON13288 is ligated with the assembled oligonucleotides and transformed into a corresponding E.coli strain. The resulting clones are searched by restriction analysis and DNA sequenced to confirm that
RO 118016 Β1
3330 the desired DNA sequence. The resulting plasmid is used as an intermediate, in which other genes such as an Ncol fragment, Hind III in the Afli 11 and Hind III sites can be cloned to create the desired fusion. The prominences created by Ncol and Afllll are compatible, but the sequence that limits recognition restriction sites is different. The Ncol and Afllll sites are lost as a result of the donation. The restriction sites mentioned above are used as examples and are not limited to those described. Also, we can obtain by engineering other unique restriction sites that serve the function of allowing regions to be replaced, in the plasmid that encodes the resulting fusion, the DNA is sequenced, to confirm that the desired DNA sequence is obtained. Other IL-3 variant genes or other colony-stimulating factor genes may be altered in a similar manner, by genetic engineering techniques, to create appropriate restriction sites that will allow cloning at either the C-terminal position. , or N-terminal of the fusion construct, described above. In the same way, alternative sites of cleavage peptidase or polypeptide linkers may be processed in fusion plasmids.
Example 2. Expression, extraction, folding and purification of fusion proteins as pMON13061 expressed as inclusion bodies in E.coli
E.coli strains harboring the plasmids of interest are grown overnight, at 37 ° C and diluted the next morning, about 1/50 in fresh M9 medium and casamino acids. The culture is raised to 37 ° C for 3 to 4 hours until mid-log (00600 = about 1) with vigorous stirring. Add nalidixic acid (10 mg / ml) in 0.1 N NaOH, to a final concentration of 50 / zg / ml. Cultures are grown after the addition of nalidixic acid at 37 ° C for 3 to 4 hours. In order to obtain the maximum production of the desired fusion protein, a high degree of aeration is maintained in the bacterial culture. In cases where fusion proteins are produced in E.coli as insoluble inclusion bodies, the cells are examined under a light microscope for the presence of inclusion bodies.
E.coli cells containing fusion proteins in inclusion bodies were lysed by sonication. A 10% (w / v) cell suspension in 10 mM Tris-HCl pH 8.0 and 1 mM EDTA was subjected to sonicore in 3 to 4 min increments. sonication using a Sonicator cell destroyer, Model W-375, obtained from Heat Systems-Ultrasonics Inc. (Farmingdale, New York). The extent of cell destruction was controlled by examining the cells under a common light microscope. When, in principle, all cells were lysed, the inclusion bodies were harvested by centrifugation at 2800xg, for 20 min. The inclusion bodies were washed twice, by suspending the pellets of the inclusion bodies, up to 10% in sonication buffer and centrifuged as above.
The fusion proteins were dissolved in 1 g of inclusion bodies in 10 ml of 8M urea with 50 mM Tris-HCl pH 9.5 and 5 mM DTT by mixing with a Bio Homogenizer, for 10-30 s and then stirring. careful, at 4 ° C, for 1 - 2 h. The dissolved fusion protein was clarified by centrifugation at 47000 xg, for 15 min.
The folding of the protein into an active conformation was done by 8-fold dilution with 2.3 M urea in 10 mM Tris-HCl pH 9.5 for 30 minutes, until the concentration was lower at 3 M urea. Folding of the fusion protein was normally between 2 and 3M urea, although it also allowed folding and higher concentrations. The fusion was slightly agitated under these conditions, exposed to air until the protein folded and the formation of the disulfide bridges was complete. Folding was controlled by reverse phase HPLC (RP-HPLC) using a 0.46 x 15 cm Vydac C4 column (Hesperia, California) with a linear gradient of 35% to 65% acetonitrile (CH3CN) / 0.1 % trifluoroacetic acid (TFA) for 25 minutes. at 1 ml / l min.
After the folding was complete, the pH of the fusion protein solution was lowered to 5.0 with glacial acetic acid and incubated at 4 ° C. After 1 h, the solution was clarified by centrifugation at 47000 xg, for 15 min. The pH of the supernatant was lowered to 4.0 with acid
3335
3340
3345
3350
3355
3360
3365
3370
3375
RO 118016 Β1 acetic and was clarified by filtration, using a 0.45 μ filter. The filtrate was dialyzed against 2 exchanges 100 x 10 mM ammonium acetate pH 4.0. The pH of the dialyzed solution was increased to 6.5 with NaOH. Then, the neutralized solution was loaded to 2 mg of fusion protein per 1 ml of resin on a DEAE Fast Flow (Pharmacia Piscataway, NJ) crown equilibrated with 10 mM Tris-HCl pH 6.5. The fusion protein was eluted, using a linear gradient of 50 to 150 mM NaCl in equilibration buffer with a linear flow of 0.28 cm / l min, for 12 h. Using RP-HPLC analysis, the fractions were collected with a purity of 93% or better. The tight fractions were dialyzed against 2 100 x 10 mM Tris-CI pH 7.5 exchanges. The dialyzed protein solution was sterile filtered using a 0.45 μ filter and stored at 4 ° C. For purification of fusion proteins, they can also be used separately or in combination with DEAE chromatography, RP-HPLC and cation exchange chromatography such as CM Fast Flow.
The purified fusion protein was analyzed by RP-HPLC, electropolished mass spectrometry, IEF and SDS-PAGE. Protein quantification was done by amino acid composition and Bradford protein determination.
In some cases, folded proteins can be affinity purified, using affinity reagents such as mAbs or receptor subunits, attached to a corresponding matrix. Alternatively (or additionally), purification can be achieved, using any of the variety of chromatographic methods, such as ion exchange, gel filtration or hydrophobic chromatography or HPLC, in reverse phase.
These and other methods of protein purification are described in detail in Methods in Enzymology Vol. 182 Guide to Protein Purification edited by Murray Deutscher, Academic Press, San Diego, CA (1990).
Example 3. Determination of in vitro activity of fusion proteins
The concentration of the fusion protein can be determined using a sandwich ELISA technique, based on a purified affinity polyclonal antibody. Alternatively, the concentration of the protein can be determined by the amino acid composition. The bioactivity of the fusion molecule can be determined in one of many in vitro assays, compared to native IL-3, variant IL-3 or G-CSF alone or together. One such test is the AML-193 cell proliferation assay. AML-193 cells respond to IL-3 and G-CSF which allows the combined bioactivity of variant IL-3 / G-CSF fusion to be determined. In addition, other factor-dependent cell lines such as M-NFS-60 (ATCC.CRL 1838) or 32D that are IL-3 dependent murine cell lines may be used. IL-3 activity is specific, in particular, whereas G-CSF is not, therefore, the bioactivity of the G-CSF component of the IL-3 / G-CSF variant can be independently determined. The methylcellulose assay can be used to determine the effect of the variant IL-3 / G-CSF fusion protein on the expansion of hematopoietic, progenitor cells and the appearance of different types of hematopoietic colonies, in vitro. The methylcellulose assay can provide an estimate of the precursor frequency, as it measures the frequency of the progenitors, per 100,000 cells initiated. In the long term, stromal-dependent cultures can be used to delineate primitive hematopoietic progenitors and stem cells. This test can be used to determine if the fusion molecule simulates the expansion of very primitive progenitors and / or stem cells. Additionally, cultures with limited dilution can be performed and will indicate the frequency of the primitive progenitors stimulated by the fusion protein.
The cleavage site factor Xa is useful for cleavage of the fusion protein, after its purification and folding to separate the IL-3 and G-CSF components of the fusion. After cleavage with factor Xa, the IL-3 and G-CSF components of the fusion can be purified to homogeneity and analyzed separately, to demonstrate that both components are in an active conformation, after they have been expressed, folded and purified as a fusion.
RO 118016 Β1
Example 4. Construction of pMON13018
Construction of pMON13018, an intermediate plasmid used for the construction of plasmids containing DNA sequences, which encode fusion proteins. The 3900 bp EcoRI, HindIII restriction fragment of pMON13288 ligated with the following pairs of complementary normalized oligonucleotides.
3425 oligo # 88Cterm1 oligo # 88Cterm4 oligo # 88Xa2 oligo # 88Xa5 oligo # Glyn3 oligo # Glyn6 (SECV.Nr.91) (SECV.Nr.92) (SECV.Nr.93) (SECV.Nr.94) (SECV.Nr .95) (SECV.Nr.96)
3430
3435
The assembled oligonucleotides create EcoRI and HindIII restriction ends and the DNA sequence encoding amino acids 106-125 of variant (15-125) hlL-3 13288 and polypeptide linker 1 (Table 1), which includes the cleavage site of factor XA and amino acid sequence (Gly<sub>3</sub>To be)<sub>2</sub>. The ligation reaction was used to transform E.coli K-12 strain JM101. The transformed bacteria were selected on plates containing antipyrin. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides. A schematic diagram of the construction of plasmid pMON13018 is shown in FIG. 2.
3440
Example 5. Construction of pMON13019
Construction of pMON13019, a plasmid, used intermediate, for the construction of plasmids, containing the DNA sequence, which encodes fusion proteins. The Xmal / Afllll restriction fragment of 4014 bp from pMON13018 was ligated with the following pair of complementary, normalized oligonucleotides, oligo # lgG2b1 (SEQ. No. 97) oligo # lgG2b2 (SEQ. No. 98)
The assembled oligonucleotides create Xmal and Afllll restriction ends and the DNA sequence encoding amino acids 9-33 of linker polypeptide 4 (Table 1), which is comprised of the cleavage site factor Xa and the murine IgG2b major region. The ligation reaction was used to transform the E.co//K12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides.
Example 6. Construction of pMON13024
Construction of pMON13024, a plasmid used intermediate, for the construction of plasmids containing DNA sequences encoding fusion proteins. The Nhel / Hindlll restriction fragment of 4091 bp from pMON13010 ligated with the following pair of complementary, normalized oligonucleotides: oligo # GCSFSnal (SEQ No. 99) oligo # GCSFSna2 (SEQ No. 100)
The assembled oligonucleotides create Nhel and HindIII restriction ends, create a SnaBI restriction site at the 3 'end of the C-CSF gene and DNA sequence, which encodes amino acids 155-175 of G-CSF. The stop codon after the G-CSF gene is deleted and the DNA sequence of the SnaBI recognition site encodes the Tyr Val amino acids in the frame at the C-terminus of G-CSF. The ligation reaction was used to transform E.coli K-12 strain JM101. The transformed bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides.
3445
3450
3455
3460
3465
3470
RO 118016 Β1
3475
3480
3485
3490
3495
3500
3505
3510
Example 7. Construction of pMON13027
Construction of pMON 13027, a plasmid used intermediate for plasmid construction, containing the DNA sequence, which encodes fusion proteins. Plasmid DNA pMON13018 was digested with restriction enzymes Ncol and SnaBI, resulting in an Ncol, SnaBI fragment of 3704 bp. Plasmid DNA pMON13024 was digested with Ncol and SnaBI, resulting in an Ncol, SnaBI fragment of 528 bp. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insertion.
Example 8. Construction of pMON13032
The construction of pMON 13032, a plasmid used intermediate, for the construction of plasmids containing DNA sequences, encoding fusion proteins, the plasmid DNA of pMON 15930 was digested with the restriction enzymes Ncol and SnaBI, resulting in a Ncol, SnaBI fragment of 3829 bp. Plasmid pMONI 3024 was digested with Ncol and SnaBI, resulting in an Ncol, SnaBI fragment of 528 bp. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert.
Example 9. Construction of pMONI3041
Construction of pMON13041, an intermediate plasmid used to construct plasmids, containing DNA sequences, which encode fusion proteins. The 4018 bp SnaBI / Xmal restriction fragment from pMON13018 was ligated with the following pair of complementary, normalized oligonucleotides:
oligo # Lysxa1 (SECV.No.101) oligo # Lysxa2 (SECV.No.102)
The assembled oligonucleotides create SnaBI and Xmal restriction ends and the DNA sequence, which encodes amino acids 1-8 of linker polypeptide 2 (Table 1), which is comprised of the cleavage site factor Xa, in which Arg is changed to Lys and the amino acid sequence (Gly<sub>3</sub>To be)<sub>2</sub>. The ligation reaction was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated from a colony grown in LB broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides.
Example 10. Construction of pMON13042
Construction of pMON13042, an intermediate plasmid, used for the construction of plasmids containing DNA sequences, which encode fusion proteins. The 4018 bp SnaBI / Xmal restriction fragment from pMONI 3018 was ligated with the following pair of complementary normalized oligonucleolides: oligo # Glyxa1 (SEQ. No. 103) oligo # Glyxa2 (SEQ. No. 104)
The assembled oligonucleotides create SnaBI and Xmal restriction ends and the DNA sequence encoding linker polypeptide 3 (Table 1).
Link polypeptide 3 is comprised of the following amino acid sequence: Tyr Val Glu Gly Gly Gly Gly Gly Ser Pro (Gly<sub>3</sub>To be)<sub>2</sub> Asn (SEQ. No. 190). The ligation reaction was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated from a colony grown in LM broth. The DNA was sequenced to determine that the sequence was that of the oligonucleotides.
3515
RO 118016 Β1
3520
Example 11. Construction of pMON13046
The construction of pMON13046, an intermediate plasmid, used for plasmid construction, containing the DNA sequence encoding fusion proteins. The DNA of plasmid pMON13018 was digested with the restriction enzymes Ncol and NsiL resulting in a Ncol, Nsil fragment of 3873 bp. Plasmid DNA was differentiated from pMON13416, WO 94/12638, which encodes a hlL-3 variant with Ncol and Nsil resulting in a 170 bp Ncol, Nsil fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K12 strain JM 101. The transforming bacteria were selected on plates containing ampicillin. The DNA fragment was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert.
Example 12. Construction of pMON 13047
Construction of pMON13047, an intermediate plasmid, used for the construction of plasmids containing the DNA sequence, which encodes fusion proteins. The DNA of plasmid pMON13019 was digested, with the restriction enzymes Ncol and Nsil, resulting in a 170 bp Ncol and Nsil fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The DNA fragment was isolated, analyzed by restriction analysis and sequenced to confirm the correct inset.
Example 13. Construction of pMON13478
A pUC18-based plasmid containing the processed gene, encoding human granulocyte colony-stimulating factor (hG-CSF), was obtained from R&T Systems (Ctalog no. BBG13, Minneapolis, MN). This plasmid was named pMON13457. The Apal, HindiII fragment of 3157 bp from pMON 13457 was ligated with the following pair of complementary, normalized oligonucleotides:
Oligo # hgcsfma1 (SECV. No.111)
Oligo # hgcsfma2 (SECV. No.112)
The assembled oligonucleotides create Hindlll and Apal restriction ends, an internal Ncol restriction site, and the DNA sequence encoding the first 4 amino acids of hG-CSF (Thr Pro Leu Gly) preceded by an initiating methionine, followed by an alanine. Methionine and alanine were added for expression in E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated, sequenced to confirm the correct insert. The resulting plasmid was designated pMON 13478.
Example 14. Construction of pMON13498
Fragment Ncol, Apal of 3163 bp from pMON 13478 was ligated with the following pair of complementary, normalized oligonucleotides: Oligo # hgcsfat3 (SEQ No. 115).
Oligo # hgcsfat4 (SECV.Nr.116)
The assembled oligonucleotides create Ncol and Apal restriction ends and increase the A / T content of the DNA sequence, which encodes the first 4 amino acids of mature hG-CSF (Thr Pro Leu Gly). The A / T content of the DNA sequence has changed to increase the levels of protein expression in E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. Plasmid DNA was isolated and sequenced to confirm the correct insert. The Apal restriction end of the oligonucleotides is compatible with the Apal site, but the Apal recognition sequence is modified. The resulting plasmid was named pMON 13498. Previous modifications to the hG-CSF gene can be found in the DNA sequence (SEQ. No. 178).
3525
3530
3535
3540
3545
3550
3555
3560
RO 118016 Β1
Example 15. Construction of pMON13010
The plasmid DNA of pMON5743 (Olins and Rangwala (1990)) was digested with restriction enzymes Ncol and EcoRI, resulting in a Ncol fragment, EcoRI of 3633 bp. Plasmid DNA pMON13498 was digested with Ncol and EcoRI, resulting in an Ncol, EcoRI fragment of 542 bp. The restriction fragments were ligated and the ligation mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. Plasmid pMON 13010 encodes the following amino acid sequence:
Peptida #
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Hly His Ser Leu Gly lle Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lle Trp Gin Gin Met Glu Glu Leu Gly with Ala Pro ala Leu Gin Pro Thr Gin gly ala with Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro (SECV. No.161)
DNA sequence # (SEQ. No. 178) encodes for the previous PMON13010 polypeptide.
Example 16. Construction of pMON13499
The Ncol fragment, Apal of 3163 bp from pMON 13478, was ligated with the following pair of complementary, normalized oligonucleotides:
Oligo # hgcsfatl (SECV. No.113)
Oligo # hgcsfat2 (SECV. No.114)
The assembled oligonucleotides create Nxol and Apal restriction ends and increase the A / T content of the DNA sequence, which encodes the first 3 amino acids of hG-CSF (Thr Pro Leu). The A / T content of the DNA sequence has changed, to increase expression levels in E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transformer batteries were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was named pMON 13499. Previous modifications to the hG-CSF gene are found in the DNA sequence (SEQ. No.177).
Example 17. Construction of luipmonl3033
The Apal, BstXI fragment of 3117 bp from pMON13499 ligated with the following pair of complementary normalized oligonucleotides:
Oligo # gcys18 (SECV.Nr.107)
Oligo # gcys1810 (SECV. No.108)
The assembled oligonucleotides create Apal and BstXI restriction ends and encode amino acids 5 to 26 of hG-CSF, except for amino acid 17, where cysteine was replaced by serine. Cysteine was replaced by a serine to increase the efficacy of in vitro folding of the isolated protein from E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13033.
RO 118016 Β1
Previous modifications to the hG-CSF gene are found in the DNA sequence (SEQ ID NO: 179). Example 18. Construction of pMON13037
The DNA of pMON5743 was digested with the restriction enzymes Ncol and EcoRI, resulting in a Ncol, EcoRI fragment of 3633 bp. The plasmid DNA of pMON13033 was digested with Ncol and EcoRI, resulting in a Ncol, EcoRI fragment of 542 bp. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. Plasmid pMON13037 encodes the following amino acid sequence.
Peptida #
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Hly His Ser Leu Gly lle Pro Trp Wing Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lle Trp Gin Gin Met Glu Glu Leu Gly with Ala Pro ala Leu Gin Pro Thr Gin gly ala with Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro (SECV. No.162)
DNA sequence # (SEQ. No. 179) encodes for the previous PMON13037 polypeptide.
Example 19. Construction of pMON13011.
A plasmid based on pUC18 was obtained, which contains the processed gene, which encodes the human macrophage granulocyte colony-stimulating factor (hGM-CSF) from R5D Systems {Catalog No.BGG12, Minneapolis MN). This plasmid was named pMON13458, ligated with the following pair of a complementary, normalized oligonucleotide: Oligo # gm-aup (SEQ. No. 105)
Oligo # gm-alow (SECV.Nr.106)
The assembled oligonucleotides create Ncol and Bsml restriction ends and the DNA sequence, which encodes the first 19 amino acids of hGM-CSF. The DNA sequence, which encodes amino acids 3, 4, 5, 7, 9, 11, 12, 13 and 15, was changed to preferred E.coli codons for increasing expression levels in E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM-101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13011. Previous modifications to hGM-CSF genes are found in the DNA sequence (SEQ No. 176).
Example 20. Construction of pMON13012
Plasmid DNA pMON5743 was digested with restriction enzymes Ncol and EcoRI, resulting in a Ncol, EcoRI fragment of 3633 bp. The DNA of plasmid pMON13011 was digested with Ncol and EcoRI, resulting in an Ncol, EcoRI fragment of 398 bp. The restriction fragments were ligated and the ligation reaction mixtures were used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. Plasmid pMON13012 encodes the following amino acid sequence:
3615
3620
3625
3630
3635
3640
3645
3650
3655
RO 118016 Β1
Peptida #
Met Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gin Pro Trp Glu His Val Asn Ala where Gin Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp Thr ala Ala Glu Met Asn Glu Thr Val Glu Val lle Ser Glu Met Phe Asp Leu Gly Glu Pro Thr Cys Leu Gin Thr Arg Leu Glu Leu Tyr Lys Gin Met Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met Met Ala Ser His Tyr Lys Gin His Cys Pro Pro Thr Glu Thr Ser Cys Ala Thr Gin where Thr Thr Glu Ser Phe Lys Glu Asn Leu Lys Asp Phe Leu Leu Val where Pro Phe Asp Cys Thr Glu Pro Val Gin Glu (SECV. No.160)
DNA sequence # (SEQ. No. 176 encodes for the previous PMON13010 polypeptide. Example 21. Construction of pMON5865
A pUC18-based plasmid containing the processed gene encoding human interleukin 6 (hlL-6) was obtained from British Biotech (Cata / ognr.BBG17). The 3170 bp Hind III / BstXI fragment of this plasmid was ligated with the following pair of complementary, normalized oligonucleotides: Oligo # HIL6231 (SEQ. No. 109)
Oligo # HIL6232 (SECV. No.110)
The assembled oligonucleotides create HindiII and BStXI restriction ends and the DNA sequence encoding the first 10 amino acids of hlL-6 plus Met Ala at the N-terminus, for E.coli protein expression.
The oligonucleotides also create an Ncol site at the 5 'end of the gene. The codons that encode the first 10 amino acids have been changed to the preferred E.coli to increase expression levels in E.coli. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON5865. Previous modifications to the hG-CSF gene are found in the DNA sequence (SEQ. No.175).
Example 22. Construction of pMON13040
Plasmid DNA pMON5743 was digested with restriction enzymes Ncol and EcoRI, resulting in an Ncol, EcoRI fragment of 3633 bp. Plasmid DNA MON5865 was digested with Ncol and EcoRI, resulting in a 572 bp Ncol, EcoRI fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. Plasmid pMON 13040 encodes the following amino acid sequence.
Peptida #
Met Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gin Pro Leu Thr Ser Ser Glu Arg where Asp Lys Gin where Arg Tyr where Leu Asp Gly where Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met ala glu Lys Asp Gly Cys Phe Gin Ser Gly Phe Asn Glu Thr Cys Leu Val Lys where Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Gin Gin Ala Arg Ala Gin Met Ser Thr Lys Val Leu where Gin Phe Leu Gin Lys Lys Ala Lys Asn Leu Asp Ala lle Thr Thr Pro Asp Pro Thr Thr Asn ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Trp Leu Gin Asp Met Thr Thr His Leu lle Leu Arg Ser Phe Lys glu Phe Leu Agn Ser Ser Leu Arg Ala Leu Arg Gin Met (SECV.Nr. 163)
RO 118016 Β1
The DNA sequence # (SEQ. No. 175) encodes for the previous pMON13040 polypeptide. Example 23. Construction of pMON15931
At the construction of pMON15931, an intermediate plasmid was used, for the construction of plasmids containing the DNA sequence, which encodes fusion proteins. The DNA sequence encoding the rich spacer region (Gly-Ser) of the pili protein of the filamentous bacteriophage fd (Schaller et al., 1975) was amplified, using PCR techniques. A plasmid containing the gene encoding the pili protein of the filamentous bacteriophage fd served as a template for the PCR reaction, using the following oligonucleotides as primers:
Oligo # prefor (SECV. No.117)
Oligo # revpre (SECV.Nr.118)
The reaction of PCR primer extension generated the following DNA sequence: CCTGTCAACC CGGGCGGCGG CTCTGGTGGT GGTTCTGGTC GCGGCTCTGA GGGTGGCGGC TCTGAGGGTG GCGGTGCTGA GGGTGGCGGGGGGGGGGGGGGGGGGGGGGGGGGG
The foregoing DNA sequence encodes amino acids 9-49 of linker polypeptide 7 (Table 1), which comprises the cleavage site factor Xa and the rich region (Gly-Ser) of the pili protein of bacteriophage fd. The PCR fragment, generated was digested with Xmal and AfliII and ligated with the Xmal, Afllll fragment of 4014 bp from pMON13018. The ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert.
Example 24. Construction of pMON5930
At the construction of pMon15930, an intermediate plasmid was used, for the construction of plasmids containing DNA sequences, which encode fusion proteins. The DNA sequence, which encodes the rich spacer region (Gly-SER), with several pili-flanking amino acids of the filamentous bacteriophage fd (Schaller et al., 1975) was amplified, using PCR techniques. As a template for the PCR reaction using the following oligonucleotides, as primers, a plasmid containing the gene encoding pili proteins of the filamentous bacteriophage fd, served.
Oligo # forxtra (SECV.Nr.119)
Oligo # xtrarev (SECV.Nr.120)
PCR primer extension reaction generated the following DNA sequence: GCTGGCGGCG GCTCTGGTGG TCCTGTCAAT CTCCCGGGCC ATCGTCTGAC GGCGGCTCTG AGGGTGGCGG CTCTGAGGGT TGGTTCTGGT AGGGTGGCGG CTCTGAGGGT GGCGGTTCTG GATTTTGATT CGGTTCCGGT GTGGCGGCTC ATGAAAACAT GGCGGTTCCG GTCAAACGCT (SECV.Nr.182)
The preceding DNA sequence encodes amino acids 9-70 of linker polypeptide 8 (Table 1), which comprises the cleavage site factor Xa and the rich region (Gly-Ser) of the pili protein of bacteriophage fd. The PCR generated fragment was digested with Xmal and Afllll and ligated with the Xmal, Afllll fragment and ligated with the Xmat, Afllll fragment of 4014 bp from pMON13018. The ligation reaction mixture was used to transform E.coli K-12 strain JM-101. The transforming bacteria were selected on plates containing ampicillin. Plasma DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert.
Example 25. Construction of pMON13038
At the construction of pMON13038, an intermediate plasmid was used, for the construction of DNA plasmids, which contain the DNA sequence, which encodes fusion proteins. Plasmid DNA pMON13019 was digested, with restriction enzymes Ncol and SnaBI, resulting in a fragment
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
RO 118016 Β1
Ncol, SnaBI of 3749 bp. The DNA of plasmid pMON13024 was digested with Ncol and SnaBI, resulting in an Ncol, SnaBI fragment of 528 bp. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13038.
Example 26. Construction of pMON13021
The DNA of plasmid pMON13018 was digested with restriction enzymes Afllll and Hindlll, resulting in an Afllll, Hindlll fragment of 4023bp. The DNA of plasmid pMON13288 was digested with Ncol and HindIII, resulting in a 345bp Ncol, Hind III fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. A schematic diagram of the plasmid construction pMON13021 is shown in FIG. 2. Plasmid pMON13021 encodes fusion with the following amino acid sequence: Peptide # (SEQ. No. 125)
DNA sequence # (SEQ. No. 54) encodes for the previous polypeptide pMON12021.
Example 27. Construction of pMON13022
The DNA of plasmid pMON13018 was digested with the restriction enzymes Afllll and Hindlll, resulting in an Afllll, Hindlll fragment of 4023 bp. Plasmid DNA pMON13012 was digested with Ncol and HindIII, resulting in a 586 bp Ncol, Hind III fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. Plasmid pMON13022 encodes the fusion with the following amino acid sequence:
Peptide # (SEQ. No. 141)
DNA sequence # (SEQ. No.55) encodes for the previous polypeptide pMON13022.
Example 28-62. The following examples of fusion proteins comprised in part of hlL-3 variants are presented in Table 2. Plasmids containing the genes encoding fusion proteins in Table 2 were constructed by methods described in Materials and Methods and Examples contained herein, in particular Examples 1, 9, 10, 26 and 27. The DNA restriction fragments indicated in Table 2 were ligated and E.coli expression plasmids (Table 2) contain DNA sequences, which encode the indicated polypeptide fusions (Table 2). Polypeptide fusions are comprised of 2 colony-stimulating factors (F ^ and R<sub>2</sub>) fused by a linker (L) polypeptide (Table 1), represented by the formula X- (L) jY, some of the genes encoding the polypeptide fusions in Table 2 were transferred from the E.coli expression vector as a fragment of restriction Ncol, HindIII in a pMON3934 expression vector in a mammalian cell (BHK). E.coli and BHK expression plasmids are presented in Table 2. Biological activity, growth promoting activity in AML193.1.3 cells. for some of the polypeptide fusions in Table 2, it is presented in Table 3. The biological activity as evaluated in the methylcellulose assay of some of the fusions in Table 2 is presented in Figures 3-7.
RO 118016 Β1
3800
Table 1
Nomenclature of linker polypeptide and amino acid sequences
<td>Polypeptide linker designation</td><td colspan="2">The amino acid sequence J</td>
<td>Links 1</td><td>YVIEGRISP(GGGS)<sub>2</sub>N</td><td>(SECV.Nr.188)</td>
<td>Left 2</td><td>YVIEGRISP(GGGS)<sub>2</sub>N</td><td>(SECV.Nr.189)</td>
<td>Links 3</td><td>YVIEGGGGSP(GGGS)<sub>2</sub>N</td><td>(SECV.Nr.190)</td>
<td>Left 4</td><td>YVIEGRISPGEPSGPISTINPSPPSKESHKSPN</td><td>(SECV.Nr.191)</td>
<td>Links 5</td><td>YVIEGKISPGEPSGPISTINPSPPSKESHKSPN</td><td>(SECV.Nr.192</td>
<td>Links 6</td><td>YVEGGGGSPGEPSGPISTINPSPPSKESHKSPN</td><td>(SECV.Nr.193</td>
<td>Links 7</td><td>YVIEGRISP(GGGS)<sub>3</sub>(EGGGS)<sub>4</sub>(GGGSGSGN</td><td>(SECV.Nr.194</td>
<td>Links 8</td><td>YVIEGRISPQPPVNA (GGGS)<sub>3</sub>(EGGGS)<sub>4</sub>GGGS GSGDFDYEN</td><td>(SECV.Nr.195</td>
<td>Links 9</td><td>EFHAYVEGGGGSP(GGGS)<sub>2</sub>N</td><td>(SECV. No. 196</td>
3805
3810
THE
->
O with w Ln
THE
What about
<td>WITH</td><td>Go</td><td>(j0</td>
<td> 00</td><td> 00</td><td> 00</td>
<td>GM</td><td>N»</td><td>i—</td>
<td>A</td><td>O</td><td>A</td>
<td>wJ sO</td><td>wJ 0</td><td>w -U</td><td>UJ CX</td><td>ONION ONION</td><td>A</td><td>«J</td><td>Ul M</td><td>Ul</td><td>tel O</td><td>NI «O</td><td>you "J</td><td>you CI</td><td>you 0</td><td></td><td> *«</td>
<td>> A · O</td><td>> L;</td><td rowspan="2">> Χ »uh</td><td>> *-O</td><td> ></td><td>> *·ϊ></td><td>> *-τ></td><td>> * · U</td><td> ></td><td rowspan="2"><sup>></sup> •‘‘'S o» «— X</td><td>FROM</td><td> ></td><td>> ATJ</td><td> ></td><td></td><td>r* <</td>
<td>*** X</td><td>»-* O x</td><td>rte · □ X</td><td>«Te» ox</td><td>rt OI</td><td>«Te. OX</td><td>rn W X</td><td>r* w Ζ</td><td>aox</td><td>rw OX</td><td>«Te» ox</td><td>«The OX</td><td></td><td></td>
<td>«-« ♦ - »o</td><td>♦·* k> O</td><td>«-« u> O</td><td>»- · 4/1 O</td><td>«-« ax o</td><td>·* c* O</td><td>«The» OX O</td><td>·“< w O</td><td>H AQ</td><td>·- to</td><td>o «uo</td><td>«u Q</td><td>· * I</td><td>«- you o</td><td></td><td>Ol O</td>
<td>M h) Z</td><td>M UJ Z</td><td>m -a Z</td><td>Muz</td><td>• those 0 Z</td><td>• these 00 Z</td><td>• these 00 Z</td><td>m «o Z</td><td>• te oo z</td><td>H « t</td><td>«Te« oz</td><td>M ui Z</td><td>»-« onion 2</td><td>• at UI 2.</td><td></td><td></td>
<td>• te ♦ -</td><td>w w</td><td>M * -</td><td>♦ M «te</td><td>♦ te U ·</td><td>►te * -</td><td>► to * te</td><td>• te · - *</td><td>Ite W</td><td>• too</td><td></td><td>• te ~</td><td>«To * - *</td><td>♦ te b-</td><td></td><td>L.</td>
<td>m cr <u >k*O o</td><td>Țte țf uj -iXJ o</td><td>m tri xi'O o</td><td> 53 5</td><td>m <r ui 'v.ti O</td><td>·-« <r Χ.Ό O</td><td></td><td>♦ the țr ut -Kt5 * o</td><td>the ui *>. <? The</td><td>· -. n · out *>»x5 «o</td><td><o σ o □ Ό o</td><td> 535</td><td> 535</td><td> 535</td><td></td><td>• n □</td>
<td>x you</td><td>X M</td><td>X such</td><td>X UJ</td><td>X u·</td><td>X —</td><td>X W</td><td>X UI</td><td>X UI</td><td>X UJ</td><td>at tu</td><td>X **</td><td>X * te</td><td>X W</td><td></td><td>GM</td>
<td>♦ - * * u</td><td> ♦— <30</td><td>►— Kl</td><td> ♦— «0</td><td>The</td><td>► * XO</td><td> ·—</td><td>*- O</td><td>M »« te</td><td> ·“</td><td>a> ***</td><td>«* «B</td><td> ►^ 0</td><td> ·— 0</td><td></td><td></td>
<td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td>♦ te</td><td> 3</td><td> 3</td><td> 3</td><td></td><td></td>
<td>a</td><td>a</td><td> 0·</td><td>a</td><td>a</td><td>a</td><td>a</td><td>Q</td><td>a</td><td>a</td><td></td><td>a</td><td>a</td><td>a</td><td></td><td></td>
<td>• te</td><td></td><td>♦ te</td><td>"to</td><td> ·-«</td><td>"to</td><td></td><td>"to</td><td> «-·</td><td>♦ te</td><td></td><td>in</td><td>out</td><td>• te</td><td></td><td></td>
<td>• te</td><td></td><td>"to</td><td>"to</td><td>• te</td><td>• te</td><td></td><td>"to</td><td>• te</td><td>♦ te</td><td></td><td>"to</td><td>• te</td><td></td><td></td><td></td>
<td>♦ te</td><td> «-4</td><td>• te</td><td>"to</td><td>"to</td><td>• te</td><td></td><td>• te</td><td>• te</td><td>"to</td><td></td><td>"to</td><td>"to</td><td>"to</td><td></td><td></td>
<td>WXJ x</td><td>U1Î3 4Γ X</td><td> 51</td><td> 51</td><td></td><td>4.0J · - X</td><td>U · X3 UI X</td><td>4AXJ VI X</td><td>iî</td><td>U »tJ UI X</td><td>mtJ • uz</td><td>*•9 ♦-* X</td><td> 51</td><td>Question 55 0 Z</td><td></td><td>m ♦*. n 9</td>
<td>v »O</td><td>ax O</td><td>v< O</td><td>VI g</td><td>UI o</td><td>♦ JO</td><td>ax O</td><td>«X o</td><td>"to</td><td>01 Q</td><td>0 o</td><td rowspan="2"><sup>M</sup>2</td><td>UI o</td><td>0 Q</td><td></td><td>0 M</td>
<td></td><td></td><td></td><td rowspan="2"> 35</td><td>_FROM</td><td>from</td><td>FROM</td><td>from</td><td>FROM</td><td>FROM</td><td>from</td><td> 2</td><td></td><td></td><td>Q ·</td>
<td> 35</td><td>a w</td><td> 35</td><td> 35</td><td></td><td> 35</td><td> 35</td><td> 35</td><td> 35</td><td> 3 5</td><td> 35</td><td> 35</td><td> 35</td><td></td><td>3 * < • TT</td>
<td> *</td><td>O</td><td>IU</td><td>you</td><td>you</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>you</td><td>O</td><td></td><td> 3</td>
<td>FROM "-*</td><td>2 onion</td><td>2 m</td><td>Z oo</td><td>2 ea</td><td>2 f</td><td>ZW</td><td>2nd century</td><td>From</td><td>2 onion</td><td>Here</td><td>2 watts</td><td> 2 0</td><td>Z u·</td><td></td><td>Cf</td>
<td>a a»</td><td>a *j</td><td>The 0</td><td>The «0</td><td>The ca.</td><td>n «u</td><td>no</td><td>(Ί O</td><td>n m</td><td>n * J</td><td>n +</td><td>n you</td><td>The 0</td><td>G O</td><td></td><td></td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> 0</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> 0</td><td></td><td></td>
<td>in</td><td>in</td><td>♦ te</td><td>• te</td><td>"to</td><td>in</td><td>"to</td><td>M</td><td>• te</td><td>♦ te</td><td>• te</td><td>• te</td><td>• te</td><td>♦ te</td><td></td><td></td>
<td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td></td><td>THAT</td><td>X</td><td>X</td><td>X</td><td></td><td></td>
<td> ♦—</td><td></td><td> «-·</td><td></td><td>"to·</td><td> ·—</td><td></td><td> »-·</td><td>H·</td><td> ·—</td><td> 3</td><td> ·—</td><td> ♦—</td><td> ·—</td><td></td><td></td>
<td> 3</td><td></td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 5</td><td>u</td><td> 3</td><td></td><td></td><td></td>
<td>a</td><td>a</td><td>a.</td><td>a</td><td>a</td><td>a</td><td>St</td><td>a</td><td>a</td><td>a</td><td> 0</td><td>a</td><td>a</td><td>â</td><td></td><td></td>
<td>♦ te</td><td>"to</td><td>"to</td><td>"to</td><td>♦ te</td><td> ·—»</td><td></td><td>"to</td><td>"to</td><td></td><td>• te</td><td>• te</td><td> »-«</td><td>"to</td><td></td><td></td>
<td>♦ te</td><td>♦ te</td><td>♦ te</td><td>"to</td><td>• te</td><td></td><td></td><td>• te</td><td>"to</td><td></td><td></td><td>• te</td><td>♦ te</td><td>♦ te</td><td></td><td></td>
<td>♦ te</td><td>• te</td><td></td><td>• te</td><td>♦ te</td><td></td><td></td><td>"to</td><td>• te</td><td>♦ te</td><td></td><td>"to</td><td>• te</td><td></td><td></td><td></td>
<td></td><td></td><td>"to</td><td> «-»</td><td>"to</td><td></td><td></td><td></td><td>in</td><td>IN</td><td>"to</td><td>IN</td><td>U</td><td>♦ te</td><td></td><td>O "</td>
<td>onion</td><td>4-J</td><td>NEW</td><td>NEW</td><td>ONION</td><td>ul</td><td>ul</td><td>ONION</td><td>ul</td><td>NEW</td><td>ONION</td><td>NEW</td><td>ONION</td><td>NEW</td><td></td><td>X ·</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> 3</td><td>«c</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td><td>O</td>
<td></td><td>new</td><td><n</td><td>ax</td><td>ONION</td><td>onion</td><td>tel</td><td>in</td><td>NEW</td><td>ax</td><td>you</td><td>you</td><td>you</td><td>you</td><td></td><td>z n</td>
<td></td><td> 0</td><td>a</td><td>onion.</td><td> 0</td><td>«Jl</td><td>4b</td><td>• bJ</td><td>"to</td><td>>u</td><td> 01</td><td>you</td><td> ·-*</td><td>"U</td><td></td><td>O</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> ♦—</td>
<td>♦ U</td><td>K></td><td>you</td><td>you</td><td>K></td><td>you</td><td>M</td><td>• u</td><td>NEW</td><td>you</td><td>ONION</td><td>Onion</td><td>you</td><td>NEW</td><td></td><td rowspan="2">p »XX</td>
<td>0x</td><td><A</td><td>ax</td><td>ax</td><td>OX</td><td>«A</td><td>ax</td><td>ox</td><td>m</td><td>ax</td><td> «0</td><td>"O</td><td> 40</td><td> 0</td><td></td>
<td></td><td>4b</td><td>A</td><td>4b</td><td></td><td></td><td></td><td></td><td>xO</td><td>4b</td><td> «0</td><td> 0</td><td> 0</td><td> 0</td><td></td><td>o x</td>
<td>in</td><td>u *</td><td>NEW</td><td>ONION</td><td>O</td><td>O</td><td> 3</td><td>O</td><td>and</td><td>• al</td><td rowspan="2">V "</td><td>X©</td><td> 0</td><td>-U</td><td></td><td>from</td>
<td>o></td><td>IN</td><td></td><td>Onion</td><td> 00</td><td>-u</td><td>cx</td><td>in</td><td></td><td>you</td><td></td><td></td><td></td><td></td><td></td>
<td>Q</td><td>IN</td><td>a</td><td>O</td><td></td><td></td><td></td><td></td><td>in</td><td></td><td>Oh</td><td>• te</td><td>"to</td><td></td><td></td><td></td>
<td></td><td>U "</td><td> ></td><td> •</td><td>new</td><td>new</td><td>u></td><td>onion</td><td>NEW</td><td>NEW</td><td></td><td>NEW</td><td>Uf</td><td>Ul</td><td></td><td></td>
<td>Q</td><td>• U</td><td>a</td><td>n</td><td>you</td><td>not</td><td>KJ</td><td>K)</td><td>bJ</td><td>you</td><td>n</td><td>• u</td><td>you</td><td>M</td><td></td><td></td>
<td>Onion</td><td> 00</td><td>out</td><td>WHAT</td><td> 00</td><td>to</td><td>0D</td><td> 00</td><td> 00</td><td> 00</td><td>u</td><td> 0</td><td>CD</td><td>X</td><td></td><td></td>
<td>the</td><td> 00</td><td>• n</td><td>’n</td><td>CD</td><td> 00</td><td> 3)</td><td> 00</td><td> 00</td><td>CD</td><td>• n</td><td> 0</td><td> 00</td><td>X</td><td></td><td></td>
<td>r</td><td>C *</td><td>r-</td><td>C“</td><td>C'</td><td>r-</td><td> -</td><td>c~</td><td>C-</td><td> -</td><td> -</td><td>C</td><td>r</td><td>r</td><td></td><td></td>
<td>r</td><td>to</td><td>from?</td><td></td><td> —</td><td> -</td><td> □</td><td>to</td><td>to</td><td></td><td><sub>=</sub></td><td></td><td> -</td><td> -</td><td></td><td></td>
<td> 77</td><td>7C</td><td> 77</td><td> 77</td><td>, v</td><td></td><td>to</td><td>.to</td><td>.v</td><td></td><td>rr</td><td>.V</td><td>• te</td><td>to</td><td></td><td></td>
<td>j</td><td> <0</td><td>O</td><td>Phi</td><td>• t)</td><td>*J</td><td></td><td>D</td><td>Phi</td><td> 5</td><td>V</td><td> »</td><td>t;</td><td></td><td></td><td>7C</td>
<td></td><td>to</td><td></td><td> ·</td><td>to</td><td></td><td></td><td></td><td></td><td></td><td>to</td><td></td><td></td><td></td><td></td><td></td>
<td> -</td><td> -</td><td>X</td><td>4b</td><td> -</td><td> -</td><td> -</td><td> -</td><td> 00</td><td>X</td><td> -</td><td> -</td><td> -</td><td> -</td><td></td><td></td>
<td></td><td>a</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Oh</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Q ca</td><td>"to</td><td> ·-·</td><td></td><td>a</td><td></td><td rowspan="2">Oh "</td><td>n</td><td>• Ί CA</td><td></td><td>Ώ</td><td></td><td></td><td></td><td></td>
<td>uf</td><td>Pi</td><td>GJ</td><td>out</td><td>Uf</td><td></td><td></td><td></td><td>-the</td><td>wJ</td><td></td><td>• bJ</td><td></td><td></td><td></td>
<td>4b</td><td>Onion</td><td>bJ CD</td><td>ru CD</td><td>bJ what</td><td>"L</td><td>• Ί <sup>r</sup>Show up</td><td>in CA</td><td>Pi</td><td>(A</td><td>you ao</td><td>n</td><td>ru 03</td><td></td><td></td><td>you</td>
<td>ah</td><td> <0 *1</td><td> 00</td><td>WHAT</td><td> 00</td><td>"PI</td><td>-the</td><td></td><td></td><td></td><td>0D</td><td></td><td> 00</td><td>this</td><td></td><td></td>
<td></td><td>in</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>'U</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>•«J</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>* L.</td><td>Onion</td><td>Onion</td><td>Onion</td><td>THAT</td><td>oh</td><td>V3</td><td>THAT</td><td>THAT</td><td>THAT</td><td>Ul</td><td>THAT</td><td>Ul</td><td></td><td></td><td>Onion</td>
<td>C</td><td>M</td><td>cn</td><td>ro</td><td>n</td><td>GL</td><td>n</td><td>m</td><td>m</td><td>Pi</td><td>tn</td><td>"I</td><td>"T?</td><td>tel</td><td></td><td>S</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>The</td><td>O</td><td>• O</td><td>"O</td><td>O</td><td>O</td><td>O</td><td>"O</td><td>O</td><td></td><td>n</td>
<td>in</td><td>"to</td><td>►te</td><td>"to</td><td>"to</td><td> «_<</td><td> •—4</td><td>"to</td><td> «-«</td><td></td><td>"to</td><td>♦ te</td><td></td><td> —</td><td></td><td>b „</td>
<td>C</td><td>O</td><td>p</td><td>O</td><td>O</td><td>p</td><td> □</td><td>p</td><td>c</td><td>O</td><td>p</td><td>p</td><td></td><td> -</td><td></td><td>i *</td>
<td>t "</td><td>from</td><td></td><td></td><td>to</td><td>to</td><td></td><td>to</td><td> —</td><td>T</td><td>to·</td><td>-r</td><td></td><td> -♦</td><td></td><td rowspan="2"></td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>The</td><td> □</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>c</td><td>O</td><td></td>
<td></td><td>VN</td><td></td><td>-J</td><td>cx</td><td><τ·</td><td></td><td></td><td>ax</td><td></td><td></td><td>cn</td><td>u *</td><td>_n</td><td></td><td></td>
<td>U "</td><td>CX</td><td>4b</td><td>new</td><td>bJ</td><td><ο</td><td> 2</td><td></td><td>fig</td><td>onion</td><td>you</td><td>Onion</td><td> ’</td><td></td><td></td><td></td>
<td>Onion</td><td>m</td><td>THAT</td><td>Onion</td><td>THAT</td><td>A</td><td>L.</td><td>Onion</td><td>THAT</td><td>Onion</td><td>Onion</td><td>THAT</td><td>Onion</td><td> -</td><td></td><td></td>
<td>BE</td><td>m</td><td>tn</td><td>n</td><td>m</td><td>Pi</td><td></td><td>cn</td><td>THAT</td><td>Linden</td><td>m</td><td>tn</td><td>Pi</td><td> “7</td><td></td><td rowspan="2"></td>
<td>O</td><td>"O</td><td>O</td><td>"O</td><td>O</td><td>THE</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td>
<td> _</td><td>"to</td><td>►te</td><td>"to</td><td>"to</td><td></td><td></td><td></td><td></td><td></td><td></td><td>• te</td><td></td><td></td><td></td><td> <</td>
<td>O</td><td>O</td><td>a</td><td>O</td><td>O</td><td>p</td><td>The</td><td>c</td><td>p</td><td>C3</td><td>p</td><td>p</td><td></td><td> ™</td><td></td><td rowspan="2">*’ ’U ' <D</td>
<td>FROM</td><td>GS.</td><td>from</td><td rowspan="2">O</td><td>from</td><td> —</td><td> —</td><td>to.</td><td> —</td><td> --</td><td>T·</td><td>-r</td><td></td><td></td><td></td>
<td>c</td><td>O</td><td>O</td><td>O</td><td>The</td><td>P</td><td>O</td><td>O</td><td>O</td><td>d</td><td>O</td><td>c</td><td>X</td><td></td><td>W r-</td>
<td></td><td>u "</td><td>"to</td><td>"to</td><td> ,—·</td><td></td><td></td><td></td><td>K.</td><td></td><td>-</td><td></td><td> »_</td><td></td><td></td><td>‘ n.</td>
<td>X»</td><td>you</td><td>onion</td><td>onion</td><td>NEW</td><td></td><td>The</td><td></td><td></td><td>^j</td><td> 4*-</td><td>Xb</td><td>M</td><td>you</td><td></td><td> Phi</td>
<td></td><td>you</td><td></td><td>O</td><td></td><td>4b</td><td> 2</td><td>ul</td><td>bJ</td><td> 0</td><td>CX</td><td></td><td>’J»</td><td></td><td></td><td></td>
<img file="RO118016B1_D0002.tif" />
<td colspan="2" rowspan="2">V» w</td><td rowspan="2">UI kj</td><td rowspan="2">m</td><td rowspan="2">Jl O</td><td rowspan="2">Jk. *0</td><td rowspan="2">L. CD</td><td rowspan="2">Jb -J</td><td rowspan="2"> 01</td><td rowspan="2">m</td><td rowspan="2"></td><td rowspan="2">in</td><td rowspan="2">JK KJ</td><td rowspan="2">A.</td><td rowspan="2">O</td><td rowspan="2"></td><td colspan="2">Zf?</td>
<td></td><td>s</td>
<td>X</td><td>wTJ</td><td>X WTJ</td><td>X WT3</td><td> ></td><td> ></td><td> 2</td><td> ></td><td> ></td><td> ></td><td> ></td><td>> c * thirst</td><td>> 0-5J</td><td> ></td><td>> A.3</td><td></td><td></td><td> <</td>
<td>d</td><td>*° X</td><td>3 «ox</td><td>2 “J</td><td>r »OX</td><td>r »OX</td><td>U * X</td><td>rt o X</td><td>r »OX</td><td>m o x</td><td>FK © X</td><td>O X</td><td>™ o X</td><td>r »NZ</td><td>«H W x</td><td></td><td></td><td> •</td>
<td> &</td><td>10 O</td><td>them me O</td><td>0 i O</td><td>huo</td><td>kj o</td><td>* - oo</td><td>in 01</td><td>EVERYTHING</td><td>M KJ O</td><td>k- kj o</td><td>K·* k> O</td><td>HKJO</td><td>K- UI O</td><td>WWO</td><td></td><td>Of</td><td>n</td>
<td>M</td><td>FROM</td><td>n «· Z</td><td>M Z</td><td>in Z</td><td>nw Z</td><td>Loz</td><td>M CD Z</td><td>M CD Z</td><td>• 1 wz</td><td>in Z</td><td>HW with</td><td>M W Z</td><td>W M Z</td><td>M Z</td><td></td><td>Q</td><td>rr</td>
<td> •</td><td> *-*</td><td></td><td>• in</td><td>H» «-*</td><td>M K-</td><td></td><td>M W</td><td>w w</td><td>• H · -</td><td>W H</td><td>in · - ·</td><td>M</td><td>in · - *</td><td>•1 t—</td><td></td><td></td><td> 0</td>
<td>X</td><td>C w XJ o</td><td>iSS</td><td>x tr w tV o</td><td>~ss</td><td>-ss</td><td>z σ w a τί o</td><td>m cr w • Ό o</td><td></td><td>m tr w - Ό o</td><td>ι-t (T w • XJ O</td><td>r^SS</td><td>m is o • XJ o</td><td>Htrw * χΌ o</td><td>m cr w o</td><td></td><td> 0 3</td><td>Pi</td>
<td> 3</td><td>a»</td><td> 3 *·</td><td>3 A.</td><td>X *·</td><td>X</td><td>MAN</td><td>X 4K</td><td>X</td><td>X A</td><td>X *·</td><td>X A</td><td>x *</td><td>X w</td><td>X «u</td><td></td><td> (1</td><td></td>
<td>a</td><td> ♦-·</td><td>a m</td><td>L -</td><td> 01</td><td>b-· 01</td><td>n w</td><td>w- M</td><td>W> M</td><td>KJ</td><td>M></td><td>M» KJ</td><td> ·* ·—</td><td>fr- CD</td><td>b* KJ</td><td></td><td></td><td></td>
<td>M</td><td></td><td>Ltd.</td><td>M</td><td> 3</td><td> 3</td><td></td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 5</td><td> 3</td><td> 3</td><td> 3</td><td></td><td></td><td></td>
<td></td><td></td><td>M</td><td>M</td><td>a</td><td>a</td><td></td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td></td><td></td><td></td>
<td></td><td></td><td>IN</td><td>M</td><td></td><td>b-4</td><td></td><td>M</td><td></td><td> »-4</td><td>in</td><td>• j</td><td>M</td><td>M</td><td>M</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td>M</td><td>IN</td><td></td><td>M</td><td>M</td><td>IN</td><td>in</td><td>M</td><td>M</td><td></td><td>M</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>M</td><td></td><td>M</td><td></td><td>M</td><td>M</td><td>M</td><td>M</td><td>IN</td><td>M</td><td></td><td></td><td></td>
<td></td><td>* -s</td><td>OlţJ</td><td>Oi XJ</td><td>WțJ</td><td></td><td>*-I.E</td><td>Onion 51</td><td>wțj</td><td>WTJ</td><td>w%J</td><td>ut5J</td><td>Out ³J</td><td>w V</td><td>w V</td><td></td><td></td><td></td>
<td></td><td>*- X</td><td>w x</td><td>w x</td><td>X</td><td>UI X</td><td>MX</td><td>Ui X</td><td>*· X</td><td></td><td>X</td><td>Ui X</td><td>ui X</td><td>a. x</td><td>0b X</td><td></td><td>Pi</td><td> 3</td>
<td></td><td>«0 o</td><td>oo</td><td>° O</td><td>ui O</td><td>01 O</td><td>OO</td><td>01 Q</td><td>ui O</td><td>ui d</td><td>m O</td><td>01 Q</td><td>0\ Q</td><td>VI o</td><td>ui o</td><td></td><td> 0</td><td> •</td>
<td></td><td>from</td><td>from</td><td>_from</td><td>from</td><td>from</td><td>from</td><td>from</td><td>from</td><td> 2</td><td>from</td><td>from</td><td> 2</td><td>from</td><td> 2</td><td></td><td>Q</td><td> •</td>
<td></td><td>"G</td><td>SG</td><td>SG</td><td>SG</td><td>sg</td><td>SS</td><td>zz</td><td>SG</td><td>SG</td><td>SG</td><td>SG</td><td>SG</td><td>SG</td><td>K 2</td><td></td><td> 9 •</td><td>*1 rr</td>
<td></td><td>O</td><td>O</td><td>O</td><td>4k</td><td>O</td><td>A</td><td>O</td><td></td><td>»J</td><td>KJ</td><td>O</td><td>O</td><td>0k</td><td></td><td></td><td> 3</td><td></td>
<td></td><td>X w</td><td>x **·</td><td>coin</td><td>2nd century</td><td>2 watts</td><td>2 watts</td><td>2 watts</td><td>with in</td><td>Z ®</td><td>2nd century</td><td>From</td><td>From</td><td>Z K-</td><td>from ► *</td><td></td><td>GM</td><td></td>
<td></td><td> 3</td><td>g ~</td><td> 2</td><td>no *</td><td>n m</td><td>no *</td><td>a m</td><td>n ui</td><td>n cd</td><td>O CD</td><td>a m</td><td>MAN</td><td>no I</td><td>η hi</td><td></td><td></td><td></td>
<td></td><td> 5</td><td> ></td><td> 0</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> 0</td><td></td><td></td><td></td>
<td></td><td>km</td><td>M</td><td></td><td> «1</td><td>km</td><td>n</td><td>in</td><td>M</td><td>M</td><td>K4</td><td>n</td><td>M</td><td>in</td><td>M</td><td></td><td></td><td></td>
<td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>FROM</td><td>X</td><td>X*</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td></td><td></td><td></td>
<td></td><td></td><td> ►*·</td><td> ·—</td><td>b—</td><td>b—</td><td> «</td><td>H-</td><td> ♦-</td><td> >-</td><td> ♦—</td><td>K-</td><td></td><td>K-</td><td> ♦—</td><td></td><td></td><td></td>
<td></td><td> 3</td><td> 3</td><td> 9</td><td> 3</td><td> 3</td><td></td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3</td><td> 3 ’</td><td> 3</td><td></td><td></td><td></td>
<td></td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>in</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td>a</td><td></td><td></td><td></td>
<td></td><td>in</td><td>• M</td><td>K4</td><td> ♦-*</td><td>km</td><td></td><td>in</td><td>M</td><td>in</td><td>in</td><td>M</td><td>F4</td><td>4-H</td><td>n</td><td></td><td></td><td></td>
<td></td><td> «-<</td><td>IN</td><td>«H</td><td></td><td>n</td><td></td><td>in</td><td> ♦-4</td><td>in</td><td> ·-·</td><td> »-4</td><td>IN</td><td>t-4</td><td>• Μ</td><td></td><td></td><td></td>
<td></td><td>ÎH</td><td> ♦1</td><td>IN</td><td></td><td>km</td><td></td><td>M</td><td>IN</td><td>in</td><td></td><td>H</td><td> ♦-<</td><td>IN</td><td></td><td></td><td></td><td></td>
<td></td><td>in</td><td>in</td><td>IN</td><td></td><td>r-*</td><td></td><td>in</td><td></td><td></td><td> ·-·</td><td> *-*</td><td> <-»</td><td>K- *</td><td>H*</td><td></td><td>p</td><td>IN</td>
<td></td><td>IN</td><td>in</td><td>in</td><td>in</td><td>in</td><td>IN</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td></td><td>X</td><td></td>
<td></td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>i</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td><td>O</td><td></td>
<td></td><td>WE</td><td> 01</td><td>we</td><td>WE</td><td>ONION</td><td> 01</td><td>ONION</td><td>ONION</td><td>ONION</td><td>ONION</td><td>ONION</td><td>out</td><td></td><td></td><td></td><td colspan="2">Z a</td>
<td></td><td>"O</td><td>O</td><td>a»</td><td>O</td><td>in</td><td> 0»</td><td>in</td><td>KJ</td><td>M</td><td>ONION</td><td> 01</td><td>century></td><td>out</td><td> 0»</td><td></td><td></td><td>O</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>in</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> >—</td>
<td></td><td>you</td><td>KJ</td><td>KJ</td><td>kj</td><td>KJ</td><td>KJ</td><td>KJ</td><td>you</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td></td><td>p</td><td>D</td>
<td></td><td> 01</td><td> 01</td><td> 01</td><td> 01</td><td> 04</td><td> 01</td><td> 01</td><td> 01</td><td> 01</td><td> 01</td><td>Be</td><td> 01</td><td> 01</td><td> 01</td><td></td><td colspan="2">X X</td>
<td></td><td>A</td><td></td><td>Jb</td><td></td><td>A»</td><td>Jb</td><td>L »</td><td></td><td></td><td></td><td>C.</td><td>A.</td><td>O"</td><td>X</td><td></td><td colspan="2">O X</td>
<td></td><td>KJ</td><td>in</td><td>KJ</td><td>KJ</td><td>KJ</td><td>IN</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td>KJ</td><td>in</td><td>in</td><td></td><td>from</td><td></td>
<td></td><td>*O</td><td>O</td><td>to</td><td>O</td><td></td><td> 01</td><td>in</td><td>KJ</td><td>• J</td><td>out</td><td> 01</td><td>JK</td><td>C0</td><td>M</td><td></td><td></td><td></td>
<td></td><td>in</td><td> ♦—</td><td></td><td>t—</td><td></td><td></td><td>r*</td><td>t·^</td><td>K-</td><td></td><td> ♦-»</td><td>r-</td><td>O</td><td>Oh</td><td></td><td></td><td></td>
<td></td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>IN</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>in</td><td>t</td><td></td><td></td><td></td><td>"the</td>
<td></td><td>KJ</td><td>KJ</td><td>KJ</td><td></td><td>A.</td><td></td><td>jk.</td><td></td><td>you</td><td>KJ</td><td>KJ</td><td>KJ</td><td>n</td><td>r.</td><td></td><td></td><td></td>
<td></td><td>a></td><td>CD</td><td>CD</td><td></td><td>LL</td><td></td><td> 4-»</td><td>f-L.</td><td>a></td><td>a></td><td>CD</td><td>CD</td><td><n</td><td>in</td><td></td><td></td><td></td>
<td></td><td>CD</td><td>CD</td><td>CD</td><td> 51</td><td> 01</td><td> 01</td><td> 01</td><td> 01</td><td> 90</td><td>CD</td><td> 00</td><td> 00</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>r</td><td></td><td>c*</td><td></td><td>r-</td><td> -</td><td>r</td><td>C“</td><td>r</td><td>r-</td><td> —</td><td>r-·</td><td>C“</td><td> -</td><td></td><td></td><td></td>
<td></td><td> ·—</td><td> *—</td><td> *-·</td><td> «->·</td><td> **·</td><td></td><td>H·</td><td>in·</td><td> ·»·</td><td> ·—</td><td></td><td></td><td> >—</td><td> —·</td><td></td><td></td><td></td>
<td></td><td> 2</td><td> 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> ·»·</td>
<td></td><td>IT</td><td>SG</td><td></td><td>.T</td><td>,T</td><td>3C</td><td>rr</td><td>.v</td><td>.T</td><td></td><td>.v</td><td>.T</td><td>7T</td><td></td><td></td><td></td><td></td>
<td></td><td> &</td><td>L.</td><td>•’J</td><td>d</td><td></td><td></td><td> 0</td><td>Phi</td><td></td><td></td><td>• D</td><td> .0</td><td>Phi</td><td></td><td></td><td></td><td></td>
<td></td><td></td><td> ·*</td><td></td><td></td><td></td><td></td><td></td><td><sup>in</sup></td><td></td><td></td><td> «1</td><td></td><td> *·</td><td></td><td></td><td></td><td>Phi</td>
<td></td><td>Out</td><td>si</td><td></td><td> -</td><td> -</td><td> -</td><td>Jb</td><td>-2b.</td><td></td><td>KJ</td><td>NEW</td><td>KJ</td><td>XL.</td><td> -</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>Oh</td><td></td><td>Oh</td><td></td><td></td><td></td><td>O</td><td>Oh</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>C</td><td></td><td>O</td><td></td><td></td><td></td><td>n</td><td>n</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td>Oh</td><td>O</td><td></td><td> 01</td><td>Oh</td><td>(L.</td><td></td><td></td><td>in*</td><td> 01</td><td> 01</td><td> ·—</td><td> —</td><td></td><td></td><td></td>
<td></td><td>in</td><td> 1</td><td> 1</td><td>in</td><td>• n</td><td> «</td><td>-n</td><td>in</td><td></td><td>in</td><td>Ί1</td><td>Ί1</td><td>in</td><td></td><td></td><td></td><td>X</td>
<td></td><td>you</td><td>the</td><td>n</td><td></td><td></td><td>n</td><td></td><td>Jk.</td><td>KJ</td><td>KJ</td><td></td><td></td><td></td><td></td><td></td><td></td><td>M</td>
<td></td><td>CD</td><td>in</td><td>IA</td><td> ♦-»</td><td>«c</td><td>from</td><td>in</td><td>in</td><td>CD</td><td> 20</td><td></td><td>V)</td><td>K-</td><td> ·—</td><td></td><td></td><td></td>
<td></td><td>CD</td><td>* Ί</td><td>-n</td><td> 01</td><td>Phi</td><td>the</td><td>Phi</td><td> 01</td><td>CD</td><td>CD</td><td>.b</td><td>Phi</td><td> 01</td><td>• Γ</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>n</td><td></td><td> •1</td><td></td><td></td><td></td><td> •1</td><td>n</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>in</td><td></td><td></td><td></td><td></td><td></td><td></td><td> *-*</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td>-J</td><td></td><td></td><td></td><td></td><td></td><td></td><td>M</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>oh</td><td>THAT</td><td>cn</td><td>tn</td><td>THAT</td><td>in</td><td>THAT</td><td> 01</td><td>THAT</td><td> 0)</td><td>V)</td><td>IN</td><td>THAT</td><td> ..</td><td></td><td>v "</td><td></td>
<td></td><td>n</td><td>fî</td><td>n</td><td>tn</td><td>m</td><td>H</td><td>BE</td><td>FJ</td><td>BE</td><td>FJ</td><td>fî</td><td>BE</td><td>FJ</td><td></td><td></td><td>I</td><td></td>
<td></td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>c</td><td>O</td><td>C</td><td>O</td><td>O</td><td>O</td><td>c</td><td></td><td></td><td> ‘ ·</td><td></td>
<td></td><td></td><td> 4—<</td><td></td><td> »-<</td><td></td><td>f-t</td><td> «-<</td><td></td><td></td><td></td><td> «—«</td><td> »-4</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>p</td><td>O</td><td>p</td><td>O</td><td>O</td><td>O</td><td>p</td><td>p</td><td>O</td><td>p</td><td>O</td><td>O</td><td>c</td><td>c</td><td></td><td colspan="2">O?</td>
<td></td><td></td><td>Lol</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>from</td><td>from</td><td></td><td>from</td><td> ></td>
<td></td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> -</td><td></td><td>O</td><td></td>
<td></td><td>p></td><td>-u</td><td>• u</td><td>CD</td><td>Phi</td><td>Phi</td><td>to</td><td> 00</td><td> 01</td><td>Out</td><td> 01</td><td>onion</td><td>-u</td><td> <</td><td></td><td></td><td></td>
<td></td><td>in</td><td> *“*</td><td>O</td><td>d</td><td>onion</td><td> -</td><td>VJ</td><td>KJ</td><td></td><td> 00</td><td>O</td><td>I</td><td>-j</td><td> -</td><td></td><td></td><td></td>
<td></td><td>(A</td><td>V)</td><td>»A</td><td><A</td><td>We</td><td>IA</td><td>(A</td><td>oh</td><td>in</td><td>oh</td><td>(A</td><td>THAT</td><td>(A</td><td> -.</td><td></td><td></td><td></td>
<td></td><td>fj</td><td>BE</td><td>BE</td><td>be</td><td>FJ</td><td>m</td><td>fî</td><td>FJ</td><td>BE</td><td>BE</td><td>BE</td><td>BE</td><td>BE</td><td></td><td></td><td></td><td>* TJ</td>
<td></td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td><td></td><td>O</td><td> 0</td>
<td></td><td>H</td><td>m</td><td>in</td><td>n</td><td>n</td><td> »—1</td><td></td><td> »-4</td><td>in</td><td>"-l</td><td><sub>in</sub></td><td>in</td><td>t-t</td><td> —</td><td></td><td><sub>(</sub> J</td><td> *<</td>
<td></td><td>O</td><td>p</td><td>c</td><td>O</td><td> □</td><td></td><td>p</td><td>O</td><td>The</td><td>p</td><td>O</td><td>p</td><td>p</td><td></td><td></td><td>p</td><td>TJ</td>
<td></td><td>from</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>The</td>
<td></td><td>O</td><td>O</td><td>O</td><td>O</td><td>c</td><td>O<sup>1</sup></td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td> *</td><td></td><td>O</td><td>rr</td>
<td></td><td> »—*</td><td> »-·</td><td></td><td>f_.</td><td></td><td></td><td></td><td></td><td></td><td> »—</td><td></td><td></td><td>r-</td><td></td><td></td><td></td><td>a</td>
<td></td><td>in</td><td>in</td><td>KJ</td><td>in</td><td>in</td><td>'^J</td><td>in</td><td></td><td>KJ</td><td>KJ</td><td>KJ</td><td>you</td><td> £»</td><td> *</td><td></td><td></td><td>rt></td>
<td></td><td>KJ</td><td>O</td><td> 10</td><td> 01</td><td></td><td></td><td>CD</td><td></td><td>-j</td><td> 01</td><td>them.</td><td>in</td><td>xo</td><td></td><td></td><td></td><td></td>
<img file="RO118016B1_D0003.tif" />
<td>Yo</td><td>in</td><td>What</td><td>What</td><td>THE</td><td>WHAT</td>
<td> 00</td><td> 00</td><td> 00</td><td> 00</td><td> 00</td><td> 00</td>
<td></td><td>Be</td><td>Be</td><td>Onion</td><td>Ln</td><td> 4></td>
<td>O</td><td>Ln</td><td>O</td><td>Ln</td><td>O</td><td>Onion</td>
<img file="RO118016B1_D0004.tif" />
<td>What</td><td>uo</td><td>UO</td><td>uo</td>
<td> 00</td><td> 00</td><td> 00</td><td> 00</td>
<td>The</td><td>The</td><td> 03</td><td> 00</td>
<td>A</td><td>O</td><td>A</td><td>O</td>
What
A
<td>O \ w</td><td>9 \ XI</td><td>cx</td><td>0 \ O</td><td>VI «o</td><td>UI 00</td><td>LA • 4</td><td>UI C \</td><td>UI UI</td><td>X.</td><td></td><td>î » * 1 u ” •</td>
<td>35 * -13 n per xowo</td><td>CA *-X3 3 U» X fi UQ</td><td>Z Λ-XJ o * x o '•IO</td><td>C0 3 Ul X fi ui o</td><td>Cj a. u □ u>X fi CD ©</td><td>" 3 ω x fi o</td><td><n 3 u »x in * OO</td><td>Ζ *-XJ a a. x 0 o o</td><td>> A. XJ OX ►— to O</td><td>X w© 3 Ό X fi mn</td><td></td><td> *« <</td>
<td>^ 5 V. w tr <-» υ m</td><td><9 -4 Z Uf ** * onion ΧΌ O</td><td>O Z '► «tr w« <0 u »</td><td>« Μ Z M U» ' <T W x<$ O</td><td>CB a »2 tM - * - at XTJ o</td><td>muz M W O</td><td>M«z M ►-* ' rr u XX) o</td><td>Μ «O Z x σ»2 < e</td><td>M CJ X</td><td>ui Z z rr w · - * © o</td><td></td><td>Q rr 9 O IT</td>
<td><▼ CA</td><td>g ±</td><td>CT (A</td><td></td><td></td><td>5 VI</td><td>9 <n</td><td>lk ui</td><td>X</td><td>3 -u</td><td></td><td></td>
<td>X ·*</td><td>fi UI</td><td>X w</td><td>fi ui</td><td>5 k »</td><td>fi o</td><td>fi CI</td><td>M Ol</td><td>a»</td><td>a> kj</td><td></td><td></td>
<td>m</td><td>IN</td><td>M</td><td>Out</td><td>M</td><td>M</td><td>M</td><td></td><td> 3</td><td>out</td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>a</td><td>M</td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>in</td><td>out</td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>M</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> «-< .</td><td></td><td></td><td></td>
<td rowspan="2"> ”1</td><td>oo</td><td>-4XJ</td><td>oa</td><td>a a</td><td>oa</td><td>a a</td><td>^ rj</td><td>VI u</td><td>* "TJ</td><td></td><td></td>
<td>u *</td><td></td><td>u- u-</td><td>u * I—</td><td> »— ►-·</td><td>t·* w</td><td>•J X</td><td rowspan="2"></td><td>W X</td><td></td><td></td>
<td rowspan="2">sâ w 2 on vj</td><td> *< ·<</td><td rowspan="2"><1 u> X o <1 w</td><td>s *<</td><td>X *<</td><td>s ·<</td><td> *<*<</td><td>oo</td><td>40 O</td><td></td><td>in M</td>
<td>• 3 u »</td><td>» M W</td><td>XX • fi M W</td><td>XX fi fi M W</td><td>XX fi fi W M</td><td>Z M</td><td>About with</td><td>z SE but go</td><td></td><td>ii • n 3</td>
<td>the M</td><td>CA U)</td><td>O</td><td><0 to</td><td>0 ta</td><td>in that</td><td>«O to</td><td>n <a</td><td>no</td><td> 3 04</td><td></td><td></td>
<td>in to</td><td>5S</td><td>in 0</td><td>"W IO O</td><td>wn yes</td><td>ww yes</td><td>w w lOO</td><td>that</td><td>the M</td><td>s w</td><td></td><td></td>
<td>ta</td><td>IN</td><td> «</td><td>Out tH</td><td>•-i Ul</td><td>Μ M</td><td>W M</td><td>X</td><td>X</td><td>X</td><td></td><td></td>
<td><▼ X Ut</td><td>About</td><td><▼ X out</td><td>o p X X</td><td>oozz</td><td>what with zz</td><td>σ σ zz</td><td>e »w- M</td><td>♦ - 3 a</td><td> ·— 3 0»</td><td></td><td></td>
<td></td><td>oo</td><td></td><td>oo</td><td>oo</td><td>oo</td><td>oo</td><td></td><td>M</td><td>out</td><td></td><td></td>
<td></td><td>u * * "</td><td></td><td>** u</td><td>♦ - · and ~</td><td>»* · W</td><td>IN</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>oo</td><td></td><td>oo</td><td>oo</td><td>oo</td><td>O o</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>NEW</td><td></td><td>Ul</td><td>A w</td><td>A w</td><td>in</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td> ““</td><td>μ m</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> *-</td><td>r*</td><td> «-*</td><td>u *</td><td></td><td> »-*</td><td>t·*</td><td></td><td> ·-*</td><td>u</td><td></td><td></td>
<td></td><td>ul</td><td>in</td><td>in</td><td></td><td>VJ</td><td> <4</td><td>NEW</td><td>IN</td><td>CJ</td><td></td><td>X ·</td>
<td></td><td> —*</td><td>u "</td><td>U "</td><td> «-*</td><td>in</td><td>in</td><td>fr—</td><td>O</td><td>O</td><td></td><td>O</td>
<td>4A</td><td>U "</td><td>«U></td><td>m</td><td>A.</td><td></td><td></td><td>A</td><td></td><td> 0»</td><td></td><td>zo</td>
<td>O</td><td>you</td><td>O</td><td> —</td><td></td><td> •4</td><td><n</td><td>THE</td><td>v></td><td></td><td></td><td>O</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>u-</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> »—</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>• o</td><td>tsJ</td><td></td><td>0 approx</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td><A</td><td> 74</td><td></td><td>X X</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O X</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>in</td><td>u></td><td></td><td>from</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ONION</td><td></td><td></td><td></td>
<td>Oh</td><td></td><td>a</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>A</td><td></td><td>n</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>oh</td><td>a</td><td>in</td><td>O</td><td></td><td></td><td> »-·</td><td></td><td></td><td></td><td></td><td></td>
<td>• η</td><td> 1</td><td>i</td><td> 1</td><td></td><td>in</td><td>ONION</td><td>ONION</td><td>ul</td><td></td><td></td><td></td>
<td rowspan="2">that</td><td>Q</td><td></td><td>n</td><td>a</td><td> *»</td><td>rfte</td><td></td><td>fJ</td><td>with</td><td></td><td></td>
<td>in</td><td>THAT</td><td>THAT</td><td></td><td></td><td> *-*</td><td></td><td>CD</td><td>Elementary school</td><td></td><td></td>
<td>be</td><td></td><td>A</td><td>• n</td><td>fig</td><td><JX</td><td>m</td><td>s \</td><td>CD</td><td>□ D</td><td></td><td></td>
<td> *1</td><td></td><td>*t</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td> «-*</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>r</td><td> -</td><td>r</td><td></td><td> -</td><td>r™</td><td></td><td></td><td>r*</td><td></td><td></td><td></td>
<td> *·*</td><td> ·**</td><td></td><td> —</td><td> —></td><td></td><td></td><td></td><td> ·_</td><td></td><td></td><td>tr</td>
<td> —</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> —</td><td></td><td></td>
<td>? V</td><td>PS</td><td>.X</td><td>-X</td><td>u</td><td>yeah</td><td>: v</td><td>rr</td><td>rr</td><td>in</td><td></td><td> 3</td>
<td>be</td><td></td><td>Phi</td><td> .9</td><td>he</td><td></td><td>Phi</td><td> *</td><td> .9</td><td> *</td><td></td><td>X</td>
<td></td><td> “</td><td></td><td> 5</td><td> —</td><td> 1</td><td></td><td></td><td></td><td> —</td><td></td><td> <9</td>
<td>X\</td><td>s \</td><td></td><td>mJ</td><td>Y.</td><td></td><td>3X</td><td></td><td> -</td><td></td><td></td><td>n</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td>Q</td><td>Ώ</td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td>n</td><td>Â</td><td></td><td></td><td></td><td></td>
<td> *—</td><td> ·-*</td><td> ♦“·</td><td></td><td></td><td></td><td>4L</td><td>L.</td><td></td><td></td><td></td><td></td>
<td></td><td>wU Jk</td><td>VJ 4te.</td><td></td><td>v-l</td><td><4 Λ.</td><td> ”1</td><td>’n</td><td>c-</td><td>«<U IU</td><td></td><td>X</td>
<td>O\</td><td>CX</td><td>A></td><td>ox</td><td> 5\</td><td>K "</td><td>CA a</td><td>M F.</td><td>m</td><td>«0 CD</td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td>-j</td><td>-J</td><td></td><td></td><td></td><td></td>
<td>tn</td><td>in</td><td>THAT</td><td>THAT</td><td></td><td>THAT</td><td>THAT</td><td>THAT</td><td>THAT</td><td>Za</td><td></td><td>(A</td>
<td>cn</td><td>m</td><td>tn</td><td>m</td><td></td><td>m</td><td>cn</td><td>n</td><td>n</td><td>Pi</td><td></td><td>tn</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td><td>O</td>
<td> ·--</td><td> ♦-«</td><td> *-<</td><td> «-«</td><td>t-</td><td>in</td><td></td><td></td><td> •-4</td><td> «_</td><td></td><td>ΙΊ n</td>
<td>p</td><td>O</td><td>O</td><td>O</td><td>p</td><td>p</td><td>p</td><td>O</td><td>p</td><td>O</td><td></td><td>° from</td>
<td> 6</td><td>O</td><td>O</td><td>d</td><td>from</td><td>O</td><td>zo</td><td>O</td><td>O</td><td>from</td><td></td><td>X o</td>
<td>CD</td><td></td><td> 00</td><td> «4</td><td>h</td><td> 50</td><td> 00</td><td> 00</td><td>Onion</td><td></td><td></td><td></td>
<td> ♦“*</td><td>*O</td><td>O</td><td>CD</td><td></td><td> 00</td><td> 40</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> *</td><td></td><td></td><td> —</td><td> —</td><td> —</td><td> —</td><td> —</td><td> —</td><td></td><td></td>
<td rowspan="2">IN</td><td> _</td><td> ^-.</td><td></td><td></td><td><sub>r</sub> 1</td><td> _</td><td></td><td></td><td></td><td></td><td></td>
<td><A</td><td>THAT</td><td>THAT</td><td>L.</td><td>V)</td><td>THAT</td><td>THAT</td><td>THAT</td><td> -.□</td><td></td><td></td>
<td>n</td><td>Pi</td><td>M</td><td>W7</td><td>«n</td><td>tn</td><td>cn</td><td>P7</td><td>m</td><td>not</td><td></td><td>E2 *d</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>C</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td></td><td>the °</td>
<td> —*</td><td></td><td> *-«</td><td>Out</td><td> ·—·</td><td>M</td><td></td><td></td><td> ·-<</td><td></td><td></td><td> .. *<</td>
<td>p</td><td>O</td><td> ©</td><td>D</td><td>p</td><td>O</td><td>The</td><td>c</td><td>D</td><td>c</td><td></td><td rowspan="2">from<sup>B</sup></td>
<td>O</td><td>O</td><td>zo</td><td>d</td><td> 5</td><td>zo</td><td>țr O</td><td>d</td><td>ZO</td><td>zo</td><td></td>
<td> -**</td><td> ♦—*</td><td> ♦—·</td><td> »-*</td><td></td><td></td><td>M "</td><td>m-</td><td></td><td></td><td></td><td>a</td>
<td>ONION</td><td>cn</td><td>onion</td><td>onion</td><td>• jn</td><td>u "</td><td>VA</td><td>•-PI</td><td></td><td></td><td></td><td>Phi</td>
<td></td><td>i '</td><td>S£></td><td>CD</td><td>Onion</td><td> '4</td><td>A</td><td>N»</td><td>Onion</td><td>v-l</td><td></td><td></td>
<td></td><td></td><td></td><td></td><td> —</td><td></td><td></td><td> —</td><td> —</td><td> —</td><td></td><td></td>
<img file="RO118016B1_D0005.tif" />
<img file="RO118016B1_D0006.tif" />
c: ω
RO 118016 Β1
3900
Example 63. Isolation of amino acid forms 1-332 and 1-153 of the c-mpl ligand (Meg-CSF)
A. Reverse transcriptase reaction (c-mpl ligand sequence based on Genbank accession # L33410). Human fetal liver RNA A + was obtained from Clontech (Palo Alto, CA). The first-band cDNA reactions were performed using a Cycle ™ Kit cDNA obtained from Invitrogen (San Diego, CA).
B. Polymerization reactions in the chain
After reverse transcriptase (RT) reaction, c-mpl 1-332 ligand was amplified by PCR technique, using c-mp1Ncol oligonucleotide primers (SEQ. No. 169), which created an Ncol site that immediately precedes the 5 'end of the gene and c -mplEcoRI (SEQ. No. 170) which created an EcoRI site immediately 3 'to the stop codon, after the TR reaction, the c-mpl 1-153 ligand was amplified using the c-mp1 Ncol primer (SEQ ID No. 169) and the 3' c-mp1 primer HindiII (SEQ. No. 171) which created a stop codon and a Hindlll site immediately 3 'up to the amino acid codon 153.
Example 64. Construction of pMON26448
The PCR product ligand c-mpl 1-153 was digested with restriction enzymes Hcol and Hind III for subcloning into pMON3934. The mammalian expression vector, pMON3934, is derived from pMON3359 (Hippenmeyer et al. (1993), but it contains a human IL-3 signal peptide sequence modified in addition to the IE110 promoter and poly-A signal. The peptide signal sequence is marginalized through the sites of the restriction enzymes BamHI and Ncol, which facilitate gene donation and expression as fragments of Ncol, Hind III. The Hindlll site is 3 'from the Ncol site. The DNA sequence of the signal peptide is shown below (restriction enzyme sites are indicated above). The ATG (methionine) codon of the Ncol site is in the frame with the signal peptide (underlined) ATG initiator;
BamHI
GGATCCACCAȚGAGCCGCCTGCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCCC MetSerArgLeuProValLeuLeuLeuLeuGInLeuLeuValArgPro
Ncol
GCCATGG (SECV No. 140)
AlaMet (SECV. Nr. 187)
The resulting plasmid was designated pMON26448. Plasmid pMON26448 encodes the fusion with the following amino acid sequence:
peptide
Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Meu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp lle Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Wing Arg Gin Gin Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala lle Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg (SECV.Nr.64)
DNA sequence (SEQ. No. 180) encodes for the previous polypeptide pMON26448 Example 65. Isolation of cDNA sequence of amino acid form 1-153 of c-mpl ligand (Meg-CSF) with modified C-terminal
A. Reverse transcriptase reaction (c-mpl ligand sequence based on Genbank accession number L33410). Human fetal liver RNA A + was obtained from Clontech (Palo Alto, CA). The first-band cDNA reactions were performed using the Cycle DNA Cycle ™ Kit obtained from Invitrogen (San Diego, CA).
3905
3910
3915
3920
3925
3930
3935
3940
3945
RO 118016 Β1
B. Polymerization reactions in the chain
Following reverse transcriptase (RT) reaction, c-mpl ligand 1-332 was amplified by PCR, using c-mp1Ncol oligonucleotide primers (SEQ. No. 169), which created an Ncol site, immediately preceding the 5 'end of the gene and c -mp1EcoRI (SEQ. No.170), which created an EcoRI restriction site immediately 3 'stop codon. Using the above PCR reaction as a template, the c-mpl 1-153 ligand was amplified, using the c-mp1Ncol primer (SEQ. No. 169) and the 3 'Eco-mpl primer (SEQ. No. 172) that created an immediate EcoRI site 3 'codon for amino acid 153 and encodes the Glu Phe amino acids in the frame at the C-terminus of the gene. The PCR product ligand c-mpl 1-153 was digested with Ncol and EcoRI. The resulting restriction fragment Nco, RcoRI of 467 bp was subsequently cloned into the intermediate plasmids, described in the Examples herein, to create fusion polypeptides.
Example 66. Construction of pMON26460
Plasmid DNA pMON13018 was digested with restriction enzymes Af1 III and Hind III, resulting in an Af1 III, Hind III III fragment of 4023 bp. Plasmid DNA pMON26448 was digested with Ncol and Hind III, resulting in a 468 bp Ncol, Hind III fragment. The restriction fragments were ligated and the ligation reaction mixture was used to transform E.coli. The transforming bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced to confirm the correct insert. The E.coli expression plasmid pMON26460 encodes the fusion with the following amino acid sequence: Peptide (SEQ. No. 165)
DNA sequence (SEQ. No. 183) encodes for the previous polypeptide pMON26460
The gene encoding the fusion was transferred as an Ncol, Hind III fragment to a mammalian expression vector pMON3934 and the resulting plasmid designated pMON26463.
Example 67. Construction of pMON26421
The Ncol fragment, 4029 bp SnaBI from pMON13057 was ligated with the Ncol PCR generated fragment, 467 bp EcoRI from Example 65 and 2 oligonucleotides (Ecosnal (SEQ. No.173), Ecosnal 2 (SEQ. No.174)). The ligation reaction mixture was used to transform E.coli. The transformed bacteria were selected on plates containing ampicillin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. The E.coli expression plasmid pMON26461 encodes the fusion with the following amino acid sequence:
Peptide # (SEQ. No. 168)
DNA sequence # (SEQ. No. 186) encodes for the previous polypeptide pMON26461.
The gene encoding the fusion was transferred as an Ncol, Hind III fragment to a mammalian expression vector pMON3934 and the resulting plasmid designated pMON26464.
Example 68. Construction of pMON26471
Fragment Ncol, Hind85 of 3285 bp of pMON3935 was ligated with restriction fragment Ncol, Smal of 362 bp of pMON26426 and fragment of Smal restriction, Hindlll of 494 bp of pMON26460 and the ligation reaction mixture was used to transform E.coli. The transforming bacteria were selected on plates containing spectinomycin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. The E.coli expression plasmid pMON25471 encodes the fusion with the following amino acid sequence:
Peptide # (SEQ. No. 186)
DNA sequence # (SEQ. No. 184) encodes for the previous polypeptide pMON26471.
The gene encoding the fusion was transferred as an Ncol, Hind III fragment to the mammalian expression vector pMON3934 and the resultant plasmid designated pMON26473.
RO 118016 Β1
Example 69. Construction of pMON26472
Fragment Ncol, 3285 bp HindIII of pMON3935 was ligated with the Ncol restriction fragment, 481 bp SnaBI of pMON26461 and the SnaBI restriction fragment, 399 bp HindIII of pMON3988 and the ligation reaction mixture was used to transform E.coli. The transforming bacteria were selected on plates containing spectinomycin. The plasmid DNA was isolated, analyzed by restriction analysis and sequenced, to confirm the correct insert. The E.coli expression plasmid pMON26472 encodes the fusion with the following amino acid sequence:
Peptide # (SEQ. No. 167)
DNA sequence # (SEQ. No. 185) encodes for the previous polypeptide pMON26472.
The gene encoding the fusion was transferred as an Ncol, Hind III fragment to the mammalian expression vector pMON3934 and the resulting plasmid designated pMON26474.
Various other examples will be apparent to the person skilled in the art, after reading the present description, without departing from the scope and scope of the invention. It is intended that all such other examples be included in the scope of the appended claims.
Example 70. Administration of hlL-3 variants, pMON13288 and mpl ligand fusion molecule has more of an effect of summation on expansion than cytokine alone
Hybrid megakaryocyte clot cultures were mounted, as described in the methods section. pMON26448 is the amino acid form 1-153 of the c-mpl ligand (Meg-CSF). pMON is a fusion molecule, consisting of hlL-3 variant, pMON13288 and amino acid form 1-153 of the c-mpl ligand. Incubation in the presence of hlL-3 variant, pMON13288, gave rise to colonies that were predominantly negative for megakaryocyte markers (86/114, (Table 4)), except for a number of small CFU-MK colonies (23/114). . pMON26448, alone, initially gave rise to CFU-MK colonies (172/176), with only a few negative colonies (3/175).
The combination of variant hlL-3, pMON 13288 and pMON26448 gave a large number of positive colonies (285/414), which were predominantly of BFU-MK morphology. There were negative colonies, such as (119/414). The total number with co-administration of positive colonies was greater than the sum with cytokine alone. The fusion molecule pMON26463 gave similar results to the combination of variant hlL-3, pMON13288 and pMON26448. The number of negative ones is lower than with the variant hlL-3, pMON13288 which is probably due to a lower concentration of pMON13288 in the preparation (approximately 10 ng / ml as part of the fusion molecule compared to 100 / zg / ml of the hlL variant -3, pMON 13288).
Table 4
3995
4000
4005
4010
4015
4020
4025
<td colspan="6">Colonies / wells</td>
<td>Cytokine treatment</td><td>Negative</td><td>CFU-MK</td><td>BFU-MK</td><td>Mixture</td><td>Total</td>
<td>pMON 13288</td><td> 86</td><td> 23</td><td> 0</td><td> 5</td><td> 114</td>
<td>PMON26448</td><td> 3</td><td> 73</td><td> 98</td><td> 1</td><td> 175</td>
<td>pMON26448 + pMON 13288</td><td> 119</td><td> 29</td><td> 244</td><td> 22</td><td> 414</td>
<td>PMON26463</td><td> 10</td><td> 30</td><td> 165</td><td> 17</td><td> 222</td>
<td colspan="6">Colonies / 100,000 spread</td>
<td>Cytokine treatment</td><td>Negative</td><td>CFU-MK</td><td>BFU-MK</td><td>Mixture</td><td>Total</td>
<td>pMON 13288</td><td> 344</td><td> 92</td><td> 0</td><td> 20</td><td> 456</td>
<td>PMON26448</td><td> 12</td><td> 292</td><td> 392</td><td> 4</td><td> 700</td>
<td>pMON26448 + pMON13288</td><td> 476</td><td> 116</td><td> 976</td><td> 88</td><td> 1656</td>
<td>pMON26463</td><td> 40</td><td> 120</td><td> 660</td><td> 68</td><td> 888</td>
4030
4035
4040
4045
In the following, 5 tests are presented that come to the aid of the invention.
Test 1 AML proliferations for bioactive human interleukin-3
Factor-dependent AML 193 cell line was obtained from the American Collection of Culture Types (ATCC, Rockville, MD). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor-dependent cell line, which showed increased growth in GM-CSF supplemented medium (Llange, B. et al. (1987); Valtieri, M et al. (1987)). The ability of AML193 cells to proliferate, in the presence of human IL-3, has also been documented (Santoli, D. et al. (1987)). An AML 1.3 variant cell line was used that was adapted for long-term growth in IL-3, by washing the growth factors and depriving the cytokine-dependent AML 193 cells of growth factor for 24 h. they reset to 1 x 10<sup>5</sup> cells / well in a plate, 24 wells in media containing 100 U / ml IL-3. It took about 2 months for the cells to grow rapidly in IL-3. These cells are maintained as AML 193 1.3 by supplementing the cell culture medium (see below) with human IL-3.
The AML 193 1.3 cells are washed 6 times in Hanks, cold saline (HBSS, Gibco, Grand Island, NY), by centrifuging the cell suspensions at 250 xg, 10 min, followed by decanting the supernatant. The pelleted cells are resuspended in HBSS and the procedure is repeated, until 6 wash cycles are completed. The cells washed 6 times, by this procedure, are resuspended in the tissue culture medium, at a density of 2 x 10<sup>5</sup>... 5 x 10<sup>5</sup> viable cells / ml. This medium is prepared by supplementing the Dulbecco modified Iscove medium (IMDM, Hazelton, Lenexa, KS) with albumin, transferin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, IN) was added at 500 / zg / ml; human transferrin (Boehringer-Mannheim, Indianopolis, IN) was added at 100 / zg / ml; soybean lipid (Boehringer-Mannheim, Indianopolis, IN) was added at 50 ^ g / ml; and 2mercaptoethanol (Sigma, St. Louis, MO) added at 5 x 10 '<sup>5</sup>M.
Serial dilutions of human interleukin-3 or fusion protein (hlL-3 mutein) are performed, in triplicate series in tissue culture media, supplemented as set out above, in 96-well Costar 3596 tissue culture plates. Each well contained 50 μ \ of medium containing interleukin-3 or fusion protein once serial solutions are completed. The control wells contained only tissue culture medium (negative control). Suspensions of AML 193 1.3 cells prepared as above were added to each well by pipetting 50 μ \ (2.5 x 10<sup>4</sup> cells) in each well. The tissue culture plates were incubated at 37 ° C with 5% CO2 in humidified air for 3 days. On day 3, 0.5 μθΐ was added<sup>3</sup>H-thymidine (2 Ci / mM, New England Nuclear, Boston, MA) in 50 μl of tissue culture medium. The cultures were incubated at 37 ° C with 5% CO2 in humidified air, 18-24 h. Cellular DNA is collected on glass cloth filters (Pharmacia LKB, Gaithersburg, MD) using a TOMTEC cell harvester. (TOMTEC, Orange, CT) using a water wash cycle, followed by a 70% ethanol wash cycle. the filter braids were allowed to air dry and then either placed in sample packs, to which scintillation fluid was added (Scintiverse II, Fisher Scientific, St. Louis, MO or Beta Platge Scintillation Fluid, Pharmacia LKB, Gaithersburg, MD). Beta emissions of samples from individual tissue culture wells are counted in a LKB Betaplate scintillation counter, model 1205 and the data are expressed as numbers per minute of<sup>3</sup>H-thymidine incorporated into the cells in each tissue culture well. The activity of each human interleukin-3 preparation or fusion protein preparation is quantified by measuring cell proliferation (incorporation).<sup>3</sup>H-thymidine), induced by graded concentrations of interleukin-3-fold fusion protein. Usually, these tests quantified concentrations in the ranges from 0.05pM-10<sup>5</sup> p.m. The activity is determined by measuring the dose of interleukin-3 times the fusion molecule, which provides 50% of the maximum proliferation (EC).<sub>50</sub> = 0,5 x
RO 118016 Β1
4095 (maximum average numbers per minute) <sup>3</sup>H-thymidine incorporated per well between triplicate cultures of all tested interleukin-3 concentrations - proliferation background measured by incorporation <sup>3</sup>H-thymidine, observed in triplicate cultures lacking interleukin-3). This EC value<sub>50</sub> it is also equivalent to a unit of bioactivity. Each test is performed with interleukin-3 as a reference standard so that relative activity levels can be assigned.
Typically, protein fusions were tested in a concentration range of 2000 pM to 0.06 titrated in 2-fold serial dilutions. The biological activity of the fusion molecules was compared to the standards below.
Protein fusions comprised, in part, G-CSF, pMON3987, pMON3995, pMON3997, pMON26406, pMON26433, pMON26415, pMON26416 and pMON26430 and were compared at the dose-response curve of equal molar concentrations of pMON or pHON-13 or pH13 or CS4
Protein fusions comprising, in part, GM-CSF, pMON3989 and pMON3998 were compared at the dose-response curve of equal molar concentrations of hGM-CSF and pMON13288.
Protein fusions comprised of dimers of hlL-3, pMON3988, pMON26425, pMON26427, pMON26420, pMON26429, and pMON26431 were compared at the dose-response curve of pMON13288 or pMON13416.
The activity for each sample was determined by the concentration that gave 50% of the maximum response, by matching to data a 4-parameter logistic model. It was observed that the upper plateau (maximum response), the sample and the control with which it was compared did not differ. Therefore, the calculation of the relative power for each sample was determined from the EC estimates<sub>50</sub> for the test and the witness, as indicated above. Relative power (EC<sub>50 </sub>of the standard divided by EC<sub>S0</sub> of the sample), reported in Table 3, is the average of at least 2 independent tests, except where otherwise indicated.
AML 193 1.3 cells proliferate in response to hlL-3, hGM-CSF and hG-CSF. Therefore, the following additional tests were performed, for some samples, to demonstrate that the G-CSF or GM-CSF portion of the fusion proteins was active. The proliferation assay was performed using neutralizing polyclonal antibodies to pMON 13288. In addition, a fusion molecule was cleaved and then purified with the cleavage site factor Xa and the halves of the molecule were analyzed for proliferative activity. These experiments showed that both components of the fusion protein were active.
4100
4105
4110
4115
4120
4125
Table 3
<td>pMON</td><td>Ri</td><td>Links</td><td>r<sub>2</sub></td><td>Bioactiviate (relative power) AML 193 1.3</td>
<td>PMON3987</td><td> 13288</td><td>Links 1</td><td>G-CSF</td><td> 0,35±0,11</td>
<td>pMON3988</td><td> 13288</td><td>Links 1</td><td> 13288</td><td> 0,64±0,13</td>
<td>pMON3989</td><td> 13288</td><td>Links 1</td><td>GM-CSF</td><td> 0,6±0,09</td>
<td>pMON3995</td><td>G-CSF</td><td>Links</td><td> 13288</td><td> 0,41 ±0,44</td>
<td>PMON3997</td><td> 13288</td><td>Links 7</td><td>G-CSF</td><td>0,26(n=1)</td>
<td>PMON3998</td><td> 13288</td><td>Links 7</td><td>GM-CSF</td><td>0,21(n=1)</td>
<td>PMON26406</td><td> 13288</td><td>Left 4</td><td>G-CSF</td><td> 0,37±0,30</td>
4130
4135
RO 118016 Β1
Table 3 (continued)
<td>pMON</td><td>R<sub>1</sub></td><td>Links</td><td>r<sub>2</sub></td><td>Bioactiviate (relative power) AML 193 1.3</td>
<td>PMON26433</td><td>G-CSF</td><td>Left 4</td><td> 13288</td><td> 0,7910,35</td>
<td>pMON26415</td><td> 13288</td><td>Links 1</td><td>G-CSF Ser</td><td> 170,4610,08</td>
<td>PMON26416</td><td>G-CSF</td><td>Links 1</td><td> 13416</td><td> 0,4310,02</td>
<td>pMON26425</td><td> 13288</td><td>Left 2</td><td> 13288</td><td> 1,3210,41</td>
<td>pMON26427</td><td> 13288</td><td>Links 3</td><td> 13288</td><td> 1,4110,91</td>
<td>PMHN26420</td><td> 13416</td><td>Links 1</td><td> 13416</td><td> 2,0910,52</td>
<td>pMON26430</td><td> 13288</td><td>Links 6</td><td>G-CSF</td><td> 1,0410,69</td>
<td>PMON26429</td><td> 13288</td><td>Links 5</td><td> 13288</td><td> 1,8810,09</td>
<td>PMON26431</td><td> 13288</td><td>Links 6</td><td> 13288</td><td> 0,6610,26</td>
Test 2 Methylcellulose test
This assay provides a reasonable approximation of the growth activity of colony-stimulating factors, stimulating normal bone marrow cells, for the in vitro production of different types of hematopoietic colonies (Bradley et al. 1966, Pluznik et al. 1965).
Approximately 30 ml of fresh, healthy, normal bone marrow aspirate were obtained from individuals. Samples were diluted under sterile 1: 5 conditions with 1 x PBS (14040059 Life Technologies, Gaithersburg, Corning MD). Ficoll stratified (Histopaque 1077 Sigma H8889), under diluted sample, and centrifuged 300 xg, 30 min. The mononuclear cell band was removed and washed twice in 1X PBS and once with 1% BSA PBS (CelIPro Co., Bothel, WA). Mononuclear cells are counted and selected CD33 + cells, using Ceprate LC (CD34) Kit - column (CelIPro Co., Bothel, WA). This fractionation is achieved, because all the stem and progenitor cells, from bone marrow, present the surface antigen CD34. Cultures are mounted in triplicate, with a final volume of 1.0 ml in a 35 x 10 mm Petri dish (Nune 174926).
The culture medium was purchased from Terry Fox Labs, HCC-4230 medium (Terry Fox Labs, Vancouver, BC Canada) and erythropoietin (Amgen, Thousands Oaks, CA) was added to the culture media. Add 3000-10000 CD34 + cells per disc. Native IL-3 and fusion molecules are added to give final concentrations in the range 0.001 nM ... 10 nM. The native IL-3 and fusion molecules provided are proprietary. G-CSF (Neupogen) is from Amgen.
The cultures were resuspended, using a 3 cm syringe<sup>3</sup> and distribute on the disk 1.0 ml. Control cultures (the basic answer) did not receive colony-stimulating factors.
Positive control cultures received conditioned media (human PHA stimulated cells: Terry Fox Labs. H2400). The cultures were incubated at 37 ° C, 5% CO<sub>2</sub> in humidified air.
Hematopoietic colonies, which are defined as larger than 50 cells, are counted in the maximal response day (days 10-11) using a reversed-phase Nikon microscope with a combination of 40X lenses. Groups of cells containing less than 50 cells are referred to as groups. Alternatively, colonies can be identified by spreading colonies on a slab, and colored, or they can be collected resuspended and rotated on cytospin blades for staining.
RO 118016 Β1
4185
Test 3
Analyzes of hematopoietic growth factor in human cord blood
Bone marrow cells are functionally used for in vitro activity assays of the hematopoietic colony-stimulating factor (CSF). However, human bone marrow is not always accessible and there is considerable variability between donors. The blood of the oblique cord is comparable to the bone marrow, as a source of stem cells and hematopoietic progenitors (Broxmeyer et al. (1992); Mayani et al. 1993). Unlike bone marrow, cordal blood is more easily accessible on a regular basis. There is also the potential to reduce the variability of the analysis, by squeezing the cell recently obtained from several donors or by creating a bank of cryopreserved cells for this purpose. By modifying the culture conditions and / or analysis for lineage-specific markers, it would be possible to analyze specifically for granulocyte / macrophage colonies (CSF-GM), for megakaryocyte CSF activity or for the high proliferative potential of colony-forming cell activity ( HPP-CEC).
Isolated mononuclear cells (MNCs) from cordal blood within 24 h of collection using a standard density gradient (1.077 g / ml Histopaque). MNCs from cordal blood were subsequently enriched for stem and progenitor cells by several procedures including immunomagnetic selection for CD14-, and CD34 + cells, shifting to SBA-, the CD34 + fraction, using balloons covered by Applied Immune Science (Santa Clara, THAT); and CD34 + selection using an Avidine CelIPro column (Bothell, WA). Enriched CD34 + cell fractions either freshly isolated or cryopreserved are used for the test. Duplicate cultures are prepared for each sample dilution (concentration range from 1 pM to 1204 pM) with 1 x 10<sup>4</sup> cells in 1 ml medium containing 0.9% methylcellulose without additional growth factors (Methocult H4230 from Stern Cell Technologies, Vancouver, BC). In some experiments, Methocult H4330, containing erythropoietin (EPO), was used instead of Methocult H4230 or stem cell factor (SCF) and 50 ng / ml (Biosource International, Camarillo, CA) was added. After cultivation 7-9 days, the colonies containing more than 30 days were counted. In order to eliminate the subjective tendency of the score, the scores of the analyzes are blind.
Test 4
Analysis of the proliferative activity of the c-mpl ligand Methods
1. Bone marrow proliferation test
a. Purification of the CD34 + cell.
Between 15-20 ml bone marrow aspirates were obtained from normal allogeneic bone marrow donors, after their consent. The cells were diluted 1: 3 in phosphate buffered saline (PBS, Gibco-BRL), stratified 30 ml on 15 ml Histopaque, -1077 (Sigma) and centrifuged 30 min at 300 RCF. Nuclear layer 1 at the interface was collected and washed with PBS. CD34 + cells were enriched from the mononuclear cell preparation, using an affinity column, following the manufacturer's instructions (CelIProInc., Bothell WA). After enrichment, the purity of CD34 + cells was on average 70%, as determined using flow cytometric analysis, using fluorescein-conjugated CD34 monoclonal antibody and phycoerythrin-conjugated anti-CD38 (Becton Dickinson, San Jose CA).
Cells were resuspended at 40,000 cells / ml in X-Vivo 10 media (Bio-Whittaker, Walkersville, MD) and 1 ml was spread on 12-well tissue culture plates (Costar). The growth factor rhlL-3 was added to some wells at 10 ng / ml (pMON5873). The hLL-3 variant, pMON13288, was used at 10 ng / ml or 100 ng / ml. Conditional media from BHK cells transfected with plasmid encoding c-mpl ligand were tested by adding 100 μΙ of supernatant to 1 ml culture (approximately 10% dilution). Cells were incubated at 37 ° C for 18-14 days at 5% CO<sub>2</sub> in a humidified incubator.
4190
4195
4200
4205
4210
4215
4220
4225
4230
RO 118016 Β1
b. Cell harvesting and analysis
At the end of the culture period, a total number of cells was obtained, from each condition. For fluorescence analysis and ploidy determination, cells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 μΜ PGE 1 11 mM glucose, 3% w / v BSA in PBS, pH 7.4) (Tomer et al. (1987)) were resuspended in 500 μΙ of MK buffer containing FITC anti-CD41a antibody (1: 200, AMAC, Westbrook, ME) and washed in buffer MK. For DNA analysis, cells were permeabilized in MK buffer, containing 0.5% Tween 20 (Fisher, Fair Lawn NJ) 20 min, on ice, followed by fixation in 0.5% Tween-20 and 1% paraformaldehyde. (Fisher Chemical), for 30 min, followed by incubation in propidium iodide (Calbiochem, La Jolla Ca) (50 μg / ml) with RNAase (400 U / ml) in 55% v / v MK buffer (200 mOsm) for 1-2 h, on ice. Cells were analyzed on a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, CA). Green fluorescence was collected (CD41a-FIIC together with linear signals and red fluorescence (PI) log for DNA ploidy determination. All cells were collected to determine the percentage of cells that were CD41. Data analysis was done using Soft LYSIS (Becton Dickinson, San Jose, CA) Percentage of CD41 antigen-expressing cells was obtained from flow cytometric analysis. The absolute number (Abs) of CD41 + cells / ml was calculated by: (Abs) = (cell number) x (percentage) / 100.
2. Analysis of fibrin megakaryocyte clot
The CD34 + enriched population was isolated as described above. Cells were suspended at 25000 cells / ml with / without cytokine (s) in a medium consisting of an additional IMDM base Iscove medium with 0.3% BSA, 0.4 mg / ml apo-transferin, 5, 67 μΜ FeC<sub>12</sub>, 25 μg / ml CaCI<sub>2</sub>, 25 μg / ml L-asparagine, 500 μg / ml E-amino-n-caproic acid and penicillin / streptomycin. Before thrusting into plates 35 mm thrombin (0.25 units / ml) was added to initiate clot formation. Cells were incubated at 37 ° C for 13 days at 5% CO<sub>2</sub>, in a humidified incubator.
At the end of the culture period, the plates were fixed with methanocetone (1: 3), air dried and stored at - 20 ° C, until stained. A peroxidase immunochemistry staining procedure (Zymed, Histostain-SP, San Francisco, CA) was used using a mixture of primary monoclonal antibodies, anti CD41a, CD42 and CD61.
Colonies were counted after staining and classified as negative CFU-MK (small colonies, 1-2 foci and less than about 25 cells), BFU-MK (large colonies, multi-foci, with more than 25 cells) or mixed colonies (a mixture of both positive or negative cells).
Test 5
IL-3-mediated sulfidoleucotriene release from human mononuclear cells
The following test is used to measure the release of sulfidoleucotriene from human mononuclear cells.
Human blood is collected, containing heparin, and placed on an equal volume of Ficoll-Pague (Pharmacia 17-0840-02) prepared for use (density 1.77 g / ml). The flask is heated to room temperature and 50 ml polystyrene transparent tubes are used. The Ficoll gradient rotates at 300 xg, 30 min. at room temperature, using an H1000B rotor, in a Sorvall RT6000B refrigerated centrifuge. The tape containing the mononuclear cells is carefully removed, the volume is brought to 50 ml with Dulbecco saline buffered phosphate (Gibco Laboratories Catalog no.310-4040PK), it is rotated at 400 xg, 10 min., At 45C and the supernatant is carefully removed. . The cell pellet was washed twice with HA buffer (20 mM Hepes (Sigma, no. H-3375), 125 mM NaCl (Fisher no. S271-5000), 5 MM KCl (Sigma no. P-9541), 0, 5 mM glucose (Sigma no. G5000), 0.025% human serum albumin (Calbiochem no. 126654)) and rotates at 300 xg, 10 min., 4 ° C. The cells are resuspended in HACM buffer
RO 118016 Β1 (HA buffer supplemented with 1 mM CaC<sub>12</sub> (Fisher no. C79-500) and 1 mM MeC<sub>12</sub> (Fisher no. M33)) at a concentration of 1 x 10<sup>6</sup> cells / ml and 180 μΙ are transferred into each well of a 96 well tissue culture plate. The cells are left for acclimatization at 37 ° C for 15 min. The cells are initiated by adding 10 μ \ of a 2 x stock of various cytokine concentrations to each well (usually 100,000, 20000, 4000, 800, 160, 32, 6 , 4, 1,28, 0 fM IL-3).
The cells are incubated for 15 min at 37 ° C. The sulfidoleucotriene release is activated by the addition of 10 μ 2 x (1000 nM fmet-leu-phe (Calbiochem no. 344252) at the final concentration 50 nM FMLP and incubated, 10 min., At 37 ° C. 350 xg, at 4 ° C, 20 min. Supernatants are removed and analyzed for sulfidoleucotriene, using Cayman Leukotriene C4 EIA Kit (Catalog no. 420211), following the manufacturer's instructions. In each assay, native hlL-3 is migrated as a standard control.
Further details, known to those skilled in the art, can be found in T. Maniatis et al. Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1982) and references cited and incorporated herein, as references in J.Sambrook et al. Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989) and references cited herein and incorporated herein by reference.
Further details of the IL-3 variants of the present invention can be found in the US patent application, pending resolution, WO 94/12638, which is incorporated herein by reference in its entirety, as if read here .
Further details on obtaining the fusion protein can be found in WO 92/04455 and WO 91/02754.
Further details about lymphokine and its variants can be found in US Patent No. 4810643 and 5218092, EP Application 02174004.
All references, patents or applications cited herein, are incorporated by reference in their entirety, as if they were read here.
Amino acids are presented here, by standard abbreviations of one letter or 3 letters, as follows:
4285
4290
4295
4300
4305
<td colspan="2">Abbreviated designation</td><td>amino Acid</td>
<td>A</td><td>Ala</td><td>Alanină</td>
<td>C</td><td>Cys</td><td>cysteine</td>
<td>D</td><td>Asp</td><td>Acid aspartic</td>
<td>IS</td><td>Glu</td><td>Acid glutamic</td>
<td>F</td><td>Faction</td><td>phenylalanine</td>
<td>G</td><td>Gly</td><td>glycine</td>
<td>H</td><td>His</td><td>histidine</td>
<td> 1</td><td>for</td><td>isoleucine</td>
<td>K</td><td>list</td><td>lysine</td>
<td>The</td><td>Lion</td><td>leucine</td>
<td>M</td><td>With</td><td>Methionine</td>
<td>N</td><td>Asn</td><td>asparagine</td>
<td>P</td><td>Pro</td><td>proline</td>
4310
4315
4320
RO 118016 Β1
Table (continued)
<td colspan="2">Abbreviated designation</td><td>amino Acid</td>
<td>Q</td><td>Gin</td><td>glutamine</td>
<td>R</td><td>Angry</td><td>arginine</td>
<td>S</td><td>To be</td><td>serine</td>
<td>T</td><td>Thr</td><td>threonine</td>
<td>V</td><td>Hours</td><td>valine</td>
<td>in</td><td>Trp</td><td>Tryptophan</td>
<td>Y</td><td>Tyr</td><td>tyrosine</td>
The following is a series of useful tests.
TF-1 proliferation assay. The TF-1 cell line was derived from the bone marrow of a patient with erythroleukemia (Kitamura et al., 1989). TF-1 cells respond to IL-3, GMCSF, EPO and IL-5.
32D proliferation test. The 32D cell line is a murine IL-3-dependent cell line that does not respond to human IL-3 but responds to human G-CSF, which is not species-restricted.
T1165 proliferation assay. T1165 cells are a murine cell line, dependent on IL-6 (Nordan et al., 1986), which responds to IL-6 and IL-11.
The meg-CSF test clots human plasma. It is used to test the activity of megacaruicute colony formation (Mazur et al., 1981).
Table 5
OLIGONUCLEOTIDE
88CTERM1.REQ Length: 000041
AATTCCGGA AAAACTGACG TTCTATCTGG TTACCCTTGA G (SECV.No.:91)
88CTERM4.REQ Length. 000 046
CTGCGCTTGC TCAAGGGTAA CCAGATAGAA CGTCAGTTT TCCCGG (SECV.Nr.92)
88XA2.REQ Length: 000039
CAAGCGCAGG AACAACAGTA CGTAATCGAG GGAAGGATT (SECV. No.93)
88XA5.REQ Length: 000039
ACCCGGGGAA ATCCTTGGGT CGATTACGTA CTGTTGTTC (SECV. No.94)
GLYN3.REQ Length: 000063
TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGTAAG GTACCGCATG
CAAGCTTAGA TCT (SEQ. No. 95)
GLYN6.REQ Length: 000058
AGCTAGATCT AAGCTTGCAT GCGGTACCTT ACATGTTGGA GCCGCCGCCA
GAACCACC (SECV. No. 96)
RO 118016 Β1
IGG2B1.REQ Length: 000074
CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC
TAAAGAATCT CATAAATCTC CAAA (SECV.Nr.97)
IGG2B2.REQ Length: 000074
CATGTTTGGA GATTTATGAG ATTCTTTAGA CGGAGGAGAC GGGTTGATAG
ACCAGACGGT TCAC (SECV.Nr.98)
GCSFSNA1.REQ Length: 000068
CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC
CTTGCGCAGC CCTACGTA (SECV No. 99)
GCSFSNA2.REQ Length: 000068
AGCTTACGTA GGGCTGCGCA AGGTGGCGTA GAACGCGGTA CGACACCTCC
AGGAAGCTCT GCAGATGG (SECV. No. 100)
LYSXA1.REQ Length: 000021
GTAATCGAGG GAAAGATTC C (SECV. Nr101)
LYSXA2.REQ Length: 000025
CCGGGGAAAT CTTTCCCTCG ATTAC (SECV. No.102)
GLYXA1.REQ Length: 000021
GTAGAGGGCG GTGGAGGCTC C (SECV No. 103)
GLYXA2.REQ Length: 000025
CCGGGGAGCC TCCACCGCCC TCTAC (SECV.Nr. 104)
GM-AUP.REQ Length: 000058
CATGGCACCA GCAAGATCAC CAATCACCATC AACTCAACCT TGGGAACATG
TGAATGCC (SECV.Nr. 105)
GM-ALOW.REQ Length: 000052
CATTCACATG TTCCCAAGGT TGAGTTGATG GTGATGGTGA TCTTGCTGGT
GC (SECV. No.106)
G-CYS18.REQ Length: 000066
CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG
AGGAAGATCC AGGGCG (SECV.Nr. 107)
GCYS18LO.REQ Length: 000066
CTGGATCTTC CTCACTTGCT CTAAAGACTT GAGCAGGAAG CTCTGGGGCA
GGGAGCTGGC AGGGGCC (SECV. No.108)
HTL6231.REQ Length: 000048
AGCTTACCTG CCATGGCTGC AGTACCACCA GGTGAAGATT CCAAAGAT (SECV.
Nr.109)
HIL6232.REQ Length: 000040
TTGGAATCTT CACCTGGTGG TACTGGAGCC ATGGCAGGTA (SECV No. 110)
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
RO 118016 Β1
HGCSFMAI.REQ Length: 000026
AGCTTCCATG GCTACCCCCC TGGGCC (SECV. No.111)
HGCSFMA2.REQ Length: 000018
CAGGGGGGTA GCCATGGA (SECV. No.112)
HGCSFATI.REQ Length: 000020
CATGGCTACA CCATTGGGCC (SECV No. 113)
HGCSFAT2.REQ Length: 000012
CAATGGTGTA GC (SECV. No.114)
HGCSFAT3.REQ Length: 000020
CATGGCTACA CCATTAGGAC (SEQ. No. 115)
HGCSFAT4.REQ Length: 000012
TAATGGTGTA GC (SECV. No.116)
PREFOR.REQ
CCTGTCAACC CGGGCGGCGG CTCTGGTGGT (SE CV. No.117)
REVPRE.REQ
TCATAATACA TGTTACCGGA ACGGAGCCGC C (SECV.Nr.118)
FORXTRA.REQ
ATCGTCTGAC CTCCCGGGAC CTCCTGTCAA TGCT (SEQ. No. 119)
XTRAREV.REQ
AGCGTTTGAC ATGTTTTCAT AATCAAAATC (SECV.Nr.120 c-mp1Ncol
ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGACCTCCGAGTC (SEQ. No. 169) (where N = G, C, T or a) c-mplECoRI
AATAGCTGAATTCTTACCCTTCCTGAGACAGATT (SECV.Nr. 170) c-mpIHindlll
TGACAAGCTTACCTGACGCAGAGGGTGGACCCT (SECV.Nr.171)
Eco-mpl
ATGCACGAATTCCCTGACGCAGAGGGTGGA (SECV.Nr. 172)
EcoSnal
AATTCCATGCATC (SECV.Nr.173)
ECOSNA2
GGTACGTATG (SEQ. No. 174)
RO 118016 Β1
4470
Table 6
DNA sequences
PMON13023
ATGGCTAACT GCTCTATAAT
ACCACCTAAC CCTTTGCTGG
ATATCCTGAT GGAACGAAAC
AGGGCTGTCA AGCACTTAGA
TAATCTCCAA CCATGTCTGC
CAATCATCAT CAAGGCAGGT
TTCTATCTGG TTACCCTTGA
GGGAAGGATT TCCCCGGGTG
CACCATTAGG CCCTGCCAGC
TTAGAGCAAG TGAGGAAGAT
GCTGTGTGCC ACCTACAAGC
GACACTCTCT GGGCATCCCC
GCCCTGCAGC TGGCAGGCTG
CTACCAGGGG CTCCTGCAGG
CCACCTTGGA CACACTGCAG
TAACTGGGAA TGGCCCCTGC
CTTCGCCTCT GCTTTCCAGC
ATCTGCAGAG CTTCCTGGAG cagccc [Secv. No. 53]
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATTCT GAAGACATGG CTTCGAACTC CAAACCTGCT CGCATTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAATCGA GTGGTTCTGG CGGCGGCTCC AACATGGCTA TCCCTGCCCC AGAGCTTCCT GCTCAAGTGC CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA TGTGCCACCC CGAGGAGCTG GTGCTGCTCG TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CCCTGGAAGG GATATCCCCC GAGTTGGGTC CTGGACGTCG CCGACTTTGC CACCACCATC CCTGCAGCCC ACCCAGGGTG CCATGCCGC-C GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC GTGTCGTACC GCGTTCTACG CCACCTTGCG
4475
4480
4485
4490
4495
PMON13021
4500
RO 118016 Β1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC CCTTTGCTGG ACCCGAACÂA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA AQGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGQGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATOGCTA ACTGCTCTAT AATGATOGAT GAAATTATAC ATCACTTAAA GAGACCACCT AACCCTTTGC TGGACCCGAA CAACCTCAAT TCTGAAGACA TCGATATCCT GATGGAACGA AACCTTCGAA CTCCAAACCT GCTCGCATTC GTAAGGGCTG TCAAGCACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CATCAAGGCA GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC tggttaccct tgagcaagcg caggaacaac by [Secv. nr. 54] pMOH13022
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
GGGAAGGATT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCAC
CGGCTCGTTC CCCGTCCCCG TCTACCCAGC CGTGGGAACA CGTGAATGCC
ATCCAGGAGG CCCGGCGTCT CCTGAACCTG AGTAGAGACA CTGCTGCTGA
GATGAATGAA ACAGTAGAAG TGATATCAGA AATGTTTGAC CTCCAGGAGC
CGACTTGCCT ACAGACCCGC CTGGAGCTGT ACAAGCAGGG CCTGCGGGGC
AGCCTCACCA AGCTCAAGGG CCCCTTGACC ATGATGGCCA GCCACTACAA
RO 118016 Β1
GCAGCACTGC CCTCCAACCC CGGAAACTTC CTGTGCAACC CAGATTATCA CCTTTGAAAG TTTCAAAGAG AACCTGAAGG ACTTCCTGCT TGTCATCCCC TTTGACTGCT GGGAGCCAGT CCAGGAG [Secv. ΙΊΓ. 55] pMON13039
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCĂT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACĂTGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC C [SeCV. ΠΓ. 56]
PMON13049
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
4550
4555
4560
4565
4570
4575
4580
4585
4590
RO 118016 Β1
GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAATCGA GTGGTTCTGG CGGCGGCTCC AACATGGCTC TCCAAAGATG TGGCCGCCCC ACACAGACAG AATTGACAAA CAAATTCGGT ACATCCTCGA AGGAGACATG TAACAAGAGT AACATGTGTG GCAGAAAACA ACCTGAACCT TCCAAAGATG CCAATCCGGA TTCAATGAGG AGACTTGCCT TTTTGGAGTT TGAGGTATAC CTCGAGTACC AGTGAGGAAC AAGCCAGAGC TGTGCAGATG GTTCCTGCAG AAAAAGGCAA AGAATCTAGA CAACCACAAA TGCATCCCTG CTGACGAAGC CTGCAGGACA TGACAACTCA TCTCATTCTG CTGAGGGCTC TTCGGCAAAT
CAATCATCAT CAAGGCAGGT
TTCTATCTGG TTACCCTTGA gggaaggatt TCCCCGGGTG CAGTACCACC AGGTGAAGAT
CCACTCACCT CTTCAGAACG
CGGGATATCA GCCCTGAGAA
NAVIGAA NSAWEA
GCTGAAAAAG ATGGATGCTT
GGTGAAAATC ATCACTGGTC
TCCAGAACAG ATTTGAGAGT
TCGACAAAAG TCCTGATCCA
TGCAATAACC ACCCCTGACC
TGCAGGCACA GAACCAGTGG
CGCAGCTTTA AGGAGTTCCT g [Secv. No. 57]
PMOH13O55
ATGGCTAACT GCTCTATAAT
ACCACCTAAC CCTTTGCTGG
ATATCCTGAT GGAACGAAAC
AGGGCTGTCA AGCACTTAGA
TAATCTCCAA CCATGTCTGC
CAATCATCAT CAAGGCAGGT
TTCTATCTGG TTACCCTTGA
GGGAAAGATT TCCCCGGGTG
ACTGCTCTAT AATGATCGAT
AACCCTTTGC TGGACCCGAA
GATGGAACGA AACCTTCGAA
TCAAGCACTT AGAAAATGCA
CAACCATGTC TGCCCTCTGC
CATCAAGGCA GGTGACTGGC
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATTCT GAAGACATGG CTTCGAACTC CAAACCTGCT CGCATTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAATCGA GTGGTTCTGG CGGCGGCTCC AACATGGCTA GAAATTATAC ATCACTTAAA GAGACCACCT CAACCTCAAT TCTGAAGACA TGGATATCCT CTCCAAACCT GCTCGCATTC GTAAGGGCTG TCAGGTATTG AGGCAATTCT TCGTAATCTC CACGGCCGCA CCCTCTCGAC ATCCAATCAT AAGAATTCCG GGAAAAACTG ACGTTCTATC
RO 118016 Β1
4640
TGGTTACCCT EETWORK CAGGAACAAC AG [Secv. . 58]
PMON13054
ATGGCTAACT ACCACCTAAC ATATCCTGAT AGGGCTGTCA TAATCTCCAA CAATCATCAT TTCTATCTGG GGGAAAGATT CACCATTGGG TTAGAGCAAG GCTGTGTGCC GACACTCTCT GCCCTGCAGC CTACCAGGGG CCACCTTGGA TGGCAGCAGA GGGTGCCATG TCCTGGTTGC CTACGCCACC
GCTCTATAAT CCTTTGCTGG GGAACGAAAC AGCACTTAGA CCATGTCTGC CAAQGCAGGT TTACCCTTGA TCCCCGGGTG CCCTGCCAGC TGAGGAAGAT ACCTACAAGC C-GGCATCCCC TGGCAGGCTG CTCCTGCAGG CACACTGCAG TGGAAGAACT CCGGCCTTCG TAGCCATCTG TTGCGCAGCC
GATCGATGAA ACCCGAACAA CTTCGAACTC AAATGCATCA CCTCTGCCAC GACTGGCAAG GCAAGCGCAG GTGGTTCTGG TCCCTGCCCC CCAGGGCGAT TGTGCCACCC TGGGCTCCCC CTTGAGCCAA CCCTGGAAGG CTGGTGGGGGGGGGGGGGGGGGGGGGGGG no. IN
ATTATACATC CCTCAATTCT CAAACCTGCT GGTATTGAGG GGCCGCACCC AATTCCGGGA GAACAACAGT CGGCGGCTCC AGAGCTTCCT GGCGCAGCGC CGAGGAGCTG TGAGCTCCTG CTCCATAGCG GATATCCCCC CCGACTTTGC CCTGCCCTGC CCAGCGCCGG TGGAGGTGTC
ACȚTAAAGAG GAAGACATGG CGCATTCGTA CAATTCTTCG TCTCGACATC AAAACTGACG ACGTAATCGA AACATGGCTA GCTCAAGTCT TCCAGGAGAA GTGCTGCTCG CCCCAGCCAG GCCTTTTCCT GAGTTGGGTC CACCACCATC AGCCCACCCA GCAGGAGGGG GTACCGCGTT
4645
4650
4655
4660
4665
4670
PMON130S6
ATGGCTAACT ACCACCTAAC ATATCCTGAT AGGGCTGTCA TAATCTCCAA CAATCATCAT
GCTCTATAAT
CCTTTGCTGG GGAACGAAAC AGCACTTAGA CCATGTCTGC CAAGGCAGGT
GATCGATGAA
ACCCGAACAA CTTCGAACTC AAATGCATCA CCTCTGCCAC GACTGGCAAG
ATTATACATC CCTCAATTCT CAAACCTGCT GGTATTGAGG GGCCGCACCC AATTCCGGGA
ACTTAAAGAG
GAAGACATGG
CGCATTCGTA CAATTCTTCG TCTCGACATC AAAACTGACG
4675
4680
RO 118016 Β1
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GMCAACAGT ACGTAGAGGG
CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA
CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT
TTAGAGCAAG TGAGGAAGĂT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA
QCTGTGTGCC ACCTACAAGC TGTGCCACCC OGAGGAGCTG GTGCTGCTCG
GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG
GCCCTQCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT
CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC
CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC
TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA
GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT
CTACGCCACC TTGCGCAGCC C [Secv. No. 60]
PKON13057
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG
CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA
ACTGCTCTAT AATGATCGAT GAAATTATAC ATCACTTAAA GAGACCACCT
AACCCTTTGC TGGACCCGAA CAACCTCAAT TCTGAAGACA TGGATATCCT
GATGGAACGA AACCTTCGAA CTCCAAACCT GCTCGCATTC GTAAGGGCTG
TCAAGCACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC
CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT
CATCAAGGCA GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC
TGGTTACCCT TGAGCAAGCG CAGGAACAAC AG [Secv. nr. 61]
RO 118016 Β1 p! £ ON130 36
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GMCMCAGT ACGTAATCGA GGOMGOMT TCCCCGGGTC AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAACTGC TCTATAATGA TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTAACCC TTTGCTGGAC CCGAACAACC TCAATTCTGA AGACATGGAT ATCCTGATGG AACGAAACCT TCGAACTCCA AACCTGCTCG CATTCGTAAG GGCTGTCAAG cacttagaâa atgcatcagg tattgaggca attcttcgta atctccaacc ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA AQGCAGGTGA ctggcaagaa ttccgggaaa aactgacgtt ctatctggtt ACCCTTGAGC AAGCGCAGGA ACAACAG [Secv. nr. 62]
PKOM13 0S9
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
GGGAAAGATT TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAACTGC TCTATAATGA TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTAACCC TTTGCTGGAC CCGAACAACC TCAATTCTGA AGACATGGAT ATCCTGATGG
4730
4735
4740
4745
4750
4755
4760
4765
AACGAAACCT TCGAACTCCA AACCTGCTCG CATTCGTAAG GGCTGTCAAG
4770
RO 118016 Β1
CACTTAGAAA ATGCATCAGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC
ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT
ACCCTTGAGC AAGCGCAGGA ACAACAG [Secv. No. 63] ptfON430Cl
ATGGCTAACT GCTCTATAAT GATOGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT QGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGQGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCMGCGCAG GAACAACAGT ACGTAGAGGG
CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAACTGC
TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTAACCC
TTTGCTGGAC CCGAACAACC TCAATTCTGA AGACATCGAT ATCCTGATGG
AACGAAACCT TCGAACTCCA AACCTGCTCG CATTCGTAAG GGCTGTCAAG
CACTTAGAAA ATGCATCAGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC
ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA
AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT
ACCCTTGAGC AAGCGCAGGA ACAACAG [Secv. ΠΓ. 64] pMON13062
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTCG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATCTCTCC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
RO 118016 Β1
4820
GGGAAGGATT TCCCCCGGGC CTCCTGTCAA TGCTGGCGGC GGCTCTGGTG
GTGGTTCTGG TGGCGGCTCT GAGGGTGGCG GCTCTGAGGG TGGCGGTTCT
GAGGGTGGCG GCTCTGAGGG TGGCGGTTCC GGTGGCGGCT CCGGTTCCGG
TGATTTTGAT TATGAAAACA TGGCTACACC ATTGGGCCCT GCCAGCTCCC
TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GAAGATCCAG
OGCGATGGCG CAGOGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG
CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG
CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTCGC AGGCTGCTTG
AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT
GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG
ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA
ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC
TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA
GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCC [Secv. No. 65] pMON13031
4825
4830
4835
4840
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td>
<td>ACCACCTAAC</td><td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATTCT</td><td>GAAGACATGG</td>
<td>ATATCCTGAT</td><td>GAAACGAAAC</td><td>CTTCGAACTC</td><td>CAAACCTGCT</td><td>CGCATTCGTA</td>
<td>AGGGCTGTCA</td><td>AGCACTTAGA</td><td>AAATGCATCA</td><td>GGTATTGAGG</td><td>CAATTCTTCG</td>
<td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td>TCTCGACATC</td>
<td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>NWISA</td><td>TRANSPORTATION</td><td>ACGTAATCGA</td>
<td>GGGAAGGATT</td><td>TCCCCCGGGC</td><td>CTCCTGTCAA</td><td>TGCTGGCGGC</td><td>GGCTCTGGTG</td>
<td>GTGGTTCTGG</td><td>TGGCGGCTCT</td><td>GAGGGTGGCG</td><td>GCTCTGAGGG</td><td>TGGCGGTTCT</td>
<td>GAGGGTGGCG</td><td>GCTCTGAGGG</td><td>TGGCGGTTCC</td><td>GGTGGCGGCT</td><td>CCGGTTCCGG</td>
<td>TGATTTTGAT</td><td>TREATMENT</td><td>TGGCACCGGC</td><td>TCGTTCCCCG</td><td>TCCCCGTCTA</td>
<td>CCCAGCCGTG</td><td>GGAACACGTG</td><td>AATGCCATCC</td><td>AGGAGGCCCG</td><td>GCGTCTCCTG</td>
<td>AACCTGAGTA</td><td>GAGACACTGC</td><td>TGCTGAGATG</td><td>YOUR MONEY</td><td>TAGAAGTGAT</td>
ATCAGAAATG TTTGACCTCC AGGAGCCGAC TTGCCTACAG ACCCGCCTGG
4845
4850
4855
4860
RO 118016 Β1
AGCTGTACAA GCAGGGCCTG CGGGGCAGCC TCACCAAGCT CAAGGGCCCC
TTGACCATGA TGGCCAGCCA CTACAAGCAG CACTGCCCTC CAACCCCGGA
AACTTCCTGT GCAACCCAGA TTATCACCTT TCAAAGTTTC AAAGAGAACC
TCAAGGACTT CCTGCTTGTC ATCCCCTTTG ACTCCTGGGA GCCAGTCCĂG GAG [Secv. No. 66]
PMC1T15937
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGĂCATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCUCAG GAACAACAGT ACGTAATCGA
GGGAAGGATT TCCCCCGGTG GCGGCGGCTC TGGTGGTGGT TCTGGTGGCG
GCTCTGAGGG TGGCCGCTCT GAGGGTGGCG GTTCTGAGGG TGGCGGCTCT
GAGGGTGGCG GTTCCOGTGG CGGCTCCGGT TCCGGTAACA TGGCTACACC
ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTGCTTAG
AGCAAGTGAG GAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG
TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA
CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC
TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC
CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC
CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC
AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT
GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT
GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC
GCCACCTTGC GCAGCCC [Secv. ΠΓ. 67]
PMON13034
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
RO 118016 Β1
ACCACCTAAC CCTTTGCTGG ACCCGAACAA
ATATCCTGAT GGAACGAAAC CTTCGAACTC
AGGGCTGTCA AGCACTTAGA AAATGCATCA
TAATCTCCAA CCATGTCTGC CCTCTGCCAC
CAATCATCAT CAAGGCAGGT GACTGGCAAG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG
GGGAAGGATT TCCCCGGGTG AACCGTCTGG
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT
TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC
GCAAGTGAGG AAGATCCAGG GCGATGGCGC
GTGCCACCTA CAAGCTGTGC CACCCCGAGG
TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC
GCAGCTGGCA GGCTGCTTGA GCCAACTCCA
AGGGGCTCCT GCAGGCCCTG GAAGGGATAT
TTGGACACAC TGCAGCTGGA CGTCGCCGAC
GCAGATGGAA GAACTGGGAA TGGCCCCTGC
CCATGCCGGC CTTCGCCTCT GCTTTCCAGC
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG
CCACCTTGCG CAGCCC [Secv. No. 68]
PKON13035
ATGGCTAACT GCTCTATAAT GATCGATGAA
ACCACCTAAC CCTTTGCTGG ACCCGAACAA
ATATCCTGAT GGAACGAAAC CTTCGAACTC
AGGGCTGTCA AGCACTTAGA AAATGCATCA
TAATCTCCAA CCATGTCTGC CCTCTGCCAC
CAATCATCAT CAAGGCAGGT GACTGGCAAG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG
GGGAAGGATT TCCCCGGGTG AACCGTCTGG
CCTCAATTCT GAAGACATGG <sup>4910</sup>
CAAACCTGCT CGCATTCGTA
GGTATTGAGG CAATTCTTCG
GGCCGCACCC TCTCGACATC . <sub>n</sub>, <sub>c</sub>
4915
AATTCCGGGA AAAACTGACG
ACGTAATCGA GAACACTT
TCCAATCTCT ACTATCAACC
4920
CTCCAAACAT GGCTACACCA
TTCCTGCTCA AGTGCTTAGA
AGCGCTCCAG GAGAAGCTGT
AGCTGGTGCT GCTCGGACAC <sub>4925</sub>
TCCTGCCCCA GCCAGGCCCT
TAGCGGCCTT TTCCTCTACC
CCCCCGAGTT GGGTCCCACC
TTTGCCACCA CCATCTGGCA <sup>493C</sup>
CCTGCAGCCC ACCCAGGGTG
GCCGGGCAGG AGGGGTCCTG
GTGTCGTACC GCGTTCTACG /,<sub>qr</sub>
<td>ATTATACATC</td><td>ACTTAAAGAG</td><td> 4940</td>
<td>CCTCAATTCT</td><td>GAAGACATGG</td><td></td>
<td>CAAACCTGCT</td><td>CGCATTCGTA</td><td></td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td> 4945</td>
<td>GGCCGCACCC</td><td>TCTCGACATC</td><td></td>
<td>AATTCCGGGA</td><td>AAAACTGACG</td><td></td>
<td>TRANSPORTATION</td><td>ACGTAATCGA</td><td> 4950</td>
TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCACCGGCT
RO 118016 Β1
GAACACGTGA ATGCCATCGA
AGACACTGCT GCTGAGATGA
TTGACCTCCA GGAGCCGACT
CAGGGCCTGC GGGGCAGCCT
GGCCAGCCAC TACAAGCAGC
CAACCCAGAT TATCACCTTT
CTGCTTGTCA TCCCCTTTGA
69]
ATTATACATC ACTTAAAGAG
CCTCAATTCT GAAGACATGG
CAAACCTGCT CGCATTCGTA
GGTATTGAGG CAATTCTTCG
GGCCGCACCC TCTCGACATC
AATTCCGGGA AAAACTCACG
ACGTAATCGA GAACACTT
TCCAATCTCT ACTATCAACC
CTCCAAACAT GGCTACACCA
TTCCTGCTCA AGTGCTTAGA
AGCGCTCCAG GAGAAGCTGT
AGCTGGTGCT GCTCGGACAC
TCCTGCCCCA GCCAGGCCCT <sup>f</sup>
TAGCGGCCTT TTCCTCTACC
CCCCCGAGTT GGGTCCCACC
TTTGCCACCA CCATCTGGCA
CCTGCAGCCC ACCCAGGGTG
GCCGGGCAGG AGGGGTCCTG
GTGTCGTACC GCGTTCTACG
CGTTCCCCGT CCCCGTCTAC CCAGCCGTGG
GGAGGCCCGG CGTCTCCTGA ACCTGAGTAG
ATGAAACAGT AGAAGTGATA TCAGAAATCT
TGCCTACAGA CCCGCCTGGA GCTGTACAAG
CACCAAGCTC AAGGGCCCCT TGACCATGAT
ACTGCCCTCC AACCCCGGAA ACTTCCTGTG
GAAAGTTTCA AAGAGAACCT GAAGGACTTC
CTGCTOGGAG CCAGTCCAGG AG [Secv. nr.
PMOH13058
ATGGCTAACT GCTCTATAAT GATCGATGAA
ACCACCTAAC CCTTTGCTGG ACCCGAACAA
ATATCCTGAT GGAACGAAAC CTTCGAACTC
AGGGCTGTCA AGCACTTAGA AAATGCATCA
TAATCTCCAA CCATGTCTGC CCTCTGCCAC
CAATCATCAT CAAGGCAGGT GACTGGCAAG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG
GGGAAAGATT TCCCCGGGTG AACCGTCTGG
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT
TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC
GCAAGTGAGG AAGATCCAGG GCGATGGCGC
GTGCCACCTA CAAGCTGTGC CACCCCGAGG
TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC
GCAGCTGGCA GGCTGCTTGA GCCAACTCCA
AGGGGCTCCT GCAGGCCCTG GAAGGGATAT
TTGGACACAC TGCAGCTGGA CGTCGCCGAC
GCAGATGGAA GAACTGGGAA TGGCCCCTGC
CCATGCCGGC CTTCGCCTCT GCTTTCCAGC
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG
CCACCTTGCG CAGCCC [SeCV. ΠΓ. 70]
RO 118016 Β1
PMON13060 atggctaact gctctatate gatcgatgaa attatacatc action day
ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG
ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA
AGOGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG
CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACACCA
TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTGCTTAGA
GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT
GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC
TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT
GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC
AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC
TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA
GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG
CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG
CCACCTTGCG CAGCCC [Secv. ΠΓ. 71]
PMON13026
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
5000
5005
5010
5015
5020
5025
5030
5035
5040
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
RO 118016 Β1
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA ggaggggtcc tggttgctag ccatctgcag agcttcctgg aggtgtcgta
CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAATCGAG GGAAGGATTT
CCCCGGGTGG TGGTTCTGGC GGCGGCTCCA ACATGGCTAA CTGCTCTATA
ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT
GGACCCGAAC AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA
ACCTTCGAĂC TCCAAACCTG CTCGCATTCG TAAGGGCTGT CAAGCACTTA
GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT
GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG gtgactggca agaattccgg gaaaaactga cgttctatct ggttaccctt
GAGCAAGCGC AGGAACAACA G [Secv. No. 72]
ISMOM130S3
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
<td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td>CATAGCGGCC</td>
<td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td>
<td>TTCGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td>
<td>CACCATCTGG</td><td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td>
<td>CCACCCAGGG</td><td>TGCCATGCCG</td><td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td>
<td>GGAGGGGTCC</td><td>TGGTTGCTAG</td><td>CCATCTGCAG</td><td>AGCTTCCTGG</td><td>AGGTGTCGTA</td>
<td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTA</td><td>CGTAATCGAG</td><td>GGAAGGATTT</td>
<td>CCCCGGGTGA</td><td>ACCGTCTGGT</td><td>CCAATCTCTA</td><td>CTATCAACCC</td><td>GTCTCCTCCG</td>
<td>TCTAAAGAAT</td><td>CTCATAAATC</td><td>TCCAAACATG</td><td>GCTAACTGCT</td><td>CTATAATGAT</td>
<td>CGATGAAATT</td><td>ATACATCACT</td><td>TAAAGAGACC</td><td>ACCTAACCCT</td><td>TTGCTGGACC</td>
<td>CGAACAACCT</td><td>CAATTCTGAA</td><td>GACATGGATA</td><td>TCCTGATGGA</td><td>ACGAAACCTT</td>
CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA
RO 118016 Β1
TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAOGM. CAACAG [Secv. ΠΓ. 73]
5090
5095
PMOM13064
ATGGCTACAC CATTAGGCCC
CAAGTGCTTA GAGCAAGTGA
AGGAGAAGCT GTGTGCCACC
CTGCTCGGAC ACTCTCTGGG
NWWRACCACCVACCVAC
TTTTCCTCTA CCAGGGGCTC
TTCGGTCCCA CCTTGGACAC
CACCATCTGG CAGCAGATGG
CCACCCAGGG TGCCATGCCG
GGAGGGGTCC TGGTTGCTAG
CCGCGTTCTA CGCCACCTTG
CCCCCGGGCC TCCTGTCAAT
GGCGGCTCTG AGGGTGGCGG
CTCTGAGGGT GGCGGTTCCG
ATGAAAACAT GGCTAACTGC
TTAAAGAGAC CACCTAACCC
AGACATGGAT ATCCTGATGG
CATTCGTAAG GGCTGTCAAG
ATTCTTCGTA ATCTCCAACC
TCGACATCCA ATCATCATCA
AACTGACGTT CTATCTGGTT [Secv. no. 74]
PMON13043
ATGGCTACAC CATTAGGCCC
CAAGTGCTTA GAGCAAGTGA
TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT GGAAGATCCA GGGCGATGGC GCAGCGCTCC TACAAGCTGT GCCACCCCGA GGAGCTQGTG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGGCTGCTT GAGCCAACTC CATAGCGGCC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG ACTGCAGCTG GACGTCGCCG ACTTTGCCAC AAGAACTGGG AATGGCCCCT GCCCTGCAGC GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CGCAGCCCTA CGTAATCGAG GGAAGGATTT GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT CTCTGAGGGT GGCGGTTCTG AGGGTGGCGG GTGGCGGCTC CGGTTCCGGT GATTTTGATT TCTATAATGA TCGATGAAAT TATACATCAC TTTGCTGGAC CCGAACAACC TCAATTCTGA AACGAAACCT TCGAACTCCA AACCTGCTCG CACTTAGAAA ATGCATCAGG TATTGAGGCA ATGTCTGCCC TCTGCCACGG CCGCACCCTC AGGCAGGTGA CTGGCAAGAA TTCCGGGAGA ACCCTCGGAGGA ACCCTCGGGAGA ACCAAC
TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT GGAAGATCCA GGGCGATGGC GCAGCGCTCC
5100
5105
5110
5115
5120
5125
5130
RO 118016 Β1
AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAQGCTGCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA
QGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA
CCGCGTTCTA CGCCACCTTC CGCAGCCCTA CGTAATCGAG GGAAGGATTT
CCCCGGGTGG TGGTTCTCGC GGCGGCTCCA ACATGGCTAA CTGCTCTATA
ATGATCGATG AAATTATACA TCACTTAAAG AQACCACCTG CACCTTTGCT
GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATCGAACGAA
ACCTTCGACT TCCAAACCTC GAGAGCTTCG TAAGGGCTGT CAAGAACTTA
GAAAATGCAT CAGGTATTCA GGCAATTCTT CGTAATCTCC AACCATGTCT
GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG
GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT
GAGCAAGCGC AGGAACAACA G [Secv. No. 75]
PMOK13044
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAGGCTCCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA
GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA
CCGCGTTCTA CGCCACCTTC CGCAGCCCTA CGTAATCGAG GGAAGGATTT
RO 118016 Β1
CCCCCGGGCC TCCTGTCAAT
GGCGGCTCTG AGGGTGGCGG
CTCTGAGGGT GGCGGTTCCG
ATGAAAACAT GGCTAACTGC
TTAAAGAGAC CACCTGCACC
AGACGTCTCT ATCCTGATGG
GCTTCGTAAG GGCTGTCAAG
ATTCTTCGTA ATCTCCAACC
TCGACATCCA ATCATCATCA
AACTGACGTT CTATCTGGTT [Secv. no. 76]
PMOS13045
ATCGCTACAC CATTAGGCCC
CAAGTGCTTA GAGCAAGTGA
AGGAGAAGCT GTGTGCCACC
CTGCTCGGAC ACTCTCTGGG
CAGCCAGGCC CTGCAGCTGG
TTTTCCTCTA CCAGGGGCTC
TTGGGTCCCA CCTTGGACAC
CACCATCTGG CAGCAGATGG
CCACCCAGGG TGCCATGCCG
GGAGGGGTCC TGGTTGCTAG
CCGCGTTCTA CGCCACCTTG
CCCCGGGTGA ACCGTCTGGT
TCTAAAGAAT CTCATAAATC
CGATGAAATT ATACATCACT
CGAACAACCT CAATGACGAA
CGACTTCCAA ACCTGGAGAG
TGCATCAGGT ATTGAGGCAA
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGTTCTG AGGGTGGCGG CTCTGAGGGT GTGGCGGCTC CGGTTCCGGT GATTTTGATT TCTATAATGA TCGATGAAAT TATACATCAC TTTGCTGGAC CCGAACAACC TCAATGACGA AACGAAACCT TCGACTTCCA AACCTOGAGA AACTTAGAAA ATGCATCAGG TATTGAGGCA ATGTCTGCCC TCTGCCAOGG CCGCACCCTC AGGCAQGTGA CTGGCAAGAA TTCCGGGAAA ACCCTTGAGC AAGCGCAGGA ACAACAG
TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT GGAAGATCCA GGGCGATGGC GCAGCGCTCC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGGCTGCTT GAGCCAACTC CATAGCGGCC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG ACTGCAGCTG GACGTCGCCG ACTTTGCCAC AAGAACTGGG AATGGCCCCT GCCCTGCAGC GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CGCAGCCCTA CGTAATCGAG GGAAGGATTT CCAATCTCTA CTATCAACCC GTCTCCTCCG TCCAAACATG GCTAACTGCT CTATAATGAT TAAAGAGACC ACCTGCACCT TTGCTGGACC GACGTCTCTA TCCTGATGGA ACGAAACCTT CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT
5180
5185
5190
5195
5200
5205
5210
5215
CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC
5220
RO 118016 Β1
TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA
AGCGCAGGAA CAACAG [Secv. No. 77]
PMON13151
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTGTCCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA
GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA
CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAGAGGGC GGTGGAGGCT
CCCCGGGTGG TGGTTCTGGC GGCGGCTCCA ACATGGCTAA CTGCTCTATA
ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG CACCTTTGCT
GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATCGAACGAA
ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA
GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT
GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG
GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT
GAGCAAGCGC AGGAACAACA G [Secv. No. 78]
PMON13152
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTCTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
RO 118016 Β1
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
5270
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA ggaggggtcc tggttgctag ccatctgcag agcttcctgg aggtgtcgta
CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAGAGGGC GGTGGAGGCT 5275
CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG
TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT
CGATCAAATT ATACATCACT TAAAGAGACC ACCTCCACCT TTGCTGGACC
5280
CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA ACGAAACCTT
CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA
TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT
CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC 5285
TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA
AGCGCAGGAA CAACAG [Secv. No. 79]
PMON13149 5290
<td colspan="6">ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT</td>
<td>CAAGTCTTTA</td><td>BETTER</td><td>GGAAGATCCA</td><td>GGGCGATGGC</td><td>WASACRE</td><td></td>
<td>AGGAGAAGCT</td><td>GTGTGCCACC</td><td>TACAAGCTGT</td><td>GCCACCCCGA</td><td>GGAGCTGGTG</td><td> 5295</td>
<td>CTGCTCGGAC</td><td>ACTCTCTGGG</td><td>CATCCCCTGG</td><td>GCTCCCCTGA</td><td>GCTCCTGCCC</td><td></td>
<td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td>CATAGCGGCC</td><td></td>
<td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td><td></td>
<td>TTGGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td><td> 5300</td>
<td>CACCATCTGG</td><td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td><td></td>
<td>CCACCCAGGG</td><td>TGCCATGCCG</td><td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td><td></td>
<td>GGAGGGGTCC</td><td>TGGTTGCTAG</td><td>CCATCTGCAG</td><td>AGCTTCCTGG</td><td>AGGTGTCGTA</td><td> 5305</td>
<td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTA</td><td>CGTAGAGGGC</td><td>GGTGGAGGCT</td><td></td>
<td>CCCCGGGTGG</td><td>TGGTTCTGGC</td><td>GGCGGCTCCA</td><td>ACATGGCTAA</td><td>CTGCTCTATA</td><td></td>
<td>ATGATCGATG</td><td>AAATTATACA</td><td>TCACTTAAAG</td><td>AGACCACCTG</td><td>CACCTTTGCT</td><td></td>
<td>GGACCCGAAC</td><td>AACCTCAATG</td><td>ACGAAGACGT</td><td>CTCTATCCTG</td><td>ATGGAACGAA</td><td> 5310</td>
ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA
RO 118016 Β1
GAAAATGCAT CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT
GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG
GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT
GAGCAAGCGC AGGAACAACA G [Secv. No. 80]
PMOV13150
ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTCTTTA GAGGATGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC
AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG
CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC
CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC
TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC
CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC
CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA
GGAGGGGTCC tggttgctag ccatctgcag agcttcctgg aggtgtcgta
CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAGAGGGC GGTGGAGGCT
CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG
TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT
CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC
CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA ACGAAACCTT
CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA
TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT
CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC
TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA
AGCGCAGGAA CAACAG [Secv. No. 81]
PMON13052
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
RO 118016 Β1
5360
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
QGGAAGGATT TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAACTGC
TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTGCACC
TTTGCTGGAC CCGAACAACC TCAATGACGA AGACGTCTCT ATCCTGATGG
AACGAAACCT TCGACTTCCA AACCTGGAGA GCTTCGTAAG GGCTGTCAAG
AACTTAGAAA ATGCATCAGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC
ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA
AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT
ACCCTTGAGC AAGCGCAGGA ACAACAG [Secv. No. 82]
PMON13053
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
GGGAAGGATT TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACACCA
TTGGGCCCTG CCAGCTCCCT GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA
GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT
GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC
TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT
GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC
5365
5370
5375
5380
5385
5390
5395
AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC
5400
RO 118016 Β1
TTGGACACAC GCAGATGGAA CCATGCCGGC GTTGCTAGCC CCACCTTGCG
TGCAGCTGGA GAACTGGGAA CTTCGCCTCT ATCTGCAGAG CAGCCCTGAT
CGTCGCCGAC TGGCCCCTGC GCTTTCCAGC CTTCCTGGAG AAGGATCCGA
TTTGCCACCA CCTGCAGCCC GCCGGGCAGG GTGTCGTACC ATTC [Secv.
CCATCTGGCA ACCCAGGGTG AQGGGTCCTG GOGTTCTACG no. 83]
PKON13066
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CTATCCTGAT AGGGCTGTCA TAATCTCCAA CAATCATCAT TTCTATCTGG GGGAAGGATT CACCATTAGG TTAGAGCAAG
GACACTCTCT GCCCTGCAGC CTACCAGGGG CCACCTTGGA TGGCAGCAGA GGGTGCCATG TCCTGGTTGC CTACGCCACC
CCTTTGCTGG GGAACGAAAC AGAACTTAGA CCATGTCTGC CAAGGCAGGT TTACCCTTGA TCCCCGGGTG CCCTGCCAGC TGAGGAAGAT ACCTACAAGC GGGCATCCCC TGGCAGGCTG CTCCTGCAGG CACACTGCAG TGGAAGAACT CCGGCCTTCG TAGCCATCTG TTGCGCAGCC
ACCCGAACAA CTTCGACTTC AAATGCATCA CCTCTGCCAC GACTGGCAAG GCAAGCGCAG GTGGTTCTGG TCCCTGCCCC CCAGGGCGAT TGTGCCACCC TGGGCTCCCC CTTGAGCCAA CCCTGGAAGG CTGGACGTCG GGGAATCTTGCC CTCAGGCTCT. No.
CCTCAATGAC CAAACCTGGA GGTATTGAGG GGCCGCACCC AATTCCGGGA GAACAACAGT CGGCGGCTCC AGAGCTTCCT GGCGCAGCGC CGAGGAGCTG TGAGCTCCTG CTCCATAGCG GATATCCCCC CCGACTTTGC CCTGCCCTGC CCAGCGCCGG TGGAGGTGTC 84]
GAAGACGTCT GAGCTTCGTA CAATTCTTCG TCTCGACATC AAAACTGACG ACGTAATCGA aacatggcta GCTCAAGTGC TCCAGGAGAA GTGCTGCTCG CCCCAGCCAG GCCTTTTCCT GAGTTGGGTC CACCACCATC AGCCCACCCA GCAGGAGGGG GTACCGCGTT
PMON130S1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
RO 118016 Β1
5450
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
GGGAAGGATT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA
CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT
TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA
GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG
GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG
GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT
CTACCAGGGG CTCCTGCAGG CCCTQGAAGG GATATCCCCC GAGTTGGGTC
CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTITOC CACCACCATC
TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCIGC AGCCCACCCA
GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT
CTACGCCACC TTGCGCAGCC C [Secv. ΠΓ. 85]
PMON13050
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA
GGGAAGGATT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA
ACTGCTCTAT AATGATCGAT GAAATTATAC ATCACTTAAA GAGACCACCT
GCACCTTTGC TGGACCCGAA CAACCTCAAT GACGAAGACG TCTCTATCCT
GATGGAACGA AACCTTCGAC TTCCAAACCT GGAGAGCTTC GTAAGGGCTG
TCAAGAACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC
5455
5460
5465
5470
5475
5480
5485
5490
RO 118016 Β1
CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT
CATCAAGGCA GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC
TGGTTACCCT EETWORK CAGGAACAAC AG [Secv. . 86]
PMOH13145
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG
CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA
CACCATTGGG CCCTGCCAGC
TTAGAGCAAG TGAGGAAGAT
GCTGTGTGCC ACCTACAAGC
GACACTCTCT GGGCATCCCC
GCCCTGCAGC TGGCAGGCTG
CTACCAGGGG CTCCTGCAGG
CCACCTTGGA CACACTGCAG
TGGCAGCAGA TGGAAGAACT
GGGTGCCATG CCGGCCTTCG
TCCTGGTTGC TAGCCATCTG
CTACGCCACC TTGCGCAGCC
PMOK13147
ATGGCTAACT GCTCTATAAT
ACCACCTGCA CCTTTGCTGG
CTATCCTGAT GGAACGAAAC
AGGGCTGTCA AGAACTTAGA
TAATCTCCAA CCATGTCTGC
TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA TGTGCCACCC CGAGGAGCTG GTGCTGCTCG TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CCCTGGAAGG GATATCCCCC GAGTTGGGTC CTGGACGTCG CCGACTTTGC CACCACCATC GGGAATGGCC CCTGCCCTGC AGCCCACCCA CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT C [SECV. No. 87]
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC
RO 118016 Β1
CAATCATCAT CAAGGCAGGT
TTCTATCTGG TTACCCTTGA
CGGTGGAGGC TCCCCGGGTG
ACTGCTCTAT AATGATCGAT
GCACCTTTGC TGGACCCGAA
GATGGAACGA AACCTTCGAC
TCAAGAACTT AGAAAATGCA
CAACCATGTC TGCCCTCTGC
CATCAAGGCA GGTGACTGGC
TGGTTACCCT TGAGCAAGCG
PHON13146
ATGGCTAACT GCTCTATAAT
ACCACCTGCA CCTTTGCTGG
CTATCCTGAT GGAACGAAAC
AGGGCTGTCA AGAACTTAGA
TAATCTCCAA CCATGTCTGC
CAATCATCAT CAAGGCAGGT
TTCTATCTGG TTACCCTTGA
CGGTGGAGGC TCCCCGGGTG
CGTCTCCTCC GTCTAAAGAA
TTGGGCCCTG CCAGCTCCCT
GCAAGTGAGG AAGATCCAGG
GTGCCACCTA CAAGCTGTGC
TCTCTGGGCA TCCCCTGGGC
CRAGGAGGGGGGGGGGGGGG
AGGGGCTCCT GCAGGCCCTG
TTGGACACAC TGCAGCTGGA
GCAGATGGAA GAACTGGGAA
CCATGCCGGC CTTCGCCTCT
GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG GTGGTTCTGG CGGCGGCTCC AACATGGCTA GAAATTATAC ATCACTTAAA GAGACCACCT CAACCTCAAT GACGAAGACG TCTCTATCCT TTCCAAACCT GGAGAGCTTC GTAAGGGCTG TCAGGTATTG AGGCAATTCT TCGTAATCTC CACGGCCGCA CCCTCTCGAC ATCCAATCAT AAGAATTCCG GGAAAAACTG ACGTTCTATC CAGGAACAAC AG [Secv. nr. 88]
GATCGATGAA ATTATACATC ACTTAAAGAG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AAATGCATCA GGTATTGAGG CAATTCTTCG CCTCTGCCAC GGCCGCACCC TCTCGACATC GACTGGCAAG AATTCCGGGA AAAACTGACG GCAAGCGCAG GAACAACAGT ACGTAGAGGG AACCGTCTGG TCCAATCTCT ACTATCAACC TCTCATAAAT CTCCAAACAT GGCTACACCA GCCCCAGAGC TTCCTGCTCA AGTCTTTAGA GCGATGGCGC AGCGCTCCAG GAGAAGCTGT CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCCAACTCCA TAGCGGCCTT TTCCTCTACC GAAGGGATAT CCCCCGAGTT GGGTCCCACC CGTCGCCGAC TTTGCCACCA CCATCTGGCA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG
5540
5545
5550
5555
5560
5565
5570 '
5575
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG
5580
RO 118016 Β1
CCACCTTGCG CAGCCC [Secv. No. 89]
PMON13148
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT
CTATCCTGAT GGAACGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA
AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
TAATCTCCAA CCATGTCTGC CCTCTOCCAC GGCCGCACCC TCTCGACATC
CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAQGG
CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC
CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTAACTGC
TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTGCACC
TTTGCTGGAC CCGAACAACC TCAATGACGA AGACGTCTCT ATCCTGATGG
AACGAAACCT TCGACTTCCA AACCTGGAGA GCTTCGTAAG GGCTGTCAAG
AACTTAGAAA ATGCATCAGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC
ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA
AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT
ACCCTTGAGC AAGCGCAGGA ACAACAG [Secv. No. 90]
PMON13040
ATGGCTCCAG TACCACCAGG TGAAGATTCC AAAGATGTGG CCGCCCCACA
CAGACAGCCA CTCACCTCTT CAGAACGAAT TGACAAACAA ATTCGGTACA
TCCTCGACGG GATATCAGCC CTGAGAAAGG AGACATGTAA CAAGAGACAC
ATGTGTGAAA GCAGCAAAGA GGCGCTAGCA TGAACCTTCC
AAAGATGGCT GAAAAAGATG GATGCTTCCA ATCCGGATTC AATGAGGAGA
CTTGCCTGGT GAAAATC.-.TC ACTGGTCTTT TGGAGTTTGA GGTATACCTC
GAGTACCTCC AGAACAGATT TGAGAGTAGT GAGGAACAAG CCAGAGCTGT
GCAGATGTCG ACAAAAGTCC TGATCCAGTT CCTGCAGAAA AAGGCAAAGA
ATCTAGATGC AATAACCACC CCTGACCCAA CCACAAATGC ATCCCTGCTG
ACGAAGCTGC AGGCACAGAA CCAGTGGCTG CAGGACATGA CAACTCATCT
RO 118016 Β1
CATTCTGCGC
AGCTTTAAGG AGTTCCTGCA
GTCCAGCCTG
AGGGCTCTTC
5630
GGCAAATGTA
G [Secv. No. 175] pMON13012
5635
ATGGCACCGG
CTCGTTCCCC
GTCCCCGTCT
ACCCAGCCGT
GGGAACACGT
GAATGCCATC
CAGGAGGCCC
GGCGTCTCCT
GAACCTGAGT
AGAGACACTG
CTGCTGAGAT
DEFINITELY
GTAGAAGTGA
TATCAGAAAT
GTTTGACCTC
5640
CAGGAGCCGA
CTTGCCTACA
GACCCGCCTG
GAGCTGTACA
AGCAGGGCCT
NWRWTP
CTCACCAAGC
TCAAGGGCCC
CTTGACCATG
ATQGCCAGCC
ACTIVITY
GCACTGCCCT
CCAACCCCGG
AAACTTCCTG
TGCAACCCAG
ATTATCACCT
TTGAAAGTTT
HELP
CTGAAGGACT
TCCTGCTTGT
5645
CATCCCCTTT
GACTGCTGGG
AGCCAGTCCA
GGAGTGATAA
GGATCCGAAT
TC [Secv. nr. 176] pMON13499
5650
ATGGCTACAC
CATTAGGCCC
TGCCAGCTCC
CTGCCCCAGA
GCTTCCTGCT
CAAGTGCTTA
BETTER
GGAAGATCCA
GGGCGATGGC
WASACRE
AGGAGAAGCT
GTGTGCCACC
TACAAGCTGT
GCCACCCCGA
GGAGCTGGTG
5655
CTGCTCGGAC
ACTCTCTGGG
CATCCCCTGG
GCTCCCCTGA
GCTCCTGCCC
CAGCCAGGCC
CTGCAGCTGG
CAGGCTGCTT
GAGCCAACTC
CATAGCGGCC
TTTTCCTCTA
CCAGGGGCTC
CTGCAGGCCC
TGGAAGGGAT
ATCCCCCGAG
TTGGGTCCCA
CCTTGGACAC
ACTGCAGCTG
GACGTCGCCG
ACTTTGCCAC
5660 t
CACCATCTGG
CAGCAGATGG
AAGAACTGGG
AATGGCCCCT
GCCCTGCAGC
CCACCCAGGG
TGCCATGCCG
GCCTTCGCCT
CTGCTTTCCA
GCGCCGGGCA
GGAGGGGTCC
TGGTTGCTAG
CCATCTGCAG
AGCTTCCTGG
AGGTGTCGTA
5665
CCGCGTTCTA
CGCCACCTTG
CGCAGCCCTG
ATAAGGATCC
GAATTC [Secv. No. 177] pMONl3498 / pMONl3010
5670
ATGGCTACAC CATTAGGACC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
RO 118016 Β1
CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTG ATAAGGATCC GAATTC [Secv. No. 178] pMON13033 / pMON13037
<td colspan="5">ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT</td>
<td>CAAGTCTTTA</td><td colspan="2">GAGAGATCCA GAGAGATCCA</td><td>GGGCGATGGC</td><td>WASACRE</td>
<td>AGGAGAAGCT</td><td>GTGTGCCACC</td><td>TACAAGCTGT</td><td>GCCACCCCGA</td><td>GGAGCTGGTG</td>
<td>CTGCTCGGAC</td><td>ACTCTCTGGG</td><td>CATCCCCTGG</td><td>GCTCCCCTGA</td><td>GCTCCTGCCC</td>
<td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td>CATAGCGGCC</td>
<td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td>
<td>TTGGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td>
<td>CACCATCTGG</td><td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td>
<td>CCACCCAGGG</td><td>TGCCATGCCG</td><td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td>
<td>GGAGGGGTCC</td><td>TGGTTGCTAG</td><td>CCATCTGCAG</td><td>AGCTTCCTGG</td><td>AGGTGTCGTA</td>
<td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTG</td><td>ATAAGGATCC</td><td>GOATTC</td>
[SECV. No. 179] pMON26448
ATGGCGTCTC
GCTTCGTGAC
TTCACCCTTT
GGAGAATGGA
CGGCGCCGCC
TCCCATGTCC GCCTACACCT AAACCCAGAT
TGCTTGTGAC
TTCACAGCAG GTCCTGCTGC GGAGGAGACC
CTCCGAGTCC
ACTGAGCCAG CTGCTGTGGA AAGGCACAGG
TCAGTAAACT
TGCCCAGAGG CTTTAGCTTG ACATTCTGGG
RO 118016 Β1
5720
AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTCG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGG [SECV. No. 180] pMON26463
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG
5725
5730
5735
<td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td>TCTCGACATC</td>
<td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>NWISA</td><td>TRANSPORTATION</td><td>ACGTAATCGA</td>
<td>GGGAAGGATT</td><td>TCCCCGGGTG</td><td>GTGGTTCTGG</td><td>CGGCGGCTCC</td><td>AACATGGCGT</td>
<td>CTCCGGCGCC</td><td>GCCTGCTTGT</td><td>GACCTCCGAG</td><td>TCCTCAGTAA</td><td>ACTGCTTCGT</td>
<td>GACTCCCATG</td><td>TCCTTCACAG</td><td>CAGACTGAGC</td><td>CAGTGCCCAG</td><td>AGGTTCACCC</td>
<td>TTTGCCTACA</td><td>CCTGTCCTGC</td><td>TGCCTGCTGT</td><td>GGACTTTAGC</td><td>TTGGGAGAAT</td>
<td>GGAAAACCCA</td><td>GATGGAGGAG</td><td>ACCAAGGCAC</td><td>AGGACATTCT</td><td>GGGAGCAGTG</td>
<td>ACCCTTCTGC</td><td>TGGAGGGAGT</td><td>GATGGCAGCA</td><td>CGGGGACAAC</td><td>TGGGACCCAC</td>
<td>TTGCCTCTCA</td><td>TCCCTCCTGG</td><td>GGCAGCTTTC</td><td>TGGACAGGTC</td><td>CGTCTCCTCC</td>
<td>TTGGGGCCCT</td><td>WASACRE</td><td>CTTGGAACCC</td><td>AGCTTCCTCC</td><td>ACAGGGCAGG</td>
<td>ACCACAGCTC</td><td>ACAAGGATCC</td><td>CAATGCCATC</td><td>TTCCTGAGCT</td><td>TCCAACACCT</td>
<td>GCTCCGAGGA</td><td>AAGGTGCGTT</td><td>TCCTGATGCT</td><td>TGTAGGAGGG</td><td>TCCACCCTCT</td>
GCGTCAGG [Secv. No. 183]
5740
5745
5750
5755 pMON26473
ATGGCTAACT
ACCACCTAAC
ATATCCTGAT
GCTCTATAAT
CCTTTGCTGG
GAAACGAAAC
GATCGATGAA
ACCCGAACAA
CTTCGAACTC
ATTATACATC
CCTCAATTCT
CAAACCTGCT
ACTTAAAGAG
GAAGACATGG
CGCATTCGTA
5760
RO 118016 Β1
AGGGCTGTCA AGCACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCGT CTCCGGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATCGAGGAG ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GCTCCGAGGA AAGGTGCGTT TCCTGATGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG [SECV. No. 184] pMON26474
ATGGCGTCTC
CGGCGCCGCC
TGCTTGTGAC
CTCCGAGTCC
TCAGTAAACT
GCTTCGTGAC
TCCCATGTCC
TTCACAGCAG
ACTGAGCCAG
TGCCCAGAGG
TTCACCCTTT
GCCTACACCT
GTCCTGCTGC
CTGCTGTGGA
CTTTAGCTTG
GGAGAATGGA
AAACCCAGAT
GGAGGAGACC
AAGGCACAGG
ACATTCTGGG
AGCAGTGACC
CTTCTGCTGG
AGGGAGTGAT
NWWISGIS
GGACAACTGG
GACCCACTTG
CCTCTCATCC
CTCCTCGGGC
AGCTTTCTGG
ACAGGTCCGT
CTCCTCCTTG
GGGCCCTGCA
GAGCCTCCTT
GGAACCCAGC
TTCCTCCACA
GGGCAGGACC
ACAGCTCACA
AGGATCCCAA
TGCCATCTTC
CTGAGCTTCC
AACACCTGCT
CCGAGGAAAG
GTGCGTTTCC
World Youth Day
AGGAGGGTCC
ACCCTCTGCG
TCAGGATCGA
GGGAAGGATT
TCCCCGGGTG
GTGGTTCTGG
CGGCGGCTCC
AACATGGCTA
ACTGCTCTAT
AATGATCGAT
GAAATTATAC
ATCACTTAAA
GAGACCACCT
AACCCTTTGC
TGGACCCGAA
CAACCTCAAT
TCTGAAGACA TGGATATCCT GATGGAACGA AACCTTCGAA CTCCAAACCT
RO 118016 Β1
GCTCGCATTC GTAAGGGCTG TCAAGCACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATTGGCACGGGGGGGGGC nr. 185]
PMON26464
ATGGCGTCTC CGGCGCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATCTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GCCTACACCT GTCCTGCTQC CTGCTCTQGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AA.CACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CCATGCATAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGGT GGTTCTGGCG GCGGCTCCAA CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CXCTTAAAGA GACCACCTAA CCCTTTGCTG GACCCGAACA ACCTC-JVTTC TGAAGACATG GATATCCTGA TGGAACGAAA CCTTCGAACT CCAAACCTGC TCGCATTCGT AAGGGCTGTC AAGCACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG [Secv. nr. 186]
5810
5815
5820
5825
5830
5835
5840
5845
LIST OF SEQUENCES (1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NUME: G.D.Searles/& Co.
(B) ROAD: POBox 5110 (C) TIME: Chicago (D) STATE: lllinois (E) COUNTRY: United States (F) POSTCARD (ZIP): 60680 (G) PHONE: (708)470-6501 ( H) TELEFAX: (708)470-6881
5850
5855
RO 118016 Β1 (A) NAME: Monsanto Company (B) ROAD: 800 North Lindbergh Boulevard (C) NOW: St.Louis (D) STATE: Missouri (E) COUNTRY: United States of America (F) POSTCARD (ZIP) : 63167 (G) PHONE: (314)694-3131 (H) TELEFAX: (314)694-5435 (ii) TITLE OF THE INVENTION: Multiple variant IL-3 fusion protein in hematopoiesis (iii) SEQUENCE NUMBER: 196 (iv) ) COMPUTER READABLE FORM:
(A) TYPE OF ENVIRONMENT: Floppy disk (B) COMPUTER: IBM compatible PC (C) OPERATING SYSTEM: PC-DOS / MS-DOS (D) SOFT: Patentin Release no. 1.0, version 1.30 (EPO) ( vi) DATA ON THE PRIORITY OF THE APPLICATION:
(A) REQUEST NUMBER: US 08/192325 (B) DEPOSIT DATE: February 14, 1994 (2) INFORMATION FOR SEQ. NUMBER 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 133 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “Mrz - may precede or not precede the amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 17 (D) OTHER INFORMATION: / Note = "Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = "Xaa at position 18 is Asn, His, Leo, Ile, Phe, Arg or Gin" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 19 (D) OTHER INFORMATION: / Note = "Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Al a or Cys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = “Xaa at position 20 is Ile, Cys, Gin,
Glu, Arg, Pro or Ala "
RO 118016 Β1
5910 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 21 (D) OTHER INFORMATION: / Note = "Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Serum or Wave "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 22 (D) OTHER INFORMATION: / Note = “Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leo, Wave or Gly ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = “Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Thr, Lys, Phe, Ser, or Arg "(Ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER INFORMATION: / Note = "Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 25 (D) OTHER INFORMATION: / Note = "Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 26 (D) OTHER INFORMATION: / Note = “Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala or Trp (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 27 (D) OTHER INFORMATION: / Note = "Xaa at position 27 is Leo, Gly, Arg, Thr, Ser or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 28 (D) OTHER IN FORMS E: / Note = "Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 29 (D) OTHER INFORMATION: / Note = "Xaa at position 29 is Gin, Asn, Leu, Pro, Arg or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 30 (D) OTHER INFORMATION: / Note = “Xaa at position 30 is Pro, His, Thr,
Gly, Asp, Gin, Ser, Leu sau Lys
5915
5920
5925
5930
5935
5940
5945
5950
5955
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = "Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leo or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Leo, Val, Arg, Gin, Asn, Gly, Ala or Glu" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 33 (D) OTHER INFORMATION / Note = "Xaa at position 33 is Pro, Leo, Gin, Ala, Thr or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 34 (D) OTHER INFORMATION: / Note = “Xaa at position 34 is Leo, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile or Met "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 35 (D) OTHER INFORMATION: / Note = "Xaa at position 35 is Leo, Ala, Gly, Asn, Pro, Gin, or Wave" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 36 (D) OTHER INFORMATION: / Note = "Xaa at position 36 is Asp, Leo or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = “Xaa at position 37 is Phe, Ser, Pro, Trp or Ile (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 38 (D) OTHER INFORMATION: / Note = "Xaa at position 38 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 40 (D) OTHER INFORMATION: / Note = "Xaa at position 40 is Leo, Trp or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 41 (D) OTHER INFORMATION: / Note = “Xaa at position 41 is Asn, Cys,
Arg, Leo, His, Met or Pro ”
RO 118016 Β1
6010 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION: / Note = “Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leo, Val, Glu, Phe, Tyr, Ile, Met, or Ala "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 43 (D) OTHER INFORMATION: / Note = “Xaa at position 43 is Glu, Asn, Tyr, Leo, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly or Ser "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 44 (D) OTHER INFORMATION: / Note = “Xaa at position 44 is Asp, Ser, Leo, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala, Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note = “Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leo, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = "Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, Ile, Val or Gly ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 47 (D) OTHER INFORMATION: / Note = "Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 48 (D) OTHER INFORMATION: / Note = “Xaa at position 48 is Leo, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn ”(ix) FEATURE.
(A) NAME / CODE: Modified site (B) LOCATION: 49 (D) OTHER INFORMATION: / Note = "Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = “Xaa at position 50 is Glu, Leo, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gin ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is Asn, Arg, Met,
Pro, Ser, Thr write His ”
6015
6020
6025
6030
6035
6040
6045
6050
6055
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 52 (D) OTHER INFORMATION: / Note = "Xaa (position 51 is Asn, His, Arg, Leo, Gly, Ser or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 53 (D) OTHER INFORMATION: / Note = "Xaa at position 53 is Leo, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 54 (D) OTHER INFORMATION: / Note = “Xaa at position 54 is Arg, Asp, lle,
Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Arg, Thr, Val, Ser, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 56 (D) OTHER INFORMATION: / Note = “Xaa at position 56 is Pro, Gly, Cys,
Serum, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leo, Val or Lys "(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 57 (D) OTHER INFORMATION: / Note = "Xaa at position 57 is Asn or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 58 (D) OTHER INFORMATION: / Note = "Xaa at position 58 is Leo, Serum, Asp, Arg, Gin, Val or Cys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 59 (D) OTHER INFORMATION: / Note = "Xaa at position 59 is Glu, Tyr, His, Leo, Pro or Arg" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 60 (D) OTHER INFORMATION: / Note = "Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn or Thr" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 61 (D) OTHER INFORMATION: / Note = “Xaa at position 61 is Phe, Asn,
Glu, Pro, Lys, Arg sheep Ser ”
RO 118016 Β1
6105 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = “Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp or Ile (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = "Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 64 (D) OTHER INFORMATION: / Note = "Xaa at position 64 is Ala, Asn, Pro, Ser or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Val, Thr, Pro, His, Leo, Phe or Ser" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 66 (D) OTHER INFORMATION: / Note = "Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu or Ser" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER IN FORMS E: / Note = "Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = "Xaa at position 68 is Leo, Val, Trp, Ser, Ile, Phe, Thr or His" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = "Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leo" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 70 (D) OTHER INFORMATION: / Note = "Xaa at position 70 is Asn, Leo, Val, Trp, Pro or Ala" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 71 (D) OTHER INFORMATION: / Note = “Xaa at position 71 is Ala, Met, Leo,
Pro, Arg, Glu, Thr, Gin, Trp or Asn
6110
6115
6120
6125
6130
6135
6140
6145
6150
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 72 (D) OTHER INFORMATION: / Note = "Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = "Xaa at position 73 is Ala, Glu, Asp, Leo, Ser, Gly, Thr or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 74 (D) OTHER INFORMATION: / Note = "Xaa at position 74 is lle, Met, Thr, Pro, Arg, Gly or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 75 (D) OTHER INFORMATION: / Note = "Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 76 (D) OTHER INFORMATION: / Note = "Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = "Xaa at position 77 is lle, Ser, Arg, Thr or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 78 (D) OTHER INFORMATION: / Note = "Xaa at position 78 is Leo, Ala, Ser, Glu, Phe, Gly or Arg" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = "Xaa at position 79 is Lys, Thr, Asn, Met, Arg, lle, Gly or Asp" (ix) FEATURE :
(A) NAME / CODE: Modified site (B) LOCATION: 80 (D) OTHER INFORMATION: / Note = "Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leo, Glu or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 81 (D) OTHER INFORMATION: / Note = “Xaa at position 81 is Leo, Gin, Gly,
Ala, Trp, Arg, Val sheep Light ”
RO 118016 Β1
6205 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = “Xaa at position 82 is Leo, Gin, Lys, Trp, Arg, Asp, Glu, Asn, Hys, Thr, Serum, Ala, Tyr, Phe, Ile, Met or Val "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 83 (D) OTHER INFORMATION: / Note = "Xaa at position 83 is Pro, Ala, Thr, Trp, Arg or Met" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 84 (D) OTHER INFORMATION: / Note = “Xaa at position 84 is Cys, Glu, Gly,
Arg, Met or Val "(ix) FEATURE:
(A) NAME / COD. Modified site (B) LOCATION: 85 (D) OTHER INFORMATION / Note = “Xaa at position 85 is Leo, Asn, Val or Gin (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 86 (D) OTHER INFORMATION: / Note = "Xaa at position 86 is Pro, Cys, Arg or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = "Xaa at position 87 is Leo, Serum, Trp or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 88 (D) OTHER INFORMATION: / Note = "Xaa at position 88 is Ala, Lys, Arg, Val or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 89 (D) OTHER INFORMATION: / Note = “Xaa at position 89 is Thr, Asp, Cys,
Leo, Val, Glu, His, Asn or Ser ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 90 (D) OTHER INFORMATION: / Note = "Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile or Met" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = “Xaa at position 91 is Ala, Pro, Ser,
Thr, Phe, Leu, Asp wrote His ”
6210
6215
6220
6225
6230
6235
6240
6245
6250
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 92 (D) OTHER IN FORMS E: / Note = “Xaa at position 92 is Phe, Arg, Ser, Lys, His, Ala, Gly, Ile, or Leo "(Ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 93 (D) OTHER IN FORMS E: / Note = "Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leo or Arg" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 94 (D) OTHER INFORMATION: / Note = “Xaa at position 94 is Arg, Ile, Ser, Glu, Leo, Val, Gin, Lys, His, Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is His, Gin, Pro, Arg, Val, Leo, Gly, Thr, Asn, Lys, Serum, Ala, Trp, Phe, Ile or Tyr "(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 96 (D) OTHER INFORMATION: / Note = “Xaa at position 96 is Pro, Lys, Tyr,
Gly, Ile or Thr "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 97 (D) OTHER INFORMATION: / Note = "Xaa at position 97 is Ile, Val, Lys, Ala or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = “Xaa at position 98 is His, Ile, Asn, Leo, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 99 (D) OTHER INFORMATION: / Note = “Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER INFORMATION: / Note = "Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin or Pro" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101
RO 118016 Β1
6305 (D) OTHER INFORMATION: / Note = "Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, lle, Leo, or Gin" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 102 (D) OTHER INFORMATION: / Note = "Xaa at position 102 is Gly, Leo, Glu, Lys, Ser, Tyr or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 103 (D) OTHER INFORMATION: / Note = “Xaa at position 103 is Asp or Ser (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 104 (D) OTHER INFORMATION: / Note = “Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leo, Gin, Lys, Ala, Phe, Gly ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 105 (D) OTHER INFORMATION: / Note = “Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leo, Lys, lle, Asp or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = "Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, lle, Gly or Pro" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER INFORMATION: / Note = "Xaa at position 108 is Arg, Lys, Asp, Leo, Thr, lle, Gin, His, Ser, Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = "Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leo, Ser or Gly" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 110 (D) OTHER INFORMATION: / Note = “Xaa at position 110 is Lys, Ala, Asn, Thr, Leo, Arg, Gin, His, Glu, Ser, Ala or Trp "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 111 (D) OTHER INFORMATION: / Note = “Xaa at position 111 is
Leu, lle, Arg, Asp sau Met ”
6310
6315
6320
6325
6330
6335
6340
6345
6350
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 112 (D) OTHER INFORMATION: / Note = “Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser or Phe (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 113 (D) OTHER INFORMATION: / Note = “Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leo, Ile, Val or Asn "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 114 (D) OTHER INFORMATION: / Note = "Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg or Leo" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 115 (D) OTHER INFORMATION: / Note = "Xaa at position 115 is Leo, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 116 (D) OTHER INFORMATION: / Note = “Xaa at position 116 is Lys, Leo, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Serum, Asn, His, Ala, Tyr, Phe, Gin or Ile ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 117 (D) OTHER INFORMATION: / Note = "Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys or Pro" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 118 (D) OTHER INFORMATION: / Note = "Xaa at position 118 is Leo, Ser, Pro, Ala, Glu, Cys, Asp or Tyr" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 119 (D) OTHER INFORMATION: / Note = "Xaa at position 119 is Glu, Ser, Lys, Pro, Leo, Thr, Tyr, or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 120 (D) OTHER INFORMATION: / Note = “Xaa at position 120 is
Asn, Ala, Pro, Leo, His, Val or Gin ”
RO 118016 Β1
6400 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 121 (D) OTHER INFORMATION: / Note = "Xaa at position 121 is Ala, Ser, lle, Asn, Pro, Lys, Asp or Gly" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 122 (D) OTHER INFORMATION: / Note = “Xaa at position 122 is
Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 123 (D) OTHER INFORMATION: / Note = “Xaa at position 123 is
Ala, Met, Glu, His, Ser, Pro, Tyr or Leo "(xi) DESCRIPTION OF THE SEQUENCE: SEQ.
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1015
X-rays are a must-have-to-do list.
2530
Xiao Xiao Xiao Xiao Xiao Xiao AQuT
4045
X-rays are a must-have-to-do list.
5560
X-rays are a must-have-to-do list.
70 7580
X-rays are a must-have-to-do list.
9095
Xiao Xiao Xiao Xiao Xiao Xiao Xia Xia Xia Xia Xia XQ AQ I AQ I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Am.
100 105110
Xaae Xaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa tn tn trlr
115 120125
Ser Leu Ala lle Phe
130 (2) INFORMATION FOR SEQ. no.2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 133 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION. 1 (D) OTHER INFORMATION: / Note -'Met- may or may not precede the amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 17 (D) OTHER INFORMATION: / Note = “Xaa at position 17 is Ser, Gly, Asp, Met or Gin
6405
6410
6415
6420
6425
6430
6435
6440
6445
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = "Xaa at position 18 is Asn, His or Ile" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 19 (D) OTHER INFORMATION: / Note = “Xaa at position 19 is Met or Ile (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 21 (D) OTHER INFORMATION: / Note = “Xaa at position 21 is Asp or Glu (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = "Xaa at position 23 is Ile, Ala, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER INFORMATION: / Note = "Xaa at position 24 is Ile, Val or Leu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 25 (D) OTHER INFORMATION: / Note = "Xaa at position 25 is Thr, His, Gin or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 26 (D) OTHER INFORMATION: / Note = "Xaa at position 26 is His or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 29 (D) OTHER INFORMATION: / Note = "Xaa at position 29 is Gin, Asn or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 30 (D) OTHER INFORMATION: / Note = "Xaa at position 30 is Pro, Gly or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = “Xaa at position 31 is
Pro, Asp, Gly or Gin ”
RO 118016 Β1
6500 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Leo, Arg, Gin, Asn, Gly, Ala or Glu" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 33 (D) OTHER INFORMATION: / Note = "Xaa at position 33 is Pro or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 34 (D) OTHER INFORMATION: / Note = “Xaa at position 34 is Leo, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, lle, Phe, Thr, Met ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 35 (D) OTHER INFORMATION: / Note = "Xaa at position 35 is Leo, Ala, Asn, Pro, Gin or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = "Xaa at position 37 is Phe, Ser, Pro or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 38 (D) OTHER INFORMATION: / Note = "Xaa at position 38 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION: / Note = “Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, lle, Leo, Met, Tyr or Arg ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 44 (D) OTHER INFORMATION: / Note = "Xaa at position 44 is Asp or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note = "Xaa at position 45 is Gin, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = “Xaa at position 46 is
Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu, His, place, Lys, Tyr, Val sau Cys ”
6505
6510
6515
6520
6525
6530
6535
6540
6545
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = "Xaa at position 50 is Glu, Ala, Asn, Ser or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = "Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 54 (D) OTHER INFORMATION: / Note = "Xaa at position 54 is Arg or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Arg, Thr, Val, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 56 (D) OTHER INFORMATION: / Note = “Xaa at position 56 is Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leo, Thr, Wave or Lys (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 60 (D) OTHER INFORMATION: / Note = “Xaa at position 60 is Ala or Ser (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = "Xaa at position 62 is Asn, Pro, Thr or Ile" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = "Xaa at position 63 is Arg or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 64 (D) OTHER INFORMATION: / Note = “Xaa at position 64 is
Ala or Asn "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = “Xaa at position 65 is
Val writes Thr ”
RO 118016 Β1
6600 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 66 (D) OTHER INFORMATION: / Note = "Xaa at position 66 is Lys or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER INFORMATION: / Note = “Xaa at position 67 is Ser, Phe or His (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = "Xaa at position 68 is Leo, lle, Phe or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = "Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 71 (D) OTHER INFORMATION: / Note = "Xaa at position 71 is Ala, Pro or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 72 (D) OTHER INFORMATION: / Note = "Xaa at position 72 is Ser, Glu, Arg or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = "Xaa at position 73 is Ala or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 76 (D) OTHER INFORMATION: / Note = "Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = "Xaa at position 77 is leu or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = “Xaa at position 79 is
Lys, Thr, Gly, Asn, Met, Arg, lle, Gly sau Asp”
6605
6610
6615
6620
6625
6630
6635
6640
6645
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 80 (D) OTHER INFORMATION: / Note = "Xaa at position 80 is Asn, Gly, Glu or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = “Xaa at position 82 is Leo, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val "(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 83 (D) OTHER INFORMATION: / Note = "Xaa at position 83 is Pro or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 85 (D) OTHER INFORMATION: / Note = "Xaa at position 85 is Leo or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = "Xaa at position 87 is Lion or Serum" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 88 (D) OTHER INFORMATION: / Note = "Xaa at position 88 is Ala or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = "Xaa at position 91 is Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 93 (D) OTHER INFORMATION: / Note = "Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leo or Arg" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is His, Pro, Arg, Val, Leo, Gly, Asn, Phe, Ser or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 96 (D) OTHER INFORMATION: / Note = “Xaa at position 96 is
Pro after Tyr ”
RO 118016 Β1
6705 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 97 (D) OTHER INFORMATION: / Note = "Xaa at position 97 is Ile or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = “Xaa at position 98 is His, Ile, Asn, Leo, Ala, Thr, Arg, Gin, Lys, Met, Serum, Tyr, Val or Pro "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 99 (D) OTHER INFORMATION: / Note = “Xaa at position 99 is
Ile, Lion or Wave (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER INFORMATION: / Note = "Xaa at position 100 is Lys, Arg, Ile, Gin, Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101 (D) OTHER INFORMATION: / Note = "Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Asn, Ile, Leo or Tyr ( ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 104 (D) OTHER INFORMATION: / Note = "Xaa at position 104 is Trp or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 105 (D) OTHER INFORMATION: / Note = "Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gin, Tyr, Leo, Lys, Ile, Asp or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = "Xaa at position 106 is Glu or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER INFORMATION: / Note = "Xaa at position 108 is Arg, Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = “Xaa at position 109 is
Arg, Thr, Glu, Leo or Serum "
6710
6715
6720
6725
6730
6735
6740
6745
6750
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 112 (D) OTHER INFORMATION: / Note = “Xaa at position 112 is Thr, Val or Gin (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 114 (D) OTHER INFORMATION: / Note = "Xaa at position 114 is Tyr or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 115 (D) OTHER INFORMATION: / Note = "Xaa at position 115 is Leo or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 116 (D) OTHER INFORMATION: / Note = “Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or lle ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 117 (D) OTHER INFORMATION: / Note = "Xaa at position 117 is Thr or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 120 (D) OTHER INFORMATION: / Note = "Xaa at position 120 is Asn, Pro, Leo, His, Val or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 121 (D) OTHER INFORMATION: / Note = "Xaa at position 121 is Ala, Ser, lle, Asn, Pro, Asp or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 122 (D) OTHER INFORMATION: / Note = "Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 123 (D) OTHER INFORMATION: / Note = “Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo (xi) SEQUENCE DESCRIPTION : SEQ. No. 2:
RO 118016 Β1
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys 15 1015
Xaaaaaaaaaaaaaaaaaaaaaaaaaaaaaae
2530
Xaa X Xaa Xaa Xaa Xn Asu Xu Glu Xaa Xaa
4045
Met Asa Leu Sleeve Asa Leu Glu Band Seal
5560
Xaae Xaa X Xaaaa Xaa Xaa X X
70 7580
Lea Xaa Pro Pro Features And Pro Features
9095
Xaa X XaaaaaaaaaaaaaaaaaaaaaaaaaT Gly Asp Xaaaaaaaaaaaaaaaaaaaaaaaaaaaaar
100 105110
Downloads Lea Glu Phu's Files
115 120125
Ser Leu Ala Ile Phe
130 (2) INFORMATION FOR SEQUENCE No.3 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 133 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “Met may or may not precede amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 17 (D) OTHER INFORMATION: / Note = “Xaa at position 17 is
Serum, Gly, Asp or Gin "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = “Xaa at position 18 is
Asn, His or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note -'Xaa at position 23 is
Ile, Ala, Leo or Gly ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 25 (D) OTHER INFORMATION: / Note = “Xaa at position 25 is
Thr, His domain Gin ”
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 26 (D) OTHER INFORMATION: / Note = “Xaa at position 26 is His or Ala (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 29 (D) OTHER INFORMATION: / Note = "Xaa at position 29 is Gin or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 30 (D) OTHER INFORMATION: / Note = "Xaa at position 30 is Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Leo, Arg, Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 34 (D) OTHER INFORMATION: / Note = “Xaa at position 34 is Leo, Val, Ser, Ala, Arg, Gin, Glu, Ile, Phe, Thr or Met ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 35 (D) OTHER INFORMATION: / Note = "Xaa at position 35 is Leo, Ala, Asn or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 38 (D) OTHER INFORMATION: / Note = "Xaa at position 38 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION: / Note = "Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leo, Met, Tyr or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note = "Xaa at position 45 is Gin, Val, Met, Leu, Ala, Asn, Glu or Lys" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = Xaa at position 46 is
Asp, Phe, Ser, Gin, Glu, His, Val writes Thr ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = “Xaa at position 50 is 6900
Glu, Asn, Serum or Asp "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is 6905
Asn, Arg, Pro, Thr or His (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER IN SIZES E: / Note = “Xaa at position 55 is 6910
Arg, Lion or Gly (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 56 (D) OTHER INFORMATION: / Note = “Xaa at position 56 is 6915
Pro, Gly, Ser, Ala, Asn, Val, Leo or Gin ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = “Xaa at position 62 is 6920
Asn, Pro or Thr "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 64 (D) OTHER INFORMATION: / Note = “Xaa at position 64 is 6925
Ala or Asn "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = “Xaa at position 65 is 6930
Wave or Thr "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER INFORMATION: / Note = “Xaa at position 67 is 6935
Serum or Phe "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = “Xaa at position 68 is 6940
Leo or Phe "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = “Xaa at position 69 is 6945
Gin, Ala, Glu or Arg ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 76 (D) OTHER INFORMATION: / Note = "Xaa at position 76 is Ser, Val, Asn, Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = "Xaa at position 77 is Ile or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = “Xaa at position 79 is Lys, Asn, Met, Arg, Ile or Gly (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 80 (D) OTHER INFORMATION: / Note = “Xaa at position 80 is Asn, Gly, Glu or Arg (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = “Xaa at position 82 is Leo, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr, Val ”” (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = “Xaa at position 87 is Leo or Serum (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 88 (D) OTHER INFORMATION: / Note = "Xaa at position 88 is Ala or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = "Xaa at position 91 is Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 93 (D) OTHER INFORMATION: / Note = "Xaa at position 93 is Thr, Asp or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = “Xaa at position 95 is
His, Pro, Arg, Val, Gly, Asn, Ser sau Thr
RO 118016 Β1
7000 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = “Xaa at position 98 is His, Ile, Asn, Ala, Thr, Gin, Glu, Lys, Met, Ser, Tyr, Val or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 99 (D) OTHER INFORMATION: / Note = "Xaa at position 99 is Ile or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER INFORMATION: / Note = "Xaa at position 100 is Lys or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101 (D) OTHER INFORMATION: / Note = "Xaa at position 105 is Asp, Pro, Met, Lys, Thr, His, Asn, Ile, Leo or Tyr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 105 (D) OTHER INFORMATION E: / Note = "Xaa at position 105 is Asn, Pro, Ser, Ile or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER INFORMATION: / Note = "Xaa at position 108 is Arg, Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = "Xaa at position 109 is Arg, Thr, Glu, Leo or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 112 (D) OTHER INFORMATION: / Note = “Xaa at position 112 is
Thr or Gin "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 116 (D) OTHER INFORMATION: / Note = "Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 117 (D) OTHER INFORMATION: / Note = “Xaa at position 117 is
Thr wrote Ser ”
7005
7010
7015
7020
7025
7030 <sub>f</sub>
7035
7040
7045
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 120 (D) OTHER INFORMATION: / Note = “Xaa at position 120 is
Asn, Pro, Leo, His, Val or Gin ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 121 (D) OTHER INFORMATION: / Note = “Xaa at position 121 is
Ala, Ser, lle, Pro or Asp "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 122 (D) OTHER INFORMATION: / Note = "Xaa at position 122 is Gin, Met, Trp, Phe, Pro, Lys, lle or Tyr" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 123 (D) OTHER INFORMATION: / Note = “Xaa at position 123 is
Ala, Met, Glu, Ser or Leu "(xi) DESCRIPTION OF THE SEQUENCE: SEQ. No. 3:
Ala Pro Met Thr Gin Thr Thr Ser Lleu Lys Thr Ser Trp Val Asn Cys
1015
Site Manager Metallic Asp Glu Productivity Pro
2530
Pro Asa Leu Asu Leu Asn Lea Asp Maca Pro
4045
Meta Shippers Asn Leu Arg Delivery Features
5560
Xaa Lys Xaa Xaa Xn As Ser Ala lle Glu
70 7580
Leu Ta Pro Pro Cys Leu Pro Seals Thr Ala Xaa Pro Pro Arg Pro Pro
9095 lly Xaa Live Po lx Lep Download
100 105110
Le Tu Leu - Lea Glu Phu Ea Gin Gin Thr Thr Leu
115 120125
Ser Leu Ala lle Phe
130 (2) INFORMATION FOR SEQ. No. 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix) FEATURE.
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “Met or Ala - may or may not precede the amino acid at position 1
RO 118016 Β1
7100 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: / Note = “Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gin or Arg (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: / Note = "Xaa at position 4 is Asn, His, Leo, lle, Phe, Arg or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 5 (D) OTHER INFORMATION: / Note = “Xaa at position 5 is Met, Phe, lle, Arg, Gly, Ala or Cys (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 6 (D) OTHER INFORMATION: / Note = "Xaa at position 6 is lle, Cys, Gin, Glu, Arg, Pro or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 7 (D) OTHER INFORMATION: / Note = “Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Gin, Asn, Thr, Ser or Wave ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 8 (D) OTHER INFORMATION: / Note = “Xaa at position 8 is Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leo, Val or Gly ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 9 (D) OTHER INFORMATION: / Note = “Xaa at position 9 is lle, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser or Arg ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 10 (D) OTHER INFORMATION: / Note = "Xaa at position 10 is lle, Gly, Val, Arg, Ser, Phe or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 11 (D) OTHER INFORMATION: / Note = "Xaa at position 11 is Thr, His, Gly, Gin, Arg, Pro or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 12 (D) OTHER INFORMATION: / Note = "Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala"
7105
7110
7115
7120
7125
7130
7135
7140
7145
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 13 (D) OTHER INFORMATION: / Note = "Xaa at position 13 is Leo, Gly, Arg, Thr, Ser or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 14 (D) OTHER INFORMATION: / Note = "Xaa at position 14 is Lys, Arg, Leo, Gin, Gly, Pro, Val or Trp" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION; 15 (D) OTHER INFORMATION: / Note = "Xaa at position 15 is Gin, Asn, Leo, Pro, Arg or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 16 (D) OTHER INFORMATION: / Note = "Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leo or Lys" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 17 (D) OTHER INFORMATION: / Note = “Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leo or Gin (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = "Xaa at position 18 is Leo, Val, Arg, Gin, Asn, Gly, Ala or Glu" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION; 19 (D) OTHER INFORMATION: / Note = "Xaa at position 19 is Pro, Leo, Gin, Ala, Thr or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = “Xaa at position 20 is Leo, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, Ile, Met "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 21 (D) OTHER INFORMATION: / Note = “Xaa at position 21 is Leo, Ala, Gly, Asn, Pro, Gin or Wave (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 22 (D) OTHER INFORMATION: / Note = “Xaa at position 22 is
Asp, Leo or Val ”
RO 118016 Β1
7200 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = "Xaa at position 23 is Phe, Ser, Pro, Trp or lle" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER INFORMATION: / Note = "Xaa at position 24 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 26 (D) OTHER INFORMATION: / Note = "Xaa at position 26 is Leo, Trp or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 27 (D) OTHER INFORMATION: / Note = "Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met or Pro" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 28 (D) OTHER INFORMATION: / Note = “Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, Phe, Tyr, lle or Met "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 29 (D) OTHER INFORMATION: / Note = “Xaa at position 29 is Glu, Asn, Tyr, Leo, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly or Ser "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 30 (D) OTHER INFORMATION: / Note = “Xaa at position 30 is Asp, Ser, Leo, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = “Xaa at position 31 is Gin, Pro, Phe, Val, Met, Leo, Thr, Lys, Asp, Asn, Arg, Ser, Ala, lle, Glu, His or Trp "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = “Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, lle, Val or Gly ”
7205
7210
7215
7220
7225
7230
7235
7240
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 33 (D) OTHER INFORMATION: / Note = "Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 34 (D) OTHER INFORMATION: / Note = “Xaa at position 34 is Leo, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 35 (D) OTHER INFORMATION: / Note = "Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His or Asp" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 36 (D) OTHER INFORMATION: / Note = “Xaa at position 36 is Glu, Leo, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gin ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = "Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 38 (D) OTHER INFORMATION: / Note = "Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 39 (D) OTHER INFORMATION: / Note = "Xaa at position 39 is Leo, Thr, Ala, Gly, Glu, Pro, Lys, Ser or Met" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 40 (D) OTHER INFORMATION: / Note = "Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 41 (D) OTHER INFORMATION: / Note = "Xaa at position 41 is Arg, Thr, Val, Ser, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42
EN 118016 Β1 (D) OTHER INFORMATION: / Note = “Xaa at position 42 is
Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val sau
7295
LYS (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 43 (D) OTHER INFORMATION: / Note = "Xaa at position 43 is Asn or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 44 (D) OTHER INFORMATION: / Note = "Xaa at position 44 is Leo, Serum, Asp, Arg, Gin, Val or Cys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note = "Xaa at position 45 is Glu, Tyr, His, Leo, Pro or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = "Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn or Thr" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 47 (D) OTHER INFORMATION: / Note = "Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg or Ser" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 48 (D) OTHER INFORMATION: / Note = "Xaa at position 48 is Asn, His, Val, Arg, Pro, Asp or lle" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 49 (D) OTHER INFORMATION: / Note = "Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro or Val" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = "Xaa at position 50 is Ala, Asn, Pro, Ser or Lys" (ix) FEATURE:
7300
7305
7310
7315
7320
7325
7330
7335 (A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is
Val, Thr, Pro, His, Leu, Phe sau Ser ”
7340
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 52 (D) OTHER INFORMATION: / Note = "Xaa at position 52 is Lys, lle, Arg, Val, Asn, Glu or Ser" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 53 (D) OTHER INFORMATION: / Note = "Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, lle, Pro or His" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 54 (D) OTHER INFORMATION: / Note = "Xaa at position 54 is Leo, Val, Trp, Ser, lle, Phe, Thr or His" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly or Leo" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 56 (D) OTHER INFORMATION: / Note = "Xaa at position 56 is Asn, Leu, Val, Trp, Pro or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 57 (D) OTHER INFORMATION: / Note = "Xaa at position 57 is Ala, Met, Leo, Pro, Arg, Glu, Thr, Gin, Trp or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION. 58 (D) OTHER INFORMATION: / Note = "Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 59 (D) OTHER INFORMATION: / Note = "Xaa at position 59 is Ala, Glu, Asp, Leo, Ser, Gly, Thr or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 60 (D) OTHER INFORMATION: / Note = "Xaa at position 60 is lle, Met, Thr, Pro, Arg, Gly, Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 61 (D) OTHER INFORMATION: / Note = “Xaa at position 61 is
Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin or Leo ”
RO 118016 Β1
7395 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = "Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly or Asp" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = "Xaa at position 63 is lle, Ser, Arg, Thr or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 64 (D) OTHER INFORMATION: / Note = "Xaa at position 64 is Leo, Ala, Ser, Glu, Phe, Gly or Arg" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, lle or Asp" (ix) FEATURE :
(A) NAME / CODE: Modified site (B) LOCATION: 66 (D) OTHER INFORMATION: / Note = "Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leo, Glu or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER INFORMATION: / Note = "Xaa at position 67 is Leo, Gin, Gly, Ala, Trp, Arg, Val or Lys" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = “Xaa at position 68 is Leo, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, lle, Met or Val "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = "Xaa at position 69 is Pro, Ala, Trp, Thr, Arg or Met" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 70 (D) OTHER INFORMATION: / Note -Xaa at position 70 is Cys, Glu, Gly, Arg, Met or Val "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 71 (D) OTHER INFORMATION: / Note - 'Xaa at position 71 is
Leo, Asn, Val or Gin ”
7400
7405
7410
7415
7420
7425
7430
7435
7440
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 72 (D) OTHER INFORMATION: / Note = “Xaa at position 72 is
Pro, Cys, Arg, Ala or Lys ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = "Xaa at position 73 is Leo, Serum, Trp or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 74 (D) OTHER INFORMATION: / Note = “Xaa at position 74 is
Ala, Lys, Arg, Val or Trp "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 75 (D) OTHER INFORMATION: / Note = "Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn or Ser" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 76 (D) OTHER INFORMATION: / Note = “Xaa at position 76 is
Ala, Pro, Ser, Thr, Gly, Asp, lle or Met "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = “Xaa at position 77 is
Ala, Pro, Ser, Thr, Phe, Leo, Asp or His ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 78 (D) OTHER INFORMATION: / Note = “Xaa at position 78 is
Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, lle or Leu ”/ (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = "Xaa at position 79 is Thr, Asp, Ser, Asn, Pro, Ala, Leo or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 80 (D) OTHER INFORMATION: / Note = “Xaa at position 80 is Arg, lle, Ser, Glu, Leu, Val, Gin, Lys, His, Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 81 (D) OTHER INFORMATION: / Note = “Xaa at position 81 is
His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, all sheep Tyr ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = "Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 83 (D) OTHER INFORMATION: / Note = “Xaa at position 83 is
Ile, Val, Lys, Ala or Asn ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 84 (D) OTHER INFORMATION: / Note = “Xaa at position 84 is His, Ile, Asn, Leo, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 85 (D) OTHER INFORMATION: / Note = “Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 86 (D) OTHER INFORMATION: / Note = "Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gin or Pro" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = “Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Serum, Ala, Gly, Ile, Leo or Gin ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 88 (D) OTHER INFORMATION: / Note = "Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 89 (D) OTHER INFORMATION: / Note = “Xaa at position 89 is
Asn or Ser "
7495
7500
7505
7510
7515
7520
7525
7530
7535 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 90 (D) OTHER INFORMATION: / Note = “Xaa at position 90 is
Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe, Gly”
7540
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = “Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leo, Lys, Ile, Asp or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 92 (D) OTHER INFORMATION: / Note = "Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly or Pro" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 94 (D) OTHER INFORMATION: / Note = "Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gin, His, Ser, Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leo, Ser or Gly" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 96 (D) OTHER INFORMATION: / Note = "Xaa at position 96 is Lys, Asn, Thr, Gin, Arg, His, Glu, Ser, Ala or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 97 (D) OTHER INFORMATION: / Note = "Xaa at position 97 is Leo, Ile, Arg, Asp or Met" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = "Xaa at position 98 is Thr, Val, Gin, Tyr, Glu, His, Ser or Phe" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 99 (D) OTHER INFORMATION: / Note = “Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leo, Ile, Val, Asn "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER INFORMATION: / Note = “Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg or Leo (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101 (D) OTHER INFORMATION: / Note = "Xaa at position 101 is Leo, Asn, Val, Pro, Arg, Ala, His, Thr, Trp or Met"
RO 118016 Β1
7595 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 102 (D) OTHER INFORMATION: / Note = “Xaa at position 102 is
Lys, Leo, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin or Ile (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 103 (D) OTHER INFORMATION: / Note = “Xaa at position 103 is
Thr, Ser, Asn, Ile, Trp, Lys or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 104 (D) OTHER INFORMATION / Note = “Xaa at position 104 is
Leo, Serum, Pro, Ala, Glu, Cys, Asp or Tyr ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 105 (D) OTHER INFORMATION: / Note = “Xaa at position 105 is
Glu, Serum, Lys, Pro, Leo, Thr, Tyr or Arg ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = “Xaa at position 106 is
Asn, Ala, Pro, Leo, His, Val or Gin (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 107 (D) OTHER INFORMATION / Note = “Xaa at position 107 is
Ala, Serum, Ile, Asn, Pro, Lys, Asp or Gly ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER INFORMATION: / Note = “Xaa at position 108 is
Gin, Serum, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr or Cys ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = “Xaa at position 109 is
Ala, Met, Glu, His, Ser, Pro, Tyr or Leu "(xi) DESCRIPTION OF THE SEQUENCE: SEQ.
Asn Cys Xia Xaa X X X X X X X X X X X 10 X1583
Xiao Xiao Xiao Xiao Xiao Xiao Xiao AQuCh
2530
X-rays are a must-have-to-do list.
4045
7600
7605
7610
7615
7620
7625
7630
7635
RO 118016 Β1
X-rays are a must-have-to-do list.
5560
X-rays are a must-have-to-do list.
70 7580
Xiao Xiao Xiao Xia Xia Xia Xia XI XI XQ D I N D I N D I N D I N D I N S I N T A N D I N T A N D I N T A M A N D I N T A M A N D T I N T A N D I N T A N D I N T A N D I N T A N D I N T A N D M A N D.
9095
Xiao Xiao Xiao Xiao Xiao Xiao AQuT
100 105110 (2) INFORMATION FOR SEQ. No. 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note -'Met or Ala- may or may not precede the amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: / Note = "Xaa at position 3 is Ser, Gly, Asp, Met or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: / Note = “Xaa at position 4 is
Asn, His or lle ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 5 (D) OTHER INFORMATION: / Note = “Xaa at position 5 is
Met or lle (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 7 (D) OTHER INFORMATION: / Note = "Xaa at position 7 is Asp or Glu" (ix) FEATURE:
(A) NAME / CODE; Modified site (B) LOCATION: 9 (D) OTHER INFORMATION: / Note = "Xaa at position 9 is lle, Ala, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 10 (D) OTHER IN SIZES E: / Note = "Xaa at position 10 is lle, Val or Leu"
RO 118016 Β1
7690 (ix) FEATURE:
(A) NAME / CODE: Situ changed (B) LOCATION: 11 (D) OTHER INFORMATION: / Note = “Xaa at position 11 is Thr, His, Gin or Ala (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 12 (D) OTHER INFORMATION: / Note = "Xaa at position 12 is His, Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 15 (D) OTHER INFORMATION: / Note = "Xaa at position 15 is Gin, Asn or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 16 (D) OTHER INFORMATION: / Note = "Xaa at position 16 is Pro, Gly or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 17 (D) OTHER INFORMATION: / Note = “Xaa at position 17 is Pro, Asp, Gly or Gin (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = “Xaa at position 18 is Leo, Arg, Gin, Asn, Gly, Ala or Glu (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 19 (D) OTHER INFORMATION: / Note = "Xaa at position 19 is Pro or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = “Xaa at position 20 is Leo, Val, Gly, Ser, Lys, Ala, Arg, Gin, Glu, Ile, Phe, Thr, Met ”(ix) FEATURE:
7695
7700
7705
7710
7715
7720
7725 (A) NAME / CODE: Modified site (B) LOCATION: 21 (D) OTHER INFORMATION: / Note = "Xaa at position 21 is Leo, Ala, Asn, Pro, Gin or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = “Xaa at position 23 is
Faction, Ser, Pro after Trp
7730
7735
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER INFORMATION: / Note = “Xaa at position 24 is Asn or Ala (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 28 (D) OTHER INFORMATION: / Note = “Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, lle, Leo, Met, Tyr or Arg ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 30 (D) OTHER INFORMATION: / Note = "Xaa at position 30 is Asp or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = "Xaa at position 31 is Gin, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = “Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gin, Glu, His, lle, Lys, Tyr, Val or Cys ”(ix)
(A) NAME / CODE: Modified site (B) LOCATION: 36 (D) OTHER IN SIZES E: / Note = "Xaa at position 36 is Glu, Ala, Asn, Ser or Asp" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER 1 INFORMATION: / Note = "Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 40 (D) OTHER INFORMATION: / Note = "Xaa at position 40 is Arg or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 41 (D) OTHER INFORMATION: / Note = "Xaa at position 41 is Arg, Thr, Val, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION: / Note -'Xaa at position 42 is
Pro, Gly, Ser, Gin, Ala, Arg, Asn, Glu, Leo, Thr, Val or Lys ”
RO 118016 Β1
7790 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = "Xaa at position 46 is Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 48 (D) OTHER INFORMATION: / Note = "Xaa at position 48 is Asn, Pro, Thr or lle" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 49 (D) OTHER INFORMATION: / Note = "Xaa at position 49 is Arg or Lys" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = "Xaa at position 50 is Ala or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is Val or Thr (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 52 (D) OTHER INFORMATION: / Note = “Xaa at position 52 is Lys or Arg (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 53 (D) OTHER INFORMATION: / Note = "Xaa at position 53 is Ser, Phe or His" (ix) FEATURE:
(A) NAME / CODE; Modified site (B) LOCATION: 54 (D) OTHER INFORMATION: / Note = "Xaa at position 54 is Leo, lle, Phe or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Gin, Ala, Pro, Thr, Glu, Arg or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 57 (D) OTHER INFORMATION: / Note = “Xaa at position 57 is
Ala, Pro or Arg ”
7795
7800
7805
7810
7815
7820
7825
7830
7835
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 58 (D) OTHER INFORMATION: / Note = "Xaa at position 58 is Ser, Glu, Arg or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 59 (D) OTHER INFORMATION: / Note = "Xaa at position 59 is Ala or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = "Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = "Xaa at position 63 is leu or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Lys, Thr, Gly, As, Met, Arg, lle, Gly or Asp" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 66 (D) OTHER INFORMATION: / Note = "Xaa at position 66 is Asn, Gly, Glu or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = “Xaa at position 68 is Leo, Gin, Trp, Arg, Asp, Ala, Asn, Glu, His, lle, Met, Phe, Ser, Thr, Tyr or Val (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = "Xaa at position 69 is Pro or Thr" "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 71 (D) OTHER INFORMATION: / Note = "Xaa at position 71 is Leo or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = “Xaa at position 73 is
Lion or Ser "
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 74 (D) OTHER INFORMATION: / Note = “Xaa at position 74 is Ala or Trp (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = “Xaa at position 77 is
Ala or Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER IN SIZES E: / Note = "Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leo or Arg" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 81 (D) OTHER INFORMATION: / Note = "Xaa at position 81 is His, Pro, Arg, Val, Leo, Gly, Asn, Phe, Ser or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = "Xaa at position 82 is Pro or Tyr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 83 (D) OTHER INFORMATION: / Note = “Xaa at position 83 is
Ile or Val ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 84 (D) OTHER INFORMATION: / Note = "Xaa at position 84 is His, Ile, Asn, Leo, Ala, Thr, Arg, Gin, Lys, Met, Ser, Tyr, Val, Pro ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 85 (D) OTHER INFORMATION: / Note = “Xaa at position 85 is
Ile, Lion or Val "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 86 (D) OTHER INFORMATION: / Note = "Xaa at position 86 is Lys, Arg, Ile, Gin, Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = “Xaa at position 87 is
Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu sau Tyr ”
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 90 (D) OTHER INFORMATION: / Note = "Xaa at position 90 is Trp or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = “Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gin, Tyr, Leo, Lys, Ile, Asp or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 92 (D) OTHER INFORMATION: / Note = "Xaa at position 92 is Glu or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 94 (D) OTHER INFORMATION: / Note = "Xaa at position 94 is Arg, Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is Arg, Thr, Glu, Leo or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = "Xaa at position 98 is Thr, Val or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER INFORMATION: / Note = "Xaa at position 100 is Tyr or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101 (D) OTHER INFORMATION: / Note = “Xaa at position 101 is
Lion or Ala "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 102 (D) OTHER IN FORMS E: / Note = “Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 103 (D) OTHER INFORMATION: / Note = “Xaa at position 103 is
Thr wrote Ser ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = “Xaa at position 106 is
Asn, Pro, Leo, His, Val or Gin ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 107 (D) OTHER INFORMATION: / Note = “Xaa at position 107 is
Ala, Ser, lle, Asn, Pro, Asp or Gly ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER INFORMATION: / Note = "Xaa at position 108 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, lle, Tyr or Cys ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = "Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr or Leo" (xi) DESCRIPTION SEQUENCE: SEQ. No. 5:
Asn Cys How To Make Away Glu Sea in Office 15 1515
Xaa X Xaaaa Xaa Xaa Xaa Asn Leu Asn Xu Glu Xaa Xaa
2530 If You Want To Know Me Asa Leu Glu Mail
4045
Xaae Xaa X Xaa Xaa Xaa Xaa Xu
5560
Site Deliveries Proxies Pro Tro Pro def
60 7580
Xaae Xaaaaaaaaaaaaa Gly Asp Xaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa ll phe aaa lys
9095
Leu Glu Bends On The Lea
100 105110 (2) INFORMATION FOR SEQ. No.6 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: linear (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “Met - or Met -Ala- may or may not precede the amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: / Note = “Xaa at position 3 is
Ser, Gly, Asp or Gene ”
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: / Note = "Xaa at position 4 is Asn, His or Ile" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 9 (D) OTHER INFORMATION: / Note = "Xaa at position 9 is Ile, Ala, Leo or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 11 (D) OTHER INFORMATION: / Note = "Xaa at position 11 is Thr, His or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 12 (D) OTHER INFORMATION: / Note = "Xaa at position 12 is His or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 15 (D) OTHER INFORMATION: / Note = "Xaa at position 15 is Gin or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 16 (D) OTHER INFORMATION: / Note = "Xaa at position 16 is Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = "Xaa at position 18 is Leo, Arg, Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = “Xaa at position 20 is Leo, Val, Ser, Ala, Arg, Gin, Glu, Ile, Phe, Thr or Met ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 21 (D) OTHER INFORMATION: / Note = "Xaa at position 21 is Leo, Ala, Asn or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER INFORMATION: / Note = “Xaa at position 24 is
Asn or Ala "
RO 118016 Β1
8090 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 28 (D) OTHER INFORMATION: / Note = "Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, lle, Leo, Met, Tyr or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = "Xaa at position 31 is Gin, Val, Met, Leu, Ala, Asn, Glu or Lys" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Asp, Phe, Ser, Ala, Gin, Glu, His, Val or Thr" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 36 (D) OTHER INFORMATION: / Note = “Xaa at position 36 is Glu, Asn, Serum or Asp (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = "Xaa at position 37 is Asn, Arg, Pro, Thr or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 41 (D) OTHER INFORMATION: / Note = "Xaa at position 41 is Arg, Leo or Gly (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION / Note = "Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leo or Gin" (ix) :
(A) NAME / CODE: Modified site (B) LOCATION: 48 (D) OTHER INFORMATION: / Note = "Xaa at position 48 is Asn, Pro or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = "Xaa at position 50 is Ala or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is
Val writes Thr ”
8095
8100
8105
8110
8115
8120
8125
8130
8135
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 53 (D) OTHER INFORMATION: / Note = "Xaa at position 53 is Ser or Phe" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 54 (D) OTHER INFORMATION: / Note = "Xaa at position 54 is Leo or Phe" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = “Xaa at position 55 is Gin, Ala, Glu or Arg (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = "Xaa at position 62 is Ser, Val, Asn, Pro or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = “Xaa at position 63 is
Ile or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Lys, Asn, Met, Arg, Ile or Gly" (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 66 (D) OTHER INFORMATION: / Note = "Xaa at position 66 is Asn, Gly, Glu or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = "Xaa at position 68 is Leo, Gin, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = "Xaa at position 73 is Lion or Serum" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 74 (D) OTHER INFORMATION: / Note = “Xaa at position 74 is
Ala or Trp "
RO 118016 Β1
8195 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = "Xaa at position 77 is Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = "Xaa at position 79 is Thr, Asp or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 81 (D) OTHER INFORMATION: / Note = "Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr" (ix) FEATURE :
(A) NAME / CODE: Modified site (B) LOCATION: 84 (D) OTHER INFORMATION: / Note = “Xaa at position 84 is His, lle, Asn, Leu, Ala, Thr, Arg, Gin, Glu, Lys, Met, Ser, Tyr, Val or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 85 (D) OTHER INFORMATION: / Note = "Xaa at position 85 is leu or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 86 (D) OTHER INFORMATION: / Note = “Xaa at position 86 is
Light Sheep Arg ”
8200
8205
8210
8215
8220 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = "Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, lle, Leo or Tyr" (ix) FEATURE:
(A) NAME / CODE: Site modified
8225 (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = "Xaa at position 91 is Asn, Pro, Ser, lle or Asp" (ix) FEATURE:
8230
8235 (A) NAME / CODE: Modified site (B) LOCATION: 94 (D) OTHER INFORMATION: / Note = “Xaa at position 94 is
Arg, Ala or Ser "
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is Arg, Thr, Glu, Leo or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = "Xaa at position 98 is Thr or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 102 (D) OTHER INFORMATION: / Note = "Xaa at position 102 is Lys, Val, Trp or lle" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 103 (D) OTHER INFORMATION: / Note = “Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = "Xaa at position 106 is Asn, Pro, Leo, His, Val or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 107 (D) OTHER INFORMATION: / Note = "Xaa at position 107 is Ala, Ser, lle, Pro or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 108 (D) OTHER IN FORMS E: / Note = "Xaa at position 108 is Gin, Met, Trp, Phe, Pro, His, lle or Tyr" (ix ) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = "Xaa at position 109 is Ala, Met, Glu, Ser or Leo" (xi) DESCRIPTION OF THE SEQUENCE: SEQ. 6:
Asn Cys Xx's Features:
5 1015
Pro Xaa Pro Asa Leu Asu Leu Asu Mail Pro
2530 ale Leu Met Sending Asn Leu Arg Arcelet
4045
Arg Xaa Laai Xuhhhh Asn Ala Ser Ala lle Glu Xaa Leu 50 5560
RO 118016 Β1
Sea Lea Pro Pro Stys Leu Pro Deliveries Pro Al Ara
70 7580
Download Pro Ile Xaa Pro Features Gly Asp Trp
9095
Leu Ta Phu Tyr Leu Nam Hu Gin Gin
100 105110 (2) INFORMATION FOR SEQ. No. 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 133 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix)
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “May or may not precede amino acid at position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = “Xaa at position 18 is
Asn or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 19 (D) OTHER INFORMATION: / Note = “Xaa at position 19 is
Met, Ala or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = “Xaa at position 20 is
Ile, Pro or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = “Xaa at position 23 is
Ile, Ala or Leo "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 25 (D) OTHER INFORMATION: / Note = “Xaa at position 25 is
Thr or His ”(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 29 (D) OTHER INFORMATION: / Note = “Xaa at position 29 is
Gin, Arg, Val sau Ile ”
8290
8295
8300
8305
8310
8315
8320
8325
8330
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Leo, Ala, Asn or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 34 (D) OTHER INFORMATION: / Note = "Xaa at position 34 is Lion or Serum" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = "Xaa at position 37 is Phe, Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 38 (D) OTHER INFORMATION: / Note = "Xaa at position 38 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) HIGH IN TRAINING: / Note = “Xaa at position 42 is Gly, Ala, Ser, Asp or Asn (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note -'Xaa at position 45 is Gin, Val or Met "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = "Xaa at position 46 is Asp or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 49 (D) OTHER INFORMATION: / Note = "Xaa at position 49 is Met, lle, Leo or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 50 (D) OTHER INFORMATION: / Note = "Xaa at position 50 is Glu or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = “Xaa at position 51 is
Asp, Arg or Ser "
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Arg, Leo or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 56 (D) OTHER INFORMATION: / Note = "Xaa at position 56 is Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 59 (D) OTHER INFORMATION: / Note = “Xaa at position 59 is Glu or Leo (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 60 (D) OTHER INFORMATION: / Note = "Xaa at position 60 is Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER INFORMATION: / Note = "Xaa at position 62 is Asn, Val or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 63 (D) OTHER INFORMATION: / Note = "Xaa at position 63 is Arg or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Wave or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER INFORMATION: / Note = "Xaa at position 67 is Ser, Asn, Hys, or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 69 (D) OTHER INFORMATION: / Note = "Xaa at position 69 is Gin or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = “Xaa at position 73 is
Ala or Gly ”
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 76 (D) OTHER INFORMATION: / Note = "Xaa at position 76 is Ser, Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = "Xaa at position 79 is" Lys, Arg or Serum (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 82 (D) OTHER INFORMATION: / Note = "Xaa at position 82 is Leo, Glu, Val or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 85 (D) OTHER INFORMATION: / Note = "Xaa at position 85 is Leo or Val" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER IN SIZES E: / Note = "Xaa at position 87 is Les, Ser or Tyr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 88 (D) OTHER INFORMATION: / Note = "Xaa at position 88 is Ala or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = "Xaa at position 91 is Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 93 (D) OTHER INFORMATION: / Note = "Xaa at position 93 is Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is His or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = “Xaa at position 98 is
His, l write Thr ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 100 (D) OTHER IN SIZES E: / Note = "Xaa at position 100 is Lys or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 101 (D) OTHER INFORMATION: / Note = "Xaa at position 101 is Asp, Ala or Met" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 105 (D) OTHER INFORMATION: / Note = "Xaa at position 105 is Asn or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = "Xaa at position 109 is Arg, Glu, Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 112 (D) OTHER INFORMATION: / Note = "Xaa at position 112 is Thr or Gin"
8485
8490
8495
8500
8505 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 116 (D) OTHER INFORMATION: / Note = "Xaa at position 116 is Lys, Val, Trp or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 117 (D) OTHER INFORMATION: / Note = "Xaa at position 117 is Thr or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 120 (D) OTHER INFORMATION: / Note = "Xaa at position 120 is Asn, Gin or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 123 (D) OTHER INFORMATION: / Note = “Xaa at position 123 is
Ala, Glu ”
8510
8515
8520
8525
RO 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. No. 7:
Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys 15 1015
Ser Sea Sep Asa Glu Sea Ile Sea His Leu Lys Xa Pro Pro
2530
Pro Asha Leu Asp Lea Asp Lea Asp Maca Pro
4045
Sending Asn Leu Arg Band Signs Asn Leu
5560
How To Find A Lea Asa Ala Ser Xa Ile Glu
70 7580
Leu Se Pro Pro Cys Pro Pro Seat Thr Ala Xaa Pro Pro Arg Pro Pro
9095
Ile Xaa Ilo Xa Gp Asp Trp |
100 105110
Phe Tyr Leu Xaa Xaa Leu Glu Xaa Lower Gin Xaa Gin Gin Thr Thr Leu
115 120125
Ser Leu Ala Ile Phe
130 (2) INFORMATION FOR SEQ. no.8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 1 (D) OTHER INFORMATION: / Note = “Met- or Met- Ala- may or may not precede position 1 (ix) FEATURE:
(A) NAME / CODE: Modified site / (B) LOCATION: 4 (D) OTHER INFORMATION: / Note = “Xaa at position 4 is
Asn or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 5 (D) OTHER INFORMATION: / Note = “Xaa at position 5 is
Met, Ala or Ile "(ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 6 (D) OTHER INFORMATION: / Note = “Xaa at position 6 is
Ile, Pro or Leo "
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 9 (D) OTHER INFORMATION: / Note = "Xaa at position 9 is lion, Ala or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 11 (D) OTHER INFORMATION: / Note = "Xaa at position 11 is Thr or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 15 (D) OTHER INFORMATION: / Note = "Xaa at position 15 is Gin, Arg, Val or lle" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 18 (D) OTHER INFORMATION: / Note = "Xaa at position 18 is Leo, Ala, Asn or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 20 (D) OTHER INFORMATION: / Note = "Xaa at position 20 is Lion or Serum" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 23 (D) OTHER INFORMATION: / Note = “Xaa at position 23 is Phe, Pro or Ser (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 24 (D) OTHER IN SIZES E: / Note = "Xaa at position 24 is Asn or Ala" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 28 (D) OTHER INFORMATION: / Note = "Xaa at position 28 is Gly, Ala, Ser, Asp or Asn" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 31 (D) OTHER INFORMATION: / Note = “Xaa at position 31 is
Gin, Val sau Met ”
8575
8580
8585
8590
8595
8600
8605 f
8610
8615
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 32 (D) OTHER INFORMATION: / Note = "Xaa at position 32 is Asp or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 35 (D) OTHER INFORMATION: / Note = "Xaa at position 35 is Met, Ile or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 36 (D) OTHER INFORMATION / Note = "Xaa at position 36 is Glu or Asp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 37 (D) OTHER INFORMATION: / Note = "Xaa at position 37 is Asn, Arg or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 41 (D) OTHER INFORMATION: / Note = "Xaa at position 41 is Arg, Leo or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 42 (D) OTHER INFORMATION: / Note = "Xaa at position 42 is Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 45 (D) OTHER INFORMATION: / Note = “Xaa at position 45 is Glu or Leo (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 46 (D) OTHER INFORMATION: / Note = "Xaa at position 46 is Ala or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 48 (D) OTHER INFORMATION: / Note = “Xaa at position 48 is
Asn, Val or Pro ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 49 (D) OTHER INFORMATION: / Note = "Xaa at position 49 is Arg or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 51 (D) OTHER INFORMATION: / Note = "Xaa at position 51 is Wave or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 53 (D) OTHER INFORMATION: / Note = "Xaa at position 53 is Ser, Asn, His or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 55 (D) OTHER INFORMATION: / Note = "Xaa at position 55 is Gin or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 59 (D) OTHER INFORMATION: / Note = "Xaa at position 59 is Ala or Gly" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 62 (D) OTHER IN SIZES E: / Note = "Xaa at position 62 is Ser, Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 65 (D) OTHER INFORMATION: / Note = "Xaa at position 65 is Lys, Arg or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 67 (D) OTHER INFORMATION: / Note = Xaa at position 67 is Leo, Glu or Val (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 68 (D) OTHER INFORMATION: / Note = “Xaa at position 68 is
Leo, Glu, Val or Trp "
8665
8670
8675
8680
8685
8690
8695
8700
8705
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 71 (D) OTHER INFORMATION: / Note = “Xaa at position 71 is Leo or Val (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 73 (D) OTHER INFORMATION: / Note = "Xaa at position 73 is Leo, Serum or Tyr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 74 (D) OTHER INFORMATION: / Note = "Xaa at position 74 is Ala or Trp" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 77 (D) OTHER INFORMATION: / Note = "Xaa at position 77 is Ala or Pro" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 79 (D) OTHER INFORMATION: / Note = "Xaa at position 79 is Pro or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 81 (D) OTHER INFORMATION: / Note = "Xaa at position 81 is His or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 84 (D) OTHER INFORMATION: / Note = "Xaa at position 84 is His, Ile or Thr" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 86 (D) OTHER INFORMATION: / Note = "Xaa at position 86 is Lys or Arg" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 87 (D) OTHER INFORMATION: / Note = “Xaa at position 87 is
Asp, Ala or Met ”
EN 118016 Β1 (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 91 (D) OTHER INFORMATION: / Note = "Xaa at position 91 is Asn or Glu" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 95 (D) OTHER INFORMATION: / Note = "Xaa at position 95 is Arg, Glu or Leo" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 98 (D) OTHER INFORMATION: / Note = "Xaa at position 98 is Thr or Gin" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 102 (D) OTHER INFORMATION: / Note = "Xaa at position 102 is Lys, Val, Trp or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 103 (D) OTHER INFORMATION: / Note = "Xaa at position 103 is Thr or Ser" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 106 (D) OTHER INFORMATION: / Note = "Xaa at position 106 is Asn, Gin or His" (ix) FEATURE:
(A) NAME / CODE: Modified site (B) LOCATION: 109 (D) OTHER INFORMATION: / Note = “Xaa at position 109 is Ala or Glu
8755
8760
8765
8770
8775
8780
8785 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. No. 8:
Asn Cys Ser Xa Pro Deliver Asp Glu Live Mail Pro 15 1015
Pro Xaa Pro Deliver Asa Leu Asu Leu Asu Lea Asp Lea Pro 20x3030 lle Leu Sea Asa Leu Sep Sea 35 4045
Ala Sera The Lion King Leu The Lion King
5560
8790
8795
Asa Xaa Pro Pro Sta Se Proa Pro Thrones Pro Arb
70 75 80
Xaa Pro Replacement
90 95
Leu Xaa Phe Tyr Leu Xuan Leu Glu
100 105 110
8800
EN 118016 Β1 (2) INFORMATION FOR SEQ. No. 9:
(SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 9
<td colspan="16">Asn Cys Ser With Met With Asp Glu With His His Leu Lys Arg Pro</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="8"> 10</td><td colspan="3"> 15</td>
<td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td colspan="2">Asn Asn</td><td>Lion</td><td>Asn</td><td>Ala</td><td>Glu</td><td>Asp</td><td>Hours</td><td>Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td colspan="2">Arg Arg</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>with</td><td>Glu</td><td>To be</td><td>with</td><td>Lion</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Pro</td><td>Xle</td><td>His</td><td>with</td><td>Glass"</td><td colspan="2">Asp Gly</td><td colspan="2">Asp Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry</td><td>list</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>, *; I</td><td></td><td></td><td>'xyis ·</td><td>JXCI.ll</td><td></td><td>j.\1X</td><td> 2</td><td>Uj.U</td><td>j? sn</td><td>And I</td><td>vxn</td><td>Ajla</td><td>Gin</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 1O (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 10
<td rowspan="2">Asn I</td><td rowspan="2">Cys</td><td colspan="10">Ser With Met With Asp Glu With His His</td><td colspan="3" rowspan="2">Leu Lys Arg fifteen</td><td rowspan="2">Pro</td>
<td colspan="4"> 5</td><td colspan="6"> 10</td>
<td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>with</td><td>Glu</td><td>To be</td><td>with</td><td>Lion</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
Hia Pro Ile His Ile Lys Asp Gly Asp Trp Aen Glu Phe Arg Arg Lys
RO 118016 Β1
90 95
Leu Thr Phe Tyr Leu Lys Thr leu Glu Asn Ala Gin Ala Gin Gin 100 105 110 (2) SEQUENCE INFORMATION ID NO. 11 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) ΊΠΡ: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide
8850
8855
8860 (») DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 11
<td>Asn</td><td>Cy·</td><td>To be</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu place</td><td>for</td><td>To</td><td>His</td><td>Lion</td><td>list</td><td>Hours</td><td>Pro</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>To be</td><td>Asn Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>for</td><td>Lion</td><td>Mat</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Arg Arg</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>Glass·</td><td>To be</td><td>Lion</td><td>Gin</td><td>Asn Ala</td><td>to be</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td><td>for</td><td>Lion</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Glass·</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for</td><td>list</td><td colspan="3">Asp Gly Asp Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td colspan="3">Arg Arg Lys</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>list</td><td>Thr</td><td>I read Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td colspan="2">Gin Gin</td><td></td>
<td></td><td></td><td></td><td>1OO</td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
8865
8870
8875 (2) SEQUENCE INFORMATION ID NO. 12 (Î) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 12
8880
8885
<td>Asn 1</td><td>Cys</td><td>To be</td><td>Asn</td><td>With 5</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for 10</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin fifteen</td><td>Pro</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>for</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion 45</td><td>Ala</td><td>Faction</td><td>Hours</td>
8890
RO 118016 Β1
<td colspan="2" rowspan="2">Arg Ala fifty</td><td rowspan="2">Hours</td><td rowspan="2">list</td><td rowspan="2">Asn</td><td colspan="10">Leu Glu Asn Ala Be Ala lle Glu Be le Leu</td>
<td colspan="2"> 55</td><td colspan="8"> 60</td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Read Allah</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for</td><td>list</td><td>Asp</td><td>Gly</td><td>Asp Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry</td><td>list</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td>1OO</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 13 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) ΠΡ: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 13
<td colspan="16">Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu Lys Gin Pro</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="5"> 15</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>for</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>To be</td><td>Faction</td><td>Hours</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>for 60</td><td>Glu</td><td>To be</td><td>for</td><td>yours</td>
<td>list 65</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for 85</td><td>list</td><td>Asp</td><td>Gly</td><td>Asp</td><td>Trp 90</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td colspan="2">Arg Lys 95</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 100</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu 105</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Gin</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 14 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 14
Asn Cys Ser Asn Met lle Asp Glu lle lle Thr His Leu Lys Gin Pro 15 IO 15
RO 118016 Β1
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td> 8940</td>
<td> 11·</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>with</td><td>Glu</td><td>To be</td><td>with</td><td>Lion</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>cys</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td colspan="2">Do not start</td><td>Pro</td><td>Thr</td><td>Angry</td><td> 8945</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>His</td><td>Pro</td><td>with</td><td>His</td><td>with</td><td>list</td><td colspan="4">Asp Gly Asp Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td colspan="3">Arg Arg Lys</td><td></td>
<td></td><td></td><td></td><td></td><td>as</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Lion</td><td colspan="2">Thr Phe</td><td>Tyr</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin</td><td></td><td rowspan="2"> 8950</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 15
8960
<td>Asn 1</td><td>Cys</td><td>To be</td><td>Asn</td><td>With 5</td><td>with</td><td>Asp</td><td>With Glu</td><td>With 10</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin fifteen</td><td>Pro</td><td></td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td><td></td>
<td>with</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Arg Arg 40</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>Ala</td><td>Faction</td><td>Asn</td><td> 8965</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>to be</td><td>Lion</td><td>Gin 55</td><td>Asn Ala</td><td>to be</td><td>Gly</td><td>with 60</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td><td></td>
<td>Angry 65</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro Ser</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>to be</td><td>Angry 80</td><td> 8970</td>
<td>His</td><td>Pro</td><td>with</td><td>with</td><td>with 85</td><td>list</td><td>Ala</td><td>Gly Asp</td><td>Trp 90</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry 95</td><td>list</td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 100</td><td>Lion</td><td>list</td><td>Thr</td><td>I read Glu 105</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Gin</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 16 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY; linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 16
8975
RO 118016 Β1
<td>(xi)</td><td colspan="15">SEQUENCE DESCRIPTIONt SEQ ID NO: 16$</td>
<td>A8P 1</td><td>CyS</td><td>To be</td><td>On</td><td>With 5</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with 10</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin fifteen</td><td>Pro</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>with</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>Lye</td><td>To be</td><td>Lion</td><td>Gin 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with 60</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td>
<td>Angry 65</td><td>Asn</td><td>Lion</td><td>Hours</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>with</td><td>Thr</td><td>with 85</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp 90</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry 95</td><td>i-ys</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 100</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu 105</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Gin</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 17
<td>(i)</td><td colspan="3">SEQUENCE CHARACTERISTICS:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>(A)</td><td colspan="3">LENGTH: 111 amino acids</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>(B)</td><td>TYPE: amino acids</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>(D)</td><td>TOPOLOGY: linear</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(Ii)</td><td colspan="2">MOLECULE TYPE: peptide</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(xi)</td><td colspan="6">SEQUENCE DESCRIPTION: SEQ. ID NO. 17</td><td></td><td></td><td></td><td></td>
<td>Aen</td><td>Cye</td><td>Ser Asn Met With Asp Glu</td><td>with</td><td>with</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin</td><td>Pro</td>
<td> 1</td><td></td><td> 5</td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Pro</td><td>Lion</td><td>Pro Leu Leu Asp Phe Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td rowspan="2">Asp</td>
<td></td><td></td><td> 20</td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>with</td><td>Lion</td><td>Met Glu Asn Asn Leu Arg</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td></td><td></td><td> 35 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Val Lys sees Leu Gin Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>with</td><td>Glu</td><td>To be</td><td>with</td><td>Lion</td>
<td></td><td> 50</td><td> 55</td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>list</td><td>Asn</td><td>Leu Leu Pro cys Leu Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td> 70</td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Pro</td><td>Ile His Ile Lys Asp Gly</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td rowspan="2">list</td>
<td></td><td></td><td> 85</td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td>Lion</td><td>Thr</td><td>Phe Tyr Leu Val Thr Leu</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td></td><td></td><td> 100</td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 18 (i) SEQUENCE CHARACTERISTICS:
EN 118016 Β1 (A) LENGTH: 111 amino acids 9030 (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide
9035 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 18
<td>Asn</td><td>cys</td><td>To be</td><td>Asn</td><td>With</td><td>for</td><td>Asp</td><td>Glu place</td><td>for</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin</td><td>Pro</td><td></td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td><td></td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn Asn</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Gin</td><td>Asp</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td> 9040</td>
<td>for</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Arg Arg</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td><td>Faction</td><td>Asn</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin</td><td>Asn Ala</td><td>To be</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td><td>for</td><td>Lion</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 9045</td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro Leu</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td><td></td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for</td><td colspan="4">Lys Asp Gly Asp Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>To be</td><td colspan="2">Leu Glu His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td> 9050</td>
<td></td><td></td><td></td><td>1OO</td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 19 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (O) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 19
9055
9060
<td>Asn 1</td><td>Cys</td><td>To be</td><td>Asn</td><td>With 5</td><td>for</td><td>Asp</td><td>Glu</td><td>for</td><td>for 10</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin 15.</td><td>Pro</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>for</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>for 60</td><td>Glu</td><td>Ala</td><td>for</td><td>Lion</td>
<td>Angry 65</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>for</td><td>for</td><td>for 85</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp 90</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu 95</td><td>list</td>
9065
9070
RO 118016 Β1
Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 (2) SEQUENCE INFORMATION ID NO. 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 20
<td colspan="16">Asn Cys Ser Asn Met With Asp Glu With Thr His Leu Lys Gin Pro</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="8"> 10</td><td colspan="3"> 15</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>with</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with 60</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td>
<td>Angry 65</td><td>Asn</td><td>Lion</td><td>Hours</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>To be</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>with</td><td>Thr</td><td>with 85</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp 90</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu 95</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 100</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu 105</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin 110</td><td>Gin</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 21 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY; linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 21
<td>Asn 1</td><td>Cys</td><td>To be</td><td>Asn</td><td>With 5</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with 10</td><td>Thr</td><td>His</td><td>Lion</td><td>list</td><td>Gin fifteen</td><td>Pro</td>
<td>Pro</td><td>Lion</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td>Asp thirty</td><td>Gin</td><td>Asp</td>
<td>with</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Angry</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>Ala</td><td>Faction</td><td>Asn</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with 60</td><td>Glu</td><td>Ala</td><td>with</td><td>Lion</td>
RO 118016 Β1
9120
<td rowspan="2">Angry 65</td><td colspan="2" rowspan="2">Asn Leu</td><td colspan="2" rowspan="2">Val Pro</td><td colspan="6">Cys Leu Pro Ser Ala Thr</td><td rowspan="2">Ala</td><td colspan="2" rowspan="2">Wing Pro</td><td rowspan="2">To be</td><td rowspan="2">Angry 80</td>
<td> 70</td><td colspan="5"> 75</td>
<td>His</td><td>Pro</td><td>for</td><td>Thr</td><td>for</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Glu</td><td>list</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>To be</td><td>Lion</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
9125 (2) SEQUENCE INFORMATION ID NO. 22 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 22
9130
<td colspan="16">Asn Cys Ser lle Met lle Asp Glu lle lle His His Leu Lys Arg Pro</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="5"> 15</td>
<td>Pro</td><td>Ala</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>Ala</td><td>Glu</td><td>Asp thirty</td><td>Hours</td><td>Asp</td>
<td>for</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu 45</td><td>To be</td><td>Faction</td><td>hour</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>for 60</td><td>Glu</td><td>To be</td><td>Xle</td><td>Lion</td>
<td>list 65</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for 85</td><td>list</td><td>Asp</td><td>Gly</td><td>AS 3</td><td>Trp 90</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry 95</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 100</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu 105</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Gin</td><td></td>
9135
9140
9145 (2) SEQUENCE INFORMATION ID NO. 23 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) ΤΊΡ: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 2. 3
9150
9155
<td>Asn Cys 1</td><td>To be</td><td>for</td><td>With 5</td><td>Asp</td><td>Glu</td><td>for</td><td>for 10</td><td>His</td><td>His</td><td>Lion</td><td>list</td><td>Angry fifteen</td><td>Pro</td>
<td>Pro Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp</td><td>With</td><td>Asp</td>
25 30
9160
RO 118016 Β1
<td>for</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Ala</td><td>Faction</td><td>Hours</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td><td>for</td><td>Lion</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>list</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>cys</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for</td><td>list</td><td colspan="3">Asp Gly Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry</td><td>Lye</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>list</td><td>Thr</td><td colspan="2">I read Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Gin.</td><td></td>
<td></td><td></td><td></td><td>1OO</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 24 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 111 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 24
<td colspan="15">Asn Cys Being Him Met Him Asp Glu Him His His Leu Lys Val</td><td rowspan="2">Pro</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="8">I</td><td colspan="2"> 15</td>
<td>Pro</td><td>Ala</td><td>Pro</td><td>Lion 20</td><td>Lion</td><td>Asp</td><td>To be</td><td>Asn</td><td>Asn 25</td><td>Lion</td><td>Asn</td><td>To be</td><td>Glu</td><td>Asp thirty</td><td>With</td><td>Asp</td>
<td>for</td><td>Lion</td><td>With 35</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry 40</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion 45</td><td>Ala</td><td>Faction</td><td>Hours</td>
<td>Angry</td><td>Ala fifty</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu 55</td><td>Asn</td><td>Ala</td><td>To be</td><td>Ala</td><td>for 60</td><td>Glu</td><td>To be</td><td>for</td><td>Lion</td>
<td>list 65</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys 70</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Ala</td><td>Thr 75</td><td>Ala</td><td>Ala</td><td>Pro</td><td>Thr</td><td>Angry 80</td>
<td>His</td><td>Pro</td><td>for</td><td>His</td><td>for 85</td><td>list</td><td colspan="2">Asp Gly</td><td>Asp</td><td>Trp 90</td><td>Asn</td><td>Glu</td><td>Faction</td><td>Angry</td><td>Angry 95</td><td>list</td>
<td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr 10O</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu 105</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Gin</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 25
RO 118016 Β1
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be 5</td><td>Asn</td><td>With</td><td>with</td><td>Asp</td><td>Glu 10</td><td>with</td><td>with</td><td>Thr</td><td>His</td><td>Lion fifteen</td><td>list</td><td> 9210</td>
<td>Gin</td><td>Pro</td><td>Pro</td><td>Lion 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Faction 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Gly thirty</td><td>Glu</td><td>Asp</td><td></td>
<td>Gin</td><td>Asp</td><td>with 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn 40</td><td>Lion</td><td colspan="2">Arg Arg</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Ala</td><td> 9215</td>
<td>Faction</td><td>Asn fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be 55</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Ala</td><td>To be 60</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td><td></td>
<td>with 65</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be 75</td><td>Ala</td><td colspan="2">Thr Ala</td><td>Ala</td><td>Pro 80</td><td></td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with 85</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td colspan="2">Gin Glu</td><td>Faction 95</td><td>Angry</td><td> 9220</td>
<td>Glu</td><td>list</td><td>lion</td><td>Thr 100</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td></td>
<td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 26 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (») DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 26
9230
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be</td><td>Asn</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>Thr</td><td>His</td><td>Lion</td><td rowspan="2">list</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td>
<td>Gin</td><td>Pro</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Faction</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Gly</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Gin</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td colspan="2">Arg Arg</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Faction</td><td>Asn</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Hours</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with</td><td>Thr</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin
9235
9240
9245
9250
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 27 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (Bj TYPE: amino acids (DJ TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27)
<td colspan="15">Met Ala Asn Cys Ser Asn Met Xle Asp Glu lle Xle Thr His Leu Lys</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="4"> 15</td>
<td>Gin</td><td>Pro</td><td>Pro</td><td>Lion 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Faction 25</td><td>Asn</td><td>Asn Leu</td><td>Asn</td><td>Gly thirty</td><td>Glu</td><td>Asp</td>
<td>Gin</td><td>Asp</td><td>for 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Asn</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Arg Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Ala</td>
<td>Faction</td><td>Asn fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To be 55</td><td>Lion</td><td>Gin</td><td>Asn</td><td>Wing Being 60</td><td>Gly</td><td>Xle</td><td>Glu</td><td>Ala</td>
<td>for 65</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Hours 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>It will be the 75</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>Xle 85</td><td>Thr</td><td>for</td><td>list</td><td>Ala</td><td>Gly 90</td><td>Asp Trp</td><td>Gin</td><td>Glu</td><td>Faction 95</td><td>Angry</td>
<td>Glu</td><td>list</td><td>Lion</td><td>Thr 100</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>hour</td><td>To be 105</td><td>Lion</td><td>Glu His</td><td>Ala</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
Gin (2) SEQUENCE INFORMATION ID NO. 28 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 28
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be 5</td><td>for</td><td>With</td><td>for</td><td>ASp</td><td>Glu 10</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion fifteen</td><td>list</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>A8P</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Ala thirty</td><td>Glu</td><td>Asp</td>
<td>Hours</td><td>Aap</td><td>with 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>To be</td>
<td>Faction</td><td>Val SO</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be 60</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td>
RO 118016 Β1
<td>11 · Leo</td><td>Lya</td><td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys Leu Pro</td><td>Lion</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td><td></td>
<td> 65</td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>Thr Arg</td><td>His</td><td>Pro</td><td>for</td><td>Hi·</td><td>for</td><td>Lya Asp Gly</td><td>Asp</td><td>Trp</td><td>Aen</td><td>Glu</td><td>Faction</td><td>Angry</td><td> 9300</td>
<td></td><td></td><td></td><td> 85</td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Arg Lys</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Lys Thr Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td><td></td>
<td></td><td></td><td> 100</td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td> 110</td><td></td><td></td><td></td>
<td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 9305</td>
(2) SEQUENCE INFORMATION ID NO. 29 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 29
9315
<td>With 1</td><td>Ala</td><td>Aen</td><td>Cys</td><td>To be 5</td><td>for</td><td>With</td><td colspan="3">where Asp Glu I</td><td>for</td><td>for</td><td>His</td><td>H1S</td><td>Lion fifteen</td><td>Lye</td><td></td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>? ro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be thirty</td><td>Glu</td><td>Asp</td><td></td>
<td>With</td><td>No</td><td>for 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Thr</td><td>pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>Ala</td><td> 9320</td>
<td>Faction</td><td>Hours fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>to be 60</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td><td></td>
<td>for 65</td><td>Lion</td><td>list</td><td>Aen</td><td>Lion</td><td>Lion 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Lion 7s</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td><td> 9325</td>
<td>Thr</td><td>Angry</td><td>HLs</td><td>For</td><td>for 85</td><td>Ris</td><td>for</td><td>list</td><td>Asp</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Faction 95</td><td>Angry</td><td></td>
<td>Angry</td><td>Lye</td><td>Lion</td><td>Thr 100</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Lye</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin 110</td><td>Ala</td><td>Gin</td><td></td>
Gin 9330 (2) SEQUENCE INFORMATION ID NO. 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (θ) ΊΠΡ: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 30
9340
RO 118016 Β1
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be 5</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu 10</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion fifteen</td><td>list</td>
<td>Hours</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>To be 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Ser 30</td><td>Glu</td><td>Asp</td>
<td>With</td><td>Asp</td><td>for 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>Ala</td>
<td>Faction</td><td>Hours fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser 60</td><td>Ala</td><td>for</td><td>Glu</td><td>To be</td>
<td>for 65</td><td>Lion</td><td>list</td><td>Asn</td><td>Lion</td><td>Lion 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Lion 75</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td>
<td>Thr</td><td>Angry</td><td>His</td><td>Pro</td><td>for 85</td><td>His</td><td>for</td><td>list</td><td>Asp</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Asn</td><td>Glu</td><td>Faction 95</td><td>Angry</td>
<td colspan="2">Angry light</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>list</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Gin</td><td>Ala</td><td>Gin</td>
100 105 110
Gin (2) SEQUENCE INFORMATION IO NO. 31 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 31
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be 5</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu 10</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion fifteen</td><td>list</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Ala thirty</td><td>Glu</td><td>Asp</td>
<td>Hours</td><td>Asp</td><td>for 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>To be</td>
<td>Faction</td><td>Hours fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be 60</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td>
<td>for 65</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be 75</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for 85</td><td>for</td><td>for</td><td>list</td><td>Ala</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction 95</td><td>Angry</td>
<td>Glu</td><td>list</td><td>Lion</td><td>Thr 100</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
Gin
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 32 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide
9385
9390 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 32
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cye</td><td>To be 5</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu 10</td><td>for</td><td>Xle</td><td colspan="2">Hi »Hi»</td><td>Lion fifteen</td><td>list</td><td> 9395</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>On</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be thirty</td><td>Glu</td><td>Asp</td><td></td>
<td>With</td><td>Asp</td><td>Xle 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>On 40</td><td>Lion</td><td>Angry</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>Ala</td><td> 9400</td>
<td>Faction</td><td>hour fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>To 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be 60</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td></td>
<td>for 65</td><td>Lion</td><td>Angry</td><td>On</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be 75</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td><td></td>
<td>To be</td><td>Angry</td><td>To</td><td>Pro</td><td>for 85</td><td>for</td><td>Xle</td><td>Lya</td><td>Ala</td><td colspan="2">Gly Asp 90</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction 95</td><td>Angry</td><td> 9405</td>
<td>Glu</td><td>Lye</td><td>Lion</td><td>Thr 100</td><td>Faction</td><td>Tyr</td><td>lion</td><td>Hours</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td></td>
9410
Gin (2) SEQUENCE INFORMATION ID NO. 33 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (Mr. TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cye</td><td>To be S</td><td>Xle</td><td>With</td><td>for</td><td>Asp</td><td>Glu 10</td><td>for</td><td>Xle</td><td>His</td><td>His</td><td>Lion fifteen</td><td>list</td><td> 9420</td>
<td>Hours</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>To be 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>To be thirty</td><td>Glu</td><td>Asp</td><td></td>
<td>With</td><td>Aep</td><td>Xle 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>Ala</td><td> 9425</td>
<td>Faction</td><td>Hours fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be 60</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td></td>
RO 118016 Β1
<td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with</td><td>with</td><td>with</td><td>list</td><td>Ala</td><td>Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td>Angry</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>I read Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin (2) SEQUENCE INFORMATION ID NO 34 (i) SEQUENCE CHARACTERISTICS:
(AJ LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear t) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION; SEQ. ID NO. 34
<td>With</td><td>Ala</td><td>Asn</td><td>Cys</td><td>to be</td><td>with</td><td>With</td><td>with</td><td>Asp</td><td>Glu</td><td>with</td><td>with</td><td>His</td><td>His</td><td>Lion</td><td rowspan="2">list</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td>
<td>Angry</td><td>Pro</td><td>Pro</td><td>Ala</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Ala</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Hours</td><td>Asp</td><td>with</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>To be</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Faction</td><td>Hours</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>To be</td><td>Gly</td><td>with</td><td>Glu</td><td>Ala</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>with</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Hours</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>with</td><td>Thr</td><td>with</td><td>list</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Faction</td><td rowspan="2">Angry</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td>Glu</td><td>list</td><td>Lion</td><td>Thr</td><td>Faction</td><td>Tyr</td><td>Lion</td><td>Hours</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin (2) SEQUENCE INFORMATION ID NO. 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 35
RO 118016 Β1
<td>With 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>To be 5</td><td>for</td><td>With</td><td>for</td><td>Asp</td><td>Glu 10</td><td>for</td><td>for</td><td>His</td><td>His</td><td>Lion fifteen</td><td>list</td><td></td>
<td>Hours</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>To be 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Ser 30</td><td>Glu</td><td>Asp</td><td> 9475</td>
<td>With</td><td>Asp</td><td>for 35</td><td>Lion</td><td>With</td><td>Glu</td><td>Angry</td><td>Asn 40</td><td>Lion</td><td>Angry</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>Ala</td><td></td>
<td>Faction</td><td>Hours fifty</td><td>Angry</td><td>Ala</td><td>Hours</td><td>list</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser 60</td><td>Gly</td><td>for</td><td>Glu</td><td>Ala</td><td> 9480</td>
<td>for 65</td><td>Lion</td><td>Angry</td><td>Asn</td><td>Lion</td><td>Val 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>To be 75</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td><td></td>
<td>To be</td><td>Angry</td><td>His</td><td>Pro</td><td>for 85</td><td>Thr</td><td>for</td><td>list</td><td>Ala</td><td colspan="3">Gly Asp Trp 90</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td><td> 9485</td>
<td>Glu</td><td>Ly»</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Thr</td><td>Leu</td><td colspan="2">Glu Gin</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
100 105 110
Gin (2) INFORMAȚIE PENTRU SECVENȚA ID NR. 36 (i) CARACTERISTICI DE SECVENȚĂ:
(A) LUNGIME : 113 aminoacizi (B) TIP : aminoacizi (D) TOPOLOGE: lineară (ii) TIPUL MOLECULEI: peptidă
9490
9495 (xi) DESCRIEREA SECVENȚEI: SECV. ID NR. 36
<td colspan="16">Met Ala Asn Cye Ser lle Met lle Asp Glu lle lle His His Leu Lys</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="7"> 10</td><td colspan="4"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Met</td><td>Asp</td><td>lle</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Leu</td><td>Leu</td><td>Ala</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Val</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>His</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>Ser</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>lle</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Ser</td><td>Arg</td><td>His</td><td>Pro</td><td>lle</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lye</td><td>Leu</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin
9500
9505
9510
RO 118016 Β1 (2] INFORMAȚIE PENTRU SECVENȚA ID NR. 37 (i) CARACTERISTICI DE SECVENȚĂ :
(A) LUNGIME : 113 aminoacizi (B) TIP : aminoacizi (D) TOPOLOGIE: lineară (ii) TIPUL MOLECULEI: peptidă (xi) DESCRIEREA SECVENȚEI: SECV. ID NR. 37
<td>Met 1</td><td>Ala</td><td>Asn</td><td>Cys</td><td>Ser 5</td><td>lle</td><td>Met</td><td>lle</td><td>Asp</td><td>Glu IO</td><td>lle</td><td>lle</td><td>His</td><td>His</td><td>Leu 15</td><td>Lys</td>
<td>Val</td><td>Pro</td><td>Pro</td><td>Ala 20</td><td>Pro</td><td>Leu</td><td>Leu</td><td>Asp</td><td>Ser 25</td><td>Asn</td><td>Asn</td><td>Leu</td><td>Asn</td><td>Ser 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>lle 35</td><td>Leu</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Leu</td><td>Arg</td><td>Leu</td><td>Pro</td><td>Asn 45</td><td>Leu</td><td>Leu</td><td>Ala</td>
<td>Phe</td><td>Val 50</td><td>Arg</td><td>Ala</td><td>Val</td><td>Lys</td><td>Asn 55</td><td>Leu</td><td>Glu</td><td>Asn</td><td>Ala</td><td>ser 60</td><td>Gly</td><td>lle</td><td>Glu</td><td>Ala</td>
<td>lle 65</td><td>Leu</td><td>Arg</td><td>Asn</td><td>Leu</td><td>Val 70</td><td>Pro</td><td>Cys</td><td>Leu</td><td>Pro</td><td>Ser 75</td><td>Ala</td><td>Thr</td><td>Ala</td><td>Ala</td><td>Pro 80</td>
<td>Sec</td><td>Arg</td><td>His</td><td>Pro</td><td>lle 85</td><td>Thr</td><td>lle</td><td>Lys</td><td>Ala</td><td colspan="2">Gly Asp 90</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Leu</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Leu</td><td>Val</td><td>Ser 105</td><td>Leu</td><td>Glu</td><td>His</td><td>Ala</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
Gin (2) SEQUENCE INFORMATION ID NO. 38 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 38
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
RO 118016 Β1
9560
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Wave</td><td>Pro</td><td>Cys</td><td>Lion</td><td>For the sake of Allah</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Thr</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>I read Glu Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td> 110</td><td></td><td></td>
Gin
9565 (2) SEQUENCE INFORMATION ID NO. 39 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 39
9570
9575
<td>Net</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td colspan="2">Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td><td rowspan="2">Lys</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>That</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td><sup>25</sup></td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Wave</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Wave</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Thr</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td colspan="2">Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td rowspan="2">Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Serum</td><td>Lion</td><td>Glu</td><td>His</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin
9580
9585
9590 (2) SEQUENCE INFORMATION ID NO. 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 40
9595
9600
RO 118016 Β1
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>authorities</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>That 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Serum</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp 90</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
Gin (2) SEQUENCE INFORMATION ID NO. 41 (i) SEQUENCE CHARACTERISTICS:
<td></td><td>(A)</td><td>LENGTH: 113 amino acids</td>
<td></td><td>(B)</td><td>TYPE: amino acids</td>
<td></td><td>(D)</td><td>TOPOLOGY: linear</td>
<td>(Ii)</td><td colspan="2">MOLECULE TYPE: peptide</td>
<td>(Xi)</td><td colspan="2">SEQUENCE DESCRIPTION: SEQ. ID NO. 41</td>
<td colspan="6">Met Ala Asn Cys Ser Ile</td><td rowspan="2">Met</td><td colspan="9">Hair Asp Glu Ala Hair His His Leu Lys</td>
<td colspan="4"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="3"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Serum</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
Gin
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 42
9645 (i) SEQUENCE CHARACTERISTICS:
<td>(A)</td><td>LENGTH: 113 amino acids</td><td></td>
<td>(B)</td><td>TYPE: amino acids</td><td></td>
<td>(D)</td><td>TOPOLOGY: linear</td><td> 9650</td>
(ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 42
<td colspan="7">Met Ala Asn cys Ser Ile Met</td><td rowspan="2">Ile</td><td colspan="2" rowspan="2">Asp Glu 10</td><td>Hair Hair</td><td colspan="2" rowspan="2">His His</td><td rowspan="2">Lion 15</td><td rowspan="2">Lys</td><td rowspan="2"> 9655</td>
<td> 1</td><td colspan="6"> 5</td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn Leu</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td><td></td>
<td>Met</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Read Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td><td> 9660</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Hello Ser 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td></td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>He went to Allah 75</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td><td></td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td><td> 9665</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td></td>
Gin (2) SEQUENCE INFORMATION ID NO. 43
9670 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 43
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>That 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
9680
9685
RO 118016 Β1
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>For the sake of Allah</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>I read Glu Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td>1OO</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td> 110</td><td></td><td></td>
Gin (2) SEQUENCE INFORMATION ID NO. 44 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (O) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 44
<td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>XLE</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>HiS</td><td>His</td><td>Lion</td><td rowspan="2">Lys</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td>
<td colspan="2">Arg Pro</td><td>Pro</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>I <I</td><td>Asn</td><td>Asp</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Wave</td><td>Serum</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>aan</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
Gin (2) SEQUENCE INFORMATION ID NO. 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 45
RO 118016 Β1
<td colspan="2">Met Ala Asn Cys Ser</td><td rowspan="2">Ile</td><td rowspan="2">Met</td><td rowspan="2">Asp</td><td colspan="2">Glu le lle His His Leu</td><td rowspan="2">Lys</td><td rowspan="2"> 9735</td>
<td> 1</td><td> 5</td><td> 10</td><td> 15</td>
<td>Arg</td><td>Pro Pro Wing Pro</td><td>Lion</td><td>Lion</td><td>Asp Pro</td><td>Asn Asn Leu Asn Asp</td><td>Glu</td><td>Asp</td><td></td>
<td></td><td> 20</td><td></td><td></td><td> 25</td><td> 30</td><td></td><td></td><td></td>
<td>Met</td><td>Be Him Read Met</td><td>Glu</td><td>Arg</td><td>Asn Leu</td><td>Arg Leu Pro Asn Leu</td><td>Glu</td><td>Serum</td><td></td>
<td></td><td> 35</td><td></td><td></td><td> 40</td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Val Arg Ala Val</td><td>Lys</td><td>Asn</td><td>I read Glu</td><td>Asn Allah Be Gly you</td><td>Glu</td><td>That</td><td> 9740</td>
<td></td><td> 50</td><td></td><td> 55</td><td></td><td> 60</td><td></td><td></td><td></td>
<td>Ile</td><td>Leu Arg Asn Leu</td><td>Gin</td><td>Pro</td><td>Cys Lee</td><td>Pro Ser Ala Thr Ala</td><td>That</td><td>Pro</td><td></td>
<td> 65</td><td></td><td> 70</td><td></td><td></td><td> 75</td><td></td><td> 80</td><td></td>
<td>Serum</td><td>Arg His Pro him</td><td>Ile</td><td>Ile</td><td>Lys Ala</td><td>Gly Asp Trp Gin Glu</td><td>Phe</td><td>Arg</td><td rowspan="2"> 9745</td>
<td></td><td> 85</td><td></td><td></td><td></td><td> 90</td><td> 95</td><td></td>
<td>Glu</td><td>Lys Leu Thr Phe</td><td>Tyr</td><td>Lion</td><td>Val Thr</td><td>Read Glu Gin Ala Gin</td><td>Glu</td><td>Gin</td><td></td>
<td></td><td> 100</td><td></td><td></td><td> 105</td><td> 110</td><td></td><td></td><td></td>
<td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
9750 (2) SEQUENCE INFORMATION ID NO. 46 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 125 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear 9755 (ii) TYPE OF MOLECULES): peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 46
<td rowspan="2">Met 1</td><td rowspan="2">That</td><td rowspan="2">Tyr</td><td rowspan="2">Pro</td><td colspan="3">Glu Thr Asp Tyr Lys Asp Asp Asp Asp Lys Asn Cys</td><td rowspan="2"> 9760</td>
<td> 5</td><td> 10</td><td> 15</td>
<td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp Glu</td><td>him His His</td><td>Read Lys Arg Pro Pro Ala</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td> 25</td><td> 30</td><td></td>
<td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Due to Asn</td><td>Asn Leu Asn Allah</td><td>Glu Asp Val Asp lle Leu</td><td>t</td>
<td></td><td></td><td> 35</td><td></td><td></td><td> 40</td><td> 45</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 9765</td>
<td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Read Arg</td><td>Leu Pro Asn Leu</td><td>Glu Ser Phe Val Arg Ala</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td> 55</td><td> 60</td><td></td>
<td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu Asn</td><td>Hi Gly you</td><td>Glu Ala Xle Leu Arg Asn</td><td></td>
<td> 65</td><td></td><td></td><td></td><td> 70</td><td></td><td> 75 80</td><td></td>
<td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Read Pro</td><td>Be Allah Thr Allah</td><td>Ala Pro Ser Arg His Pro</td><td> 9770</td>
<td></td><td></td><td></td><td></td><td> 85</td><td> 90</td><td> 95</td><td></td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>Hi Gly</td><td>Asp Trp Gin Glu</td><td>Phe Arg Glu Lys Leu Thr</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td> 105</td><td> 110</td><td></td>
<td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr Leu</td><td>Glu Gin Ala Gin</td><td>Glu Gin Gin</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td> 120</td><td> 125</td><td> 9775</td>
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 47 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 125 amino acids (B) TYPE: amino acids (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 47
<td>Met</td><td>That</td><td>Tyr</td><td>Pro</td><td>Glu</td><td>Thr</td><td>Asp</td><td>Tyr</td><td>Lys</td><td>Asp</td><td colspan="2">Asp Asp</td><td>Asp</td><td>Lys</td><td>Asn</td><td>Cys</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>HiS</td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Lion</td><td>Gir.</td><td>Pro</td><td rowspan="2">Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td>
<td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Ile</td><td>XLE</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Phe</td><td rowspan="2">Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td>
<td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 48 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acids (O) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 48
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Lion</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Ile</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Serum</td><td>Lion</td><td>Asp</td><td>Serum 25</td><td>That</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly lle Glu Ala 50 55 6<sub>0</sub>
RO 118016 Β1
9825
<td>Ile</td><td>Lion</td><td>Arg</td><td>aan</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>For the sake of Allah</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lye</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>read Glu Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td> 110</td><td></td><td></td>
Gin
9830 (2) SEQUENCE INFORMATION ID NO. 49 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 134 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 49
9835
<td>Met</td><td>That</td><td>Pro</td><td>Met</td><td>Thr</td><td>Gin</td><td>Thr</td><td>Thr</td><td>Serum</td><td>Lion</td><td>Lys</td><td>Thr</td><td>To be Trp</td><td>wave</td><td>Asn</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Cys</td><td>Serum</td><td>Asn</td><td>Met</td><td>authorities</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>Thr</td><td>His</td><td>Lion</td><td>Lys Gin</td><td>Pro</td><td>Pro</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Lion</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Phe</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Gly</td><td colspan="2">Glu Asp Gin</td><td>Asp</td><td>Ile</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td>
<td>Lion</td><td>Met</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Arg</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Ala Phe</td><td>Asn</td><td>Arg</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td>
<td>That</td><td>Wave</td><td>Lys</td><td>Serum</td><td>Lion</td><td>Gin</td><td>Asn</td><td>That</td><td>Serum</td><td>That</td><td>Ile</td><td>Glu</td><td>Ser Ile</td><td>Lion</td><td>Lys</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td> 80</td>
<td>Asn</td><td>Lion</td><td>Lion</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Lion</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro Thr</td><td>Arg</td><td>His</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Pro</td><td>Ile</td><td>His</td><td>Ile</td><td>Lys</td><td colspan="2">Asp Gly</td><td>Asp</td><td>Trp</td><td>ASU</td><td>Glu</td><td>Phe</td><td>Arg Arg</td><td>Lys</td><td>Lion</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Lys</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Gin</td><td>That</td><td>Gin Gin</td><td>Thr</td><td>Thr</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td>
9840
9845
9850
9855
Leu Ser Leu Ala Ile Phe 130 (2) SEQUENCE INFORMATION ID NO. 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids (B) TYPE: amino acid
9860
RO 118016 Β1 (DJ TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION; SEQ ID NO: 50
Gly Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Gly 15 10 15
Gly Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser 20 25 30
Gly Gly Gly Ser (2) SEQUENCE INFORMATION ID NO. 51 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 51
Hair Ser Glu Pro Ser Gly Pro Hair Ser Thr Hair Asn Pro Ser Pro Pro 15 10 15
Ser Lys Glu Ser His Lys Ser Pro (2) SEQUENCE INFORMATION ID NO. 52 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 52
Hair Glu Gly Arg Hair Ser Glu Pro Ser Gly Pro Hair Ser Thr Hair Asn 1 5 10 15
Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro
25 (2) SEQUENCE INFORMATION ID NO. 53 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 906 base pairs (B) TYPE: nucleic acid (C) FILLING: double
EN 118016 Β1 (D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ ID NO 53 (2) SEQUENCE INFORMATION ID NO 54
9910
9915
ATOGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAfiAC ACCACCTAAC60
CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC120
CTTCGAACTC CAAACCTGCT COCATTCGTK AGGGCTOTCA AGCACTTAOA AAATGCATCA180
GGTATTGAGe CAATTCTTCG TAATCTCCAA CCATGTCTOC CCTCTCCCAC GGCCGCACCC240
TCTCGACATC CAATCATGAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG300
TTCTATCTGO TTACCCTTGA GCAACCGCAG GAACAACAGT ACGTAATCGA GQGAAQGATT360
TCCCCCGGTG GTGGTTCTGG COGCGGCTCC AACATGGCTA CACCATTAGG CCCTGCCAGC420
TCCCTGCCCC AGAGCTTCCT GCTCAAGTGC TTAGMCAAG TGAGGAAGAT CCAGGGCGAT480
GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAeC TGTQCCAOCC CGAGGAGCTG540
GTGCTGCTCO GACACTCTCT GGGCATCCCC TGGGCTCCCC TOAGCTCCTO CCCCAGCCAG600
GCCCTGCAfiC TGGCAeGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CT & CCAGGGG660
CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAO720
CTGGACGTCG CCGACTTTGC CACCACCATC TRACTGGGAA TGGCCCCTGC CCTGCAGCCC780
ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGCTCCTG840
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG900
CAGCCC906 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 54
9920
9925
9930
9935
9940
9945
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG
ACCACCTAAC
CCTTTGCTGG
ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC
CTTCOAACTC
CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA
100
120
9950
RO 118016 Β1
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT</td><td> 360</td>
<td>TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA ACTGCTCTAT AATGATCGAT</td><td> 420</td>
<td>GAAATTATAC ATCACTTAAA GAGACCACCT AACCCTTTGC TGGACCCGAA CAACCTCAAT</td><td> 480</td>
<td>TCTGAAGACA TGGATATCCT GATGGAACGA AACCTTCGAA CTCCAAACCT GCTCGCATTC</td><td> 540</td>
<td>GTAAGGGCTG TCAAGCACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC</td><td> 600</td>
<td>CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCQAATCAT CATCAAGGCA</td><td> 660</td>
<td>GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TGAGCAAGCG</td><td> 720</td>
<td>CAGGAACAAC AG</td><td> 732</td>
(2) SEQUENCE INFORMATION ID NO. 55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 55
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC 60 CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC 120 CTTCGAACTC CAAACCTCCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCAC CGGCTCGTTC CCCGTCCCCG 420 TCTACCCAGC CGTGAATGCC CGTGGGAACA CTGCTGCTGA AGTAGAGACA ATCCAGGAGG GATGAATGAA CCCGGCGTCT ACAGTAGAAG CCTGAACCTG TGATATCAGA 480 540 CTCCAGGAGC AATGTTTGAC CGACTTGCCT AGCCTCACCA ACAGACCCGC AGCTCAAGGG CTGGAGCTGT CCCCTTGACC ACAAGCAGGG ATGATGGCCA CCTGCGGGGC GCCACTACAA 600 660 CCTCCAACCC GCAGCACTGC CGGAAACTTC AACCTGAAGG CTGTGCAACC ACTTCCTGCT CAGATTATCA TGTCATCCCC CCTTTGAAAG TTTGACTGCT TTTCAAAGAG GGGAGCCAGT 720 777 CCAGGAG
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 56 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) TYPE: Nucleic acid (C) FILLING: double IOOOO (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 56
10005
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TCCCTGCCCC AOAGCTTCCT GCTCAAGTCT TTAGAGCAAG ggcgcagcgc tccaggagaa GCTGTGTGCC ACCTACAAGC GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG GCAGGAGGGG TCCTGGTTGC TAGCCAT CAGG
<td colspan="2">ACTTAAAGAG ACCACCTAAC</td><td colspan="2"> 60</td>
<td>ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td><td></td>
<td>AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td><td></td>
<td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td><td rowspan="2"> 10010</td>
<td colspan="2">AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td colspan="2">ACGTAATCGA GGGAAGGATT</td><td> 360</td><td></td>
<td>CACCKTTGGG</td><td>CCCTGCCAGC</td><td> 420</td><td></td>
<td>TGAGGAAGAT</td><td>CCAGGGCGAT</td><td> 480</td><td> 10015</td>
<td>TGTGCCACCC</td><td>CGAGGAGCTG</td><td> 540</td><td></td>
<td>TGAGCTCCTG</td><td>CCCCAGCCAG</td><td> 600</td><td></td>
<td>GCCTTTTCCT</td><td>CTACCAGGGG</td><td> 660</td><td></td>
<td>CCACCTTGGA</td><td>CACACTGCAG</td><td> 720</td><td> 10020</td>
<td>TGGAAGAACT</td><td>GGGAATGGCC</td><td> 780</td><td></td>
<td>CCTCTGCTTT</td><td>CCAGCGCCGG</td><td> 840</td><td></td>
<td>TGGAGGTGTC</td><td>GTACCGCGTT</td><td> 900</td><td></td>
<td></td><td></td><td> 921</td><td> 10025</td>
(2) SEQUENCE INFORMATION ID NO. 57 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH; 951 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULATION: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 57
10035
RO 118016 Β1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC 60 CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC 120 CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CAGTACCACC AGGTGAAGAT 420 TCCAAAGATG ACACAGACAG TGGCCGCCCC ACATCCTCGA CCACTCACCT CGGGATATCA CAAATTCGGT CTTCAGAACG GCCCTGAGAA AATTGACAAA AGGAGACATG 480 540 AACATGTGTG TAACAAGAGT AAAGCAGCAA GCTGAAAAAG AGAGGCGCTA ATGGATGCTT GCAGAAAACA CCAATCCGGA ACCTGAACCT TTCAATGAGG TCCAAAGATG AGACTTGCCT 600 660 ATCACTGGTC GGTGAAAATC TTTTGGAGTT AGTGAGGAAC TGAGGTATAC AAGCCAGAGC CTCGAGTACC TGTGCAGATG TCCAGAACAG TCGACAAAAG ATTTGAGAGT TCCTGATCCA 720 780 GTTCCTGCAG TCCATCCCTG AAAAAGGCAA 840 CAACCACAAA ACCCCTGACC AGAATCTAGA CTGACGAAGC TGCAATAACC TGCAGGCACA GAACCAGTGG CTGCAGGACA TGACAACTCA TCTCATTCTG 900 CGCAGCTTTA AGGAGTTCCT GCAGTCCAGC CTGAGGGCTC TTCGGCAAAT G 951 (2) SEQUENCE INFORMATION ID NO. 58 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 58
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td><td>ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATTCT</td><td>GAAGACATGG</td><td>ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC</td><td>CAAACCTGCT</td><td>CGCATTCGTA</td><td>AGGGCTGTCA</td><td>AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>GCAAGCGCAG</td><td>GAACAACAGT</td><td>ACGTAATCGA</td><td>GGGAAAGATT</td><td> 360</td>
<td>TCCCCGGGTG</td><td>GTGGTTCTGG</td><td>CGGCGGCTCC</td><td>AACATGGCTA</td><td>ACTGCTCTAT</td><td>AATGATCGAT</td><td> 420</td>
RO 118016 Β1
QAAATTATAC ATCACTTAAA GAGACCACCT AACCCTTTGC TCTGAAGACA TGGATATCCT GATGGAACGA AACCTTCGAA CTAAGGGCTG TCMGCACTT AGAAAATGCA TCAGGTATTG CAACCATGTC TGCCCTCTGC CACGGCCGACGTC CCTC
<td>TGGACCCGAA CAACCTCAAT</td><td> 480</td><td> 10080</td>
<td>CTCCAAACCT GCTCGCATTC</td><td> 540</td><td></td>
<td>AGGCAATTCT TCGTAATCTC</td><td> 600</td><td></td>
<td>ATCCAATCAT CATCAAGGCA</td><td> 660</td><td></td>
<td></td><td></td><td> 10085</td>
<td>TGGTTACCCT TGAGCAAGCG</td><td> 720</td><td></td>
<td></td><td> 732</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 59
<td>li)</td><td>SEQUENCE CHARACTERISTICS:</td><td> 10090</td>
<td>(I <)</td><td>(A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY; linear MOLECULE TYPE: DNA (genome)</td><td></td>
<td>(Xi)</td><td>SEQUENCE DESCRIPTION: SEQ. ID NO. 59</td><td> 10095</td>
ATGGCTAACT
GCTCTATAAT
GATCGATGAA
ATTATACATC
ACTTAAAGAG
ACCACCTAAC
CCTTTGCTGG
ACCCGAACAA
CCTCAATTCT
GAAGACATGG
ATATCCTGAT
GGAACGAAAC
120
10100
CTTCGAACTC
CAAACCTGCT
CGCATTCGTA
AGGGCTGTCA
AGCACTTAGA
ÂAATGCATCA
180
GGTATTGAGG
CAATTCTTCG
TAATCTCCAA
CCATGTCTGC
CCTCTGCCAC
GGCCGCACCC
240
TCTCGACATC
CAATCATCAT
CAAGGCAGGT
GACTGGCAAG
AATTCCGGGA
AAAACTGACG
300
TTCTATCTGG
TTACCCTTGA
GCAAGCGCAG
GAACAACAGT
ACGTAATCGA
GGGAAAGATT
360
10105
TCCCCGGGTG
GTGGTTCTGG
CGGCGGCTCC
AACATGGCTA
CACCATTGGG
CCCTGCCAGC
420
TCCCTGCCCC
AGAGCTTCCT
GCTCAAGTCT
TTAGAGCAAG
TGAGGAAGAT
CCAGGGCGAT
480
GGCGCAGCGC
TCCAGGAGAA
GCTGTGTGCC
ACCTACAAGC
TGTGCCACCC
CGAGGAGCTG
540
GTGCTGCTCG GACACTCTCT
GGGCATCCCC
TGGGCTCCCC
TGAGCTCCTG
CCCCAGCCAG
600
10110
GCCCTGCAGC
TGGCAGGCTG
CTTGAGCCAA
CTCCATAGCG
GCCTTTTCCT
CTACCAGGGG
660
CTCCTGCAGG
CCCTGGAAGG
GATATCCCCC
GAGTTGGGTC
CCACCTTGGA
CACACTGCAG
720
CTGGACGTCG
CCGACTTTGC
CACCACCATC
TGGCAGCAGA
TGGAAGAACT
GGGAATGGCC
780
CCTGCCCTGC
AGCCCACCCA
GGGTGCCATG
CCGGCCTTCG
CCTCTGCTTT
CCAGCGCCGG
840
10115
GCAGGAGGGG
TCCTGGTTGC
TAGCCATCTG
CAGAGCTTCC
TGGAGGTGTC
GTACCGCGTT
900
CTACGCCACC
TTGCGCAGCC
921 (2) SEQUENCE INFORMATION ID NO. 60
10120
EN 118016 Β1 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH; 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULATION: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 60
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC60
CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC120
CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA180
GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC240
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG300
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC360
TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CACCATTGGG CCCTGCCAGC420
TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT480
GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG540
GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG600
GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG660
CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG720
CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC780
CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG840
GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT900
CTACGCCACC TTGCGCAGCC C921 (2) SEQUENCE INFORMATION ID NO. 61 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 61
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC
RO 118016 Β1
CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC120
CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA180
GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC240
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG300
TTCTATCTGG TTACCCTTGA GCAAGCGCAO GAACAACAGT ACGTACAGGG CGGTGGAGGC360
TCOCCGGGTG GTGGTXCTGG CGGCGGCTCC AACATGGCTA ACTGCTCTAT AATGATCGAT420
GAAATTATAC ATCACTTAAA GAGACCACCT AACCCTTTGC TGGACCCGAA CAACCTCAAT480
TCTGAAGACA TGGATATCCT GATGGAACGA AACCTTCGAA CTCCAAACCT GCTCGCATTC540
GTAAGGGCTG TCAAGCACTT AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC600
CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CATCAAGGCA660
GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TGAGCAAGCG720
CAGGAACAAC AG732 (2) SEQUENCE INFORMATION ID NO. 62 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. S2
10165
10170
10175
10180
10185
10190
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td><td>ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATTCT</td><td>GAAGACATGG</td><td>ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC</td><td>CAAACCTGCT</td><td>CGCATTCGTA</td><td>AGGGCTGTCA</td><td>AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>GCAAGCGCAG</td><td>GAACAACAGT</td><td>ACGTAATCGA</td><td>GGGAAGGATT</td><td> 360</td>
<td>TCCCCGGGTG</td><td>AACCGTCTGG</td><td>TCCAATCTCT</td><td>ACTATCAACC</td><td>CGTCTCCTCC</td><td>GTCTAAAGAA</td><td> 420</td>
<td>TCTCATAAAT</td><td>CTCCAAACAT</td><td>GGCTAACTGC</td><td>TCTATAATGA</td><td>TCGATGAAAT</td><td>TATACATCAC</td><td> 480</td>
<td>TTAAAGAGAC</td><td>CACCTAACCC</td><td>TTTGCTGGAC</td><td>CCGAACAACC</td><td>TCAATTCTGA</td><td>AGACATGGAT</td><td> 540</td>
<td>ATCCTGATGG</td><td>AACGAAACCT</td><td>TCGAACTCCA</td><td>AACCTGCTCG</td><td>CATTCGTAAG</td><td>GGCTGTCAAG</td><td> 600</td>
<td>CACTTAGAAA</td><td>ATGCATCAGG</td><td>TATTGAGGCA</td><td>ATTCTTCGTA</td><td>ATCTCCAACC</td><td>ATGTCTGCCC</td><td> 660</td>
10195
10200
RO 118016 Β1
TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA AGGCAGGTGA CTGGCAAGAA
TTCCGGGAAA AACTGACGTT CTATCTGGTT ACCCTTGAGC AAGCGCAGGA ACAACAG
720
777 (2) SEQUENCE INFORMATION ID NO. 63 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (iii TYPE OF MOLECULE: DNA (genomic) (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 63
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG</td><td>ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA</td><td>GGGAAAGATT</td><td> 360</td>
<td>TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC</td><td>GTCTAAAGAA</td><td> 420</td>
<td>TCTCATAAAT CTCCAAACAT GGCTAACTGC TCTATAATGA TCGATGAAAT</td><td>TATACATCAC</td><td> 480</td>
<td>TTAAAGAGAC CACCTAACCC TTTGCTGGAC CCGAACAACC TCAATTCTGA</td><td>AGACATGGAT</td><td> 540</td>
<td>ATCCTGATGG AACGAAACCT TCGAACTCCA AACCTGCTCG CATTCGTAAG</td><td>GGCTGTCAAC</td><td> 600</td>
<td>CACTTAGAAA ATGCATCAGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC</td><td>ATGTCTGCCC</td><td> 660</td>
<td>TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA AGGCAGGTGA</td><td>CTGGCAAGAA</td><td> 720</td>
<td>TTCCGGGAAA AACTGACGTT CTATCTGGTT ACCCTTGAGC AAGCGCAGGA</td><td>ACAACAG</td><td> 777</td>
(21 SEQUENCE INFORMATION ID NO. 64 (ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi] SEQUENCE DESCRIPTION: SEQ ID NO: 64
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC
RO 118016 Β1
CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAAOGAAAC120
CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA180
GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC240
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG300
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC360
TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA420
TCTCATAAAT CTCCAAACAT GGCTAACTGC TCTATAATGA TCGATGAAAT TAXACATCAC480
TTAAAGAGAC CACCTAACCC TTTGCTGGAC CCGAACAACC TCAATTCTGA AGACATGGAT540
ATCCTGATGG AACGAAACCT TCGAACTCCA AACCTGCTOG CATTCGTAAG GGCTGTCAAG600
CACTTAGAAA AXGCASCMGG TATTGAGGCA ATTCTTCGTA ATCTCCAACC AXGTCTGCCC660
TCTGCCACGG CCGCACCCTC TCGACATCCA ATCATCATCA AGGCA0GXGA CTGGCAAGAA720
TTCCGGGAAA AACTGACGTT CTATCTGGTT ACCCTTGAGC AAGCGCAGGA ACAACAG777 (2) SEQUENCE INFORMATION ID NO. 65 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (C) FILLING: double (Mr. TOPOLOGY: linear (ii) MOLECULB TYPE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65
10250
10255
10260
10265
10270
<td>atggctaacx</td><td>GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC</td><td>CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT</td><td> 360</td>
<td>TCCCCCGGGC</td><td>CTCCTGTCAA TGCTGGCGGC GGCTCTGGTG GTGGTTCTGG TGGCGGCTCT</td><td> 420</td>
<td>GAGGGTGGCG</td><td>GCTCTGAGGG TGGCGGTTCT GAGGGTGGCG GCTCTGAGGG TGGCGGTTCC</td><td> 480</td>
<td>ggtggcggct</td><td>CCGGTTCCGG TGATTTTGAT TATGAAAACA TGGCTACACC ATTGGGCCCT</td><td> 540</td>
<td>GCCAGCTCCC</td><td>TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG GAAGATCCAG</td><td> 600</td>
<td>GGCGATGGCG</td><td>CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG</td><td> 660</td>
10275
10280
10285
RO 118016 Β1
GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 960 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 1020 CGCGTTCTAC GCCACCTTGC GCAGCCC 1047 (2) INFORMATION FOR THE SEQUENCE ID NO. 66 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 903 base pairs (B) ΊΊΡ: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 66
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC60
CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC120
CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA180
GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC240
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG300
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT360
TCCCCCGGGC CTCCTGTCAA TGCTGGCGGC GGCTCTGGTG GTGGTTCTGG TGGCGGCTCT420
GAGGGTGGCG GCTCTGAGGG TGGCGGTTCT GAGGGTGGCG GCTCTGAGGG TGGCGGTTCC480
GGTGGCGGCT CCGGTTCCGG TGATTTTGAT TATGAAAACA TGGCACCGGC TCGTTCCCCG540
TCCCCGTCTA CCCAGCCGTG GGAACACGTG AATGCCATCC AGGAGGCCCG GCGTCTCCTG600
AACCTGAGTA GAGACACTGC TGCTGAGATG AATGAAACAG TAGAAGTGAT ATCAGAAATG660
TTTGACCTCC AGGAGCCGAC TTGCCTACAG ACCCGCCTGG AGCTGTACAA GCAGGGCCTG720
CGGGGCAGCC TCACCAAGCT CAAGGGCCCC TTGACCATGA TGGCCAGCCA CTACAAGCAG780
CACTGCCCTC CAACCCCGGA AACTTCCTGT GCAACCCAGA TTATCACCTT TGAAAGTTTC840
AAAGAGAACC TGAAGGACTT CCTGCTTGTC ATCCCCTTTG ACTGCTGGGA GCCAGTCCAG900
GAG
903
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 67
10330 (I)
SEQUENCE CHARACTERISTICS:
(A B C D)
MOLECULE TYPE: DNA (genome)
LENGTH: 1017 base pairs TYPE: Nucleic acid FILLING: double TOPOLOGY: linear
10335 (Xi)
SEQUENCE DESCRIPTION: SEQ. ID NO. 67
ATGGCTAACT
GCrCrMMT GATCGATGAA
ATTATACKTC ACTTAAAGAG ACCACCTAAC
10340
CCTTTGCTGG
ACCCGAACAA CCTCAATTCT
GAAGACATGG ATATCCTGAT GGAACGAAAC
120
CTTCGAACTC aUkACCTGCT
CGCATTCGTA
AGGGCTGTCA AGCACTTAGA AAATGCATCA
180
GGTATTGAGG
CAATTCTTCG
TAATCTCCAA
CCXTGTCTGC
CCTCTGCCAC GGCCGCACCC
240
TCTOGACATC
CAATCAICAT
CAAGGCAQGT
GACTQGCMG
AATTCOGGGA AAAACTOACG
300
10345
TTCTATCTGG
TTACCCTTGA
OCMOCOCAC
GMCMCAGT
ACGTAATCGA GGGAAGGATT
360
TCCCCCGGTG
GCGGCGGCTC
TGGTQGTGGT
TCTGGTGGCG
GCTCIGAGGG
TGGCGGCTCT
420
GAGGGTGGCG
GTTCTGAGGG
TGGCGGCTCT
GAGGGTGGCG
GTTCCGGTGG
CGGCTCCGGT
480
TCCGGTAACA
TGGCTACACC
ATTMGCCCT
GCCAGCTCCC
TGCCCCAGAG
CTTCCTGCTC
540
10350
AAGTGCTTM
AGCAAGTGAG
GAAGATCCAG
GGCGATGGCG
CAGCGCTCCA
GGAGAAGCTG
600
TGTGCCACCT ACAAGCTGTG
CCACCCCGAG
GAGCTGGTGC
TGCTCGGACA
CTCTCTGGGC
660
ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC
AGGCTGCTTG
720
AGCCAACTCC ATAfiCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT
GGAAGGGATA
780
10355
TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA
CTTTGCCACC
840
ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC
CACCCAGGGT
900
GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT
GGTTGCTAGC
960
10360
CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC
GCAGCCC
1017 (2) SEQUENCE INFORMATION ID NO. 68 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 68
10365
10370
RO 118016 Β1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC 60 CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC 120 CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT 360 TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC OGTCTCCTCC GTCTAAAGAA 420 TCTCATAAAT CTCCAAACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 480 TTCCTGCTCA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG AGTGCTTAGA GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG 540 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC 600 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT 660 TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT 720 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 780 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC 840 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 900 GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 960 CAGCCC 966 (2) INFORMATION FOR SECURITY NO. 69 [i] SEQUENCE FEATURES:
(A) LENGTH: 822 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 69
ATGGCTAACT GCTCTATAAT GATCGATGAA CCTTTGCTGG ACCCGAACAA CCTCAATTCT CTTCGAACTC CAAACCTGCT CGCATTCGTA GGTATTGAGG CAATTCTTCG TAATCTCCAA TCTCGACATC CAATCATCAT CAAGGCAGGT
ATTATACATC ACTTAAAGAG ACCACCTAAC60
GAAGACATGG ATATCCTGAT GGAACGAAAC120
AGGGCTGTCA AGCACTTAGA AAATGCATCA180
CCATGTCTGC CCTCTGCCAC GGCCGCACCC240
GACTGGCAAG AATTCCGGGA AAAACTGACG300
RO 118016 Β1
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC
TCTCATAAAT CTCCAAACAT GGCACCGGCT CGTTCCCCGT CCCCGTCTAC
GAACACGTGA ATGCCATCCA GGAGGCCCGG CGTCTCCTGA ACCTGAGTAG
GCTGAGATGA ATGAAACAGT AGAAGTGATA TCAGAAATGT TTGACCTCCA
TGCCTACAGA CCCGCCTGGA GCTGTACAAG CAGGGCCTGC GGGGCAGCCT
AAGGGCCCCT TGACCATGAT GGCCAGCCAC TACAAGCAGC ACTGCCCTCC
ACTTCCTGTG CAACCCAGAT TATCACCTTT GAAAGTTTCA AAGAGAACCT
10425
CTGCTTGTCA TCCCCTTTGA CTGCTGGGAG CCAGTCCAGG AG 822 (2) SEQUENCE INFORMATION ID NO. 70 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs 10430 (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 70 10435
<td>GGGAAGGATT</td><td> 360</td><td> 10415</td>
<td>GTCTAAAGAA</td><td> 420</td><td></td>
<td>CCAGCCGTGG</td><td> 480</td><td></td>
<td>AGACACTGCT</td><td> 540</td><td></td>
<td></td><td></td><td> 10420</td>
<td>GGAGCCGACT</td><td> 600</td><td></td>
<td>CACCAAGCTC</td><td> 660</td><td></td>
<td>AACCCCGGAA</td><td> 720</td><td></td>
<td>GAAGGACTTC</td><td> 780</td><td></td>
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA</td><td> 180 10440</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAAGATT</td><td> 360</td>
<td>TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA</td><td><sup>420</sup> 10445</td>
<td>TCTCATAAAT CTCCAAACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC</td><td> 480</td>
<td>TTCCTGCTCA AGTGCTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG</td><td> 540</td>
<td>GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC</td><td> 600</td>
<td>TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA</td><td> 660 10450</td>
<td>GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG</td><td> 720</td>
<td>GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC</td><td> 780</td>
<td>TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC</td><td> 840</td>
RO 118016 Β1
ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG
GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG
CAGCCC
900
960
966 (2) SEQUENCE INFORMATION ID NO. 71 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 71
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td><td>ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATTCT</td><td>GAAGACATGG</td><td>ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC</td><td>CAAACCTGCT</td><td>CGCATTCGTA</td><td>AGGGCTGTCA</td><td>AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>GCAAGCGCAG</td><td>GAACAACAGT</td><td>ACGTAGAGGG</td><td>CGGTGGAGGC</td><td> 360</td>
<td>TCCCCGGGTG</td><td>AACCGTCTGG</td><td>TCCAATCTCT</td><td>ACTATCAACC</td><td>CGTCTCCTCC</td><td>GTCTAAAGAA</td><td> 420</td>
<td>TCTCATAAAT</td><td>CTCCAAACAT</td><td>GGCTACACCA</td><td>TTAGGCCCTG</td><td>CCAGCTCCCT</td><td>GCCCCAGAGC</td><td> 480</td>
<td>TTCCTGCTCA</td><td>AGTGCTTAGA</td><td>GCAAGTGAGG</td><td>AAGATCCAGG</td><td>GCGATGGCGC</td><td>AGCGCTCCAG</td><td> 540</td>
<td>GAGAAGCTGT</td><td>GTGCCACCTA</td><td>CAAGCTGTGC</td><td>CACCCCGAGG</td><td>AGCTGGTGCT</td><td>GCTCGGACAC</td><td> 600</td>
<td>TCTCTGGGCA</td><td>TCCCCTGGGC</td><td>TCCCCTGAGC</td><td>TCCTGCCCCA</td><td>GCCAGGCCCT</td><td>GCAGCTGGCA</td><td> 660</td>
<td>GGCTGCTTGA</td><td>GCCAACTCCA</td><td>TAGCGGCCTT</td><td>TTCCTCTACC</td><td>AGGGGCTCCT</td><td>GCAGGCCCTG</td><td> 720</td>
<td>GAAGGGATAT</td><td>CCCCCGAGTT</td><td>GGGTCCCACC</td><td>TTGGACACAC</td><td>TGCAGCTGGA</td><td>CGTCGCCGAC</td><td> 780</td>
<td>TTTGCCACCA</td><td>CCATCTGGCA</td><td>GCAGATGGAA</td><td>GAACTGGGAA</td><td>TGGCCCCTGC</td><td>CCTGCAGCCC</td><td> 840</td>
<td>ACCCAGGGTG</td><td>CCATGCCGGC</td><td>CTTCGCCTCT</td><td>GCTTTCCAGC</td><td>GCCGGGCAGG</td><td>AGGGGTCCTG</td><td> 900</td>
<td>GTTGCTAGCC</td><td>ATCTGCAGAG</td><td>CTTCCTGGAG</td><td>GTGTCGTACC</td><td>GCGTTCTACG</td><td>CCACCTTGCG</td><td> 960</td>
CAGCCC
966 (2) SEQUENCE INFORMATION ID NO. 72 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double
EN 118016 Β1 (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 72
10500
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA 60 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAATCGAG 540 GGAAGGATTT TGGTTCTGGC GGCGGCTCCA ACATGGCTAA CTGCTCTATA CCCCGGGTGG 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG CAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921
10505
10510
10515
10520 (2) SEQUENCE INFORMATION ID NO. 73 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double (DJ TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73
10525
10530
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT
CAAGTGCTTA
10535
GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC
120
TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG
CATCCCCTGG
180
RO 118016 Β1
<td>GCTCCCCTGA</td><td>GCTCCTGCCC</td><td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td> 240</td>
<td>CATAGCGGCC</td><td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td><td> 300</td>
<td>TTGGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td><td>CACCATCTGG</td><td> 360</td>
<td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td><td>CCACCCAGGG</td><td>TGCCATGCCG</td><td> 420</td>
<td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td><td>GGAGGGGTCC</td><td>tggttgctag</td><td>CCATCTGCAG</td><td> 480</td>
<td>AGCTTCCTGG</td><td>AGGTGTCGTA</td><td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTA</td><td>CGTAATCGAG</td><td> 540</td>
<td>GGAAGGATTT</td><td>CCCCGGGTGA</td><td>ACCGTCTGGT</td><td>CCAATCTCTA</td><td>CTATCAACCC</td><td>GTCTCCTCCG</td><td> 600</td>
<td>TCTAAAGAAT</td><td>CTCATAAATC</td><td>TCCAAACATG</td><td>GCTAACTGCT</td><td>CTATAATGAT</td><td>CGATGAAATT</td><td> 660</td>
<td>ATACATCACT</td><td>TAAAGAGACC</td><td>ACCTAACCCT</td><td>TTGCTGGACC</td><td>CGAACAACCT</td><td>CAATTCTGAA</td><td> 720</td>
<td>GACATGGATA</td><td>TCCTGATGGA</td><td>ACGAAACCTT</td><td>CGAACTCCAA</td><td>ACCTGCTCGC</td><td>ATTCGTAAGG</td><td> 780</td>
<td>GCTGTCAAGC</td><td>ACTTAGAAAA</td><td>TGCATCAGGT</td><td>ATTGAGGCAA</td><td>TTCTTCGTAA</td><td>TCTCCAACCA</td><td> 840</td>
<td>TGTCTGCCCT</td><td>CTGCCACGGC</td><td>CGCACCCTCT</td><td>CGACATCCAA</td><td>TCATCATCAA</td><td>GGCAGGTGAC</td><td> 900</td>
<td>TGGCAAGAAT</td><td>TCCGGGAAAA</td><td>ACTGACGTTC</td><td>TATCTGGTTA</td><td>CCCTTGAGCA</td><td>AGCGCAGGAA</td><td> 960</td>
CAACAG 966 (2) SEQUENCE INFORMATION ID NO. 74 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (CJ FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74
<td>ATGGCTACAC</td><td>CATTAGGCCC</td><td>TGCCAGCTCC</td><td>CTGCCCCAGA</td><td>GCTTCCTGCT</td><td>CAAGTGCTTA</td><td> 60</td>
<td>GAGCAAGTGA</td><td>GGAAGATCCA</td><td>GGGCGATGGC</td><td>GCAGCGCTCC</td><td>AGGAGAAGCT</td><td>GTGTGCCACC</td><td> 120</td>
<td>TACAAGCTGT</td><td>GCCACCCCGA</td><td>GGAGCTGGTG</td><td>CTGCTCGGAC</td><td>ACTCTCTGGG</td><td>CATCCCCTGG</td><td> 180</td>
<td>GCTCCCCTGA</td><td>GCTCCTGCCC</td><td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td> 240</td>
<td>CATAGCGGCC</td><td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td><td> 300</td>
<td>TTGGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td><td>CACCATCTGG</td><td> 360</td>
<td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td><td>CCACCCAGGG</td><td>TGCCATGCCG</td><td> 420</td>
<td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td><td>GGAGGGGTCC</td><td>TGGTTGCTAG</td><td>CCATCTGCAG</td><td> 480</td>
<td>AGCTTCCTGG</td><td>AGGTGTCGTA</td><td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTA</td><td>CGTAATCGAG</td><td> 540</td>
RO 118016 Β1
GGAAGGATTT CCCCCGGGCC TCCTGTCAAT GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT600
GGCGGCTCTG AGGGTGGCGG CTCTGAGGGT GGCGGTTCTG AGGGTGGCGG CTCTGAGGGT660
GGCGGTTCCG GTGGCGGCTC CGGTTCCGGT GATTTTGATT ATGAAAACAT GGCTAACTGC720
TCTATAATGA TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTAACCC TTTGCTGGAC780
CCGAACAACC TCAATTCTGA AGACATGGAT ATCCTGATGG AAOGAAACCT TCGAACTCCA840
AACCTGCTCG CATTCGTAAG GGCTGTCAAG CACTTAGAAA ATGCATCAGG TATTGAGGCA900
ATTCTTCGTA ATCTCCAACC ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA960
ATCATCATCA AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT1020
ACCCTTGAGC AAGCGCAGGA ACAACAG1047
10580
10585
10590 (2) SEQUENCE INFORMATION ID NO. 75 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) ΊΊΡ: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION; SEQ. ID NO. 75
10595
10600
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA60
GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC120
TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG180
GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC240
CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAQGCCC TGGAAGGGAT ATCCCCCGAG300
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG360
CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG420
GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG480
AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAATCGAG540
GGAAGGATTT CCCCGGGTGG TGGTTCTGGC GGCGGCTCCA ACATGGCTAA CTGCTCTATA600
ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG CACCTTTGCT GGACCCGAAC660
AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGAACGAA ACCTTCGACT TCCAAACCTG720
GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT780
CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC840
10605
10610
10615
RO 118016 Β1
ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT
GAGCAAGCGC AGGAACAACA G
900
921 (2) SEQUENCE INFORMATION ID NO. 76 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1047 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (iij. TYPE OF MOLECULE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA60
GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC120
TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG180
GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC240
CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG300
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG360
CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCOG420
GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG480
AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAATCGAG540
GGAAGGATTT CCCCCGGGCC TCCTGTCAAT GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT600
GGCGGCTCTG AGGGTGGCGG CTCTGAGGGT GGCGGTTCTG AGGGTGGCGG CTCTGAGGGT660
GGCGGTTCCG GTGGCGGCTC CGGTTCCGGT GATTTTGATT ATGAAAACAT GGCTAACTGC720
TCTATAATGA TCGATGAAAT TATACATCAC TTAAAGAGAC CACCTGCACC TTTGCTGGAC780
CCGAACAACC TCAATGACGA AGACGTCTCT ATCCTGATGG AACGAAACCT TCGACTTCCA840
AACCTGGAGA GCTTCGTAAG GGCTGTCAAG AACTTAGAAA ATGCATCAGG TATTGAGGCA900
ATTCTTCGTA ATCTCCAACC ATGTCTGCCC TCTGCCACGG CCGCACCCTC TCGACATCCA960
ATCATCATCA AGGCAGGTGA CTGGCAAGAA TTCCGGGAAA AACTGACGTT CTATCTGGTT1020
ACCCTTGAGC AAGCGCAGGA ACAACAG1047 (2) SEQUENCE INFORMATION ID NO. 77 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double
EN 118016 Β1 (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 77
10665
10670
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA 60 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120 TACMOCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240 CATAGCGGCC TTTTCCTCTA CCACGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAATCGAG 540 GGAAGGATTT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG 600 TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT CGATGAAATT 660 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA 720 GACGTCTCTA TCCTGATGGA ACGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 780 GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 840 TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC 900 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 960 CAACAG 966
10675
10680
10685
10690 (2) SEQUENCE INFORMATION ID NO. 78 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 78
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA 60
GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120
10695
10700
10705
RO 118016 Β1
<td>TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG</td><td>CATCCCCTGG</td><td> 180</td>
<td>GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT</td><td>GAGCCAACTC</td><td> 240</td>
<td>CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT</td><td>ATCCCCCGAG</td><td> 300</td>
<td>TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC</td><td>CACCATCTGG</td><td> 360</td>
<td>CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG</td><td>TGCCATGCCG</td><td> 420</td>
<td>GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG</td><td>CCATCTGCAG</td><td> 480</td>
<td>AGCTTCCTGG AGGTCTOGTA CCGCGTTCTA OGCCACCTTO CGCAGCCCTA</td><td>CGTAGAGGGC</td><td> 540</td>
<td>ggtggaggct ccccgggtgg tggttctggc GGCGGCTCCA ACATGGCTAA</td><td>CTGCTCTATA</td><td> 600</td>
<td>ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG CACCTTTGCT</td><td>GGACCCGAAC</td><td> 660</td>
<td>AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGAACGAA ACCTTCGACT</td><td>TCCAAACCTG</td><td> 720</td>
<td>GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA</td><td>GGCAATTCTT</td><td> 780</td>
<td>CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA</td><td>TCCAATCATC</td><td> 840</td>
<td>ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT</td><td>GGTTACCCTT</td><td> 900</td>
<td>GAGCAAGCGC AGGAACAACA G</td><td></td><td> 921</td>
(2) SEQUENCE INFORMATION ID NO. 79 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 79
<td>ATGGCTACAC</td><td>CATTAGGCCC</td><td>TGCCAGCTCC</td><td>CTGCCCCAGA</td><td>GCTTCCTGCT</td><td>CAAGTGCTTA</td><td> 60</td>
<td>GAGCAAGTGA</td><td>GGAAGATCCA</td><td>GGGCGATGGC</td><td>GCAGCGCTCC</td><td>AGGAGAAGCT</td><td>GTGTGCCACC</td><td> 120</td>
<td>TACAAGCTGT</td><td>GCCACCCCGA</td><td>GGAGCTGGTG</td><td>CTGCTCGGAC</td><td>ACTCTCTGGG</td><td>CATCCCCTGG</td><td> 180</td>
<td>GCTCCCCTGA</td><td>GCTCCTGCCC</td><td>CAGCCAGGCC</td><td>CTGCAGCTGG</td><td>CAGGCTGCTT</td><td>GAGCCAACTC</td><td> 240</td>
<td>CATAGCGGCC</td><td>TTTTCCTCTA</td><td>CCAGGGGCTC</td><td>CTGCAGGCCC</td><td>TGGAAGGGAT</td><td>ATCCCCCGAG</td><td> 300</td>
<td>TTGGGTCCCA</td><td>CCTTGGACAC</td><td>ACTGCAGCTG</td><td>GACGTCGCCG</td><td>ACTTTGCCAC</td><td>CACCATCTGG</td><td> 360</td>
<td>CAGCAGATGG</td><td>AAGAACTGGG</td><td>AATGGCCCCT</td><td>GCCCTGCAGC</td><td>CCACCCAGGG</td><td>TGCCATGCCG</td><td> 420</td>
<td>GCCTTCGCCT</td><td>CTGCTTTCCA</td><td>GCGCCGGGCA</td><td>GGAGGGGTCC</td><td>TGGTTGCTAG</td><td>CCATCTGCAG</td><td> 480</td>
<td>AGCTTCCTGG</td><td>AGGTGTCGTA</td><td>CCGCGTTCTA</td><td>CGCCACCTTG</td><td>CGCAGCCCTA</td><td>CGTAGAGGGC</td><td> 540</td>
RO 118016 Β1
GGTGGAGGCT CCCCGGGTGA ACCGTCTGOT CCAATCTCTA TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC GACGTCTCTA TCCTGATGGA ACGAAACCTT CGACTTCCAA GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TGGCAAGAAT TCCGGGAAAA ACTQACGTTC TATCTGGTTA
<td>CTATCAACCC GTCTCCTCCG</td><td> 600</td><td> 10750</td>
<td>CTATAATGAT CGATGAAATT</td><td> 660</td><td></td>
<td>CGAACAACCT CAATGACQAA</td><td> 720</td><td></td>
<td>ACCTGGAQAG CTTCGTAAGG</td><td> 780</td><td> 10755</td>
<td>TTCTTCGTAA TCTCCAACCA</td><td> 840</td><td></td>
<td>TCATCATCAA GGCAGGTGAC</td><td> 900</td><td></td>
<td>CCCTTGAGCA AGCGCAGGAA</td><td> 960</td><td></td>
<sup>966</sup> 10760
CAACAG (2) SEQUENCE INFORMATION ID NO. 80 (i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 921 base pairs (8) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome)
10765 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 80
ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GAGCAAGTGA GGAAGATCCA GGGCGAXGGC GCAGCGCTCC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG catagcggcc ttttcctcta ccaggggctc ctgcaggccc TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC AGCTTCCTGG AGGTGTCGTA COGCGTTCTA CGCCACCTTG GGTGGAGGCT CCCCGGGTGG TGGTTCTGGC GGCGGCTCCA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGAACGAA GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA
10770
GCTTCCTGCT CAAGTCTTTA 60
AGGAGAAGCTGTGTGCCACC 120
<td>ACTCTCTGGG CATCCCCTGG</td><td> 180</td>
<td>CAGGCTGCTT GAGCCAACTC</td><td> 240 10775</td>
<td>TGGAAGGGAT ATCCCCCGAfi</td><td> 300</td>
<td>ACTTTGCCAC CACCATCTGG</td><td> 360</td>
CCACCCAGGG TGCCATGCCG 420
<td></td><td></td><td> 10780</td>
<td>TGGTTGCTAG CCATCTGCAG</td><td> 480</td><td></td>
<td>CGCAGCCCTA CGTAGAGGGC</td><td> 540</td><td></td>
<td>ACATGGCTAA CTGCTCTATA</td><td> 600</td><td></td>
<td>CACCTTTGCT GGACCCGAAC</td><td> 660</td><td> 10785</td>
<td>ACCTTCGACT TCCAAACCTG</td><td> 720</td><td></td>
<td>CAGGTATTGA GGCAATTCTT</td><td> 780</td><td></td>
<td>CCTCTCGACA TCCAATCATC</td><td> 840</td><td></td>
<td>CGTTCTATCT GGTTACCCTT</td><td> 900</td><td> 10790</td>
RO 118016 Β1
GAGCAAGCGC AGGAACAACA G
921 (2) SEQUENCE INFORMATION ID NO 81 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 81
ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 60 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTA CGTAGAGGGC 540 GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG 600 TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT CGATGAAATT 660 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA 720 GACGTCTCTA TCCTGATGGA ACGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 780 GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 840 TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC 900 TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 960 CAACAG 966 (2) SEQUENCE INFORMATION ID NO. 82 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 82
RO 118016 Β1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA
CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGAACGAAAC
120
10840
CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA
180
GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC
240
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG
300
TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT
360
10845
TCCCCGGGTG
AACCGTCTGG TCCAATCTCT ACTATCAACC
GTCTAAAGAA
420
TCTCATAAAT CTCCAAACAT GGCTAACTGC TCTATAATGA TCGATGAAAT TATACATCAC
480
TTAAAGAGAC CACCTGCACC TTTGCTGGAC CCGAACAACC TCAATGACGA AGACGTCTCT
540
ATCCTGATGG AACGAAACCT TCGACTTCCA AACCTGGAGA GCTTCGTAAG GGCTGTCAAG
600
10850
AACTTAGAAA ATGCATCAGG
TATTGAGGCA ATTCTTCGTA ATCTCCAACC ATGTCTGCCC
660
TCTGCCACGG
CCGCACCCTC TCGACATCCA ATCATCATCA AGGCAGGTGA CTGGCAAGAA
720
TTCCGGGAAA AACTGACGTT CTATCTGGTT ACCCTTGAGC AAGCGCAGGA ACAACAG
777
10855 (2) SEQUENCE INFORMATION ID NO. 83 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 984 base pairs (B) TYPE: Nucleic acid (C) FILLING: double (DJ TOP OLOGIE: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83
10860
10865
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGAACGAAAC</td><td> 120</td>
<td>CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT</td><td> 360</td>
<td>TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA</td><td> 420</td>
<td>TCTCATAAAT CTCCAAACAT GGCTACACCA TTGGGCCCTG CCAGCTCCCT GCCCCAGAGC</td><td> 480</td>
10870
10875
RO 118016 Β1
<td>TTCCTGCTCA</td><td>agtctttaga</td><td>GCAAGTGAGG</td><td>AAGATCCAGG</td><td>GCGATGGCGC</td><td>AGCGCTCCAG</td><td> 540</td>
<td>GAGAAGCTGT</td><td>GTGCCACCTA</td><td>CAAGCTGTGC</td><td>CACCCCGAGG</td><td>AGCTGGTGCT</td><td>GCTCGGACAC</td><td> 600</td>
<td>TCTCTGGGCA</td><td>TCCCCTGGGC</td><td>TCCCCTGAGC</td><td>TCCTGCCCCA</td><td>GCCAGGCCCT</td><td>GCAGCTGGCA</td><td> 660</td>
<td>GGCTGCTTGA</td><td>GCCAACTCCA</td><td>TAGCGGCCTT</td><td>TTCCTCTACC</td><td>AGGGGCTCCT</td><td>GCAGGCCCTG</td><td> 720</td>
<td>GAAGGGATAT</td><td>CCCCCGAGTT</td><td>GGGTCCCACC</td><td>TTGGACACAC</td><td>TGCAGCTGGA</td><td>CGTCGCCGAC</td><td> 780</td>
<td>TTTGCCACCA</td><td>CCATCTGGCA</td><td>GCAGATGGAA</td><td>GAACTGGGAA</td><td>TGGCCCCTGC</td><td>CCTGCAGCCC</td><td> 840</td>
<td>ACCCAGGGTG</td><td>CCATGCCGGC</td><td>CTTCGCCTCT</td><td>GCTTTCCAGC</td><td>GCCGGGCAGG</td><td>AGGGGTCCTG</td><td> 900</td>
<td>GTTGCTAGCC</td><td>ATCTGCAGAG</td><td>CTTCCTGGAG</td><td>GTGTCGTACC</td><td>GCGTTCTACG</td><td>CCACCTTGCG</td><td> 960</td>
<td>CAGCCCTGAT</td><td>AAGGATCCGA</td><td>ATTC</td><td></td><td></td><td></td><td> 984</td>
(2) SEQUENCE INFORMATION ID NO. 84 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 84
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td><td>ACCACCTGCA</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATGAC</td><td>GAAGACGTCT</td><td>CTATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGACTTC</td><td>CAAACCTGGA</td><td>GAGCTTCGTA</td><td>AGGGCTGTCA</td><td>AGAACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>GCAAGCGCAG</td><td>GAACAACAGT</td><td>ACGTAATCGA</td><td>GGGAAGGATT</td><td> 360</td>
<td>TCCCCGGGTG</td><td>GTGGTTCTGG</td><td>CGGCGGCTCC</td><td>AACATGGCTA</td><td>CACCATTAGG</td><td>CCCTGCCAGC</td><td> 420</td>
<td>TCCCTGCCCC</td><td>AGAGCTTCCT</td><td>GCTCAAGTGC</td><td>TTAGAGCAAG</td><td>TGAGGAAGAT</td><td>CCAGGGCGAT</td><td> 480</td>
<td>GGCGCAGCGC</td><td>TCCAGGAGAA</td><td>GCTGTGTGCC</td><td>ACCTACAAGC</td><td>TGTGCCACCC</td><td>CGAGGAGCTG</td><td> 540</td>
<td>GTGCTGCTCG</td><td>GACACTCTCT</td><td>GGGCATCCCC</td><td>TGGGCTCCCC</td><td>TGAGCTCCTG</td><td>CCCCAGCCAG</td><td> 600</td>
<td>GCCCTGCAGC</td><td>TGGCAGGCTG</td><td>CTTGAGCCAA</td><td>CTCCATAGCG</td><td>GCCTTTTCCT</td><td>CTACCAGGGG</td><td> 660</td>
<td>CTCCTGCAGG</td><td>CCCTGGAAGG</td><td>GATATCCCCC</td><td>GAGTTGGGTC</td><td>CCACCTTGGA</td><td>CACACTGCAG</td><td> 720</td>
<td>CTGGACGTCG</td><td>CCGACTTTGC</td><td>CACCACCATC</td><td>TGGCAGCAGA</td><td>TGGAAGAACT</td><td>GGGAATGGCC</td><td> 780</td>
<td>CCTGCCCTGC</td><td>AGCCCACCCA</td><td>GGGTGCCATG</td><td>CCGGCCTTCG</td><td>CCTCTGCTTT</td><td>CCAGCGCCGG</td><td> 840</td>
RO 118016 Β1
<td colspan="2">GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT</td><td> 900 10920</td>
<td colspan="2">CTACGCCACC TTGCGCAGCC C</td><td> 921</td>
<td colspan="2">(2) SEQUENCE INFORMATION ID NO. 85</td><td></td>
<td>(I)</td><td>SEQUENCE CHARACTERISTICS: (A) LENGTH: 921 base pairs</td><td> 10925</td>
<td></td><td>(B) TYPE: nucleic acid (C) FILLING: double</td><td></td>
<td></td><td>(D) TOPOLOGY: linear</td><td></td>
<td>(Ii)</td><td>MOLECULE TYPE: DNA (genome)</td><td> 10930</td>
<td>(Xi)</td><td>SEQUENCE DESCRIPTION: SEQ. ID NO. 85</td><td></td>
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGAOGTCT CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG GGCGCAGCGC tccaggagaa gctgtgtgcc acctacaagc gtgctgctcg gacactctct gggcatcccc tgggctcccc GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG GCAGGAGGGG TCCTGGTTGC TAGCCAT CAGG
<td>ACTTAAAGAG ACCACCTGCA</td><td> 60</td>
<td>CTATCCTGAT GGAACGAAAC</td><td> 120</td>
<td></td><td> 10935</td>
<td>AGAACTTAGA AAATGCATCA</td><td> 180</td>
<td>CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>ACGTAATCGA GGGAAGGATT</td><td> 360</td>
<td></td><td> 10940</td>
<td>CACCATTGGG CCCTGCCAGC</td><td> 420</td>
<td>TGAGGAAGAT CCAGGGCGAT</td><td> 480</td>
<td>TGTGCCACCC CGAGGAGCTG</td><td> 540</td>
<td>TGAGCTCCTG CCCCAGCCAG</td><td><sup>600</sup> 10945</td>
<td>GCCTTTTCCT CTACCAGGGG</td><td> 660</td>
<td>CCACCTTGGA CACACTGCAG</td><td> 720</td>
<td>TGGAAGAACT GGGAATGGCC</td><td> 780</td>
<td>CCTCTGCTTT CCAGCGCCGG</td><td> 840 10950</td>
<td>TGGAGGTGTC GTACCGCGTT</td><td> 900</td>
<td></td><td> 921</td>
(2) SEQUENCE INFORMATION ID NO. 86 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs (B) ΊΊΡ: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome)
10955
10960 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 86
RO 118016 Β1
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGAACGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA ACTGCTCTAT AATGATCGAT 420 GAAATTATAC ATCACTTAAA GAGACCACCT TGGACCCGAA CAACCTCAAT 480 GACGAAGACG GCACCTTTGC AACCTTCGAC TCTCTATCCT TTCCAAACCT GATGGAACGA AGAAAATGCA TCAGGTATTG GGAGAGCTTC S40 AGGCAATTCT TCGTAATCTC TCAAGAACTT GTAAGGGCTG 600 CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CATCAAGGCA 660 GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TGAGCAAGCG 720 CAGGAACAAC AG 732 (2) INFORMATION FOR SEQUENCE ID NO. 87 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 921 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 87
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGAACGAAAC</td><td> 120</td>
<td>CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC</td><td> 360</td>
<td>TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CACCATTGGG CCCTGCCAGC</td><td> 420</td>
<td>TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT</td><td> 480</td>
RO 118016 Β1
11005
GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA GTGCTGCTCG GACACTCTCT GGGCATCCCC CTGGACGTCG CCGACTTTGC CACCACCATC CTCCTGGAGG CCCTGGAAGG GATATCCCCC GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CCTGCCCTGC AGCCCACCCA GGGTGCCATG CTACGCCACC TTGCGCAGCC C
ACCTACAAGC TGTGCCACCC CGAGGAGCTG540
TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG600
CTCCATAGCG GCCTTTTCCT CTACCAGGGG660
GAGTTGGGTC CCACCTTGGA CACACTGCAG720
TGGCAGCAGA TGGAAGAACT GGGAATGGCC780
CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG840
CAGAGCTTCC TGGAGGTGTC GTACOGCGTT900
921
11010 (2) SEQUENCE INFORMATION ID NO. 88 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 732 base pairs (B) TYPE: Nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) MOLECULAR OPUL: DNA (genomic)
11015 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 88
11020
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATOCTGAT GGAACGAAAC 120 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360 TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA ACTGCTCTAT AATGATCGAT 420 GAAATTATAC ATCACTTAAA GAGACCACCT TGGACCCGAA CAACCTCAAT 480 GCACCTTTGC AACCTTCGAC TTCCAAACCT GACGAAGACG GGAGAGCTTC TCTCTATCCT 540 GTAAGGGCTG GATGGAACGA AGAAAATGCA TCAGGTATTG AGGCAATTCT TCGTAATCTC TCAAGAACTT 600 CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CATCAAGGCA 660 GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TGAGCAAGCG 720 CAGGAACAAC AG 732
11025
11030
11035 (2) SEQUENCE INFORMATION ID NO. 89 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 966 base pairs (B) ΊΠΡ: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 89
11040
11045
RO 118016 Β1
<td>ATGGCTAACT</td><td>GCTCTATAAT</td><td>GATCGATGAA</td><td>ATTATACATC</td><td>ACTTAAAGAG</td><td>ACCACCTGCA</td><td> 60</td>
<td>CCTTTGCTGG</td><td>ACCCGAACAA</td><td>CCTCAATGAC</td><td>GAAGACGTCT</td><td>CTATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGACTTC</td><td>CAAACCTGGA</td><td>GAGCTTCGTA</td><td>AGGGCTGTCA</td><td>AGAACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG</td><td>CAATTCTTCG</td><td>TAATCTCCAA</td><td>CCATGTCTGC</td><td>CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC</td><td>CAATCATCAT</td><td>CAAGGCAGGT</td><td>GACTGGCAAG</td><td>AATTCCGGGA</td><td>AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG</td><td>TTACCCTTGA</td><td>GCAAGCGCAG</td><td>GAACAACAGT</td><td>ACGTAGAGGG</td><td>CGGTGGAGGC</td><td> 360</td>
<td>TCCCCGGGTG</td><td>AACCGTCTGG</td><td>TCCAATCTCT</td><td>ACTATCAACC</td><td>CGTCTCCTCC</td><td>GTCTAAAGAA</td><td> 420</td>
<td>TCTCATAAAT</td><td>CTCCAAACAT</td><td>GGCTACACCA</td><td>TTGGGCCCTG</td><td>CCAGCTCCCT</td><td>GCCCCAGAGC</td><td> 480</td>
<td colspan="2">TTCCTGCTCA AGTCTTTAGA</td><td>GCAAGTGAGG</td><td>AAGATCCAGG</td><td>GCGATGGCGC</td><td>AGCGCTCCAG</td><td> 540</td>
<td>GAGAAGCTGT</td><td>GTGCCACCTA</td><td>CAAGCTGTGC</td><td>CACCCCGAGG</td><td>AGCTGGTGCT</td><td>GCTCGGACAC</td><td> 600</td>
<td>TCTCTGGGCA</td><td>TCCCCTGGGC</td><td>TCCCCTGAGC</td><td>TCCTGCCCCA</td><td>GCCAGGCCCT</td><td>GCAGCTGGCA</td><td> 660</td>
<td>GGCTGCTTGA</td><td>GCCAACTCCA</td><td>TAGCGGCCTT</td><td>TTCCTCTACC</td><td>AGGGGCTCCT</td><td>GCAGGCCCTG</td><td> 720</td>
<td>GAAGGGATAT</td><td>CCCCCGAGTT</td><td>GGGTCCCACC</td><td>TTGGACACAC</td><td>TGCAGCTGGA</td><td>CGTCGCCGAC</td><td> 780</td>
<td>TTTGCCACCA</td><td>CCATCTGGCA</td><td>GCAGATGGAA</td><td>GAACTGGGAA</td><td>TGGCCCCTGC</td><td>CCTGCAGCCC</td><td> 840</td>
<td>ACCCAGGGTG</td><td>CCATGCCGGC</td><td>CTTCGCCTCT</td><td>GCTTTCCAGC</td><td>GCCGGGCAGG</td><td>AGGGGTCCTG</td><td> 900</td>
<td>GTTGCTAGCC</td><td>ATCTGCAGAG</td><td>CTTCCTGGAG</td><td>GTGTCGTACC</td><td>GCGTTCTACG</td><td>CCACCTTGCG</td><td> 960</td>
<td>CAGCCC</td><td></td><td></td><td></td><td></td><td></td><td> 966</td>
(2) SEQUENCE INFORMATION ID NO. 90 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs (B) TYPE: Nucleic acid (CJ FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90
ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA
CCTTTGCTGG ACCCGAACAA CTTCGACTTC CAAACCTGGA GGTATTGAGG CAATTCTTCG TCTCGACATC CAATCATCAT TTCTATCTGG TTACCCTTGA TCCCCGGGTG AACCGTCTGG TCTCATAAAT CTCCAAACAT TTAAAGAGAC CACCTGCACC ATCCTGATGG AACGAAACCT AACTTAGAAA ATGCATCAGG TCTGCCACGG CCGCACCCTC TTCCGGGAAA AACTGACGTT
CCTCAATGAC GAAGACGTCT GAGCTTCGTA AGGGCTGTCA TAATCTCCAA CCATGTCTGC CAAGGCAGGT GACTGGCAAG GCAAGCGCAG GAACAACAGT TCCAATCTCT ACTATCAACC GGCTAACTGC TCTATAATGA TTTGCTGGAC CCGAACAACC TCGACTTCCA AACCTGGAGA TATTGAGGCA ATTCTTCGTA TCGACATCCA ATCATCATCA CTATCTGGTT ACCCTTGAGC
CTATCCTGAT GGAACGAAAC AGAACTTAGA AAATGCATCA CCTCTGCCAC GGCCGCACCC AATTCCGGGA AAAACTGACG ACGTAGAGGG CGGTGGAGGC CGTCTCCTCC GTCTAAAGAA TCGATGAAAT TATACATCAC TCAATGACGA AGACGTCTCT GCTTCGTAAG GGCTGTCAAG ATCTCCAACC ATGTCTGCCC AGGCAGGTGA CTGGCAAGAA AAGCGCAGGA ACAACAG
120
180
240
300
360
420
480
540
600
660
720
777
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 91 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = 'synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 91 (2) SEQUENCE INFORMATION ID NO. 92 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-'synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 92 (2) SEQUENCE INFORMATION ID NO. 93 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs (B) ΊΊΡ: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 93
CAAGCGCAGG AACAACAGTA CGTAATCGAG GGAAGGATT 39 (2) SEQUENCE INFORMATION ID NO. 94 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs (B) TYPE: Nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear
11100
11105
11110
11115
11120
11125
11130
11135
EN 118016 Β1 (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic deoDNA (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 94
ACCCGGGGAA ATCCTTCCCT CGATTACGTA CTGTTGTTC 39 (2) SEQUENCE INFORMATION ID NO. 95 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-ΌΝΑ synthetic (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 95
TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGTAAG GTACCGCATG 50 CAAGCTTAGA TCT 63 (2) SEQUENCE INFORMATION ID NO. 96 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) FILLING: plain (D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 96
AGCTAGATCT AAGCTTGCAT GCGGTACCTT ACATGTTGGA GCCGCCHCCA 50 GAACCACC 58 (2) SEQUENCE INFORMATION ID NO. 97 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 74 base pairs (B) TYPE: nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-'synthetic DNA
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 97
CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC 50 TAAAGAATCT CATAAATCTC CAAA 74 (2) SEQUENCE INFORMATION ID NO. 98 (1) SEQUENCE CHARACTERISTICS:
(AJ LENGTH: 74 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc »synthetic DNA (xi) DESCRIPTION OF THE SEQUENCE : SEQ ID NO: 98
CATGTTTGGA GATTTATGAG ATTCTTTAGA CGGAGGAGAC GGGTTGATAG 50
TAGAGATTGG ACCAGACGGT TCAC 74 (2) SEQUENCE INFORMATION ID NO. 99 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-'synthetic DNA (xi) SEQUENCE DESCRIPTION !: SEQ. ID NO. 99
CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 50
CTTGCGCAGC CCTACGTA 68 (2) SEQUENCE INFORMATION ID NO. 100 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE; SEQ. ID NO. 100
11180
11185
11190
11195
11200
11205
11210
11215
RO 118016 Β1
AGCTTACGTA GGGCTGCGCA AGGTGGCGTA GAACGCGGTA CGACACCTC 50
AGGAAGCTCT GCAGATGG 68 (2) SEQUENCE INFORMATION ID NO. 101 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 101
GTAATCGAGG GAAAGATTC C 21 (2) SEQUENCE INFORMATION ID NO. 102 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = Synthetic wave (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 102
CCGGGGAAAT CTTTCCCTCG ATTAC 25 (2) SEQUENCE INFORMATION ID NO. 103 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) ΊΠΡ: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc «» synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 103
GTAGAGGGCG GTGGAGGCTC C 21 (2) SEQUENCE INFORMATION ID NO. 104
EN 118016 Β1 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = * 'synthetic DNA (xi) ) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 104
CCGGGGAGCC TCCACCGCCC TCTAC 25 (2) SEQUENCE INFORMATION ID NO. 105 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-ΌΝΑ synthetic (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 105
CATGGCACCA GCAAGATCAC CATCACCATC AACTCAACCT TGGGAACATG 50 TGAATGCC 58 (2) SEQUENCE INFORMATION ID NO. 106 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 52 base pairs (B) TYPE: Nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION; / desc-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 106
CATTCAGATG TTCCCAAGGT TGAGTTGATG GTGATGGTGA TCTTGCTGGT GC 52 (2) SEQUENCE INFORMATION ID NO. 107 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 base pairs (B) TYPE: nucleic acid
11260
11265
11270
11275
11280
11285
11290
11295
EN 118016 Β1 (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-'Synthetic DNA (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 107
CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 50 AGGAAGATCC AGGGCG 66 (2) SEQUENCE INFORMATION ID NO. 108 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 base pairs (B) TYPE: Nucleic acid (C) FILLING: plain (D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-ΌΝΑ synthetic (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 108
CTGGATCTTC CTCACTTGCT CTAAAGACTT GAGCAGGAAG CTCT eie.ee · □ A
GGGAGCTGGC AGGGCC (2) INFORMED FOR SEQUENCE ID NO. 108 (i) SEQUENCE CHARACTERISTICS;
(A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 109
AGCTTACCTG CCATGGCTCC AGTACCACCA GGTGAAGATT CCAAAGAT 48 (2) SEQUENCE INFORMATION ID NO. 110 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs (B) TYPE: Nucleic acid (C) FILLING: plain (D) TOPOLOGY: linear
EN 118016 Β1 (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic synthetic DNA (xi) DESCRIPTION OF THE SEQUENCE; SEQ. ID NO. 110
TTGGAATCTT CACCTGGTGG TACTGGAGCC ATGGCAGGTA 40 (2) SEQUENCE INFORMATION ID NO. 111 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 111
AGCTTCCATG GCTACCCCCC TGGGCC 26 (2) SEQUENCE INFORMATION ID NO. 112 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 112
GAGGGGGGTA GCCATGGA 18 (2) SEQUENCE INFORMATION ID NO. 113 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 113
11340
11345
11350
11355
11360
11365
11370
11375
RO 118016 Β1
CATGGCTACA CCATTGGGCC 20 (2) SEQUENCE INFORMATION ID NO. 114 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs (B) ΊΊΡ: nucleic acid (C) FILLING: simple (D) TDPOLOGE: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = ”synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 114
CAATGGTGTAGC 12 (2) SEQUENCE INFORMATION ID NO. 115 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TDPOLOGE: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc «Synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 115
CATGGCTACA CCATTAGGAC 20 (2) SEQUENCE INFORMATION ID NO. 116 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) FILLING: plain (D) TDPOLOGE: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc- "synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 116
TAATGGTGTA GC 12 (2) SEQUENCE INFORMATION ID NO. 117
EN 118016 Β1 (1) SEQUENCE CHARACTERISTICS:
(AJ LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-'synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ ID NO 117
CCTGTCAACC CGGGCGGCGG CTCTGGTGGT 30 (2) SEQUENCE INFORMATION ID NO. 118 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 118
TCATAATACA TGTTACCGGA ACGGAGCCGC C 31 (2) SEQUENCE INFORMATION ID NO. 119 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = ”Synthetic DIMA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 119
ATCGTCTGAC CTCCCGGGAC CTCCTGTCAA TGCT 34 (2) SEQUENCE INFORMATION ID NO. 120 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) FILLING; simple
11420
11425
11430
11435
11440
11445
11450
11455
EN 118016 Β1 (D) TOPOLOGY: linear (s) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 120
AGCGTTTGAC ATGTTTTCAT AATCAAAATC (2) SEQUENCE INFORMATION ID NO. 121 (i) SEQUENCE CHARACTERISTICS:
(AJ LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 121
<td>Met</td><td>That</td><td>Asn</td><td>• Cys</td><td>Serum</td><td>XLE</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td><td>Lys</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td rowspan="2">Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td>
<td>Met</td><td>Asp</td><td>XLE</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>XLE</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>XLE</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Aap</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
RO 118016 Β1
<td colspan="2" rowspan="2">Gly Ser 130</td><td colspan="3" rowspan="2">Asn Met Ala</td><td rowspan="4">Thr Cys 150</td><td colspan="6">Pro Leu Gly Pro Ala Ser Ser</td><td colspan="4">Read Pro Gin</td>
<td colspan="2" rowspan="3">135 I read Glu</td><td rowspan="3">Gin</td><td></td><td colspan="2"> 140</td><td rowspan="3">Gin</td><td colspan="2" rowspan="3">Gly Asp 160</td><td rowspan="3"> 11495</td>
<td rowspan="2">Serum 145</td><td rowspan="2">Phe</td><td rowspan="2">Lion</td><td colspan="2" rowspan="2">Read Lys</td><td>Val Arg</td><td rowspan="2">Lys</td><td rowspan="2">Ile</td>
<td> 155</td>
<td>Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin 165</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>Allah Thr 170</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 175</td><td>His</td><td></td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion 180</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>HiS 185</td><td>Be Lee</td><td>Gly</td><td>Ile</td><td>Pro 190</td><td>Trp</td><td>That</td><td> 11500</td>
<td>Pro</td><td>Lion</td><td>Serum 195</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin two hundred</td><td>That</td><td>Read Gin</td><td>Lion</td><td>That 205</td><td>Gly</td><td>Cys</td><td>Lion</td><td></td>
<td>Serum</td><td>Gin 210</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion 215</td><td>Phe</td><td>Lion</td><td>Tyr Gin</td><td>Gly 220</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td> 11505</td>
<td>Lion 225</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 230</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro Thr 235</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin 240</td><td></td>
<td>Lion</td><td>Asp</td><td>Wave</td><td>That</td><td>Asp 245</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Hair Trp 250</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 255</td><td>Glu</td><td> 11510</td>
<td>Lion</td><td>Gly</td><td>Met</td><td>That 260</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro 265</td><td>Thr Gin</td><td>Gly</td><td>That</td><td>Met 270</td><td>Pro</td><td>That</td><td></td>
<td>Phe</td><td>That</td><td>Serum 275</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg 2Θ0</td><td>That</td><td>Gly Gly</td><td>Wave</td><td>Lion 285</td><td>Wave</td><td>That</td><td>Serum</td><td></td>
<td>His</td><td>Lion 290</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu 295</td><td>Wave</td><td>Serum</td><td>Tyr Arg</td><td>Wave 300</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td> 11515</td>
Ala Gin Pro
305 (2) SEQUENCE INFORMATION ID NO. 122 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) OLE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 122
11520
11525
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Being 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
40 45
11530
11535
Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile Glu Ala
RO 118016 Β1
55 60
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>serum</td><td rowspan="2">Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td rowspan="2">Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>wave</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td colspan="2">Gly Gly</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td rowspan="2">Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion</td><td colspan="2">Pro Gin</td>
<td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td colspan="2">Gly Asp</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td rowspan="2">Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td>
<td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td>Pro</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td>Serum</td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>Lion</td><td rowspan="2">Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td>
<td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>Lion</td><td rowspan="2">Gly</td><td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td>
<td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Phe</td><td>That</td><td>Serum</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td>His</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td>
<td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td><td></td>
Ala Gin Pro
305 (2) SEQUENCE INFORMATION ID NO. 123 (ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: protein (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 123
RO 118016 Β1
<td>Met 1</td><td>That</td><td>Aen</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp 90</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Lys</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>Serum</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>Serum<sup>130</sup></td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 135</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Be 140</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td>
<td>Serum 145</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum 150</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg 155</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp 160</td>
<td>Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin 165</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 170</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 175</td><td>His</td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>I read 180</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His 185</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 190</td><td>Trp</td><td>That</td>
<td>Pro</td><td>Lion</td><td>Being 195</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin 200</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 205</td><td>Gly</td><td>Cys</td><td>Lion</td>
<td>Serum</td><td>Gin 210</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion 215</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 220</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td>
<td>Lion 225</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 230</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr 235</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin 240</td>
<td>Lion</td><td>Asp</td><td>Wave</td><td>That</td><td>Asp 245</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile 250</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 255</td><td>Glu</td>
<td>Lion</td><td>Gly</td><td>Met</td><td>That 260</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro 265</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met 270</td><td>Pro</td><td>That</td>
<td>Phe</td><td>That</td><td>Be 275</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg 280</td><td>That</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Read 285</td><td>Wave</td><td>That</td><td>Serum</td>
<td>His</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td>
290 295 300
11585
11590
11595
11600
11605
11610
11615
11620
Ala Gin Pro
11625
RO 118016 Β1
305 (2) SEQUENCE INFORMATION ID NO. 124 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) ΊΠΡ: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
<td colspan="8">SEQUENCE DESCRIPTION: SEQ.</td><td colspan="8">ID NO. 124</td>
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Be 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>wave 115</td><td>Glu</td><td>Gly</td><td colspan="3">Gly Gly Gly 120</td><td>Serum</td><td>Pro</td><td colspan="3">Gly Gly Gly 125</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td>Gly</td><td>serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 135</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum 140</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td>
<td>Serum 145</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum 150</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg 155</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp 160</td>
<td>Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin 165</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 170</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 175</td><td>His</td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion 180</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His 185</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 190</td><td>Trp</td><td>That</td>
<td>Pro</td><td>Lion</td><td>Serum 195</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin two hundred</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 205</td><td>Gly</td><td>Cys</td><td>Lion</td>
<td>Serum</td><td>Gin 210</td><td>Lion</td><td>His</td><td>serum</td><td>Gly</td><td>Lion 215</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 220</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td>
225 230 235 240
RO 118016 Β1
<td colspan="4">Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gin Gin Met Glu Glu</td><td rowspan="2"> 11675</td>
<td></td><td> 245</td><td> 250</td><td> 255</td>
<td>Read Gly Met Ala</td><td>Because of Ala Leu Gin</td><td>Pro Thr Gin Gly Ala</td><td>Met Pro Ala</td><td></td>
<td> 260</td><td></td><td> 265</td><td> 270</td><td></td>
<td>Phe Ala Ser Ala</td><td>Phe Gin Arg Arg</td><td>Ala Gly Gly Val Leu</td><td>Val Ala Ser</td><td></td>
<td> 275</td><td> 280</td><td> 285</td><td></td><td> 11680</td>
<td>His Leu Gin Ser</td><td>Phe Leu Glu Val</td><td>Be Tyr Arg Val Leu</td><td>Arg His Leu</td><td></td>
<td> 290</td><td> 295</td><td> 300</td><td></td><td></td>
Ala Gin Pro
305 (2) SEQUENCE INFORMATION ID NO. 125 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
11685
11690
<td colspan="10">(xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO.</td><td colspan="6"> 125</td>
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>Serum</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys 135</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp 140</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td>
<td>His 145</td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro 150</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 155</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 160</td>
Ser Glu Asp Met Asp Ile Leu Met Glu Arg Asn Leu Arg Thr Pro Asn
11695
11700
11705
11710
11715
RO 118016 Β1
11720
11725
165 170 175
<td>Lion</td><td>Lion</td><td>That</td><td>Phe 180</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys 185</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 190</td><td>Serum</td><td>Gly</td>
<td>Ile</td><td>Glu</td><td>That 195</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion two hundred</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 205</td><td>Serum</td><td>That</td><td>Thr</td>
<td>That</td><td>That 210</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 215</td><td>Ile</td><td>XLE</td><td>Ile</td><td>Lys</td><td>That 220</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu 225</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lye</td><td>Lion 230</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 235</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 240</td>
Gin Glu Gin Gin
11730
11735
11740 (2) SEQUENCE INFORMATION ID NO. 126 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 amino acids (B) ΉΡ: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 126
11745
11750
11755
<td rowspan="2">Met 1</td><td rowspan="2">That</td><td colspan="2" rowspan="2">Asn Cys</td><td colspan="11">Be Him Met Xle Asp Glu Xle Him His His Leu</td><td rowspan="2">Lys</td>
<td colspan="2"> 5</td><td colspan="7"> 10</td><td colspan="2"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Being 60</td><td>Gly</td><td>XLE</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>XLE 85</td><td>Ile</td><td>XLE</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Lys</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>Serum</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td>
130 135 140
11760
His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn 145 150 155 160
RO 118016 Β1
<td>Serum</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp 165</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg 170</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro 175</td><td>Asn</td><td> 11765</td>
<td>Lion</td><td>Lion</td><td>That</td><td>Phe 180</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys 185</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 190</td><td>serum</td><td>Gly</td><td></td>
<td>Ile</td><td>Glu</td><td>That 195</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion two hundred</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 205</td><td>Serum</td><td>That</td><td>Thr</td><td> 11770</td>
<td>That</td><td>That 210</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 215</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 220</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td></td>
<td>Glu 225</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 230</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 235</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 240</td><td></td>
<td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 11775</td>
(2) SEQUENCE INFORMATION ID NO. 127 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOQOI CplC?
(ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 127
11780
11785
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Being 30</td><td>Glu</td><td>Asp</td><td> 11790</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td><td></td>
<td>Phe</td><td>wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td>t</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td><td> 11795</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td> 11800</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Glu</td><td>Gly</td><td colspan="3">Gly Gly Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>Serum</td><td colspan="2">Gly Gly</td><td></td>
<td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td></td>
130 135 140
His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn
11805
RO 118016 Β1
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td>Serum</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp 165</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg 170</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro 175</td><td>Asn</td>
<td>Lion</td><td>Lion</td><td>That</td><td>Phe 180</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys 185</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 190</td><td>Serum</td><td>Gly</td>
<td>Ile</td><td>Glu</td><td>That 195</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion two hundred</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 205</td><td>Serum</td><td>That</td><td>Thr</td>
<td>That</td><td>That 210</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 215</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 220</td><td colspan="3">Gly Asp Trp</td><td>Gin</td>
<td>Glu 225</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 230</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 235</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 240</td>
<td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 128 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 128
<td colspan="4" rowspan="2">Met Ala Asn Cys 1</td><td rowspan="2">Serum 5</td><td colspan="3" rowspan="2">Hair Met Hair</td><td colspan="8">Asp Glu Ile Ile His His Leu Lys</td>
<td colspan="2"> 10</td><td colspan="6"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td rowspan="2">Gly</td><td>Pro</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td>
<td>Ile</td><td>serum</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His</td><td rowspan="2">Lys</td><td>Serum</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td>
RO 118016 Β1
<td colspan="16">Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser</td>
<td colspan="3"> 145</td><td colspan="5"> 150</td><td colspan="7"> 155</td><td> 160</td>
<td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Cys 165</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td colspan="2">Arg Lys 170</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp 175</td><td>Gly</td>
<td>That</td><td>That</td><td>Lion</td><td>Gin 180</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 185</td><td>Thr</td><td colspan="2">Tyr Lys</td><td>Lion</td><td>Cys 190</td><td>His</td><td>Pro</td>
<td>Glu</td><td>Glu</td><td>Lion 195</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His two hundred</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 205</td><td>Trp</td><td>That</td><td>Pro</td>
<td>Lion</td><td>Serum 210</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin 215</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 220</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td>
<td>Gin 225</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion 230</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 235</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion 240</td>
<td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 245</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr 250</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin 255</td><td>Lion</td>
<td>Asp</td><td>Wave</td><td>That</td><td>Asp 260</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile 265</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 270</td><td>Glu</td><td>Lion</td>
<td>Gly</td><td>Met</td><td>That 275</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro 280</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met 285</td><td>Pro</td><td>That</td><td>Phe</td>
<td>That</td><td>Serum 290</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg 295</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion 300</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td>
<td>Lion 305</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu 310</td><td>Wave</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave 315</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That 320</td>
Gin Pro
11850
11855
11860
11865
11870 (2) SEQUENCE INFORMATION ID NO. 129 (ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 129
11875
11880
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly lle Glu Ala
11885
11890
RO 118016 Β1
<td> 11895</td><td colspan="4"> 50</td><td colspan="4"> 55</td><td colspan="8"> 60</td>
<td></td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td></td><td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td></td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td> 11900</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td></td><td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Lys</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td></td><td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td rowspan="2"> 11905</td><td>Ile</td><td>serum</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Sar</td><td>His</td><td>Lye</td><td>Serum</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td></td><td>Pro</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td>
<td></td><td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td></td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>wave</td><td colspan="2">Arg Lys</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly</td>
<td> 11910</td><td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td></td><td>That</td><td>That</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td>
<td></td><td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td></td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td>
<td></td><td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td> 11915</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td>
<td></td><td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td></td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td>
<td></td><td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td></td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td>
<td> 11920</td><td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td></td><td>Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td>
<td></td><td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td></td><td rowspan="2">Gly</td><td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td>Phe</td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td> 11925</td><td>That</td><td>Serum</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td>
<td></td><td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td><td></td>
<td></td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td>
305 310 315 320 (2) SEQUENCE INFORMATION ID NO. 130 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
EN 118016 Β1 (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 130
11940
<td colspan="5">Met Ala Asn Cys Ser</td><td colspan="2" rowspan="2">him Met</td><td rowspan="2">Ile</td><td colspan="7">Asp Glu li His His Leu</td><td rowspan="2">Lys</td>
<td colspan="2"> 1</td><td colspan="3"> 5</td><td colspan="2"> 10</td><td colspan="5"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Glu</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td>Ile</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
<td>Pro 145</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 150</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum 155</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum 160</td>
<td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Cys 165</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg 170</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td colspan="2">Asp Gly 175</td>
<td>That</td><td>That</td><td>Lion</td><td>Gin 180</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 185</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 190</td><td>His</td><td>Pro</td>
<td>Glu</td><td>Glu</td><td>Lion 195</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His two hundred</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 205</td><td>Trp</td><td>That</td><td>Pro</td>
<td>Lion</td><td>Serum 210</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin 215</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 220</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td>
<td>Gin 225</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion 230</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 235</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion 240</td>
<td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 245</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr 250</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin 255</td><td>Lion</td>
<td>Asp</td><td>Wave</td><td>That</td><td>Asp 260</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile 265</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 270</td><td>Glu</td><td>Lion</td>
11945
11950
11955
11960
11965
11970
11975
11980
Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 275 280 285
RO 118016 Β1
Ala ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 290 295 300
Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 305 310 315 320
Gin Pro (2) SEQUENCE INFORMATION ID NO. 131 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 259 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 131
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Being 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Being 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td>Ile</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
<td>Pro 145</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys 150</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp 155</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His 160</td>
<td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro 165</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 170</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 175</td><td>Serum</td>
<td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td>
1Θ0 185 190
Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly Ile
RO 118016 Β1
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td>Glu</td><td>That 210</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion 215</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 220</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td>
<td>That 225</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 230</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 235</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu 240</td>
<td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 245</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 250</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 255</td><td>Gin</td>
Glu Gin Gin
12030
12035 (2) SEQUENCE INFORMATION ID NO. 132
12040 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 259 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
12045
<td colspan="9">(xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID</td><td>NO.</td><td colspan="2"> 132</td><td></td><td></td><td></td><td></td>
<td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>HiS</td><td>His</td><td>Lion</td><td>Lys</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td rowspan="2">Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td>
<td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 65</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Lys</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td>Ile</td><td>serum</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td>Pro</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cye</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td>15S</td><td></td><td></td><td></td><td></td><td> 160</td>
12050
12055
12060
12065
Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser
165 170 175
12070
RO 118016 Β1
<td>G1U</td><td rowspan="2">Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td>
<td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td>Lion</td><td>That</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>XLE</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td>That</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>XLE</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>Phe</td><td rowspan="2">Arg</td><td>Glu</td><td rowspan="2">Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td>
<td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
Glu Gin Gin (2) SEQUENCE INFORMATION ID NO. 133 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 259 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 133
<td colspan="4" rowspan="2">Met Ala Asn Cys 1</td><td rowspan="2">Serum 5</td><td colspan="3" rowspan="2">him Met him</td><td colspan="8">Asp Glu lle Xle His His Leu Lys</td>
<td colspan="5"> 10</td><td colspan="3"> 15</td>
<td>Arg</td><td>pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cye</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>XLE</td><td>XLE</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Αβρ</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 11S</td><td>Glu</td><td>Gly</td><td colspan="3">Gly Gly Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td>Ile</td><td>Serum 130</td><td>Thr</td><td>XLE</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
Pro Asn Met ALa Asn Cys Ser lle Met lle Asp Glu He lle His His
RO 118016 Β1
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td><td> 12115</td>
<td>Lion</td><td>Lye</td><td>Arg</td><td>Pro</td><td>Pro 165</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 170</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 175</td><td>Serum</td><td></td>
<td>Glu</td><td>Asp</td><td>Met</td><td>Asp 180</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg 185</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro 190</td><td>Asn</td><td>Lion</td><td></td>
<td>Lion</td><td>That</td><td>Phe 195</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys two hundred</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 205</td><td>Serum</td><td>Gly</td><td>Ile</td><td> 12120</td>
<td>Glu</td><td>That 210</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion 215</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 220</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td></td>
<td>That 225</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 230</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 235</td><td>Gly</td><td colspan="2">Asp Trp</td><td>Gin</td><td>Glu 240</td><td> 12125</td>
<td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 245</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 250</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 255</td><td>Gin</td><td></td>
<td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 134 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30? amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
12130
12 135 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 134
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td><td> 12140</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>AEP</td><td></td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td><td></td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Being 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td> 12145</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Being 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td><td></td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td><td> 12150</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
100 105 110
Gin Tyr Val Hair Glu Gly Arg Hair Ser Pro Gly Gly Gly Ser Gly Gly 115 120 125
12155
RO 118016 Β1
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 135</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum 140</td><td>Serum</td><td>Lion</td><td colspan="2">Pro Gin</td>
<td>Serum 145</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Cys 150</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg 155</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp 160</td>
<td>Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin 165</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 170</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 175</td><td>His</td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion 180</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His 185</td><td>serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 190</td><td>Trp</td><td>That</td>
<td>Pro</td><td>Lion</td><td>Serum 195</td><td>Serum</td><td>Cys</td><td>Pro</td><td>serum</td><td>Gin two hundred</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 205</td><td>Gly</td><td>Cys</td><td>Lion</td>
<td>Serum</td><td>Gin 210</td><td>Lion</td><td>His</td><td>serum</td><td>Gly</td><td>Lion 215</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 220</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td>
<td>Lion 225</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 230</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr 235</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin 240</td>
<td>Lion</td><td>Asp</td><td>Wave</td><td>That</td><td>Asp 245</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile 250</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 255</td><td>Glu</td>
<td>Lion</td><td>Gly</td><td>Met</td><td>That 260</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro 265</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met 270</td><td>Pro</td><td>That</td>
<td>Phe</td><td>That</td><td>Serum 275</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg 280</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion 285</td><td>Wave</td><td>That</td><td>Serum</td>
<td>His</td><td>Lion 290</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu 295</td><td>Wave</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave 300</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td>
Ala Gin Pro
305 (2) INFORMATION FOR SEQUENCE ID NO. 135 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: protein (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 135
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lle Glu Ala
RO 118016 Β1
55 60
<td colspan="6">leu Arg Asn Leu Gin</td><td colspan="10">Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro</td><td rowspan="2"> 12205</td>
<td colspan="2"> 65</td><td colspan="4"> 70</td><td colspan="8"> 75</td><td colspan="2"> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile</td><td>serum</td><td>Pro</td><td colspan="3">Gly Gly Gly</td><td>Serum</td><td colspan="2">Gly Gly</td><td> 12210</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td><td></td>
<td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>serum</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td></td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp</td><td></td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td><td> 12215</td>
<td>Gly</td><td>That</td><td>That</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td></td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td><td></td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td></td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td><td></td>
<td>Pro</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td> 12220</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td></td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td></td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 12225</td>
<td>Lion</td><td>Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td></td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td><td></td>
<td>Lion</td><td>Gly</td><td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td></td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td><td></td>
<td>Phe</td><td>That</td><td>Serum</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td></td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td><td> 12230</td>
<td>His</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td></td>
290 295 300
Ala Gin Pro
305 (2) SEQUENCE INFORMATION ID NO. 136 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
12235
12240 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 136
RO 118016 Β1
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>AEP</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Being 60</td><td>Gly</td><td> 11«</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp 90</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td colspan="2">Gly Gly</td><td>Gly 125</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys 135</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp 140</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td>
<td>His 145</td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro 150</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 155</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 160</td>
<td>Asp</td><td>Glu</td><td>Asp</td><td>Wave</td><td>I'll be 165</td><td>Ile</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg 170</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro 175</td><td>Asn</td>
<td>Lion</td><td>Glu</td><td>Serum</td><td>Phe 180</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td colspan="2">Lys Asn 185</td><td>Lion</td><td>Glu</td><td>Asn</td><td>Thread 190</td><td>Serum</td><td>Gly</td>
<td>Ile</td><td>Glu</td><td>That 195</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion two hundred</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 205</td><td>Serum</td><td>That</td><td>Thr</td>
<td>That</td><td>That 210</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 215</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 220</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td>Glu</td><td>Phe</td><td colspan="2">Arg Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td>
<td> 225</td><td> 230</td><td> 235</td><td colspan="2"> 240 /</td>
<td>Gin Glu Gin Gin</td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 137 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 259 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 137
12290
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td><td></td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td><td> 12295</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td></td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td><td> 12300</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="4">Gly Asp Trp Gin 90</td><td>Glu</td><td>Phe 95</td><td>Arg</td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td><td> 12305</td>
<td>Ile</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td><td></td>
<td>Pro 145</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys 150</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp 155</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His 160</td><td> 12310</td>
<td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro 165</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 170</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 175</td><td>Asp</td><td></td>
<td>Glu</td><td>Asp</td><td>Wave</td><td>Serum 180</td><td>Ile</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg 185</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro 190</td><td>Asn</td><td>Lion</td><td></td>
<td>Glu</td><td>Serum</td><td>Phe 195</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys two hundred</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 205</td><td>Serum</td><td>Gly</td><td>Ile</td><td> 12315</td>
<td>Glu</td><td>That 210</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion 215</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 220</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td></td>
<td>That 225</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 230</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 235</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu 240</td><td> 12320</td>
<td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 245</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 250</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 255</td><td>Gin</td><td></td>
Glu Gin Gin (2) SEQUENCE INFORMATION ID NO. 138 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
12330
RO 118016 Β1
12335 (DJ TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138
<td rowspan="2"></td><td colspan="2" rowspan="2">Met Allah 1</td><td colspan="2" rowspan="2">Asn Cys</td><td colspan="2" rowspan="2">Be him 5</td><td colspan="9">Met him Asp Glu him His His Leu</td><td rowspan="2">Lys</td>
<td colspan="4"> 10</td><td colspan="5"> 15</td>
<td> 12340</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Αβρ</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu</td><td>Asp</td>
<td></td><td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td></td><td>wave</td><td>Serum</td><td>Ile</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td></td><td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td></td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td> 12345</td><td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td></td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td></td><td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td></td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td> 12350</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td></td><td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td></td><td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td></td><td>Ile</td><td>Serum</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
<td> 12355</td><td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td></td><td>Pro</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td>
<td></td><td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td></td><td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td colspan="2">Asp Gly</td>
<td></td><td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td> 12360</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>That</td><td>That</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td>
<td></td><td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td></td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td>
<td></td><td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td> 12365</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td>
<td></td><td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td></td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td>
<td></td><td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td></td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td>
<td> 12370</td><td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td></td><td>Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td>
260 265 270
Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe
RO 118016 Β1
275
280
285
12375
Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His 290 295 300
Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 305 310 315 320
Gin Pro
12380 (2) SEQUENCE INFORMATION ID NO. 139 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 349 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 139
<td colspan="4">Met Ala Asn Cys</td><td colspan="3" rowspan="2">Ser Ile Met 5</td><td colspan="10">Hair Asp Glu Hair Hair His His Leu Lys</td>
<td colspan="3" rowspan="3">1 Arg Pro Pro</td><td rowspan="3">Asn 20</td><td colspan="7"> 10</td><td colspan="2" rowspan="3">15 Glu Asp</td><td rowspan="3"> 12395</td>
<td rowspan="2">Pro</td><td colspan="2" rowspan="2">Leu Leu</td><td rowspan="2">Asp</td><td colspan="6">Pro Asn Asn Leu Asn Ser</td>
<td> 25</td><td colspan="5"> 30</td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td rowspan="2"> 12400</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td><td></td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td rowspan="2">Arg</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td> 12405</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Wave</td><td>Asn</td><td>That</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td><td></td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td colspan="3">Gly Gly Gly</td><td> 12410</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td rowspan="2">Gly</td><td rowspan="2">Gly</td><td>Serum</td><td></td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td> 160</td><td></td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Asp</td><td>Phe</td><td>Aap</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td></td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td><td> 12415</td>
<td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Lion</td><td rowspan="2">Lys</td><td>Serum</td><td></td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
RO 118016 Β1
<td colspan="3">I read Glu Gin</td><td rowspan="2">Wave</td><td colspan="12">Arg Lys lle Gin Gly Asp Gly Ala Ala Leu Gin Glu</td>
<td></td><td colspan="2"> 195</td><td colspan="7"> 200</td><td colspan="5"> 205</td>
<td rowspan="2">Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td>
<td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Met</td><td>That</td><td>Pro</td><td>That</td>
<td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td>That</td><td>Phe</td><td>Gin</td>
<td> 305</td><td></td><td></td><td></td><td></td><td> 310</td><td></td><td></td><td></td><td></td><td> 315</td><td></td><td></td><td></td><td></td><td> 320</td>
<td rowspan="2">Arg</td><td>Arg</td><td>That</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td>
<td></td><td></td><td></td><td> 325</td><td></td><td></td><td></td><td></td><td> 330</td><td></td><td></td><td></td><td></td><td> 335</td><td></td>
<td>Glu</td><td>Wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin</td><td>Pro</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td> 340</td><td></td><td></td><td></td><td></td><td> 345</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 140 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 base pairs (B) ΊΠΡ: nucleic acid (C) FILLING: simple (D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 140
GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC ATGG (2) SEQUENCE INFORMATION ID NO. 141 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear
EN 118016 Β1 (ii) TYPE OF MOLECULE: protein
12460 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 141
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>AEP</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Α8Π 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="3">Gly Asp Trp 90</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td colspan="3">Gly Gly Gly 125</td><td>Serum</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Pro</td><td>That 135</td><td>Arg</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Pro 140</td><td>Serum</td><td>Thr</td><td>Gin</td><td>Pro</td>
<td>Trp 145</td><td>Glu</td><td>His</td><td>Wave</td><td>Asn</td><td>That 150</td><td>Ile</td><td>Gin</td><td>Glu</td><td>That</td><td colspan="2">Arg Arg 155</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion 160</td>
<td>Serum</td><td>Arg</td><td>Asp</td><td>Thr</td><td>That 165</td><td>That</td><td>Glu</td><td>Met</td><td>Asn</td><td>Glu 170</td><td>Thr</td><td>Wave</td><td>Glu</td><td>Wave</td><td>Ile 175</td><td>Serum</td>
<td>Glu</td><td>Met</td><td>Phe</td><td>Asp 180</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Pro</td><td>Thr 185</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Arg 190</td><td>Lion</td><td>Glu</td>
<td>Lion</td><td>Tyr</td><td>Lys 195</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Arg</td><td>Gly two hundred</td><td>Serum</td><td>Lion</td><td>Thr</td><td>Lys</td><td>Lion 205</td><td>Lys</td><td>Gly</td><td>Pro</td>
<td>Lion</td><td>Thr 210</td><td>Met</td><td>Met</td><td>That</td><td>Serum</td><td>His 215</td><td>Tyr</td><td>Lys</td><td>Gin</td><td>His</td><td>Cys 220</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td>
<td>Glu 225</td><td>Thr</td><td>Serum</td><td>Cys</td><td>That</td><td>Thr 230</td><td>Gin</td><td>Ile</td><td>Ile</td><td>Thr</td><td>Phe 235</td><td>Glu</td><td>Serum</td><td>Phe</td><td>Lys</td><td>Glu 240</td>
<td>Asn</td><td>Lion</td><td>Lys</td><td>Asp</td><td>Phe 245</td><td>Lion</td><td>Lion</td><td>Wave</td><td>Ile</td><td>Pro 250</td><td>Phe</td><td>Asp</td><td>Cys</td><td>Trp</td><td>Glu 255</td><td>Pro</td>
Val Gin Glu
12465
12470
12475
12480
12485
12490
12495 (2) SEQUENCE INFORMATION ID NO. 142 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 301 amino acids (B) TYPE: amino acid (C) FILLING:
12500
EN 118016 Β1 (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 142
<td colspan="4" rowspan="2">Met Ala Asn Cys 1</td><td rowspan="2">Serum 5</td><td colspan="2" rowspan="2">Hair Met</td><td colspan="9">Hair Asp Glu Hair Hair His His Leu Lys</td>
<td colspan="7"> 10</td><td colspan="2"> 15</td>
<td rowspan="2">Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td>
<td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Met</td><td rowspan="2">Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Glu</td><td rowspan="2">Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td rowspan="2">Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Wave</td><td>Asn</td><td>That</td>
<td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td colspan="3">Gly Gly Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td><td>serum</td><td>Glu</td><td colspan="3">Gly Gly Gly</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td colspan="3">Gly Gly Gly</td><td>Serum</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Asp</td><td>Phe</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>Met</td><td>That</td><td>Pro</td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td>That</td><td rowspan="2">Arg</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td>Glu</td><td>His</td><td>Wave</td><td>Asn</td><td>That</td>
<td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td>Ile</td><td>Gin</td><td>Glu</td><td>That</td><td>Arg</td><td>Arg</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>Serum</td><td>Arg</td><td>Asp</td><td>Thr</td><td>That</td><td>That</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td>Glu</td><td>Met</td><td>Asn</td><td>Glu</td><td>Thr</td><td>Wave</td><td>Glu</td><td>Wave</td><td>Ile</td><td>Serum</td><td>Glu</td><td>Met</td><td>Phe</td><td>Asp</td><td>Lion</td><td>Gin</td>
<td></td><td> 210.</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Arg</td><td>Lion</td><td>Glu</td><td>Lion</td><td>Tyr</td><td>Lys</td><td>Gin</td><td>Gly</td><td>Lion</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td rowspan="2">Arg</td><td>Gly</td><td>Serum</td><td>Lion</td><td>Thr</td><td>Lys</td><td>Lion</td><td>Lys</td><td>Gly</td><td>Pro</td><td>Lion</td><td>Thr</td><td>Met</td><td>Met</td><td>That</td><td>Serum</td>
<td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>His</td><td>Tyr</td><td>Lys</td><td>Gin</td><td>His</td><td>Cys</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Glu</td><td>Thr</td><td>Serum</td><td>Cys</td><td>That</td><td>Thr</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Gin</td><td>. Ile</td><td>Ile</td><td>Thr</td><td>Phe</td><td>: G1U</td><td>Serum</td><td>Phe</td><td>and Lys</td><td>Glu</td><td>Asn</td><td>Lion</td><td>LyB</td><td>Asp</td><td>• Phe</td><td> Lion</td>
<td></td><td></td><td colspan="2"> 275</td><td></td><td></td><td></td><td colspan="2"> 280</td><td></td><td></td><td></td><td colspan="2"> 285</td><td></td><td></td>
RO 118016 Β1
Leu Val lle Pro Phe Asp cys Trp Glu Pro Val Gin Glu 290 295 300 (2) SEQUENCE INFORMATION ID NO. 143
12550 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 335 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
<td colspan="9">SEQUENCE DESCRIPTION: SEQ. ID</td><td>NO.</td><td colspan="2"> 143</td><td></td><td></td><td></td><td></td><td> 12560</td>
<td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td><td>Lys</td><td></td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td> 12565</td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Aen</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td><td> 12570</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td><td> 12575</td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Pro</td><td>Wave</td><td>Asn</td><td>That</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td><td></td>
<td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td></td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 12580</td>
<td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Asn</td><td>Met</td><td></td>
<td colspan="2"> 145</td><td colspan="4"> 150</td><td colspan="5"> 155</td><td colspan="6"> 160</td>
<td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly 165</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion 170</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion 175</td><td>Lion</td><td></td>
<td>Lys</td><td>Cys</td><td>Lion</td><td>Glu 180</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>him 185</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly</td><td>That 190</td><td>That</td><td>Lion</td><td> 12585</td>
<td>Gin</td><td>Glu</td><td>Lys 195</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr 200</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro 205</td><td>Glu</td><td>Glu</td><td>Lion</td><td></td>
<td>Wave</td><td>Lion 210</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion 215</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That 220</td><td>Pro</td><td>Lion</td><td>Serum</td><td>Serum</td><td> 12590</td>
Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His
RO 118016 Β1
22S 230 235 240
<td>serum</td><td rowspan="2">Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td>
<td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Wave</td><td>That</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td rowspan="2">Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Met</td><td>That</td>
<td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td>That</td>
<td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td><td></td>
<td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin</td><td>Serum</td>
<td> 305</td><td></td><td></td><td></td><td></td><td> 310</td><td></td><td></td><td></td><td></td><td> 315</td><td></td><td></td><td></td><td></td><td> 320</td>
<td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin</td><td>Pro</td><td></td>
<td></td><td></td><td></td><td></td><td> 325</td><td></td><td></td><td></td><td></td><td> 330</td><td></td><td></td><td></td><td></td><td> 335</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 144 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 247 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 144
<td rowspan="2">Met 1</td><td rowspan="2">That</td><td rowspan="2">Asn</td><td rowspan="2">Cys</td><td colspan="3" rowspan="2">Ser Ile Met 5</td><td colspan="9">Hair Asp Glu Hair Hair His His Leu Lys</td>
<td colspan="6"> 10</td><td colspan="3"> 15</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum 30</td><td>Glu</td><td>Asp</td>
<td>Met</td><td>Asp</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Lion</td><td>That</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td>Ile</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
RO 118016 Β1
<td>Pro</td><td>Asn</td><td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Arg</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td rowspan="2"> 12640</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td>Glu</td><td>His</td><td>Wave</td><td>Asn</td><td>That</td><td>Ile</td><td>Gin</td><td>Glu</td><td>That</td><td colspan="2">Arg Arg</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>Serum</td><td></td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td><td></td>
<td colspan="2">Arg Asp</td><td>Thr</td><td>That</td><td>That</td><td>Glu</td><td>Met</td><td>Asn</td><td>Glu</td><td>Thr</td><td>Wave</td><td>Glu</td><td>Wave</td><td>Ile</td><td>Serum</td><td>Glu</td><td></td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td><td> 12645</td>
<td>Met</td><td>Phe</td><td>Asp</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Arg</td><td>Lion</td><td>Glu</td><td>Lion</td><td></td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td><td></td>
<td>Tyr</td><td>Lys</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Arg</td><td>Gly</td><td>Serum</td><td>Lion</td><td>Thr</td><td>Lys</td><td>Lion</td><td colspan="2">Lys Gly</td><td>Pro</td><td>Lion</td><td></td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td><td></td>
<td>Thr</td><td>Met</td><td>Met</td><td>That</td><td>serum</td><td>His</td><td>Tyr</td><td>Lys</td><td>Gin</td><td>His</td><td>Cys</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Glu</td><td> 12650</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td><td></td>
<td>Thr</td><td>Serum</td><td>Cys</td><td>That</td><td>Thr</td><td>Gin</td><td>Ile</td><td>Ile</td><td>Thr</td><td>Phe</td><td>Glu</td><td>Serum</td><td>Phe</td><td>Lys</td><td>Glu</td><td>Asn</td><td></td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td><td></td>
<td>Lion</td><td>Lys</td><td>Asp</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Wave</td><td>Ile</td><td>Pro</td><td>Phe</td><td>Asp</td><td>Cys</td><td>Trp</td><td>Glu</td><td>Pro</td><td>wave</td><td></td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td><td> 12655</td>
Gin Glu (2) SEQUENCE INFORMATION ID NO. 145
<td>(I)</td><td>SEQUENCE CHARACTERISTICS:</td><td> 12660</td>
<td> («)</td><td>(A) LENGTH: 317 amino acids (B) TYPE: amino acid (C) FILLING: (D) TOPOLOGY: linear TYPE OF MOLECULE: protein</td><td> 12665</td>
(xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 145
<td colspan="2">Met Allah 1</td><td colspan="3">Asn Cys Ser 5</td><td>Ile</td><td colspan="4">Met him Asp Glu 10</td><td>Ile</td><td colspan="2">Him</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin
12670
12675
12680
RO 118016 Β1
100 105 110
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td colspan="2">Gly Arg</td><td>Ile 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Pro</td><td>Wave 135</td><td>Pro</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Asp 140</td><td>Serum</td><td>Lys</td><td colspan="2">Asp Val</td>
<td>That 145</td><td>That</td><td>Pro</td><td>His</td><td>Arg</td><td>Gin 150</td><td>Pro</td><td>Lion</td><td>Thr</td><td>Serum</td><td>Serum 155</td><td>Glu</td><td>Arg</td><td>XLE</td><td>Asp</td><td>Lys 160</td>
<td>Gin</td><td>Ile</td><td>Arg</td><td>Tyr</td><td>Ile 165</td><td>Lion</td><td colspan="2">Asp Gly</td><td>Ile</td><td>Serum 170</td><td>That</td><td>Lion</td><td colspan="2">Arg Lys</td><td>Glu 175</td><td>Thr</td>
<td>Cys</td><td>Asn</td><td>Lys</td><td>Serum 180</td><td>Asn</td><td>Met</td><td>Cys</td><td>Glu</td><td>Serum 185</td><td>Serum</td><td>Lys</td><td>Glu</td><td>That</td><td>Lion 190</td><td>That</td><td>Glu</td>
<td>Asn</td><td>Asn</td><td>Lion 195</td><td>Asn</td><td>Lion</td><td>Pro</td><td>Lys</td><td>Met two hundred</td><td>That</td><td>Glu</td><td>Lys</td><td>Asp</td><td>Gly 205</td><td>Cys</td><td>Phe</td><td>Gin</td>
<td>Serum</td><td>Gly 210</td><td>Phe</td><td>Asn</td><td>Glu</td><td>Glu</td><td>Thr 215</td><td>Cys</td><td>Lion</td><td>Wave</td><td>Lys</td><td>Ile 220</td><td>XLE</td><td>Thr</td><td>Gly</td><td>Lion</td>
<td>Lion 225</td><td>Glu</td><td>Phe</td><td>Glu</td><td>Wave</td><td>Tyr 230</td><td>Lion</td><td>Glu</td><td>Tyr</td><td>Lion</td><td>Gin 235</td><td>Asn</td><td>Arg</td><td>Phe</td><td>Glu</td><td>Serum 240</td>
<td>Serum</td><td>Glu</td><td>Glu</td><td>Gin</td><td>That 245</td><td>Arg</td><td>That</td><td>Wave</td><td>Gin</td><td>Met 250</td><td>Serum</td><td>Thr</td><td>Lys</td><td>Wave</td><td>Lion 255</td><td>XLE</td>
<td>Gin</td><td>Phe</td><td>Lion</td><td>Gin 260</td><td>Lys</td><td>Lys</td><td>That</td><td>Lys</td><td>Asn 265</td><td>Lion</td><td>Asp</td><td>That</td><td>Ile</td><td>Thr 270</td><td>Thr</td><td>Pro</td>
<td>Asp</td><td>Pro</td><td>Thr 275</td><td>Thr</td><td>Asn</td><td>That</td><td>Serum</td><td>Lion 280</td><td>Lion</td><td>Thr</td><td>Lys</td><td>Lion</td><td>Gin 285</td><td>That</td><td>Gin</td><td>Aen</td>
<td>Gin</td><td>Trp 290</td><td>Lion</td><td>Gin</td><td>Asp</td><td>Met</td><td>Thr 295</td><td>Thr</td><td>His</td><td>Lion</td><td>Ile</td><td>Lion 300</td><td>Arg</td><td>Serum</td><td>Phe</td><td>Lye</td>
<td>Glu 305</td><td>Phe</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Serum 310</td><td>Lion</td><td>Arg</td><td>That</td><td>Lion</td><td>Arg 315</td><td>Gin</td><td>Met</td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 146 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 146
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Sar Phe Leu 15 IO 15
Leu Lys Cys Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala 20 25 30
RO 118016 Β1
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Being 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td>Being 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Read 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Read 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td>
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td>
<td>Tyr</td><td>Wave</td><td>Ile</td><td colspan="2">Glu Gly 180</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro 185</td><td colspan="3">Gly Gly Gly</td><td>Serum</td><td colspan="3">Gly Gly Gly 190</td>
<td>Serum</td><td>Asn</td><td>Met 195</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile two hundred</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile 205</td><td>Ile</td><td>His</td><td>His</td>
<td>Lion</td><td>Lys 210</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro 215</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn 220</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td>
<td>Glu 225</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion 230</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion 235</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion 240</td>
<td>Lion</td><td>That</td><td>Phe</td><td>Wave</td><td>Arg 245</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion 250</td><td>Glu</td><td>Asn</td><td>That</td><td>serum</td><td>Gly 255</td><td>Ile</td>
<td>Glu</td><td>That</td><td>Ile</td><td>Lion 260</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro 265</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>Wing 270</td><td>Thr</td><td>That</td>
<td>That</td><td>Pro</td><td>Serum 275</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile 280</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp 285</td><td>Trp</td><td>Gin</td><td>Glu</td>
<td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td>
290 295 300
12725
12730
12735
12740
12745
12750
12755
Glu Gin Gin
305 (2) SEQUENCE INFORMATION ID NO. 147 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear
12760
12765
EN 118016 Β1 (ii) TYPE OF MOLECULE: protein
12770 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 147
<td rowspan="2"></td><td colspan="4" rowspan="2">Met Ala Thr Pro 1</td><td rowspan="2">Lion 5</td><td colspan="2" rowspan="2">Gly Pro</td><td colspan="9">Ala Ser Ser Leu Pro Gin Ser Phe Leu</td>
<td colspan="3"> 10</td><td colspan="6"> 15</td>
<td> 12775</td><td>Lion</td><td>Lys</td><td>Cys</td><td>I <I 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly 30</td><td>That</td><td>That</td>
<td></td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cye</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td></td><td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td></td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td></td><td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td> 12780</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion</td>
<td></td><td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td></td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td rowspan="2">Gly</td>
<td></td><td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td></td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td rowspan="2">Asp</td><td>Wave</td>
<td> 12785</td><td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td>
<td></td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td><td rowspan="2">Gly</td><td>Met</td>
<td></td><td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td>
<td></td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td></td><td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td> 12790</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin</td>
<td></td><td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td></td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>wave</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin</td><td>Pro</td>
<td></td><td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td></td><td>Tyr</td><td>wave</td><td>XLE</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly</td>
<td></td><td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td rowspan="2"> 190</td><td></td><td></td>
<td> 12795</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td>
<td></td><td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td></td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td>
<td></td><td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td rowspan="2"> 12800</td><td>Glu</td><td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td></td><td>Glu</td><td>Serum</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td>
<td></td><td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td></td><td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td>
<td></td><td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td> 12805</td><td>That</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>XLE</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td>
<td></td><td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
RO 118016 Β1
Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin
290 295 300 12810
Glu Gin Gin
305 (2) SEQUENCE INFORMATION ID NO. 148 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 337 amino acids (B) ΊΠΡ: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) MOLECULE OIL: protein
12815
12820 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 148
<td>Met 1</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion 5</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum 10</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe 15</td><td>Lion</td><td> 12825</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Read 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly 30</td><td>That</td><td>That</td><td></td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td colspan="2">Tyr Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td><td></td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td><td> 12830</td>
<td>Serum 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Read 80</td><td></td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td><td> 12835</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td><td></td>
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td><td></td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td> 12840</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td><td></td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td><td> 12845</td>
<td>Tyr</td><td>Wave</td><td>Pro</td><td>Gin 180</td><td>Pro</td><td>Pro</td><td>Wave</td><td>Asn</td><td>That 185</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Serum</td><td>Gly 190</td><td colspan="2">Gly Gly</td><td></td>
<td>Serum</td><td colspan="3">Gly Gly Gly</td><td>Serum</td><td>Glu</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td></td>
195 200 205
Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly
RO 118016 Β1
210 215 220
<td>Asp 225</td><td>Phe</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn 230</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 235</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 240</td>
<td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 245</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That 250</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 255</td><td>Asn</td>
<td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 260</td><td>Glu</td><td>Asp</td><td>Wave</td><td>Serum</td><td>Ile 265</td><td>Lion</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn 270</td><td>Lion</td><td>Arg</td>
<td>Lion</td><td>Wave</td><td>Arg 275</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion 280</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly 285</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile</td><td>Lion 290</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro 295</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That 300</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td>Serum 305</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile 310</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp 315</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg 320</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe 325</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion 330</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu 335</td><td>Gin</td>
Gin (2) SEQUENCE INFORMATION ID NO. 149 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 149
<td colspan="16">Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="5"> 15</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td colspan="2">Asp Gly</td><td>That</td><td>That</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td rowspan="2">Gly</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td rowspan="2">Asp</td><td>Wave</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td>
RO 118016 Β1
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td><td> 12895</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td></td>
<td>That 145</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td><td> 12900</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td><td></td>
<td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu 180</td><td colspan="2">Gly Arg</td><td>Ile</td><td>Serum</td><td>Pro 185</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly 190</td><td>Pro</td><td>Ile</td><td></td>
<td>Serum</td><td>Thr</td><td>Ile 195</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro two hundred</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His 205</td><td>Lys</td><td>Serum</td><td>Pro</td><td> 12905</td>
<td>Asn</td><td>Met 210</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>XLE 215</td><td>Met</td><td>XLE</td><td>Asp</td><td>Glu</td><td>XLE 220</td><td>XLE</td><td>His</td><td>Hie</td><td>Lion</td><td></td>
<td>Lys 225</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro 230</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn 235</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu 240</td><td></td>
<td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion 245</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn</td><td>Lion 250</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>X> I 255</td><td>Glu</td><td> 12910</td>
<td>Serum</td><td>Phe</td><td>Wave</td><td>Arg 260</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion 265</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly 270</td><td>Ile</td><td>Glu</td><td></td>
<td>That</td><td>Ile</td><td>Lion 275</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro 280</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That 285</td><td>Thr</td><td>That</td><td>That</td><td> 12915</td>
<td>Pro</td><td>Serum 290</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>XLE 295</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp 300</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td></td>
<td>Arg 305</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe 310</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion 315</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu 320</td><td></td>
Gin Gin 12920 (2) SEQUENCE INFORMATION ID NO. 150 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 150
12925
12930
Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu 15 10 15
Leu Lys Cys Leu Glu Gin Val Arg Lys lle Gin Gly Asp Gly Ala Ala
RO 118016 Β1
<td> 12935</td><td colspan="8"> 20</td><td colspan="4"> 25</td><td colspan="4"> 30</td>
<td></td><td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td></td><td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td></td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td></td><td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td> 12940</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td>serum</td><td>Gin</td><td>Lion</td>
<td></td><td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td></td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td rowspan="2">Gly</td>
<td></td><td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td rowspan="2"> 12945</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Wave</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td></td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Lion</td><td rowspan="2">Gly</td><td>Met</td>
<td></td><td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td>
<td></td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>pro</td><td>Thr</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td> 12950</td><td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td></td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin</td>
<td></td><td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td></td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin</td><td>Pro</td>
<td></td><td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td> 12955</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly</td><td>Pro</td><td>Ile</td>
<td></td><td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td></td><td>Serum</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His</td><td rowspan="2">Lys</td><td>Serum</td><td>Pro</td>
<td></td><td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td>
<td></td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td>
<td> 12960</td><td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td></td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td>
<td></td><td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td></td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td>
<td rowspan="2"> 12965</td><td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>That</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td>
<td></td><td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td></td><td>That</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td>
<td></td><td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td rowspan="2"> 12970</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td>
<td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td><td></td>
<td></td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td>
<td></td><td> 305</td><td></td><td></td><td></td><td></td><td> 310</td><td></td><td></td><td></td><td></td><td> 315</td><td></td><td></td><td></td><td></td><td> 320</td>
Gin Gin
12975 (2) SEQUENCE INFORMATION ID NO. 151
EN 118016 Β1 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 349 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
12980
12985 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 151
<td>Met 1</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion 5</td><td>Gly</td><td>Pro</td><td>That</td><td>serum</td><td>Be 10</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe 15</td><td>Lion</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Lion 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly 30</td><td>That</td><td>That</td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>G1U</td><td>Glu</td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Being 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td>Serum 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Read 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td>
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td><td>That 150</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td>
<td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu 180</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro 185</td><td>Gin</td><td>Pro</td><td>Pro</td><td>Wave</td><td>Asn 190</td><td>That</td><td>Gly</td>
<td>Gly</td><td>Gly</td><td>Serum 195</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Serum</td><td>Gly 20C</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td colspan="2">Gly Gly 205</td><td>Gly</td><td>Serum</td>
<td>Glu</td><td>Gly 210</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly 215</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Glu</td><td>Gly 220</td><td colspan="2">Gly Gly</td><td>Serum</td><td>Gly</td>
<td>Gly</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Asp</td><td>Phe</td><td>Asp</td><td>Tyr</td><td>Glu</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td>
225 230 235 240
12990
12995
13000
13005
13010
13015
Being him Met. Hair Asp Glu lle His His Leu Lys Arg Pro Pro Asn
245 250 255
13020
RO 118016 Β1
<td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td><td>Met</td><td>Asp</td><td>Ile</td><td>Lion</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Het</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td>
<td>Wave</td><td>Lye</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td rowspan="2">Arg</td><td>Asn</td>
<td></td><td> 290</td><td></td><td></td><td></td><td></td><td> 295</td><td></td><td></td><td></td><td></td><td> 300</td><td></td><td></td><td></td>
<td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td>
<td> 305</td><td></td><td></td><td></td><td></td><td> 310</td><td></td><td></td><td></td><td></td><td> 315</td><td></td><td></td><td></td><td></td><td> 320</td>
<td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td>
<td></td><td></td><td></td><td></td><td> 325</td><td></td><td></td><td></td><td></td><td> 330</td><td></td><td></td><td></td><td></td><td> 335</td><td></td>
<td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td>
340 345 (2) SEQUENCE INFORMATION ID NO. 152
<td colspan="2">SEQUENCE CHARACTERISTICS:</td>
<td>(A)</td><td>LENGTH: 307 amino acids</td>
<td>(B)</td><td>TYPE: amino acid</td>
<td>(C)</td><td>plaited</td>
<td>(D)</td><td>TOPOLOGY: linear</td>
(ii) TYPE OF MOLECULE: protein
<td colspan="10">SEQUENCE DESCRIPTION: SEQ. ID NO.</td><td colspan="6"> 152</td>
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly 90</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly 125</td><td>serum</td><td>Gly</td><td>Gly</td>
<td>Gly</td><td>Serum 130</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 135</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum 140</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td>
Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys Ile Gin Gly Asp
RO 118016 Β1
145 150 155 160 13065
<td colspan="17">Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His</td>
<td colspan="3"></td><td colspan="2"> 165</td><td colspan="6"> 170</td><td colspan="6"> 175</td>
<td>Pro</td><td>Glu</td><td>Glu</td><td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td></td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td><td></td>
<td>Pro</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td>Cys</td><td>Lion</td><td> 13070</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Gin</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td></td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Glu</td><td>Gly</td><td>Ile</td><td>serum</td><td>Pro</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td rowspan="2"> 13075</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>Lion</td><td rowspan="2">Asp</td><td>Wave</td><td>That</td><td>Asp</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td></td>
<td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td><td></td>
<td>Lion</td><td rowspan="2">Gly</td><td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr</td><td>Gin</td><td rowspan="2">Gly</td><td>That</td><td>Met</td><td>Pro</td><td>That</td><td></td>
<td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td> 270</td><td></td><td></td><td> 13080</td>
<td>Phe</td><td>That</td><td>Serum</td><td>That</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td><td>That</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave</td><td>That</td><td>Serum</td><td></td>
<td></td><td></td><td> 275</td><td></td><td></td><td></td><td></td><td> 280</td><td></td><td></td><td></td><td></td><td> 285</td><td></td><td></td><td></td><td></td>
<td>His</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td></td>
290 295 300
<td>Ala Gin Pro</td><td> 13085</td>
<td> 305</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 153 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 244 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 153
13090
13095
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td><td></td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td><td> 13100</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td><td></td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td> 13105</td>
<td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td><td></td>
RO 118016 Β1
<td colspan="2" rowspan="2">Be Arg</td><td colspan="2" rowspan="2">His Pro</td><td colspan="12">Hair Hair Hair Lys Ala Gly Asp Trp Gin Glu Phe Arg</td>
<td> 85</td><td colspan="8"> 90</td><td colspan="3"> 95</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td colspan="2">Tyr Leu</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td colspan="2">Glu Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Glu</td><td>Gly</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly</td><td>Gly</td><td>serum</td><td colspan="2">Gly Gly</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td>
<td>His</td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td>Asp</td><td>Glu</td><td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td>Lion</td><td>Glu</td><td>Serum</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td>
<td>Ile</td><td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td>
<td>That</td><td>That</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td>
<td>Glu</td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
Gin Glu Gin Gin (2) SEQUENCE INFORMATION ID NO. 154 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 154
<td>Met 1</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum 5</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu 10</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td>Lion 15</td><td>Lys</td>
<td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>AEP</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td>AEP</td><td>Arg</td><td>Aen 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
Hair Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro
RO 118016 Β1
<td colspan="3" rowspan="2"> 65</td><td rowspan="3">Pro</td><td colspan="5" rowspan="2"> 70</td><td colspan="4" rowspan="2"> 75</td><td colspan="4"> 80</td>
<td rowspan="2">Glu</td><td rowspan="2">Phe 95</td><td rowspan="2">Arg</td><td rowspan="2"> 13155</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Ile 85</td><td colspan="4">Hair Hair Lys Ala</td><td>Gly 90</td><td colspan="2">Asp Trp</td><td>Gin</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td><td> 13160</td>
<td>zle</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td><td></td>
<td>Pro 145</td><td>Asn</td><td>Met</td><td>That</td><td>Thr</td><td>Pro 150</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum 155</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum 160</td><td> 13165</td>
<td>Phe</td><td>Lion</td><td>Lion</td><td>Lys</td><td>Serum 165</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg 170</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp 175</td><td>Gly</td><td></td>
<td>That</td><td>That</td><td>Lion</td><td>Gin 180</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That 185</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys 190</td><td>His</td><td>Pro</td><td></td>
<td>Glu</td><td>Glu</td><td>Lion 195</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His two hundred</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro 205</td><td>Trp</td><td>That</td><td>Pro</td><td> 13170</td>
<td>lion</td><td>Serum 210</td><td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin 215</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That 220</td><td>Gly</td><td>Cys</td><td>Lion</td><td>Serum</td><td></td>
<td>Gin 225</td><td>Lion</td><td>His</td><td>Serum</td><td>Gly</td><td>Lion 230</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly 235</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion 240</td><td> 13175</td>
<td>Glu</td><td>Gly</td><td>Ile</td><td>Serum</td><td>Pro 24.5</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Pro</td><td> 585</td><td>Lion</td><td>Asn</td><td>Thr</td><td>Lion</td><td>Gin 255</td><td>T.A41</td><td></td>
<td>Asp</td><td>Wave</td><td>That</td><td>Asp 260</td><td>Phe</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile 265</td><td>Trp</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu 270</td><td>Glu</td><td>Lion</td><td></td>
13180
<td>Gly</td><td>Met</td><td>That 275</td><td>Pro</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro 280</td><td>Thr Gin</td><td>Gly</td><td>That</td><td>Met 285</td><td>Pro</td><td>That</td><td>Phe</td><td></td>
<td>That</td><td>Serum 290</td><td>That</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg 295</td><td>That</td><td>Gly Gly</td><td>Wave</td><td>Lion 300</td><td>Wave</td><td>That</td><td>Serum</td><td>His</td><td></td>
<td>Lion 305</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td><td>Glu 310</td><td>Wave</td><td>Serum</td><td>Tyr Arg</td><td>Wave 315</td><td>Lion</td><td>Arg</td><td>His</td><td>Lion</td><td>That 320</td><td> 13185</td>
<td>Gin</td><td>Pro</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 155 (i) SEQUENCE CHARACTERISTICS: 13190 (A) LENGTH: 259 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein <sub>13195</sub> (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 155
RO 118016 Β1
<td> 13200</td><td>Met 1</td><td colspan="8">Ala Asn Cys Ser Ile Met Hair Asp 5</td><td colspan="5">Glu Ile Ile His His 10</td><td>Lion 15</td><td>Lys</td>
<td></td><td>Arg</td><td>Pro</td><td>Pro</td><td>That 20</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro 25</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp 30</td><td>Glu</td><td>Asp</td>
<td></td><td>Wave</td><td>Serum</td><td>Ile 35</td><td>Lion</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn 40</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn 45</td><td>Lion</td><td>Glu</td><td>Serum</td>
<td> 13205</td><td colspan="16"></td>
<td></td><td>Phe</td><td>Wave 50</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn 55</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum 60</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td>Ile 65</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin 70</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum 75</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro 80</td>
<td> 13210</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile 85</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="3">Gly Asp Trp 90</td><td>Gin</td><td>Glu</td><td>Phe 95</td><td>Arg</td>
<td></td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr 100</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr 105</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin 110</td><td>Glu</td><td>Gin</td>
<td> 13215</td><td>Gin</td><td>Tyr</td><td>Wave 115</td><td>Glu</td><td colspan="2">Gly Gly</td><td>Gly</td><td>Gly 120</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro 125</td><td>Serum</td><td>Gly</td><td>Pro</td>
<td></td><td>Ile</td><td>Serum 130</td><td>Thr</td><td>Ile</td><td>Asn</td><td>Pro</td><td>Serum 135</td><td>Pro</td><td>Pro</td><td>Serum</td><td>Lys</td><td>Glu 140</td><td>Serum</td><td>His</td><td>Lys</td><td>Serum</td>
<td></td><td>Pro 145</td><td>Asn</td><td>Met</td><td>That</td><td>Asn</td><td>Cys 150</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile</td><td>Asp 155</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His 160</td>
<td> 13220</td><td>Lion</td><td>Lys</td><td>Arg</td><td>Pro</td><td>Pro 165</td><td>That</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp 170</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn 175</td><td>Asp</td>
<td></td><td>Glu</td><td>Asp</td><td>Wave</td><td>Serum 180</td><td>Ile</td><td>Lion</td><td>Met</td><td>Asp</td><td>Arg 185</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Lion</td><td>Pro 190</td><td>Asn</td><td>Lion</td>
<td> 13225</td><td>Glu</td><td>Serum</td><td>Phe 195</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys two hundred</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That 205</td><td>Serum</td><td>Gly</td><td>Ile</td>
<td></td><td>Glu</td><td>That 210</td><td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion 215</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro 220</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td>
<td></td><td>That 225</td><td>Pro</td><td>Serum</td><td>Arg</td><td>His</td><td>Pro 230</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That 235</td><td>Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu 240</td>
<td> 13230</td><td colspan="16"></td>
<td></td><td>Phe</td><td>Arg</td><td>Glu</td><td>Lys</td><td>Lion 245</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave 250</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That 255</td><td>Gin</td>
Glu Gin Gin (2) SEQUENCE INFORMATION ID NO. 156 13235
13240 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 156
13245
<td colspan="16">Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu</td>
<td> 1</td><td colspan="5"> 5</td><td colspan="7"> 10</td><td colspan="3"> 15</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Lion 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly 30</td><td>That</td><td>That</td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td colspan="2">Tyr Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Being 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td>Serum 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gly</td><td>Lion 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td>
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td>Arg</td><td>Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>serum</td><td>His</td><td>Lion</td><td>Gin 160</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>wave 165</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td>
<td>Tyr</td><td>Wave</td><td>Glu</td><td>Gly 180</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Pro 185</td><td>Gly</td><td>Glu</td><td>Pro</td><td>serum</td><td>Gly 190</td><td>Pro</td><td>Ile</td>
<td>Serum</td><td>Thr</td><td>Ile 195</td><td>Asn</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Pro two hundred</td><td>Serum</td><td>Lys</td><td>Glu</td><td>Serum</td><td>His 205</td><td>Lys</td><td>Serum</td><td>Pro</td>
<td>Asn</td><td>Met 210</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile 215</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile 220</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td>
<td>Lys 225</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro 230</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn 235</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td>Glu 240</td>
<td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion 245</td><td>Met</td><td>Asp</td><td>Arg</td><td>Asn</td><td>Lion 250</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion 255</td><td>Glu</td>
<td>Serum</td><td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td>
260 265 270
13250
13255
13260
13265
13270
13275
13280
Ala lle Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala
275 280 285
RO 118016 Β1
Pro Ser Arg His Pro li le Lys Ala Gly Asp Trp Gin Glu Phe 290 295 300
Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu 305 310 315 320
Gin Gin (2) SEQUENCE INFORMATION ID NO. 157 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 322 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 157
<td>Met 1</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion 5</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Be 10</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe 15</td><td>Lion</td>
<td>Lion</td><td>Lys</td><td>Serum</td><td>Read 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td>Gly</td><td>Asp</td><td>Gly 30</td><td>That</td><td>That</td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td>Being 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gly</td><td>Lion 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>AEP</td><td>Wave</td>
<td colspan="2">Ala Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td><td>That 150</td><td>Gly</td><td>Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td>
<td>Tyr</td><td>Wave</td><td>Glu</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Pro</td><td>Serum</td><td>Gly</td><td>Pro</td><td>Ile</td>
180 185 190
Ser Thr le Asn Pro ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro
RO 118016 Β1
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td><td></td><td> 13330</td>
<td>Asn</td><td>Met 210</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile 215</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile 220</td><td>Ile</td><td>His</td><td>His</td><td>Lion</td><td></td>
<td>Lys 225</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro 230</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn 235</td><td>Asn</td><td>Lion</td><td>aan</td><td>Asp</td><td>Glu 240</td><td></td>
<td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion 245</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn</td><td>Lion 250</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion 255</td><td>Glu</td><td> 13335</td>
<td>Serum</td><td>Phe</td><td>Wave</td><td>Arg 260</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion 265</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly 270</td><td>Ile</td><td>Glu</td><td></td>
<td>That</td><td>Ile</td><td>Lion 275</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro 280</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That 285</td><td>Thr</td><td>That</td><td>That</td><td> 13340</td>
<td>Pro</td><td>Serum 290</td><td>Arg</td><td>encore</td><td>Pro</td><td>Ile</td><td>Ile 295</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp 300</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td></td>
<td>Arg 305</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe 310</td><td>Tyr</td><td>Lion</td><td>wave</td><td>Thr</td><td>Lion 315</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu 320</td><td></td>
<td>Gin</td><td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 13345</td>
<td colspan="3">(2) SEQUENCE INFORMATION 10 NO. 158</td>
<td>(I)</td><td>SEQUENCE CHARACTERISTICS:</td><td></td>
<td></td><td>(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING: (D) TOPDLOGE: linear</td><td> 13350</td>
<td>(Ii)</td><td>TYPE OF MOLECULE: protein</td><td></td>
<td>(Xi)</td><td>SEQUENCE DESCRIPTION: SEQ. ID NO. 158</td><td> 13355</td>
<td colspan="17">Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu</td>
<td colspan="2"> 1</td><td colspan="5">S</td><td colspan="3"> 10</td><td colspan="7"> 15</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td colspan="2">Arg Lys</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly</td><td>That</td><td>That</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td> 13360</td>
<td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly</td><td rowspan="2">Cys</td><td>Lion</td><td>Serum</td><td rowspan="2">Gly</td><td>Lion</td><td rowspan="2"> 13365</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td> 80</td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu</td><td rowspan="2">Gly</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
lle Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val
100 105 110
RO 118016 Β1
<td>That</td><td>Asp</td><td>Phe 115</td><td colspan="2">Allah Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>serum</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td>Tyr</td><td>Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td>
<td>Tyr</td><td>Wave</td><td>Glu</td><td colspan="4">Gly Gly Gly Gly 180</td><td>Serum</td><td>Pro 185</td><td>Gly</td><td colspan="2">Gly Gly</td><td>Serum</td><td colspan="3">Gly Gly Gly 190</td>
<td>Serum</td><td>Asn</td><td>Met 195</td><td>That</td><td>Asn</td><td>Cys</td><td>Serum</td><td>Ile two hundred</td><td>Met</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile 205</td><td>Ile</td><td>His</td><td>His</td>
<td>Lion</td><td>Lys 210</td><td>Arg</td><td>Pro</td><td>Pro</td><td>That</td><td>Pro 215</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn 220</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td>
<td>Glu 225</td><td>Asp</td><td>Wave</td><td>Serum</td><td>Ile</td><td>Lion 230</td><td>Met</td><td colspan="2">Asp Arg</td><td>Asn</td><td>Lion 235</td><td>Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion 240</td>
<td>Glu</td><td>Serum</td><td>Phe</td><td>Wave</td><td>Arg 245</td><td>That</td><td>Wave</td><td>Lys</td><td>Asn</td><td>Lion 250</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly 255</td><td>Ile</td>
<td>Glu</td><td>That</td><td>Ile</td><td>Lion 260</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro 265</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That 270</td><td>Thr</td><td>That</td>
<td>That</td><td>Pro</td><td>Serum 275</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile 280</td><td>Ile</td><td>Lys</td><td>That</td><td>Gly</td><td colspan="2">Asp Trp 285</td><td>Gin</td><td>Glu</td>
<td>Phe</td><td>Arg 290</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe 295</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion 300</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td>
<td>Glu 305</td><td>Gin</td><td>Gin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 159 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 307 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 159
<td>Met</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe</td><td>Lion</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td>SE</td><td></td>
<td>Lion</td><td>Lys</td><td>Serum</td><td>Lion</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys</td><td>Ile</td><td>Gin</td><td>Gly</td><td colspan="2">Asp Gly</td><td>That</td><td>That</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Lion</td><td>Gin</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His</td><td>Pro</td><td>Glu</td><td>Glu</td>
RO 118016 Β1
<td colspan="3"> 35</td><td colspan="3"> 40</td><td colspan="2"> 45</td><td rowspan="3">Lion</td><td rowspan="3">Serum</td><td rowspan="3"> 13415</td>
<td colspan="2">I read Val</td><td rowspan="2">Leu Leu</td><td rowspan="2">Gly</td><td colspan="2">His Ser Leu Gly lle Pro Trp</td><td rowspan="2">That</td><td rowspan="2">Pro</td>
<td></td><td> 50</td><td> 55</td><td> 60</td>
<td>Serum</td><td>Cys</td><td>Pro Ser</td><td>Gin</td><td>Hello Lee</td><td>Gin Leu Ala Gly Cys</td><td>Lion</td><td>Serum</td><td>Gly</td><td>Lion</td><td></td>
<td> 65</td><td></td><td></td><td></td><td> 70</td><td> 75</td><td></td><td></td><td></td><td> 80</td><td></td>
<td>His</td><td>Serum</td><td>Gly Leu</td><td>Phe</td><td>Read Tyr</td><td>Gin Gly Leu Leu Gin</td><td>That</td><td>Lion</td><td>Glu</td><td>Gly</td><td> 13420</td>
<td></td><td></td><td></td><td> 85</td><td></td><td> 90</td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Ile</td><td>Serum</td><td>Pro Glu</td><td>Lion</td><td>Gly Pro</td><td>Thr Leu Asp Thr Leu</td><td>Gin</td><td>Lion</td><td>Asp</td><td>Wave</td><td></td>
<td></td><td></td><td> 100</td><td></td><td></td><td> 105</td><td></td><td> 110</td><td></td><td></td><td></td>
<td>That</td><td>Asp</td><td>Phe Ala</td><td>Thr</td><td>Thr him</td><td>Trp Gin Gin Met Glu</td><td>Glu</td><td>Lion</td><td>Gly</td><td>Met</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td> 120</td><td> 125</td><td></td><td></td><td></td><td> 13425</td>
<td>That</td><td>Pro</td><td>Hello Lee</td><td>Gin</td><td>Pro Thr</td><td>Gin Gly Ala Met Pro</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td></td>
<td></td><td> 130</td><td></td><td></td><td> 135</td><td> 140</td><td></td><td></td><td></td><td></td><td></td>
<td>That</td><td>Phe</td><td colspan="2">Gin Arg Arg</td><td>Hi Gly</td><td>Gly Val Leu Val Ala</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin</td><td></td>
<td> 145</td><td></td><td></td><td></td><td> 150</td><td> 155</td><td></td><td></td><td></td><td> 160</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 13430</td>
<td>Serum</td><td>Phe</td><td colspan="2">Read Glu Val</td><td>Ser Tyr</td><td>Arg Val Leu Arg His</td><td>Lion</td><td>That</td><td>Gin</td><td>Pro</td><td></td>
<td></td><td></td><td></td><td> 165</td><td></td><td> 170</td><td></td><td></td><td> 175</td><td></td><td></td>
<td>Tyr</td><td>wave</td><td colspan="3">Glu Gly Gly Gly Gly</td><td>Be Pro Gly Gly Gly</td><td>Serum</td><td colspan="3">Gly Gly Gly</td><td></td>
<td></td><td></td><td> 180</td><td></td><td></td><td> 185</td><td></td><td> 190</td><td></td><td></td><td></td>
<td>Serum</td><td>Asn</td><td>Met Allah</td><td>Asn</td><td>Cye Sar</td><td>him Met him Asp Glu</td><td>Ile</td><td>Ile</td><td>His</td><td>His</td><td></td>
<td></td><td></td><td> 195</td><td></td><td></td><td> 200</td><td> 205</td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Lys</td><td>Arg Pro</td><td>Pro</td><td>Wing Pro</td><td>Leu Leu Asp Pro Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Asp</td><td></td>
<td></td><td> 210</td><td></td><td></td><td> 215</td><td> 220</td><td></td><td></td><td></td><td></td><td></td>
<td>Glu</td><td>Asp</td><td>It's worth it</td><td>Ile</td><td>Read Met</td><td>Asp Arg Asn Leu Arg</td><td>Lion</td><td>Pro</td><td>Asn</td><td>Lion</td><td></td>
<td> 225</td><td></td><td></td><td></td><td> 230</td><td> 235</td><td></td><td></td><td></td><td> 240</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 13440</td>
<td>Glu</td><td>Serum</td><td>Phe val</td><td>Arg</td><td>Alas</td><td>Lys Asn Leu Glu Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td></td>
<td></td><td></td><td></td><td> 245</td><td></td><td> 250</td><td></td><td></td><td> 255</td><td></td><td></td>
<td>Glu</td><td>That</td><td>you read it</td><td>Arg</td><td>Asn Leu</td><td>Gin Pro Cys Leu Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td></td>
<td></td><td></td><td> 260</td><td></td><td></td><td> 265</td><td></td><td> 270</td><td></td><td></td><td></td>
<td>That</td><td>Pro</td><td>Be Arg</td><td>His</td><td>For him</td><td>you Lys Ala Gly</td><td>Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td> 13445</td>
<td></td><td></td><td> 275</td><td></td><td></td><td> 280</td><td> 285</td><td></td><td></td><td></td><td></td>
<td>Phe</td><td>Arg</td><td>Glu Lys</td><td>Lion</td><td>Thr Phe</td><td>Tyr Leu Val Thr Leu</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td></td>
<td></td><td> 290</td><td></td><td></td><td> 295</td><td> 300</td><td></td><td></td><td></td><td></td><td></td>
Glu Gin Gin
305 13450 (2) SEQUENCE INFORMATION ID NO. 160 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 128 amino acids (B) TYPE: amino acid
EN 118016 Β1 (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
<td> «)</td><td colspan="10">SEQUENCE DESCRIPTION: SEQ. ID NO.</td><td colspan="5"> 160</td>
<td>Met</td><td>That</td><td>Pro</td><td>That</td><td>Arg</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Pro</td><td>Serum</td><td>Thr</td><td>Gin</td><td>Pro</td><td>Trp</td><td>Glu</td><td>His</td>
<td> 1</td><td></td><td></td><td></td><td> 5</td><td></td><td></td><td></td><td></td><td> 10</td><td></td><td></td><td></td><td></td><td> 15</td><td></td>
<td>Wave</td><td>Asn</td><td>That</td><td>Ile</td><td>Gin</td><td>Glu</td><td>That</td><td colspan="2">Arg Arg</td><td>Lion</td><td>Lion</td><td>Asn</td><td>Lion</td><td>Serum</td><td colspan="2">Arg Asp</td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td>
<td>Thr</td><td>That</td><td>That</td><td>Glu</td><td>Met</td><td>Asn</td><td>Glu</td><td>Thr</td><td>Wave</td><td>Glu</td><td>Wave</td><td>Ile</td><td>Serum</td><td>Glu</td><td>Met</td><td>Phe</td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Asp</td><td>Lion</td><td>Gin</td><td>Glu</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Gin</td><td>Thr</td><td>Arg</td><td>Lion</td><td>Glu</td><td>Lion</td><td>Tyr</td><td>Lys</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Gin</td><td>Gly</td><td>Lion</td><td>Arg</td><td>Gly</td><td>Serum</td><td>Lion</td><td>Thr</td><td>Lys</td><td>Lion</td><td>Lys</td><td>Gly</td><td>Pro</td><td>Lion</td><td>Thr</td><td>Met</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Met</td><td>That</td><td>Serum</td><td>His</td><td>Tyr</td><td>Lys</td><td>Gin</td><td>His</td><td>Cys</td><td>Pro</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Glu</td><td>Thr</td><td>Serum</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td>
<td>Cys</td><td>That</td><td>Thr</td><td>Gin</td><td>Ile</td><td>Ile</td><td>Thr</td><td>Phe</td><td>Glu</td><td>Serum</td><td>Phe</td><td>Lys</td><td>Glu</td><td>Asn</td><td>Lion</td><td>Lys</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Asp</td><td>Phe</td><td>Lion</td><td>Lion</td><td>Wave</td><td>Ile</td><td>Pro</td><td>Phe</td><td colspan="2">Asp Cys</td><td>Trp</td><td>Glu</td><td>Pro</td><td>Wave</td><td>Gin</td><td>Glu</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
(2) SEQUENCE INFORMATION ID NO. 161 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 176 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 161
<td>Met 1</td><td>That</td><td>Thr</td><td>Pro</td><td>Lion 5</td><td>Gly</td><td>Pro</td><td>That</td><td>Serum</td><td>Serum 10</td><td>Lion</td><td>Pro</td><td>Gin</td><td>Serum</td><td>Phe 15</td><td>Lion</td>
<td>Lion</td><td>Lys</td><td>Cys</td><td>Lion 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td colspan="2">Gly Gly</td><td>Asp</td><td>Gly 30</td><td>That</td><td>That</td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td>Tyr</td><td>Lye</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>serum 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td>
<td>Serum 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion 80</td>
RO 118016 Β1
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td><td> 13505</td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>AEP</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td><td></td>
<td>That</td><td>AEP</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td><td></td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td> 13510</td>
<td>That 145</td><td>Phe</td><td>Gin</td><td colspan="2">Arg Arg</td><td>That 150</td><td colspan="2">Gly Gly</td><td>Wave</td><td>Lion</td><td>Wave 155</td><td>That</td><td>Serum</td><td>His</td><td>Lion</td><td>Gin 160</td><td></td>
<td>Serum</td><td>Phe</td><td>Lion</td><td>Glu</td><td>Wave 165</td><td>Serum</td><td colspan="2">Tyr Arg</td><td>Wave</td><td>Lion 170</td><td>Arg</td><td>His</td><td>Lion</td><td>That</td><td>Gin 175</td><td>Pro</td><td> 13515</td>
(2) SEQUENCE INFORMATION ID NO. 162 (i) SEQUENCE CHARACTERISTICS:
<td></td><td>(A)</td><td>LENGTH: 176 amino acids</td><td rowspan="2"> 13520</td>
<td></td><td>(B)</td><td>ΊΠΡ: amino acid</td>
<td></td><td>(CJ</td><td>plaited</td><td></td>
<td></td><td>(D)</td><td>TOPOLOGY: linear</td><td></td>
<td>(Ii)</td><td colspan="2">TYPE OF MOLECULE: protein</td><td></td>
<td>(Xi)</td><td colspan="2">SEQUENCE DESCRIPTION: SEQ. ID NO. 162</td><td> 13525</td>
<td colspan="17">Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu</td>
<td colspan="3"> 1</td><td colspan="2"> 5</td><td colspan="6"> 10</td><td colspan="6"> 15</td>
<td>Lion</td><td>Lys</td><td>Serum</td><td>Lion 20</td><td>Glu</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lys 25</td><td>Ile</td><td>Gin</td><td colspan="3">Gly Asp Gly 30</td><td>That</td><td>That</td><td> 13530</td>
<td>Lion</td><td>Gin</td><td>Glu 35</td><td>Lys</td><td>Lion</td><td>Cys</td><td>That</td><td>Thr 40</td><td>Tyr</td><td>Lys</td><td>Lion</td><td>Cys</td><td>His 45</td><td>Pro</td><td>Glu</td><td>Glu</td><td></td>
<td>Lion</td><td>Wave 50</td><td>Lion</td><td>Lion</td><td>Gly</td><td>His</td><td>Serum 55</td><td>Lion</td><td>Gly</td><td>Ile</td><td>Pro</td><td>Trp 60</td><td>That</td><td>Pro</td><td>Lion</td><td>Serum</td><td> 13535</td>
<td>Serum 65</td><td>Cys</td><td>Pro</td><td>Serum</td><td>Gin</td><td>That 70</td><td>Lion</td><td>Gin</td><td>Lion</td><td>That</td><td>Gly 75</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Lion 80</td><td></td>
<td>His</td><td>Serum</td><td>Gly</td><td>Lion</td><td>Phe 85</td><td>Lion</td><td>Tyr</td><td>Gin</td><td>Gly</td><td>Lion 90</td><td>Lion</td><td>Gin</td><td>That</td><td>Lion</td><td>Glu 95</td><td>Gly</td><td></td>
<td>Ile</td><td>Serum</td><td>Pro</td><td>Glu 100</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Lion 105</td><td>Asp</td><td>Thr</td><td>Lion</td><td>Gin</td><td>Lion 110</td><td>Asp</td><td>Wave</td><td> 13540</td>
<td>That</td><td>Asp</td><td>Phe 115</td><td>That</td><td>Thr</td><td>Thr</td><td>Ile</td><td>Trp 120</td><td>Gin</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu 125</td><td>Lion</td><td>Gly</td><td>Met</td><td></td>
<td>That</td><td>Pro 130</td><td>That</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Thr 135</td><td>Gin</td><td>Gly</td><td>That</td><td>Met</td><td>Pro 140</td><td>That</td><td>Phe</td><td>That</td><td>Serum</td><td> 13545</td>
RO 118016 Β1
Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin
145 150 155 160
Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro
165 170 175 (2) SEQUENCE INFORMATION ID NO. 163 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 186 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE; protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 163
<td>Met 1</td><td>That</td><td>Pro</td><td>Wave</td><td>Pro 5</td><td>Pro</td><td>Gly</td><td>Glu</td><td>Asp</td><td>Be 10</td><td>Lys</td><td>Asp</td><td>Wave</td><td>That</td><td>That 15</td><td>Pro</td>
<td>His</td><td>Arg</td><td>Gin</td><td>Pro 20</td><td>Lion</td><td>Thr</td><td>Serum</td><td>Serum</td><td>Glu 25</td><td>Arg</td><td>Ile</td><td>Asp</td><td>Lys</td><td>Gin 30</td><td>XLE</td><td>Arg</td>
<td>Tyr</td><td>Ile</td><td>Lion 35</td><td colspan="2">Asp Gly</td><td>XLE</td><td>Serum</td><td>That 40</td><td>Lion</td><td>Arg</td><td>Lys</td><td>Glu</td><td>Thr 45</td><td>Cys</td><td>Asn</td><td>Lys</td>
<td>Serum</td><td>Asn 50</td><td>Met</td><td>Cys</td><td>Glu</td><td>Serum</td><td>Serum 55</td><td>Lys</td><td>Glu</td><td>That</td><td>Lion</td><td>That 60</td><td>Glu</td><td>Asn</td><td>Asn</td><td>Lion</td>
<td>Asn 65</td><td>Lion</td><td>Pro</td><td>Lys</td><td>Met</td><td>That 70</td><td>Glu</td><td>Lys</td><td>Asp</td><td>Gly</td><td>Cys 75</td><td>Phe</td><td>Gin</td><td>Serum</td><td>Gly</td><td>Phe 80</td>
<td>Asn</td><td>Glu</td><td>Glu</td><td>Thr</td><td>Cys 85</td><td>Lion</td><td>Wave</td><td>Lys</td><td>Ile</td><td>Ile 90</td><td>Thr</td><td>Gly</td><td>Lion</td><td>Lion</td><td>Glu 95</td><td>Phe</td>
<td>Glu</td><td>Wave</td><td>Tyr</td><td>Lion 100</td><td>Glu</td><td>Tyr</td><td>Lion</td><td>Gin</td><td>Asn 105</td><td>Arg</td><td>Phe</td><td>Glu</td><td>Serum</td><td>Serum 110</td><td>Glu</td><td>Glu</td>
<td>Gin</td><td>That</td><td>Arg 115</td><td>That</td><td>Wave</td><td>Gin</td><td>Met</td><td>Serum 120</td><td>Thr</td><td>Lys</td><td>Wave</td><td>Lion</td><td>Ile 125</td><td>Gin</td><td>Phe</td><td>Lion</td>
<td>Gin</td><td>Lys 130</td><td>Lys</td><td>That</td><td>Lys</td><td>Asn</td><td>Lion 135</td><td>Asp</td><td>That</td><td>Ile</td><td>Thr</td><td>Thr 140</td><td>Pro</td><td>Asp</td><td>Pro</td><td>Thr</td>
<td>Thr 145</td><td>Asn</td><td>That</td><td>Serum</td><td>Lion</td><td>Lion 150</td><td>Thr</td><td>Lys</td><td>Lion</td><td>Gin</td><td>That 155</td><td>Gin</td><td>Asn</td><td>Gin</td><td>Trp</td><td>Lion 160</td>
<td>Gin</td><td>Asp</td><td>Met</td><td>Thr</td><td>Thr 165</td><td>His</td><td>Lion</td><td>Ile</td><td>Lion</td><td>Arg 170</td><td>Serum</td><td>Phe</td><td>Lys</td><td>Glu</td><td>Phe 175</td><td>Lion</td>
<td>Gin</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Arg</td><td>That</td><td>Lion</td><td>Arg</td><td>Gin</td><td>Met</td><td></td><td></td><td></td><td></td><td></td><td></td>
180 185 (2) SEQUENCE INFORMATION ID NO. 164 (i) SEQUENCE CHARACTERISTICS:
EN 118016 Β1 (A) LENGTH: 155 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 164
13595
13600
<td rowspan="2">Met 1</td><td rowspan="2">That</td><td rowspan="2">Serum</td><td rowspan="2">Pro</td><td colspan="11">Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser</td><td colspan="2" rowspan="2">Lys</td>
<td colspan="2"> 5</td><td colspan="4"> 10</td><td colspan="5"> 15</td>
<td>Lion</td><td>Lion</td><td colspan="2">Arg Asp</td><td>Serum</td><td>His</td><td>Wave</td><td>Lion</td><td>His</td><td>Serum</td><td>Arg</td><td>Lion</td><td>Serum</td><td>Gin</td><td>Cys</td><td>Pro</td><td></td>
<td></td><td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td> 13605</td>
<td>Glu</td><td>Wave</td><td>His</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Pro</td><td>That</td><td>Wave</td><td>Asp</td><td>Phe</td><td></td>
<td></td><td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Serum</td><td>Lion</td><td>Gly</td><td>Glu</td><td colspan="2">Trp Lys</td><td>Thr</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Thr</td><td>Lys</td><td>That</td><td>Gin</td><td>Asp</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Gly</td><td>That</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Wave</td><td>Met</td><td>That</td><td>That</td><td>Arg</td><td> 13610</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td><td></td>
<td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Gin</td><td>Lion</td><td>Serum</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td rowspan="2">Gly</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lion</td><td>Lion</td><td>Lion</td><td rowspan="2">Gly</td><td>That</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Lion</td><td>Lion</td><td rowspan="2">Gly</td><td>Thr</td><td rowspan="2"> 13615</td>
<td></td><td></td><td> 100</td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td>
<td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td colspan="2">Gly Arg</td><td>Thr</td><td>Thr</td><td>That</td><td>His</td><td>Lys</td><td>Asp</td><td>Pro</td><td>Asn</td><td>That</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Phe</td><td>Lion</td><td>Serum</td><td>Phe</td><td>Gin</td><td>His</td><td>Lion</td><td>Lion</td><td>Arg</td><td colspan="2">Gly Lys</td><td>Wave</td><td>Arg</td><td>Phe</td><td>Lion</td><td></td>
130 135 140
13620
Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg
145 150 155
<td colspan="4">(2) SEQUENCE INFORMATION ID NO. 165</td>
<td>(I)</td><td>SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) FILLING: (D) TOPOLOGY: linear</td><td></td><td> 13625</td>
<td>(Ii)</td><td>TYPE OF MOLECULE: protein</td><td></td><td> 13630</td>
<td>(Xi)</td><td>SEQUENCE DESCRIPTION: SEQ. ID NO. 165 Met Ala Asn Cys Being Him Met Him Asp Glu Him His 15 10 Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn</td><td>His Leu Lys 15 Ser Glu Asp</td><td> 13635</td>
RO 118016 Β1
25 30
<td>Met</td><td rowspan="2">AEP</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td>
<td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td>
<td> 65</td><td></td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="3">Gly Asp Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td rowspan="2">Arg</td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td>
<td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td>
<td></td><td></td><td></td><td> 100</td><td></td><td></td><td></td><td></td><td> 105</td><td></td><td></td><td></td><td></td><td> 110</td><td></td><td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly</td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly</td><td colspan="2">Gly Gly</td><td>Serum</td><td colspan="2">Gly Gly</td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td>
<td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Serum</td><td>Pro</td><td>That</td><td>Pro</td><td>Pro</td><td>That</td><td>Cye</td><td>Asp</td><td>Lion</td><td rowspan="2">Arg</td><td>Wave</td>
<td></td><td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td>
<td>Lion</td><td>Serum</td><td>Lys</td><td>Lion</td><td>Lion</td><td>Arg</td><td>Asp</td><td>Serum</td><td>His</td><td>wave</td><td>Lion</td><td>His</td><td>Serum</td><td>Arg</td><td>Lion</td><td>Serum</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td>
<td>Gin</td><td>Cys</td><td>Pro</td><td>Glu</td><td>Wave</td><td>His</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Pro</td><td>That</td>
<td></td><td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td>
<td>wave</td><td>Asp</td><td>Phe</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Glu</td><td>Trp</td><td>Lys</td><td>Thr</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Thr</td><td rowspan="2">Lys</td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td>
<td>That</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Gly</td><td>That</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td rowspan="2">Gly</td><td>Wave</td><td>Met</td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td> 205</td><td></td><td></td>
<td>That</td><td>That</td><td>Arg</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Lion</td><td rowspan="2">Gly</td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td>
<td>Gin</td><td>Lion</td><td>Serum</td><td>Gly</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>That</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Lion</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>Lion</td><td>Gly</td><td>Thr</td><td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Arg</td><td>Thr</td><td>Thr</td><td>That</td><td>His</td><td>Lys</td><td>Asp</td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>Pro</td><td>Asn</td><td>That</td><td>Ile</td><td>Phe</td><td>Lion</td><td>Serum</td><td>Phe</td><td>Gin</td><td>His</td><td>Lion</td><td>Lion</td><td>Arg</td><td>Gly</td><td>Lys</td><td>Wave</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Arg</td><td>Phe</td><td>Lion</td><td>Met</td><td>Lion</td><td>Wave</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Wave</td><td>Arg</td><td></td><td></td>
275 280 285 (2) SEQUENCE INFORMATION ID NO. 166 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 166
<td colspan="4" rowspan="2">Met Ala Asn Cys 1</td><td colspan="3" rowspan="2">Ser Ile Met 5</td><td colspan="2" rowspan="2">Hair Asp</td><td colspan="8">Glu Ile Ile His His Leu Lys</td>
<td colspan="4"> 10</td><td colspan="4"> 15</td>
<td rowspan="2">Arg</td><td>Pro</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp</td><td></td>
<td></td><td></td><td> 20</td><td></td><td></td><td></td><td></td><td> 25</td><td></td><td></td><td></td><td></td><td> 30</td><td></td><td></td><td></td>
<td>Met</td><td rowspan="2">Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td>That</td><td> 13690</td>
<td></td><td> 35</td><td></td><td></td><td></td><td></td><td> 40</td><td></td><td></td><td></td><td></td><td> 45</td><td></td><td></td><td></td><td></td>
<td>Phe</td><td>Wave</td><td>Arg</td><td>That</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu</td><td>Asn</td><td>That</td><td>serum</td><td>Gly</td><td>Ile</td><td>Glu</td><td>That</td><td></td>
<td></td><td> 50</td><td></td><td></td><td></td><td></td><td> 55</td><td></td><td></td><td></td><td></td><td> 60</td><td></td><td></td><td></td><td></td><td></td>
<td>Ile</td><td>Lion</td><td rowspan="2">Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td rowspan="2">Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td><td>Pro</td><td rowspan="2"> 13695</td>
<td> 65</td><td></td><td></td><td></td><td> 70</td><td></td><td></td><td></td><td> 75</td><td></td><td></td><td></td><td></td><td> 80</td>
<td>Serum</td><td>Arg</td><td>His</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp</td><td>Trp</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td></td>
<td></td><td></td><td></td><td></td><td> 85</td><td></td><td></td><td></td><td></td><td> 90</td><td></td><td></td><td></td><td></td><td> 95</td><td></td><td></td>
<td>Glu</td><td rowspan="2">Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td><td>Gin</td><td></td>
<td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"> 100</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"> 105</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"> 110</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"> 13700</td>
<td></td>
<td>Gin</td><td>Tyr</td><td>Wave</td><td>Glu</td><td colspan="4">Gly Gly Gly Gly</td><td>Serum</td><td>Pro</td><td colspan="3">Gly Gly Gly</td><td>Serum</td><td colspan="2">Gly Gly</td><td></td>
<td></td><td></td><td> 115</td><td></td><td></td><td></td><td></td><td> 120</td><td></td><td></td><td></td><td></td><td> 125</td><td></td><td></td><td></td><td></td>
<td rowspan="2">Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That</td><td>Serum</td><td>Pro</td><td>That</td><td>Pro</td><td>Pro</td><td>That</td><td>Cys</td><td>Asp</td><td>Lion</td><td>Arg</td><td>Wave</td><td></td>
<td> 130</td><td></td><td></td><td></td><td></td><td> 135</td><td></td><td></td><td></td><td></td><td> 140</td><td></td><td></td><td></td><td></td><td></td>
<td>Lion</td><td>Serum</td><td>Lys</td><td>Lion</td><td>Lion</td><td colspan="2">Arg Asp</td><td>Serum</td><td>His</td><td>Wave</td><td>Lion</td><td>His</td><td>Serum</td><td>Arg</td><td>Lion</td><td>Serum</td><td> 13705</td>
<td> 145</td><td></td><td></td><td></td><td></td><td> 150</td><td></td><td></td><td></td><td></td><td> 155</td><td></td><td></td><td></td><td></td><td> 160</td><td></td>
<td>Gin</td><td rowspan="2">Cys</td><td>Pro</td><td>Glu</td><td>Wave</td><td>His</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Pro</td><td>That</td><td></td>
<td></td><td></td><td></td><td> 165</td><td></td><td></td><td></td><td></td><td> 170</td><td></td><td></td><td></td><td></td><td> 175</td><td></td><td></td>
<td>Wave</td><td>Asp</td><td>Phe</td><td>Serum</td><td>Lion</td><td>Gly</td><td>Glu</td><td>Trp</td><td>Lys</td><td>Thr</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Thr</td><td>Lys</td><td></td>
<td></td><td></td><td></td><td> 180</td><td></td><td></td><td></td><td></td><td> 185</td><td></td><td></td><td></td><td></td><td> 190</td><td></td><td></td><td> 13710</td>
<td>That</td><td>Gin</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Gly</td><td>That</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly</td><td>Wave</td><td>Met</td><td></td>
<td></td><td></td><td> 195</td><td></td><td></td><td></td><td></td><td> 200</td><td></td><td></td><td></td><td></td><td>20S</td><td></td><td></td><td></td><td></td>
<td>That</td><td>That</td><td>Arg</td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Serum</td><td>Lion</td><td>Lion</td><td>Gly</td><td>f</td>
<td></td><td> 210</td><td></td><td></td><td></td><td></td><td> 215</td><td></td><td></td><td></td><td></td><td> 220</td><td></td><td></td><td></td><td></td><td></td>
<td>Gin</td><td>Lion</td><td>Serum</td><td>Gly</td><td>Gin</td><td>Wave</td><td>Arg</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>That</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Lion</td><td> 13715</td>
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td><td></td>
<td>Lion</td><td>Gly</td><td>Thr</td><td>Gin</td><td>Lion</td><td>Pro</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Arg</td><td>Thr</td><td>Thr</td><td>That</td><td>His</td><td>Lys</td><td>Asp</td><td></td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td><td></td>
<td>Pro</td><td>Asn</td><td>That</td><td>Ile</td><td>Phe</td><td>Lion</td><td>Serum</td><td>Phe</td><td>Gin</td><td>His</td><td>Lion</td><td>Lion</td><td rowspan="2">Arg</td><td>Gly</td><td rowspan="2">Lys</td><td>Wave</td><td></td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td> 270</td><td></td><td> 13720</td>
<td>Arg</td><td>Phe</td><td>Lion</td><td>Met</td><td>Lion</td><td>Wave</td><td>Gly</td><td>Gly</td><td>Serum</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Wave</td><td>Arg</td><td></td><td></td><td></td>
275 280 285 (2) SEQUENCE INFORMATION ID NO. 167
13725 (i) SEQUENCE CHARACTERISTICS:
RO 118016 Β1
13730 (A) LENGTH: 286 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear [ii] TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 167
<td rowspan="2"></td><td colspan="3" rowspan="2">Met Allah be 1</td><td colspan="10">Pro Ala Pro Pro Ala Cys Asp Leu Arg Val</td><td rowspan="2">Lion</td><td colspan="2" rowspan="2">Be Lys 15</td>
<td colspan="2"> 5</td><td colspan="8"> 10</td>
<td></td><td>Lion</td><td>Lion</td><td>Arg</td><td>Asp 20</td><td>Serum</td><td>His</td><td>Wave</td><td>Lion</td><td>His 25</td><td>Serum</td><td>Arg</td><td>Lion</td><td>Serum</td><td>Gin 30</td><td>Cys</td><td>Pro</td>
<td> 13740</td><td colspan="16"></td>
<td></td><td>Glu</td><td>Wave</td><td>His 35</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro 40</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Pro</td><td>That 45</td><td>Wave</td><td>Asp</td><td>Phe</td>
<td></td><td>Serum</td><td>Lion 50</td><td>Gly</td><td>Glu</td><td>Trp</td><td>Lys</td><td>Thr 55</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Thr 60</td><td>Lys</td><td>That</td><td>Gin</td><td>Asp</td>
<td> 13745</td><td>Ile 65</td><td>Lion</td><td>Gly</td><td>That</td><td>Wave</td><td>Thr 70</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly 75</td><td>Wave</td><td>Met</td><td>That</td><td>That</td><td>Arg 80</td>
<td></td><td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro 85</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Serum 90</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Gin</td><td>Lion 95</td><td>Serum</td>
<td> 13750</td><td>Gly</td><td>Gin</td><td>Wave</td><td>Arg 100</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>That 105</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Lion</td><td>Lion 110</td><td>Gly</td><td>Thr</td>
<td></td><td>Gin</td><td>Lion</td><td>Pro 115</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Arg</td><td>Thr 120</td><td>Thr</td><td>That</td><td>His</td><td>Lys</td><td>Asp 125</td><td>Pro</td><td>Asn</td><td>That</td>
<td></td><td>Ile</td><td>PBE 130</td><td>Lion</td><td>Serum</td><td>Phe</td><td>Gin</td><td>His 135</td><td>Lion</td><td>Lion</td><td>Arg</td><td>Gly</td><td>Lys 140</td><td>Wave</td><td>Arg</td><td>Phe</td><td>Lion</td>
<td> 13755</td><td>Met 145</td><td>Lion</td><td>Wave</td><td>Gly</td><td>Gly</td><td>Serum 150</td><td>Thr</td><td>Lion</td><td>Cys</td><td>wave</td><td>Arg 155</td><td>Tyr</td><td>Wave</td><td>Ile</td><td>Glu</td><td>Gly 160</td>
<td></td><td>Arg</td><td>Ile</td><td>Serum</td><td>Pro</td><td>Gly 165</td><td colspan="2">Gly Gly</td><td>serum</td><td>Gly</td><td>Gly 170</td><td>Gly</td><td>Serum</td><td>Asn</td><td>Met</td><td>That 175</td><td>Asn</td>
<td> 13760</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met 180</td><td>Ile</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile 185</td><td>His</td><td>His</td><td>Lion</td><td>Lys</td><td>Arg 190</td><td>Pro</td><td>Pro</td>
<td></td><td>Asn</td><td>Pro</td><td>Lion 195</td><td>Lion</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn two hundred</td><td>Lion</td><td>Asn</td><td>Serum</td><td>Glu</td><td>Asp 205</td><td>Met</td><td>Asp</td><td>Ile</td>
<td></td><td>Lion</td><td>Met 210</td><td>Glu</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg 215</td><td>Thr</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion 220</td><td>That</td><td>Phe</td><td>Wave</td><td>Arg</td>
<td> 13765</td><td colspan="16"></td>
<td></td><td>That 225</td><td>Wave</td><td>Lys</td><td>His</td><td>Lion</td><td>Glu 230</td><td>Aen</td><td>That</td><td>Serum</td><td>Gly</td><td>Ile 235</td><td>Glu</td><td>That</td><td>Ile</td><td>Lion</td><td>Arg 240</td>
<td></td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys 245</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr 250</td><td>That</td><td>That</td><td>Pro</td><td>Serum</td><td>Arg 255</td><td>His</td>
<td> 13770</td><td>Pro</td><td>Ile</td><td>Ile</td><td>Ile 260</td><td>Lys</td><td>That</td><td>Gly</td><td>Asp</td><td>Trp 265</td><td>Gin</td><td>Glu</td><td>Phe</td><td>Arg</td><td>Glu 270</td><td>Lys</td><td>Lion</td>
RO 118016 Β1
Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin
275 280 285 (2) SEQUENCE INFORMATION ID NO. 168 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 290 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 168
13775
13780
13785
<td>Met 1</td><td>That</td><td>serum</td><td>Pro</td><td>That 5</td><td>Pro</td><td>Pro</td><td>That</td><td>Cys</td><td>Asp 10</td><td>Lion</td><td>Arg</td><td>Wave</td><td>Lion</td><td>Serum 15</td><td>Lys</td><td></td>
<td>Lion</td><td>Lion</td><td>Arg</td><td>Asp 20</td><td>Serum</td><td>His</td><td>Wave</td><td>Lion</td><td>His 25</td><td>Serum</td><td>Arg</td><td>Lion</td><td>Serum</td><td>Gin 30</td><td>Cys</td><td>Pro</td><td> 13790</td>
<td>Glu</td><td>Wave</td><td>His 35</td><td>Pro</td><td>Lion</td><td>Pro</td><td>Thr</td><td>Pro 40</td><td>Wave</td><td>Lion</td><td>Lion</td><td>Pro</td><td>That 45</td><td>Wave</td><td>Asp</td><td>Phe</td><td></td>
<td>Serum</td><td>Lion 50</td><td>Gly</td><td>Glu</td><td>Trp</td><td>Lys</td><td>Thr 55</td><td>Gin</td><td>Met</td><td>Glu</td><td>Glu</td><td>Thr 60</td><td>Lys</td><td>That</td><td>Gin</td><td>Asp</td><td></td>
<td>Ile 65</td><td>Lion</td><td>Gly</td><td>That</td><td>Wave</td><td>Thr 70</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Glu</td><td>Gly 75</td><td>Wave</td><td>Met</td><td>That</td><td>That</td><td>Arg 80</td><td> 13795</td>
<td>Gin</td><td>Gin</td><td>Lion</td><td>Gly</td><td>Pro 85</td><td>Thr</td><td>Cys</td><td>Lion</td><td>Serum</td><td>Serum 90</td><td>Lion</td><td>Lion</td><td>Gly</td><td>Gin</td><td>Lion 95</td><td>Serum</td><td></td>
<td>Gly</td><td>Gin</td><td>Wave</td><td>Arg 100</td><td>Lion</td><td>Lion</td><td>Lion</td><td>Gly</td><td>That 105</td><td>Lion</td><td>Gin</td><td>Serum</td><td>Lion</td><td>Lion 110</td><td>Gly</td><td>Thr</td><td> 13800</td>
<td>Gin</td><td>Lion</td><td>Pro 115</td><td>Pro</td><td>Gin</td><td>Gly</td><td>Arg</td><td>Thr 120</td><td>Thr</td><td>That</td><td>His</td><td>Lys</td><td>AEP 125</td><td>Pro</td><td>Asn</td><td>That</td><td></td>
<td>Ile</td><td>Phe 130</td><td>Lion</td><td>Serum</td><td>Phe</td><td>Gin</td><td>His 135</td><td>Lion</td><td>Lion</td><td>Arg</td><td>Gly</td><td>Lys 140</td><td>Wave</td><td>Arg</td><td>Phe</td><td>Lion</td><td> 13805</td>
<td>Met 145</td><td>Lion</td><td>Wave</td><td colspan="2">Gly Gly</td><td>Serum 150</td><td>Thr</td><td>Lion</td><td>Cys</td><td>Wave</td><td>Arg 155</td><td>Glu</td><td>Phe</td><td>His</td><td>That</td><td>Tyr 160</td><td></td>
<td>Wave</td><td>Glu</td><td colspan="4">Gly Gly Gly Gly 165</td><td>Serum</td><td>Pro</td><td>Gly</td><td>Gly 170</td><td>Gly</td><td>Serum</td><td>Gly</td><td>Gly</td><td>Gly 175</td><td>Serum</td><td></td>
<td>Asn</td><td>Met</td><td>That</td><td>Asn 180</td><td>Cys</td><td>Serum</td><td>Ile</td><td>Met</td><td>Ile 185</td><td>Asp</td><td>Glu</td><td>Ile</td><td>Ile</td><td>His 190</td><td>His</td><td>Lion</td><td> 13810</td>
<td>Lys</td><td>Arg</td><td>Pro 195</td><td>Pro</td><td>Asn</td><td>Pro</td><td>Lion</td><td>Lion two hundred</td><td>Asp</td><td>Pro</td><td>Asn</td><td>Asn</td><td>Lion 205</td><td>Asn</td><td>Serum</td><td>Glu</td><td></td>
<td>Asp</td><td>Met 210</td><td>Asp</td><td>Ile</td><td>Lion</td><td>Met</td><td>Glu 215</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Arg</td><td>Thr 220</td><td>Pro</td><td>Asn</td><td>Lion</td><td>Lion</td><td> 13815</td>
Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly lle Glu
RO 118016 Β1
<td> 225</td><td></td><td></td><td></td><td></td><td> 230</td><td></td><td></td><td></td><td></td><td> 235</td><td></td><td></td><td></td><td></td><td> 240</td>
<td>That</td><td>XLE</td><td>Lion</td><td>Arg</td><td>Asn</td><td>Lion</td><td>Gin</td><td>Pro</td><td>Cys</td><td>Lion</td><td>Pro</td><td>Serum</td><td>That</td><td>Thr</td><td>That</td><td>That</td>
<td></td><td></td><td></td><td></td><td> 245</td><td></td><td></td><td></td><td></td><td> 250</td><td></td><td></td><td></td><td></td><td> 255</td><td></td>
<td>Pro</td><td>Serum</td><td>Arg</td><td>Hie</td><td>Pro</td><td>XLE</td><td>XLE</td><td>XLE</td><td>Lys</td><td>That</td><td colspan="2">Gly Asp</td><td rowspan="2">Trp</td><td>Gin</td><td>Glu</td><td>Phe</td>
<td></td><td></td><td></td><td> 260</td><td></td><td></td><td></td><td></td><td> 265</td><td></td><td></td><td></td><td> 270</td><td></td><td></td>
<td>Arg</td><td>Glu</td><td>Lys</td><td>Lion</td><td>Thr</td><td>Phe</td><td>Tyr</td><td>Lion</td><td>Wave</td><td>Thr</td><td>Lion</td><td>Glu</td><td>Gin</td><td>That</td><td>Gin</td><td>Glu</td>
275 280 285
Gin Gin
290 (2) SEQUENCE INFORMATION ID NO. 169 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 169
ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGACCTCC GAGTC 45 (2) SEQUENCE INFORMATION ID NO. 170 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = ”synthetic DNA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 170
AATAGCTGAA TTCTTACCCT TCCTGAGACA GATT 34 (2) SEQUENCE INFORMATION ID NO. 171 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid
EN 118016 Β1 (A) DESCRIPTION: / synthetic desc-DNA
TGACAAGCTT ACCTGACGCA GAGGGTGGAC CCT 33 (2) SEQUENCE INFORMATION ID NO. 172 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE. * Nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / Synthetic deso'ONA (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 172
ATGCACGAAT TCCCTGACGC AGAGGGTGGA 30 (2) SEQUENCE INFORMATION ID NO. 173 (1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 pairs bases (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc-desc synthetic (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 173
AATTCCATGC ATAC 14 (2) SEQUENCE INFORMATION ID NO. 174 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) FILLING: simple (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / desc = synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 174
GGTACGTATG 1O
13860
13865
13870
13875
13880
13885
13890
13895 (2) SEQUENCE INFORMATION ID NO. 175
EN 118016 Β1 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 561 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: other nucleic acid (A) DESCRIPTION: / synthetic-synthetic DNA (xi) DESCRIPTION SEQUENCE: SEQ. ID NO. 175
<td>ATGGCTCCAG TACCACCAGG TGAAGATTCC AAAGATGTGG CCGCCCCACA CAGACAGCCA</td><td> 60</td>
<td>CTCACCTCTT CAGAACGAAT TGACAAACAA ATTCGGTACA TCCTCGACGG GATATCAGCC</td><td> 120</td>
<td>CTGAGAAAGG AGACATGTAA CAAGAGTAAC ATGTGTGAAA GCAGCAAAGA GGCGCTAGCA</td><td> 180</td>
<td>GAAAACAACC TGAACCTTCC AAAGATGGCT GAAAAAGATG GATGCTTCCA ATCCGGATTC</td><td> 240</td>
<td>AATGAGGAGA CTTGCCTGGT GAAAATCATC ACTGGTCTTT TGGAGTTTGA GGTATACCTC</td><td> 300</td>
<td>GAGTACCTCC AGAACAGATT TGAGAGTAGT GAGGAACAAG ccagagctgt gcagatgtcg</td><td> 360</td>
<td>ACAAAAGTCC TGATCCAGTT CCTGCAGAAA AAGGCAAAGA ATCTAGATGC AATAACCACC</td><td> 420</td>
<td>CCTGACCCAA CCACAAATGC ATCCCTGCTG ACGAAGCTGC AGGCACAGAA CCAGTGGCTG</td><td> 480</td>
<td>caggacatga caactcatct cattctgcgc AGCTTTAAGG agttcctgca gtccagcctg</td><td> 540</td>
<td>agggctcttc ggcaaatgta g</td><td> 561</td>
(2) SEQUENCE INFORMATION ID NO. 176 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 402 base pairs (BJ TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) MOLECULEIONA TYPE (genome) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176
<td>ATGGCACCGG CTCGTTCCCC GTCCCCGTCT ACCCAGCCGT</td><td>GGGAACACGT GAATGCCATC</td><td> 60</td>
<td>CAGGAGGCCC GGCGTCTCCT GAACCTGAGT AGAGACACTG</td><td>CTGCTGAGAT GAATGAAACA</td><td> 120</td>
<td>GTAGAAGTGA TATCAGAAAT GTTTGACCTC CAGGAGCCGA</td><td>CTTGCCTACA GACCCGCCTG</td><td> 180</td>
<td>GAGCTGTACA AGCAGGGCCT GCGGGGCAGC CTCACCAAGC</td><td>TCAAGGGCCC CTTGACCATG</td><td> 240</td>
<td>ATGGCCAGCC ACTACAAGCA GCACTGCCCT CCAACCCCGG</td><td>AAACTTCCTG TGCAACCCAG</td><td> 300</td>
<td>ATTATCACCT TTGAAAGTTT CAAAGAGAAC CTGAAGGACT</td><td>TCCTGCTTGT CATCCCCTTT</td><td> 360</td>
GACTGCTGGG AGCCAGTCCA GGAGTGATAA GGATCCGAAT TC
402
EN 118016 Β1 (2) SEQUENCE INFORMATION ID NO. 177 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 546 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome)
13940
13945
13950 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 177
ATGGCTACAC CATTAGGCCC TGCCAGCTCC CTGCCCCAGA. GCTTCCTGCT CAAGTGCTTA60
GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC120
TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG180
GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC240
13955
CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG300
TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG360
CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG420
GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 48013960
AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTG ATAAGGATCC540
GAATTC546 (2) SEQUENCE INFORMATION ID NO. 178
13965 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 546 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) <sup>13970</sup> (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 178
<td>ATGGCTACAC CATTAGGACC</td><td>TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA</td><td> 60</td>
<td>GAGCAAGTGA GGAAGATCCA</td><td>GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC</td><td> 120 13975</td>
<td>TACAAGCTGT GCCACCCCGA</td><td>GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG</td><td> 180</td>
<td>GCTCCCCTGA GCTCCTGCCC</td><td>CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC</td><td> 240</td>
<td>CATAGCGGCC TTTTCCTCTA</td><td>CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG</td><td> 300</td>
<td>TTGGGTCCCA CCTTGGACAC</td><td>ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG</td><td> 13980 360</td>
RO 118016 Β1
CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTG ATAAGGATCC 540 GAATTC 546 (2) INFORMATION FOR SEQUENCE ID NO. 179 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 546 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 179
ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 60 GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120 TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180 GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360 CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420 GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTG ATAAGGATCC 540 GAATTC 546 (2) SEQUENCE INFORMATION 180 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH; 465 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 180
ATGGCGTCTC CGGCGCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC 60
TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GCCTACACCT 120
RO 118016 Β1
GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG GGAGAATGGA AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC gtgcgtttcc tgatgcttgt aggagggtcc accctctgcg
<td>AAACCCAGAT GGAGGAGACC</td><td> 180</td><td> 14025</td>
<td>AGGGAGTGAT GGCAGCACGG</td><td> 240</td><td></td>
<td>AGCTTTCTGG ACAGGTCCGT</td><td> 300</td><td></td>
<td>TTCCTCCACA GGGCAGGACC</td><td> 360</td><td></td>
<td></td><td></td><td> 14030</td>
<td>AACACCTGCT CCGAGGAAAG</td><td> 420</td><td></td>
<td>TCAGG</td><td> 465</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 181 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 143 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 181
14035
14040
CCTGTCAACC
CGGGCGGCGG CTCTGGTGGT GGTTCTGGTG GCGGCTCTGA GGGTGGCGGC
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGC TCTGAGGGTG GCGGTTCCGG TGGCGGCTCC
GGTTCCGGTA ACATGTATTA TGA (2) SEQUENCE INFORMATION ID NO. 182 (i) SEQUENCE CHARACTERISTICS;
(A) LENGTH: 180 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genomic)
120
14045
143
14050 (Xi)
SEQUENCE DESCRIPTION: SEQ. ID NO. 182
14055
ATCGTCTGAC
CTCCCGGGCC
TCCTGTCAAT
GCTGGCGGCG
GCTCTGGTGG
TGGTTCTGGT
GGCGGCTCTG
AGGGTGGCGG
CTCTGAGGGT
GGCGGTTCTG
AGGGTGGCGG
CTCTGAGGGT
120
GGCGGTTCCG
GTGGCGGCTC
CGGTTCCGGT
GATTTTGATT
ATGAAAACAT
GTCAAACGCT
180
14060 (2) INFORMATION FOR SEQUENCE ID NO. 183 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 858 base pairs (B) TYPE: nucleic acid 14065 (C) FILLING: double
EN 118016 Β1 (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 183
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC</td><td> 240</td>
<td>TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG</td><td> 300</td>
<td>TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAATCGA GGGAAGGATT</td><td> 360</td>
<td>TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCGT CTCCGGCGCC GCCTGCTTGT</td><td> 420</td>
<td>GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG TCCTTCACAG CAGACTGAGC</td><td> 480</td>
<td>CAGTGCCCAG AGGTTCACCC TTTGCCTACA CCTGTCCTGC TGCCTGCTGT GGACTTTAGC</td><td> 540</td>
<td>TTGGGAGAAT GGAAAACCCA GATGGAGGAG ACCAAGGCAC AGGACATTCT GGGAGCAGTG</td><td> 600</td>
<td>ACCCTTCTGC TGGAGGGAGT GATGGCAGCA CGGGGACAAC TGGGACCCAC TTGCCTCTCA</td><td> 660</td>
<td>TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC</td><td> 720</td>
<td>CTTGGAACCC AGCTTCCTCC ACAGGGCAGG ACCACAGCTC ACAAGGATCC CAATGCCATC</td><td> 780</td>
<td>TTCCTGAGCT TCCAACACCT GCTCCGAGGA AAGGTGCGTT TCCTGATGCT TGTAGGAGGG</td><td> 840</td>
<td>TCCACCCTCT GCGTCAGG</td><td> 858</td>
(2) SEQUENCE INFORMATION ID NO. 184 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 858 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 184 (2) SEQUENCE INFORMATION ID NO. 185
<td>ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG</td><td>ACCACCTAAC</td><td> 60</td>
<td>CCTTTGCTGG ACCCGAACAA CCTCAATTCT GAAGACATGG ATATCCTGAT</td><td>GGAACGAAAC</td><td> 120</td>
<td>CTTCGAACTC CAAACCTGCT CGCATTCGTA AGGGCTGTCA AGCACTTAGA</td><td>AAATGCATCA</td><td> 180</td>
<td>GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC</td><td>GGCCGCACCC</td><td> 240</td>
RO 118016 Β1
TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT GACTCCCATG CAGTGCCCAG AGGTTCACCC TTTGCCTACA CCTOTCCTGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG ACCAAGGCAC ACCCTTCTGC TGGAGGGAGT GATGGCAGCA CGGGGACAAC TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG ACCACAGCTC TTOCTGAGCT TCCAACACCT GCTCCGAGGA AAGGTGCGTT TCCACCCTCT GCGTCAGG
<td>AATTCCGGGA AAAACTGACG</td><td> 300</td><td> 14110</td>
<td>ACGTAGAGGG CGGTGGAGGC</td><td> 360</td><td></td>
<td>CTCCGGCGCC GCCTGCTTGT</td><td> 420</td><td></td>
<td>TCCTTCACAG CAGACTGAGC</td><td> 480</td><td></td>
<td>TGCCTGCTGT GGACTTTAGC</td><td> 540</td><td> 14115</td>
<td>AGGACATTCT GGGAGCAGTG</td><td> 600</td><td></td>
<td>TMnBi'W'ic rrrmt «rt w λ</td><td> 660</td><td></td>
<td>• ntsaaofwrr <scAfiwîry<sup>w</sup>·*'</td><td> 720</td><td></td>
<td>ACAAGGATCC CAATGCCATC</td><td> 780</td><td> 14120</td>
<td>TCCTGATGCT TGTAGGAGGG</td><td> 840</td><td></td>
<td></td><td> 858</td><td></td>
(2) SEQUENCE INFORMATION ID NO. 185 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 852 base pairs (B) TYPE: nucleic acid (C) FILLING: double (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome)
14125
14130 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 185
<td>ATGGCGTCTC</td><td>CGGCGCCGCC</td><td>TGCTTGTGAC</td><td>CTCCGAGTCC</td><td>TCAGTAAACT</td><td>GCTTCGTGAC</td><td> 60</td><td></td>
<td>TCCCATGTCC</td><td>TTCACAGCAG</td><td>to »JLSa</td><td>TGCCCAGAGG</td><td>TTCACCCTTT</td><td>GCCTACACCT</td><td> 120</td><td> 14135</td>
<td>GTCCTGCTGC</td><td>CTGCTGTGGA</td><td>CTTTAGCTTG</td><td>GGAGAATGGA</td><td>AAACCCAGAT</td><td>GGAGGAGACC</td><td> 180</td><td></td>
<td>AAGGCACAGG</td><td>ACATTCTGGG</td><td>AGCAGTGACC</td><td>CTTCTGCTGG</td><td>AGGGAGTGAT</td><td>GGCAGCACGG</td><td> 240</td><td></td>
<td>GGACAACTGG</td><td>GACCCACTTG</td><td>CCTCTCATCC</td><td>CTCCTGGGGC</td><td>AGCTTTCTGG</td><td>ACAGGTCCGT</td><td> 300</td><td></td>
<td>CTCCTCCTTG</td><td>GGGCCCTGCA</td><td>GAGCCTCCTT</td><td>GGAACCCAGC</td><td>TTCCTCCACA</td><td>GGGCAGGACC</td><td> 360</td><td> 14140</td>
<td>ACAGCTCACA</td><td>AGGATCCCAA</td><td>TGCCATCTTC</td><td>CTGAGCTTCC</td><td>AACACCTGCT</td><td>CCGAGGAAAG</td><td> 420</td><td></td>
<td>GTGCGTTTCC</td><td>TGATGCTTGT</td><td>AGGAGGGTCC</td><td>ACCCTCTGCG</td><td>TCAGGATCGA</td><td>GGGAAGGATT</td><td> 480</td><td></td>
<td>TCCCCGGGTG</td><td>GTGGTTCTGG</td><td>CGGCGGCTCC</td><td>AACATGGCTA</td><td>ACTGCTCTAT</td><td>AATGATCGAT</td><td> 540</td><td></td>
<td>GAAATTATAC</td><td>ATCACTTAAA</td><td>GAGACCACCT</td><td>AACCCTTTGC</td><td>TGGACCCGAA</td><td>CAACCTCAAT</td><td> 600</td><td> 14145</td>
<td>TCTGAAGACA</td><td>TGGATATCCT</td><td>GATGGAACGA</td><td>AACCTTCGAA</td><td>CTCCAAACCT</td><td>GCTCGCATTC</td><td> 660</td><td></td>
<td>GTAAGGGCTG</td><td>TCAAGCACTT</td><td>AGAAAATGCA</td><td>TCAGGTATTG</td><td>AGGCAATTCT</td><td>TCGTAATCTC</td><td> 720</td><td></td>
RO 118016 Β1
14150
CAACCATGTC TGCCCTCTGC CACGGCCGCA CCCTCTCGAC ATCCAATCAT CATCAAGGCA
780
GGTGACTGGC AAGAATTCCG GGAAAAACTG ACGTTCTATC TGGTTACCCT TGAGCAAGCG
CAGGAACAAC AG
840
852 (2) SEQUENCE INFORMATION ID NO. 186 14155 (i) SEQUENCE FEATURES:
(A) LENGTH: 870 base pairs (B) TYPE: nucleic acid (C) FILLING: double
,.. ,<sub>n</sub> (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: DNA (genome) (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 186
<td></td><td>ATGGCGTCTC</td><td>CGGCGCCGCC</td><td>TGCTTGTGAC</td>
<td> 14165</td><td>TCCCATGTCC</td><td>TTCACAGCAG</td><td>ACTGAGCCAG</td>
<td></td><td>GTCCTGCTGC</td><td>CTGCTGTGGA</td><td>CTTTAGCTTG</td>
<td></td><td>AAGGCACAGG</td><td>ACATTCTGGG</td><td>AGCAGTGACC</td>
<td></td><td>GGACAACTGG</td><td>GACCCACTTG</td><td>CCTCTCATCC</td>
<td> 14170</td><td>CTCCTCCTTG</td><td>GGGCCCTGCA</td><td>GAGCCTCCTT</td>
<td></td><td>ACAGCTCACA</td><td>AGGATCCCAA</td><td>TGCCATCTTC</td>
<td></td><td>GTGCGTTTCC</td><td>TGATGCTTGT</td><td>AGGAGGGTCC</td>
<td> 14175</td><td>GTAGAGGGCG</td><td>GTGGAGGCTC</td><td>CCCGGGTGGT</td>
<td></td><td>TGCTCTATAA</td><td>TGATCGATGA</td><td>AATTATACAT</td>
<td></td><td>GACCCGAACA</td><td>ACCTCAATTC</td><td>TGAAGACATG</td>
<td></td><td>CCAAACCTGC</td><td>TCGCATTCGT</td><td>AAGGGCTGTC</td>
<td> 14180</td><td>GCAATTCTTC</td><td>GTAATCTCCA</td><td>ACCATGTCTG</td>
<td></td><td>CCAATCATCA</td><td>TCAAGGCAGG</td><td>TGACTGGCAA</td>
<td></td><td>GTTACCCTTG</td><td>AGCAAGCGCA</td><td>GGAACAAGAG</td>
CTCCGAGTCC TCAGTAAACT GCTTCGTGAC60
TGCCCAGAGG TTCACCCTTT GCCTACACCT120
GGAGAATGGA AAACCCAGAT GGAGGAGACC180
CTTCTGCTGG AGGGAGTGAT GGCAGCACGG240
CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT300
GGAACCCAGC TTCCTCOACA GGGCAGGACC360
CTGAGCTTCC AACACCTGCT CCGAGGAAAG420
ACCCTCTGCG TCAGGGAATT CCATGCATAC480 ggttctggcg gcggctccaa CATGGCTAAC540
CACTTAAAGA GACCACCTAA CCCTTTGCTG600
GATATCCTGA TGGAACGAAA CCTTCGAACT660
AAGCACTTAG AAAATGCATC AGGTATTGAG720
CCCTCTGCCA CGGCCGCACC CTCTCGACAT780
GAATTCCGGG AAAAACTGAC GTTCTATCTG840
870 (2) SEQUENCE INFORMATION ID NO. 187
14185 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear
14190 (ii) TYPE OF MOLECULE: peptide
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 187 Met Ser Arg Pro Val Leu Leu Leu Leu Gin Leu Leu Val Arg Pro Ala Met
10 15 (2) SEQUENCE INFORMATION ID NO. 188 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 188
14195
14200
14205
Tyr Val Hair Glu Gly Arg Hair Ser Pro Gly Gly Gly Ser Gly Gly Gly 15 10 15
Ser Asn (2) SEQUENCE INFORMATION ID NO. 189 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 189
14210
14215
14220
Tyr Val Hair Glu Gly Lys Hair Ser Pro Gly Gly Gly Ser Gly Gly Gly 1 5 10 ÎS
Ser Asn (2) SEQUENCE INFORMATION ID NO. 190 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) OPUL MOLECULE: peptide
14225
14230
14235
EN 118016 Β1 (xi) DESCRIPTION OF SEQUENCES: SEQ. ID NO. 190
Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly 15 10 15
Ser Asn (2) SEQUENCE INFORMATION ID NO. 191 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 191
Tyr Val lle Glu Gly Arg lle Ser Pro Gly Glu Pro Ser Gly Pro lle 15 IO 15
Ser Thr lle Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 25 30
Asn (2) SEQUENCE INFORMATION ID NO. 192 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids (Β) ΊΠΡ: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 192
Tyr Val lle Glu Gly Lys lle Ser Pro Gly Glu Pro Ser Gly Prolle
5 1015
Ser Thr le Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys SerPro
2530
Asn (2) SEQUENCE INFORMATION ID NO. 193
EN 118016 Β1 (i) SEQUENCE CHARACTERISTICS: 14280 (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 193
Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro ser Gly Pro le 15 1015
Ser Thr him Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 2530
Asn (2) SEQUENCE INFORMATION ID NO. 194
14290
14295 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGIES: linear (ii) TYPE OF MOLECULE: peptide (xi) SEQUENCE DESCRIPTION: SEQ. ID NO. 194
Tyr Val lle Glu
Ser Gly Gly Gly
Gly Gly Gly Ser
Asn
Gly Arg him Ser
I'll be Glu Gly Gly
Glu Gly Gly Gly
Pro Gly Gly Gly
Gly Ser Glu Gly 25
Ser Gly Gly Gly
Ser Gly Gly Gly 15
Gly Gly Se'r Glu 30
Ser Gly Ser Gly
14305
14310 (2) SEQUENCE INFORMATION ID NO. 195
<td rowspan="2">(I)</td><td colspan="2">SEQUENCE CHARACTERISTICS:</td><td rowspan="2"> 14315</td>
<td>(A) (B)</td><td>LENGTH: 60 amino acids TYPE: amino acid</td>
<td></td><td>(C)</td><td>plaited</td><td></td>
<td></td><td>(D)</td><td>TOPOLOGY: linear</td><td></td>
<td>(Ii)</td><td colspan="2">MOLECULE TYPE: peptide</td><td> 14320</td>
EN 118016 Β1 (xi) DESCRIPTION OF THE SEQUENCE: SEQ. ID NO. 195
Tyr Val lle Glu Gly Arg lle Ser Pro Gin Pro Pro Val Asn Ala Gly 15 1015
Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Gly Ser 20 2530
Gly Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly 35 4045
Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Asn
5560 (2) SEQUENCE INFORMATION ID NO. 196 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) FILLING:
(D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: peptide (xi] SEQUENCE DESCRIPTION: SEQ ID NO 196
Glu Phe His Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly 1 5 10 15
Ser Gly Gly Gly Ser Asn
Contents1193
6 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6
147 members in 22 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 19232594 | United States of America | A | |
| 9501185 | United States of America | W |
Members147
| Document | Office | Kind | |
|---|---|---|---|
| CA2150116A1 | Canada | A1 | |
| CA2150117A1 | Canada | A1 | |
| WO9412638A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO9412639A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5612594A | Australia | A | |
| AU5670994A | Australia | A | |
| WO9412639A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO9412638A3 | World Intellectual Property Organization (WIPO) | A3 | |
| CA2182473A1 | Canada | A1 | |
| CA2182474A1 | Canada | A1 | |
| CA2182483A1 | Canada | A1 | |
| CA2182484A1 | Canada | A1 | |
| WO9520976A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO9520977A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO9521197A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO9521254A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1680595A | Australia | A | |
| AU1695395A | Australia | A | |
| AU1835695A | Australia | A | |
| AU1909995A | Australia | A | |
| EP0670898A1 | European Patent Office (EPO) | A1 | |
| EP0672145A1 | European Patent Office (EPO) | A1 | |
| KR950704490A | Republic of Korea | A | |
| JPH08503489A | Japan | A | |
| JPH08503706A | Japan | A | |
| NO963225D0 | Norway | D0 | |
| FI963072A | Finland | A | |
| FI963072L | Finland | L | |
| NO963225L | Norway | L | |
| EP0741576A1 | European Patent Office (EPO) | A1 | |
| EP0742720A1 | European Patent Office (EPO) | A1 | |
| EP0742796A1 | European Patent Office (EPO) | A1 | |
| EP0742826A1 | European Patent Office (EPO) | A1 | |
| PL315791A1 | Poland | A1 | |
| CZ229896A3 | Czechia | A3 | |
| KR970700766A | Republic of Korea | A | |
| US5604116A | United States of America | A | |
| MX9603205A | Mexico | A | |
| JPH09508524A | Japan | A | |
| JPH09508625A | Japan | A | |
| BR9506733A | Brazil | A | |
| US5677149A | United States of America | A | |
| JPH10502801A | Japan | A | |
| US5738849A | United States of America | A | |
| AU690088B2 | Australia | B2 | |
| NZ279624A | New Zealand | A | |
| NZ281421A | New Zealand | A | |
| AU6078398A | Australia | A | |
| US5772992A | United States of America | A | |
| US5817486A | United States of America | A | |
| AU697433B2 | Australia | B2 | |
| AU700220B2 | Australia | B2 | |
| US5858347A | United States of America | A | |
| NZ329952A | New Zealand | A | |
| CN1227604A | China | A | |
| HK1013655A1 | Hong Kong, China | A1 | |
| NZ330060A | New Zealand | A | |
| US5997857A | United States of America | A | |
| US5997860A | United States of America | A | |
| US6022535A | United States of America | A | |
| US6030812A | United States of America | A | |
| US6051217A | United States of America | A | |
| US6057133A | United States of America | A | |
| US6060047A | United States of America | A | |
| US6074639A | United States of America | A | |
| US6093395A | United States of America | A | |
| US6132991A | United States of America | A | |
| US6153183A | United States of America | A | |
| US6361976B1 | United States of America | B1 | |
| US6361977B1 | United States of America | B1 | |
| CA2182483C | Canada | C | |
| CZ289904B6 | Czechia | B6 | |
| EP1199080A2 | European Patent Office (EPO) | A2 | |
| US6379662B1 | United States of America | B1 | |
| US6403076B1 | United States of America | B1 | |
| EP0741576B1 | European Patent Office (EPO) | B1 | |
| AT218882T | Austria | T | |
| ATE218882T1 | Austria | T1 | |
| US6413509B1 | United States of America | B1 | |
| DE69527041D1 | Germany | D1 | |
| US6436387B1 | United States of America | B1 | |
| US6440407B1 | United States of America | B1 | |
| PT741576E | Portugal | E | |
| US6458931B1 | United States of America | B1 | |
| DK0741576T3 | Denmark | T3 | |
| US6479261B1 | United States of America | B1 | |
| KR100332139B1 | Republic of Korea | B1 | |
| DE69527041T2 | Germany | T2 | |
| RO118016B1This record | Romania | B1 | |
| EP1283264A2 | European Patent Office (EPO) | A2 | |
| ES2180624T3 | Spain | T3 | |
| EP0742796B1 | European Patent Office (EPO) | B1 | |
| EP0672145B1 | European Patent Office (EPO) | B1 | |
| EP0742720B1 | European Patent Office (EPO) | B1 | |
| KR100370264B1 | Republic of Korea | B1 | |
| AT237641T | Austria | T | |
| AT238421T | Austria | T | |
| AT239496T | Austria | T | |
| ATE237641T1 | Austria | T1 | |
| ATE238421T1 | Austria | T1 |
Numbers
- Application
- 9601594
Titles2
- English
- FUSION PROTEIN
- Romanian
- PROTEINA DE FUZIUNE
Classification
- CPC, 8
- C07K14/5403
- C07K14/00
- A61K38/00
- C07K2319/00
- C07K2319/02
- A61P7/00
- C07K19/00
- A61K38/20
- IPC, 21
- A47B47 02
- A61K38 00
- A61K38 20
- A61K38 22
- C12N15 09
- A61K38 27
- A61P7 00
- C07H21 04
- C07K
- C07K14 52
- C07K14 53
- C07K14 54
- C07K19 00
- C12N1 21
- C12N15 24
- C12N15 26
- C12N15 27
- C12N15 62
- C12N15 63
- C12P21 02
- C12R1 19